参考文献

1 针对临床流行病学背景的肝癌风险预测分子生物标志物

[1] Adeniji, N., & Dhanasekaran, R. (2021). Current and emerging tools for hepatocellular carcinoma surveillance. *Hepatology Communications*. https://doi.org/10.1002/hep4.1823.

[2] Aref, S., Zaki, A., El Mahdi, E. M., Adel, E., Bahgat, M., & Gouda, E. (2021). Predictive value of interferon γ receptor gene polymorphisms for hepatocellular carcinoma susceptibility. *Asian Pacific Journal of Cancer Prevention*, *22*(6), 1821–1826. https://doi.org/10.31557/apjcp.2021.22.6.1821.

[3] Assi, N., Fages, A., Vineis, P., Chadeau-Hyam, M., Stepien, M., Duarte-Salles, T., et al. (2015). A statistical framework to model the meeting-in-the-middle principle using metabolomic data: Application to hepatocellular carcinoma in the EPIC study. *Mutagenesis*, *30*(6), 743–753. https://doi.org/10.1093/mutage/gev045.

[4] Athuluri-Divakar, S. K., & Hoshida, Y. (2019). Generic chemoprevention of hepatocellular carcinoma. *Annals of the New York Academy of Sciences*, *1440*(1), 23–35. https://doi.org/10.1111/nyas.13971.

[5] Baumert, T. F., Juhling, F., Ono, A., & Hoshida, Y. (2017). Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. *BMC Medicine*, *15*(1), 52. https://doi.org/10.1186/s12916-017-0815-7.

[6] Beyoğlu, D., & Idle, J. R. (2013). The metabolomic window into hepatobiliary disease. *Journal of Hepatology*, *59*(4), 842–858. https://doi.org/10.1016/j.jhep.2013.05.030.

[7] Beyoğlu, D., & Idle, J. R. (2020). Metabolomic and lipidomic biomarkers for premalignant liver disease diagnosis and therapy. *Metabolites*, *10*(2). https://doi.org/10.3390/metabo10020050.

[8] Bianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., et al. (2021). Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. *Journal of Hepatology*, *74*(4), 775–782. https://doi.org/10.1016/j.jhep.2020.11.024.

[9] Carrat, F., Fontaine, H., Dorival, C., Simony, M., Diallo, A., Hezode, C., et al. (2019). Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study. *Lancet*, *393*(10179), 1453–1464. https://doi.org/10.1016/s0140-6736(18)32111-1.

[10] Chang, M. H., You, S. L., Chen, C. J., Liu, C. J., Lai, M. W., Wu, T. C., et al. (2016). Long-term effects of hepatitis B immunization of infants in preventing liver cancer. *Gastroenterology*, *151*(3), 472–480.e1. https://doi.org/10.1053/j.gastro.2016.05.048.

[11] Chen, C. H., Lee, C. M., Lai, H. C., Hu, T. H., Su, W. P., Lu, S. N., et al. (2017). Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. *Oncotarget*, *8*(54), 92431–92441. https://doi.org/10.18632/oncotarget.21369.

[12] Chen, C. J., Yang, H. I., Su, J., Jen, C. L., You, S. L., Lu, S. N., et al. (2006). Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA*, *295* (1), 65–73. https://doi.org/10.1001/jama.295.1.65.

[13] Choi, W. M., Choi, J., & Lim, Y. S. (2021). Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: A systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*, *19*(2), 246–258.e249. https://doi.org/10.1016/j.cgh.2020.05.008.

[14] Chun, H. S., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., Han, K. H., et al. (2020). Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. *European Journal of Gastroenterology & Hepatology*, *32*(3), 378–385. https://doi.org/10.1097/meg.0000000000001512.

[15] Crouchet, E., Bandiera, S., Fujiwara, N., Li, S., El Saghire, H., Fernández-Vaquero, M., et al. (2021). A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. *Nature Communications*, *12*(1), 5525. https://doi.org/10.1038/s41467-021-25468-9.

[16] Dalton-Fitzgerald, E., Tiro, J., Kandunoori, P., Halm, E. A., Yopp, A., & Singal, A. G. (2015). Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis.

Clinical Gastroenterology and Hepatology, *13*(4), 791–798.e791. https://doi.org/10.1016/j.cgh.2014.06.031.

[17] Degasperi, E., Galmozzi, E., Pelusi, S., D'Ambrosio, R., Soffredini, R., Borghi, M., et al. (2020). Hepatic fat-genetic risk score predicts hepatocellular carcinoma in patients with cirrhotic HCV treated with DAAs. *Hepatology*, *72*(6), 1912–1923. https://doi.org/10.1002/hep.31500.

[18] Dirchwolf, M., Marciano, S., Ruf, A. E., Singal, A. G., D'Ercole, V., Coisson, P., et al. (2021). Failure in all steps of hepatocellular carcinoma surveillance process is frequent in daily practice. *Annals of Hepatology*, *25*, 100344. https://doi.org/10.1016/j.aohep.2021.100344.

[19] Donati, B., Dongiovanni, P., Romeo, S., Meroni, M., McCain, M., Miele, L., et al. (2017). MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. *Scientific Reports*, *7*(1), 4492. https://doi.org/10.1038/s41598-017-04991-0.

[20] Dragani, T. A. (2010). Risk of HCC: Genetic heterogeneity and complex genetics. *Journal of Hepatology*, *52*(2), 252–257. https://doi.org/10.1016/j.jhep.2009.11.015.

[21] Du, Y., Du, B., Fang, X., Shu, M., Zhang, Y., Chung, H., et al. (2020). ALT flare predicts hepatocellular carcinoma among antiviral treated patients with chronic hepatitis B: A cross-country cohort study. *Frontiers in Oncology*, *10*, 615203. https://doi.org/10.3389/fonc.2020.615203.

[22] Duarte-Salles, T., Misra, S., Stepien, M., Plymoth, A., Muller, D., Overvad, K., et al. (2016). Circulating osteopontin and prediction of hepatocellular carcinoma development in a large European population. *Cancer Prevention Research (Philadelphia, Pa.)*, *9*(9), 758–765. https://doi.org/10.1158/1940-6207.CAPR-15-0434.

[23] El-Serag, H. B., Sardell, R., Thrift, A. P., Kanwal, F., & Miller, P. (2021). Texas has the highest hepatocellular carcinoma incidence rates in the USA. *Digestive Diseases and Sciences*, *66*(3), 912–916. https://doi.org/10.1007/s10620-020-06231-4. Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018). Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. *Hepatology*, *67*(1), 123–133. https://doi.org/10.1002/hep.29466.

[24] Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., et al. (2020). aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. *Journal of Hepatology*, *73*(6), 1368–1378. https://doi.org/10.1016/j.jhep.2020.07.025.

[25] Farid, A. A., Afify, N. A., Alsharnoby, A. A., Abdelsameea, E., & Bedair, H. M. (2021). Predictive role of AURKA rs 1047972 gene polymorphism and the risk of development of hepatocellular carcinoma. *Immunological Investigations*, *1-11*. https://doi.org/10.1080/08820139.2021.1920609.

[26] Farvardin, S., Patel, J., Khambaty, M., Yerokun, O. A., Mok, H., Tiro, J. A., et al. (2017). Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. *Hepatology*, *65*(3), 875–884. https://doi.org/10.1002/hep.28770.

[27] Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004). Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. *Gastroenterology*, *127*(5 Suppl. 1), S35–S50. https://doi.org/10.1053/j.gastro.2004.09.014.

[28] Finkin, S., Yuan, D., Stein, I., Taniguchi, K., Weber, A., Unger, K., et al. (2015). Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. *Nature Immunology*, *16*(12), 1235–1244. https://doi.org/10.1038/ni.3290.

[29] Flemming, J. A., Yang, J. D., Vittinghoff, E., Kim, W. R., & Terrault, N. A. (2014). Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADRESS-HCC risk model. *Cancer* , *120*(22), 3485–3493. https://doi.org/10.1002/cncr.28832.

[30] Franco, R. A., Fan, Y., Jarosek, S., Bae, S., & Galbraith, J. (2018). Racial and geographic disparities in hepatocellular carcinoma outcomes. *American Journal of Preventive Medicine*, *55* (5 Suppl. 1), S40–s48. https://doi.org/10.1016/j.amepre.2018.05.030.

[31] Fujiwara, N., Fobar, A. J., Raman, I., Li, Q. Z., Marrero, J. A., Parikh, N. D., et al. (2021). A blood-based prognostic liver secretome signature predicts long-term risk of hepatic decompensation in cirrhosis. *Clinical Gastroenterology and Hepatology*. https://doi.org/10.1016/j.cgh.2021.03.019.

[32] Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018). Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. *Journal of Hepatology*, *68* (3), 526–549. https://doi.org/10.1016/j.jhep.2017.09.016.

[33] Fujiwara, N., & Hoshida, Y. (2020). Viral exposure signature associated with liver cancer risk. *Trends in Molecular Medicine*, *26*(8), 711–713. https://doi.org/10.1016/j.molmed.2020.06.008.

[34] Fujiwara, N., Kobayashi, M., Fobar, A. J., Hoshida, A., Marquez, C. A., Koneru, B., et al. (2021). A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. *Med (New York, N.Y.)*, *2*(7), 836–850.e810. https://doi.org/10.1016/j.medj.2021.03.017.

[35] Fujiwara, N., Liu, P. H., Athuluri-Divakar, S. K., Zhu, S., & Hoshida, Y. (2019). Risk factors of hepatocellular carcinoma for precision personalized care. In Y. Hoshida (Ed.), *Hepatocellular carcinoma: Translational precision medicine approaches* (pp. 3–25). Cham (CH): Humana Press. Springer Nature Switzerland AG.

[36] Fujiwara, N., Trépo, E., Raman, I., Li, Q. Z., Degré, D., Gustot, T., et al. (2021). Plasmasignature-model for end-stage liver disease score to predict survival in severe alcoholic hepatitis. *Clinical Gastroenterology and Hepatology*. https://doi.org/10.1016/j.cgh.2021.02.041.

[37] Ganne-Carrié, N., Layese, R., Bourcier, V., Cagnot, C., Marcellin, P., Guyader, D., et al. (2016). Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). *Hepatology*, *64*(4), 1136−1147. https://doi.org/10.1002/hep.28702.

[38] Gellert-Kristensen, H., Richardson, T. G., Davey Smith, G., Nordestgaard, B. G., Tybjaerg-Hansen, A., & Stender, S. (2020). Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. *Hepatology*, *72*(3), 845−856. https://doi.org/10.1002/hep.31238.

[39] Goossens, N., Singal, A. G., King, L. Y., Andersson, K. L., Fuchs, B. C., Besa, C., et al. (2017). Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. *Clinical and Translational Gastroenterology*, *8*(6), e101. https://doi.org/10.1038/ctg.2017.26.

[40] Hernandez, B. Y., Zhu, X., Risch, H. A., Lu, L., Ma, X., Irwin, M. L., et al. (2021). Oral cyanobacteria and hepatocellular carcinoma. *Cancer Epidemiology, Biomarkers & Prevention*. https://doi.org/10.1158/1055-9965.EPI-21-0804.

[41] Higashi, T., Friedman, S. L., & Hoshida, Y. (2017). Hepatic stellate cells as key target in liver fibrosis. *Advanced Drug Delivery Reviews*, *121*, 27–42. https://doi.org/10.1016/j.addr.2017.05.007.

[42] Hiraoka, A., Kumada, T., Ogawa, C., Kariyama, K., Morita, M., Nouso, K., et al. (2019). Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: Multicenter analysis. *Journal of Gastroenterology and Hepatology*, *34*(2), 436–441. https://doi.org/10.1111/jgh.14378.

[43] Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D. Y., Camargo, A., et al. (2008). Gene expression in fixed tissues and outcome in hepatocellular carcinoma. *The New England Journal of Medicine*, *359*(19), 1995−2004. https://doi.org/10.1056/NEJMoa0804525.

[44] Hoshida, Y., Villanueva, A., Sangiovanni, A., Sole, M., Hur, C., Andersson, K. L., et al. (2013). Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. *Gastroenterology*, *144*(5), 1024−1030. https://doi.org/10.1053/j.gastro.2013.01.021.

[45] Hsu, Y. C., Jun, T., Huang, Y. T., Yeh, M. L., Lee, C. L., Ogawa, S., et al. (2018). Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. *Alimentary Pharmacology & Therapeutics*, *48*(10), 1128–1137. https://doi.org/10.1111/apt.15006.

[46] Hsu, Y. C., Yip, T. C., Ho, H. J., Wong, V. W., Huang, Y. T., El-Serag, H. B., et al. (2018). Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. *Journal of Hepatology*, *69*(2), 278–285. https://doi.org/10.1016/j.jhep.2018.02.032.

[47] Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021). Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. *Nature Reviews. Gastroenterology & Hepatology*, *18*(4), 223–238. https://doi.org/10.1038/s41575-020-00381-6.

[48] Huang, Y. H., Liang, K. H., Chien, R. N., Hu, T. H., Lin, K. H., Hsu, C. W., et al. (2017). A circulating MicroRNA signature capable of assessing the risk of hepatocellular carcinoma in cirrhotic patients. *Scientific Reports*, *7*(1), 523. https://doi.org/10.1038/s41598-017-00631-9.

[49] Hughes, D. M., Berhane, S., Emily de Groot, C. A., Toyoda, H., Tada, T., Kumada, T., et al. (2021). Serum levels of α-fetoprotein increased more than 10 years before detection of hepatocellular carcinoma. *Clinical Gastroenterology and Hepatology*, *19*(1), 162−170. e164. https://doi.org/10.1016/j.cgh.2020.04.084.

[50] Hung, Y. C., Lin, C. L., Liu, C. J., Hung, H., Lin, S. M., Lee, S. D., et al. (2015). Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. *Hepatology* , *61*(6), 1934−1944. https://doi.org/10.1002/hep.27610.

[51] Ioannou, G. N., Green, P., Kerr, K. F., & Berry, K. (2019). Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. *Journal of Hepatology*. https://doi.org/10.1016/j.jhep.

2019.05.008.

[52] Islami, F., Miller, K. D., Siegel, R. L., Fedewa, S. A., Ward, E. M., & Jemal, A. (2017). Disparities in liver cancer occurrence in the United States by race/ethnicity and state. *CA: A Cancer Journal for Clinicians*, *67*(4), 273–289. https://doi.org/10.3322/caac.21402.

[53] Jee, S. H., Kim, M., Kim, M., Yoo, H. J., Kim, H., Jung, K. J., et al. (2018). Metabolomics profiles of hepatocellular carcinoma in a Korean prospective cohort: The Korean Cancer Prevention Study-II. *Cancer Prevention Research (Philadelphia, Pa.)*, *11*(5), 303–312. https://doi.org/10.1158/1940-6207.capr-17-0249.

[54] Ji, J., Eggert, T., Budhu, A., Forgues, M., Takai, A., Dang, H., et al. (2015). Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. *Hepatology*, *62*(2), 481–495. https://doi.org/10.1002/hep.27822.

[55] Jiang, D. K., Sun, J., Cao, G., Liu, Y., Lin, D., Gao, Y. Z., et al. (2013). Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. *Nature Genetics*, *45*(1), 72–75. https://doi.org/10.1038/ng.2483.

[56] Jiang, G., Yu, K., Shao, L., Yu, X., Hu, C., Qian, P., et al. (2015). Association between epidermal growth factor gene + 61A/G polymorphism and the risk of hepatocellular carcinoma: A meta-analysis based on 16 studies. *BMC Cancer*, *15*, 314. https://doi.org/10.1186/s12885-015-1318-6.

[57] Kim, J. H., Kang, S. H., Lee, M., Youn, G. S., Kim, T. S., Jun, B. G., et al. (2020). Serum myostatin predicts the risk of hepatocellular carcinoma in patients with alcoholic cirrhosis: A multicenter study. *Cancers (Basel)*, *12*(11). https://doi.org/10.3390/cancers12113347.

[58] Kim, J. H., Kim, Y. D., Lee, M., Jun, B. G., Kim, T. S., Suk, K. T., et al. (2018). Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. *Journal of Hepatology*, *69*(5), 1066–1073. https://doi.org/10.1016/j.jhep.2018.07.018.

[59] Kim, H. Y., Lampertico, P., Nam, J. Y., Lee, H. C., Kim, S. U., Sinn, D. H., et al. (2021). An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. *Journal of Hepatology*. https://doi.org/10.1016/j.jhep.2021.09.025.

[60] Kim, N. J., Rozenberg-Ben-Dror, K., Jacob, D. A., Rich, N. E., Singal, A. G., Aby, E. S., et al. (2020). Provider attitudes toward risk-based hepatocellular carcinoma surveillance in patients with cirrhosis in the United States. *Clinical Gastroenterology and Hepatology*. https://doi.org/10.1016/j.cgh.2020.09.015.

[61] Kim, J. H., Sohn, B. H., Lee, H. S., Kim, S. B., Yoo, J. E., Park, Y. Y., et al. (2014). Genomic predictors for recurrence patterns of hepatocellular carcinoma: Model derivation and validation. *PLoS Medicine*, *11*(12), e1001770. https://doi.org/10.1371/journal.pmed.1001770.

[62] Kim, H. S., Yu, X., Kramer, J., Thrift, A. P., Richardson, P., Hsu, Y. C., et al. (2021). Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. *Journal of Hepatology*. https://doi.org/10.1016/j.jhep.2021.09.009.

[63] King, L. Y., Canasto-Chibuque, C., Johnson, K. B., Yip, S., Chen, X., Kojima, K., et al. (2015). A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. *Gut*, *64*(8), 1296–1302. https://doi.org/10.1136/gutjnl-2014-307862.

[64] Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjaerg-Hansen, A., et al. (2014). Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. *Nature Genetics*, *46*(4), 352–356. https://doi.org/10.1038/ng.2901.

[65] Kubota, N., Fujiwara, N., & Hoshida, Y. (2020). Clinical and molecular prediction of hepatocellular carcinoma risk. *Journal of Clinical Medicine*, *9*(12). https://doi.org/10.3390/jcm9123843.

[66] Lee, M. H., Lu, S. N., Yuan, Y., Yang, H. I., Jen, C. L., You, S. L., et al. (2014). Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. *PLoS One*, *9*(5), e94760. https://doi.org/10.1371/journal.pone.0094760.

[67] Lee, H. W., Park, S. Y., Lee, M., Lee, E. J., Lee, J., Kim, S. U., et al. (2020). An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. *Liver International*, *40*(7), 1736–1743. https://doi.org/10.1111/liv.14451.

[68] Lee, H. W., Yoo, E. J., Kim, B. K., Kim, S. U., Park, J. Y., Kim, D. Y., et al. (2014). Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. *The American Journal of Gastroenterology*, *109*(8), 1241–1249. https://doi.org/10.1038/ajg.2014.157.

[69] Letouze, E., Shinde, J., Renault, V., Couchy, G., Blanc, J. F., Tubacher, E., et al. (2017). Mutational signatures reveal the

dynamic interplay of risk factors and cellular processes during liver tumorigenesis. *Nature Communications*, *8*(1), 1315. https://doi.org/10.1038/s41467-017-01358-x.

[70] Liang, K. H., Cheng, M. L., Lo, C. J., Lin, Y. H., Lai, M. W., Lin, W. R., et al. (2020). Plasma phenylalanine and glutamine concentrations correlate with subsequent hepatocellular carcinoma occurrence in liver cirrhosis patients: An exploratory study. *Scientific Reports*, *10*(1), 10926. https://doi.org/10.1038/s41598-020-67971-x.

[71] Liang, K. H., Lai, M. W., Lin, Y. H., Chu, Y. D., Lin, C. L., Lin, W. R., et al. (2021). Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients. *BMC Gastroenterology*, *21*(1), 177. https://doi.org/10.1186/s12876-021-01761-1.

[72] Liang, Y., Yang, Z., & Zhong, R. (2012). Primary biliary cirrhosis and cancer risk: A systematic review and meta-analysis. *Hepatology*, *56*(4), 1409–1417. https://doi.org/10.1002/hep.25788.

[73] Liu, J., Ayada, I., Zhang, X., Wang, L., Li, Y., Wen, T., et al. (2021). Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. *Clinical Gastroenterology and Hepatology*. https://doi.org/10.1016/j.cgh.2021.02.030.

[74] Liu, Q., Liu, G., Lin, Z., Lin, Z., Tian, N., Lin, X., et al. (2021). The association of lncRNA SNPs and SNPs-environment interactions based on GWAS with HBV-related HCC risk and progression. *Molecular Genetics & Genomic Medicine*, *9*(2), e1585. https://doi.org/10.1002/mgg3.1585.

[75] Liu, W., Ma, N., Zhao, D., Gao, X., Zhang, X., Yang, L., et al. (2019). Correlation between the DEPDC5 rs1012068 polymorphism and the risk of HBV-related hepatocellular carcinoma. *Clinics and Research in Hepatology and Gastroenterology*, *43*(4), 446–450. https://doi.org/10.1016/j.clinre.2018.12.005.

[76] Liu, J., Tang, W., Budhu, A., Forgues, M., Hernandez, M. O., Candia, J., et al. (2020). A viral exposure signature defines early onset of hepatocellular carcinoma. *Cell*, *182*(2), 317–328.e310. https://doi.org/10.1016/j.cell.2020.05.038.

[77] Loomba, R., Friedman, S. L., & Shulman, G. I. (2021). Mechanisms and disease consequences of nonalcoholic fatty liver disease. *Cell*, *184*(10), 2537–2564. https://doi.org/10.1016/j.cell.2021.04.015.

[78] Luo, X., Wang, Y., Shen, A., Deng, H., & Ye, M. (2019). Relationship between the rs2596542 polymorphism in the MICA gene promoter and HBV/HCV infection-induced hepatocellular carcinoma: A meta-analysis. *BMC Medical Genetics*, *20*(1), 142. https://doi.org/10.1186/s12881-019-0871-2.

[79] Luo, P., Yin, P., Hua, R., Tan, Y., Li, Z., Qiu, G., et al. (2018). A large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. *Hepatology*, *67*(2), 662−675. https://doi.org/10.1002/hep.29561.

[80] Luo, Y. Y., Zhang, H. P., Huang, A. L., & Hu, J. L. (2019). Association between KIF1B rs17401966 genetic polymorphism and hepatocellular carcinoma susceptibility: An updated meta-analysis. *BMC Medical Genetics*, *20*(1), 59. https://doi.org/10.1186/s12881-019-0778-y.

[81] Mancebo, A., González-Diéguez, M. L., Cadahía, V., Varela, M., Pérez, R., Navascués, C. A., et al. (2013). Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. *Clinical Gastroenterology and Hepatology*, *11*(1), 95–101. https://doi.org/10.1016/j.cgh.2012.09.007.

[82] Mangoud, N. O. M., Ali, S. A., El Kassas, M., & Soror, S. H. (2021). Chitinase 3-like-1, Tolloid-like protein 1, and intergenic gene polymorphisms are predictors for hepatocellular carcinoma development after hepatitis C virus eradication by direct-acting antivirals. *IUBMB Life*, *73*(2), 474–482. https://doi.org/10.1002/iub.2444.

[83] Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., et al. (2018). Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology*, *68*(2), 723–750. https://doi.org/10.1002/hep.29913.

[84] Martinez, M. A., & Franco, S. (2020). Therapy implications of hepatitis C virus genetic diversity. *Viruses*, *13*(1). https://doi.org/10.3390/v13010041.

[85] Massarweh, N. N., & El-Serag, H. B. (2017). Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *Cancer Control*, *24*(3). https://doi.org/10.1177/1073274817729245. 1073274817729245.

[86] Matsuura, K., Sawai, H., Ikeo, K., Ogawa, S., Iio, E., Isogawa, M., et al. (2017). Genome-wide association study identifies TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus infection. *Gastroenterology*, *152*(6), 1383−1394. https://doi.org/10.1053/j.gastro.2017.01.041.

[87] Mazziotti, G., Sorvillo, F., Morisco, F., Carbone, A., Rotondi, M., Stornaiuolo, G., et al. (2002). Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: A prospective study. *Cancer*, *95*(12), 2539–2545. https://doi.org/10.1002/cncr.11002.

[88] McGlynn, K. A., Petrick, J. L., & El-Serag, H. B. (2021). Epidemiology of hepatocellular carcinoma. *Hepatology*, *73*(Suppl. 1), 4–13. https://doi.org/10.1002/hep.31288.

[89] Meroni, M., Longo, M., Paolini, E., Alisi, A., Miele, L., De Caro, E. R., et al. (2021). The rs599839 A>G variant disentangles cardiovascular risk and hepatocellular carcinoma in NAFLD patients. *Cancers (Basel)*, *13*(8). https://doi.org/10.3390/cancers13081783.

[90] Miller, K. D., Ortiz, A. P., Pinheiro, P. S., Bandi, P., Minihan, A., Fuchs, H. E., et al. (2021). Cancer statistics for the US Hispanic/Latino population, 2021. *CA: A Cancer Journal for Clinicians*. https://doi.org/10.3322/caac.21695.

[91] Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., et al. (2016). Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. *Clinical Gastroenterology and Hepatology*, *14*(1), 124–131.e121. https://doi.org/10.1016/j.cgh.2015.07.019.

[92] Moeini, A., Torrecilla, S., Tovar, V., Montironi, C., Andreu-Oller, C., Peix, J., et al. (2019). An immune gene expression signature associated with development of human hepatocellular carcinoma identifies mice that respond to chemopreventive agents. *Gastroenterology*, *157*(5), 1383–1397.e1311. https://doi.org/10.1053/j.gastro.2019.07.028.

[93] Morgan, T. R., Mandayam, S., & Jamal, M. M. (2004). Alcohol and hepatocellular carcinoma. *Gastroenterology*, *127*(5 Suppl. 1), S87–S96. https://doi.org/10.1053/j.gastro.2004.09.020.

[94] Nakagawa, H., Maeda, S., Yoshida, H., Tateishi, R., Masuzaki, R., Ohki, T., et al. (2009). Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: An analysis based on gender differences. *International Journal of Cancer*, *125*(10), 2264–2269. https://doi.org/10.1002/ijc.24720.

[95] Nakagawa, S., Wei, L., Song, W. M., Higashi, T., Ghoshal, S., Kim, R. S., et al. (2016). Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition. *Cancer Cell*, *30*(6), 879–890. https://doi.org/10.1016/j.ccell.2016.11.004.

[96] Nault, J. C., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., et al. (2015). Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. *Nature Genetics*, *47*(10), 1187–1193. https://doi.org/10.1038/ng.3389.

[97] Ono, A., Goossens, N., Finn, R. S., Schmidt, W. N., Thung, S. N., Im, G. Y., et al. (2017). Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature. *Hepatology*, *66*(4), 1344–1346. https://doi.org/10.1002/hep.29203.

[98] Palmer, W. C., & Patel, T. (2012). Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. *Journal of Hepatology*, *57*(1), 69–76. https://doi.org/10.1016/j.jhep.2012.02.022.

[99] Papatheodoridis, G., Dalekos, G., Sypsa, V., Yurdaydin, C., Buti, M., Goulis, J., et al. (2016). PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. *Journal of Hepatology*, *64*(4), 800–806. https://doi.org/10.1016/j.jhep.2015.11.035.

[100] Papatheodoridis, G. V., Sypsa, V., Dalekos, G. N., Yurdaydin, C., Van Boemmel, F., Buti, M., et al. (2020). Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. *Journal of Hepatology*, *72*(6), 1088–1096. https://doi.org/10.1016/j.jhep.2020.01.007.

[101] Poh, Z., Shen, L., Yang, H. I., Seto, W. K., Wong, V. W., Lin, C. Y., et al. (2016). Real-world risk score for hepatocellular carcinoma (RWS-HCC): A clinically practical risk predictor for HCC in chronic hepatitis B. *Gut*, *65*(5), 887–888. https://doi.org/10.1136/gutjnl-2015-310818.

[102] Poynard, T., Peta, V., Deckmyn, O., Munteanu, M., Moussalli, J., Ngo, Y., et al. (2019). LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. *Alimentary Pharmacology & Therapeutics*, *49*(3), 308–320. https://doi.org/10.1111/apt.15082.

[103] Qin, S., Wang, J., Zhou, C., Xu, Y., Zhang, Y., Wang, X., et al. (2019). The influence of interleukin 28B polymorphisms on the risk of hepatocellular carcinoma among patients with HBV or HCV infection: An updated meta-analysis. *Medicine (Baltimore)*, *98*(38), e17275. https://doi.org/10.1097/md.0000000000017275.

[104] Qu, C., Wang, Y., Wang, P., Chen, K., Wang, M., Zeng, H., et al. (2019). Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. *Proceedings of the National Academy of Sciences of the United States of America*, *116*(13), 6308–6312. https://doi.org/10.1073/pnas.1819799116.

[105] Ren, Z., Li, A., Jiang, J., Zhou, L., Yu, Z., Lu, H., et al. (2019). Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. *Gut*, *68*(6), 1014–1023. https://doi.org/10.1136/gutjnl-2017-315084.

[106] Rich, N. E., Carr, C., Yopp, A. C., Marrero, J. A., & Singal, A. G. (2020). Racial and ethnic disparities in survival among patients with hepatocellular carcinoma in the United States: A systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*. https://doi.org/10.1016/j.cgh.2020.12.029.

[107] Rich, N. E., Murphy, C. C., Yopp, A. C., Tiro, J., Marrero, J. A., & Singal, A. G. (2020). Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. *Alimentary Pharmacology & Therapeutics*, *52*(4), 701–709. https://doi.org/10.1111/apt.15917.

[108] Roudot-Thoraval, F. (2021). Epidemiology of hepatitis C virus infection. *Clinics and Research in Hepatology and Gastroenterology*, *45*(3), 101596. https://doi.org/10.1016/j.clinre.2020.101596.

[109] Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., et al. (2021). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. *The New England Journal of Medicine*, *385*(17), 1559–1569. https://doi.org/10.1056/NEJMoa2029349.

[110] Schäffer, A. A., Dominguez, D. A., Chapman, L. M., Gertz, E. M., Budhu, A., Forgues, M., et al. (2021). Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis. *BMC Genomics*, *22*(1), 814. https://doi.org/10.1186/s12864-021-08098-9.

[111] Schwabe, R. F., & Greten, T. F. (2020). Gut microbiome in HCC—Mechanisms, diagnosis and therapy. *Journal of Hepatology*, *72*(2), 230–238. https://doi.org/10.1016/j.jhep.2019.08.016.

[112] Sharma, S. A., Kowgier, M., Hansen, B. E., Brouwer, W. P., Maan, R., Wong, D., et al. (2017). Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. *Journal of Hepatology*. https://doi.org/10.1016/j.jhep.2017.07.033.

[113] Shinkai, N., Nojima, M., Iio, E., Matsunami, K., Toyoda, H., Murakami, S., et al. (2018). High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. *Journal of Gastroenterology*, *53*(7), 883–889. https://doi.org/10.1007/s00535-017-1424-0.

[114] Simmons, O. L., Feng, Y., Parikh, N. D., & Singal, A. G. (2019). Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. *Clinical Gastroenterology and Hepatology*, *17*(4), 766–773. https://doi.org/10.1016/j.cgh.2018.07.029.

[115] Simon, T. G., & Chan, A. T. (2020). Lifestyle and environmental approaches for the primary prevention of hepatocellular carcinoma. *Clinics in Liver Disease*, *24*(4), 549–576. https://doi.org/10.1016/j.cld.2020.06.002.

[116] Simon, T. G., Roelstraete, B., Sharma, R., Khalili, H., Hagstrom, H., & Ludvigsson, J. F. (2021). Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: A population-based cohort study. *Hepatology*, *74*(5), 2410–2423. https://doi.org/10.1002/hep.31845.

[117] Singal, A. G., & El-Serag, H. B. (2021). Rational screening approaches for HCC in NAFLD patients. *Journal of Hepatology*. https://doi.org/10.1016/j.jhep.2021.08.028.

[118] Singal, A. G., Manjunath, H., Yopp, A. C., Beg, M. S., Marrero, J. A., Gopal, P., et al. (2014). The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: A meta-analysis. *The American Journal of Gastroenterology*, *109*(3), 325–334. https://doi.org/10.1038/ajg.2013.476.

[119] Singal, A. G., Mukherjee, A., Elmunzer, B. J., Higgins, P. D., Lok, A. S., Zhu, J., et al. (2013). Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. *The American Journal of Gastroenterology*, *108*(11), 1723–1730. https://doi.org/10.1038/ajg.2013.332.

[120] Singal, A. G., Tiro, J. A., Murphy, C. C., Blackwell, J. M., Kramer, J. R., Khan, A., et al. (2021). Patient-reported barriers are associated with receipt of hepatocellular carcinoma surveillance in a multicenter cohort of patients with cirrhosis. *Clinical Gastroenterology and Hepatology*, *19*(5), 987–995.e981. https://doi.org/10.1016/j.cgh.2020.06.049.

[121] Sinn, D. H., Kang, D., Cho, S. J., Paik, S. W., Guallar, E., Cho, J., et al. (2020). Risk of hepatocellular carcinoma in individuals without traditional risk factors: Development and validation of a novel risk score. *International Journal of Epidemiology*, *49*(5), 1562–1571. https://doi.org/10.1093/ije/dyaa089.

[122] Sinn, D. H., Lee, J. H., Kim, K., Ahn, J. H., Lee, J. H., Kim, J. H., et al. (2017). A novel model for predicting hepatocellular carcinoma development in patients with chronic hepatitis B and Normal alanine aminotransferase levels. *Gut and Liver*, *11*(4), 528–534. https://doi.org/10.5009/gnl16403.

[123] Sohn, W., Cho, J. Y., Kim, J. H., Lee, J. I., Kim, H. J., Woo, M. A., et al. (2017). Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. *Clinical and Molecular Hepatology*, *23*(2), 170–178. https://doi.org/10.3350/cmh.2016.0086.

[124] Stepien, M., Keski-Rahkonen, P., Kiss, A., Robinot, N., Duarte-Salles, T., Murphy, N., et al. (2021). Metabolic perturbations prior to hepatocellular carcinoma diagnosis: Findings from a prospective observational cohort study. *International Journal of Cancer*, *148*(3), 609–625. https://doi.org/10.1002/ijc.33236.

[125] Stickel, F., Lutz, P., Buch, S., Nischalke, H. D., Silva, I., Rausch, V., et al. (2020). Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers. *Hepatology*, *72*(1), 88–102. https://doi.org/10.1002/hep.30996.

[126] Strnad, P., McElvaney, N. G., & Lomas, D. A. (2020). Alpha(1)-antitrypsin deficiency. *The New England Journal of Medicine*, *382*(15), 1443–1455. https://doi.org/10.1056/NEJMra1910234.

[127] Su, F., Weiss, N. S., Beste, L. A., Moon, A. M., Jin, G. Y., Green, P., et al. (2021). Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B. *Journal of Hepatology*, *74*(4), 850–859. https://doi.org/10.1016/j.jhep.2020.11.023.

[128] Suh, B., Park, S., Shin, D. W., Yun, J. M., Yang, H. K., Yu, S. J., et al. (2015). High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. *Hepatology*, *61*(4), 1261–1268. https://doi.org/10.1002/hep.27654.

[129] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209–249. https://doi.org/10.3322/caac.21660.

[130] Tang, S., Zhang, J., Mei, T. T., Guo, H. Q., Wei, X. H., Zhang, W. Y., et al. (2019). Association of TM6SF2 rs58542926 T/C gene polymorphism with hepatocellular carcinoma: A meta-analysis. *BMC Cancer*, *19*(1), 1128. https://doi.org/10.1186/s12885-019-6173-4.

[131] Thilakarathna, W., Rupasinghe, H. P. V., & Ridgway, N. D. (2021). Mechanisms by which probiotic bacteria attenuate the risk of hepatocellular carcinoma. *International Journal of Molecular Sciences*, *22*(5). https://doi.org/10.3390/ijms22052606.

[132] Thylur, R. P., Roy, S. K., Shrivastava, A., LaVeist, T. A., Shankar, S., & Srivastava, R. K. (2020). Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. *JGH Open* , *4*(3), 351–359. https://doi.org/10.1002/jgh3.12336.

[133] Trépo, E., Caruso, S., Yang, J., Imbeaud, S., Couchy, G., Bayard, Q., et al. (2021). Common genetic variation in alcohol-related hepatocellular carcinoma: A case-control genome-wide association study. *The Lancet Oncology*. https://doi.org/10.1016/s1470-2045(21)00603-3.

[134] Tseng, T. C., Peng, C. Y., Hsu, Y. C., Su, T. H., Wang, C. C., Liu, C. J., et al. (2020). Baseline mac-2 binding protein glycosylation isomer level stratifies risks of hepatocellular carcinoma in chronic hepatitis B patients with oral antiviral therapy. *Liver Cancer*, *9*(2), 207–220. https://doi.org/10.1159/000504650.

[135] Verhelst, X., Vanderschaeghe, D., Castéra, L., Raes, T., Geerts, A., Francoz, C., et al. (2017). A glycomics-based test predicts the development of hepatocellular carcinoma in cirrhosis. *Clinical Cancer Research*, *23*(11), 2750–2758. https://doi.org/10.1158/1078-0432.ccr-16-1500.

[136] Voulgaris, T., Papatheodoridi, M., Lampertico, P., & Papatheodoridis, G. V. (2020). Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. *Liver International*, *40* (3), 484–495. https://doi.org/10.1111/liv.14334.

[137] Wang, C., Hann, H.-W., Ye, Z., Hann, R. S., Wan, S., Ye, X., et al. (2016). Prospective evidence of a circulating microRNA signature as a non-invasive marker of hepatocellular carcinoma in HBV patients. *Oncotarget*. Retrieved from https://www.oncotarget.com/article/9429/.

[138] Wang, B., Rudnick, S., Cengia, B., & Bonkovsky, H. L. (2019). Acute hepatic porphyrias: Review and recent progress. *Hepatology Communications*, *3*(2), 193–206. https://doi.org/10.1002/hep4.1297.

[139] Wolf, E., Rich, N. E., Marrero, J. A., Parikh, N. D., & Singal, A. G. (2021). Use of hepatocellular carcinoma surveillance in patients with cirrhosis: A systematic review and meta-analysis. *Hepatology*, *73*(2), 713–725. https://doi.org/10.1002/hep.31309.

[140] Wong, V. W., Chan, S. L., Mo, F., Chan, T. C., Loong, H. H., Wong, G. L., et al. (2010). Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. *Journal of Clinical Oncology*, *28*(10), 1660–1665. https://doi.org/10.1200/jco.2009.26.2675.

[141] Wong, G. L., Chan, H. L., Wong, C. K., Leung, C., Chan, C. Y., Ho, P. P., et al. (2014). Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. *Journal of Hepatology*, *60*(2), 339–345. https://doi.org/10.1016/j.jhep.2013.09.029.

[142] Woolen, S. A., Singal, A. G., Davenport, M. S., Troost, J. P., Khalatbari, S., Mittal, S., et al. (2021). Patient preferences for hepatocellular carcinoma surveillance parameters. *Clinical Gastroenterology and Hepatology*. https://doi.org/10.1016/j.cgh.2021.02.024.

[143] World Health Organization. (2021). *Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021*. Retrieved from http://apps.who.int/iris/bitstream/handle/10665/342813/9789240030992-eng.pdf.

[144] Wu, H. C., Yang, H. I., Wang, Q., Chen, C. J., & Santella, R. M. (2017). Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population. *Carcinogenesis*, *38*(10), 1021–1028. https://doi.org/10.1093/carcin/bgx078.

[145] Xu, J., Zhan, Q., Fan, Y., Lo, E. K. K., Zhang, F., Yu, Y., et al. (2021). Clinical aspects of gut microbiota in hepatocellular carcinoma management. *Pathogens*, *10*(7). https://doi.org/10.3390/pathogens10070782.

[146] Yamasaki, K., Tateyama, M., Abiru, S., Komori, A., Nagaoka, S., Saeki, A., et al. (2014). Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. *Hepatology*, *60*(5), 1563−1570. https://doi.org/10.1002/hep.27305.

[147] Yamashita, T., Koshikawa, N., Shimakami, T., Terashima, T., Nakagawa, M., Nio, K., et al. (2021). Serum laminin γ2 monomer as a diagnostic and predictive biomarker for hepatocellular carcinoma. *Hepatology*, *74*(2), 760−775. https://doi.org/10.1002/hep.31758.

[148] Yang, J. D., Kim, W. R., Coelho, R., Mettler, T. A., Benson, J. T., Sanderson, S. O., et al. (2011). Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. *Clinical Gastroenterology and Hepatology*, *9*(1), 64–70. https://doi.org/10.1016/j.cgh.2010.08.019.

[149] Yang, H. I., Sherman, M., Su, J., Chen, P. J., Liaw, Y. F., Iloeje, U. H., et al. (2010). Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. *Journal of Clinical Oncology*, *28*(14), 2437–2444. https://doi.org/10.1200/jco.2009.27.4456.

[150] Yang, H. I., Yeh, M. L., Wong, G. L., Peng, C. Y., Chen, C. H., Trinh, H. N., et al. (2020). Real-world effectiveness from the Asia Pacific rim liver consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy. *The Journal of Infectious Diseases*, *221*(3), 389–399. https://doi.org/10.1093/infdis/jiz477.

[151] Yang, H. I., Yuen, M. F., Chan, H. L., Han, K. H., Chen, P. J., Kim, D. Y., et al. (2011). Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score. *The Lancet Oncology*, *12*(6), 568−574. https://doi.org/10.1016/s1470-2045(11)70077-8.

[152] Yeo, Y. H., & Nguyen, M. H. (2021). Review article: Current gaps and opportunities in HBV prevention, testing and linkage to care in the United States-a call for action. *Alimentary Pharmacology & Therapeutics*, *53*(1), 63−78. https://doi.org/10.1111/apt.16125.

[153] Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., et al. (2019). Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology* , *69*(6), 2672–2682. https://doi.org/10.1002/hep.30251.

[154] Yousafzai, M. T., Bajis, S., Alavi, M., Grebely, J., Dore, G. J., & Hajarizadeh, B. (2021). Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis. *Journal of Viral Hepatitis*, *28*(10), 1340–1354. https://doi.org/10.1111/jvh.13574.

[155] Yu, J. H., Suh, Y. J., Jin, Y. J., Heo, N. Y., Jang, J. W., You, C. R., et al. (2019). Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir. *European Journal of Gastroenterology & Hepatology*, *31*(7), 865–872. https://doi.org/10.1097/meg.0000000000001357.

[156] Yuan, J. M., Wang, Y., Wang, R., Luu, H. N., Adams-Haduch, J., Koh, W. P., et al. (2021). Serum IL27 in relation to risk of hepatocellular carcinoma in two nested case-control studies. *Cancer Epidemiology, Biomarkers & Prevention*, *30*(2), 388−395. https://doi.org/10.1158/1055-9965.epi-20-1081.

[157] Yuen, M. F., Tanaka, Y., Fong, D. Y., Fung, J., Wong, D. K., Yuen, J. C., et al. (2009). Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. *Journal of Hepatology*, *50*(1), 80−88. https://doi.org/10.1016/j.jhep.2008.07.023.

[158] Zhang, D. Y., Goossens, N., Guo, J., Tsai, M. C., Chou, H. I., Altunkaynak, C., et al. (2016). A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. *Gut*, *65*(10), 1754–1764. https://doi.org/10.1136/gutjnl-2015-309655.

[159] Zhang, L., Xu, K., Liu, C., & Chen, J. (2017). Meta-analysis reveals an association between signal transducer and

activator of transcription-4 polymorphism and hepatocellular carcinoma risk. *Hepatology Research*, *47*(4), 303–311. https://doi.org/10.1111/hepr.12733.

[160] Zhao, C., & Nguyen, M. H. (2016). Hepatocellular carcinoma screening and surveillance: Practice guidelines and real-life practice. *Journal of Clinical Gastroenterology*, *50*(2), 120–133. https://doi.org/10.1097/mcg.0000000000000446.

[161] Zheng, R., Wang, G., Pang, Z., Ran, N., Gu, Y., Guan, X., et al. (2020). Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma. *Cancer Medicine*, *9*(12), 4232–4250. https://doi.org/10.1002/cam4.3045.

[162] Zhou, A., Tang, L., Zeng, S., Lei, Y., Yang, S., & Tang, B. (2020). Gut microbiota: A new piece in understanding hepatocarcinogenesis. *Cancer Letters*, *474*, 15–22. https://doi.org/10.1016/j.canlet.2020.01.002.

[163] Zhu, M., Lu, T., Jia, Y., Luo, X., Gopal, P., Li, L., et al. (2019). Somatic mutations increase hepatic clonal fitness and regeneration in chronic liver disease. *Cell*, *177*(3), 608–621.e612. https://doi.org/10.1016/j.cell.2019.03.026.

2 炎症通路与胆管癌风险机制及预防

[1] Affo, S., Nair, A., Brundu, F., Ravichandra, A., Bhattacharjee, S., Matsuda, M., et al. (2021). Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. *Cancer Cell*, *39*, 866–882. e11. https://doi.org/10.1016/j.ccell.2021.03.012.

[2] Affo, S., Yu, L. X., & Schwabe, R. F. (2017). The role of cancer-associated fibroblasts and fibrosis in liver cancer. *Annual Review of Pathology*, *12*, 153–186. https://doi.org/10.1146/annurev-pathol-052016-100322.

[3] Aishima, S., Kubo, Y., Tanaka, Y., & Oda, Y. (2014). Histological features of precancerous and early cancerous lesions of biliary tract carcinoma. *Journal of Hepato-Biliary-Pancreatic Sciences*, *21*, 448–452. https://doi.org/10.1002/jhbp.71.

[4] Aoki, S., Mizuma, M., Takahashi, Y., Haji, Y., Okada, R., Abe, T., et al. (2016). Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: Clinicopathological features and therapeutic potential for cancer stem cell-like properties. *BMC Cancer*, *16*, 854. https://doi.org/10.1186/s12885-016-2919-4.

[5] Aune, D., Sen, A., Norat, T., Riboli, E., & Folseraas, T. (2021). Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: A systematic review and meta-analysis of cohort studies. *Scientific Reports*, *11*, 10646. https://doi.org/10.1038/s41598-021-90175-w.

[6] Bajer, L., Kverka, M., Kostovcik, M., Macinga, P., Dvorak, J., Stehlikova, Z., et al. (2017). Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. *World Journal of Gastroenterology*, *23*, 4548–4558. https://doi.org/10.3748/wjg.v23.i25.4548.

[7] Banales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., et al. (2016). Expert consensus document: Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). *Nature Reviews. Gastroenterology & Hepatology*, *13*, 261–280. https://doi.org/10.1038/nrgastro.2016.51.

[8] Banales, J. M., Huebert, R. C., Karlsen, T., Strazzabosco, M., LaRusso, N. F., & Gores, G. J. (2019). Cholangiocyte pathobiology. *Nature Reviews. Gastroenterology & Hepatology*, *16*, 269–281. https://doi.org/10.1038/s41575-019-0125-y.

[9] Banales, J. M., Marin, J., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., et al. (2020). Cholangiocarcinoma 2020: The next horizon in mechanisms and management. *Nature Reviews. Gastroenterology & Hepatology*, *17*, 557–588. https://doi.org/10.1038/s41575-020-0310-z.

[10] Banales, J. M., Masyuk, T. V., Gradilone, S. A., Masyuk, A. I., Medina, J. F., & LaRusso, N. F. (2009). The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). *Hepatology*, *49*, 160–174. https://doi.org/10.1002/hep.22636.

[11] Basu, D., Reyes-Múgica, M., & Rebbaa, A. (2013). Histone acetylation-mediated regulation of the Hippo pathway. *PLoS One*, *8*, e62478. https://doi.org/10.1371/journal.pone.0062478.

[12] Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., & Bellentani, S. (2005). Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. *Hepatology*, *42*, 44–52. https://doi.org/10.1002/hep.20734.

[13] Bergenfelz, C., & Leandersson, K. (2020). The generation and identity of human myeloid-derived suppressor cells. *Frontiers in Oncology*, *10*, 109. https://doi.org/10.3389/fonc.2020.00109.

[14] Bjøro, K., Brandsaeter, B., Foss, A., & Schrumpf, E. (2006). Liver transplantation in primary sclerosing cholangitis. *Seminars in Liver Disease*, *26*, 69–79. https://doi.org/10.1055/s-2006-933565.

[15] Braconi, C., Huang, N., & Patel, T. (2010). MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor

suppressor gene expression by interleukin-6 in human malignant cholangiocytes. *Hepatology*, *51*, 881–890. https://doi.org/10.1002/hep.23381.

[16] Brindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A., Sirica, A. E., et al. (2021). Cholangiocarcinoma. *Nature Reviews. Disease Primers*, *7*, 65. https://doi.org/10.1038/s41572-021-00300-2.

[17] Brivio, S., Cadamuro, M., Strazzabosco, M., & Fabris, L. (2017). Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness. *World Journal of Hepatology*, *9*, 455–468. https://doi.org/10.4254/wjh.v9.i9.455.

[18] Cadamuro, M., Brivio, S., Stecca, T., Kaffe, E., Mariotti, V., Milani, C., et al. (2018). Animal models of cholangiocarcinoma: What they teach us about the human disease. *Clinics and Research in Hepatology and Gastroenterology*, *42*, 403–415. https://doi.org/10.1016/j.clinre.2018.04.008.

[19] Cadamuro, M., Lasagni, A., Lamarca, A., Fouassier, L., Guido, M., Sarcognato, S., et al. (2021). Targeted therapies for extrahepatic cholangiocarcinoma: Preclinical and clinical development and prospects for the clinic. *Expert Opinion on Investigational Drugs*, *30*, 377–388. https://doi.org/10.1080/13543784.2021.1880564.

[20] Cadamuro, M., Stecca, T., Brivio, S., Mariotti, V., Fiorotto, R., Spirli, C., et al. (2018). The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. *Biochimica et Biophysica Acta, Molecular Basis of Disease*, *1864*, 1435–1443. https://doi.org/10.1016/j.bbadis.2017.07.028.

[21] Cannito, S., Milani, C., Cappon, A., Parola, M., Strazzabosco, M., & Cadamuro, M. (2018). Fibroinflammatory liver injuries as preneoplastic condition in cholangiopathies. *International Journal of Molecular Sciences*, *19*, 3875. https://doi.org/10.3390/ijms19123875.

[22] Cardoso Alves, L., Corazza, N., Micheau, O., & Krebs, P. (2021). The multifaceted role of TRAIL signaling in cancer and immunity. *The FEBS Journal*, *288*, 5530–5554. https://doi.org/10.1111/febs.15637.

[23] Clements, O., Eliahoo, J., Kim, J. U., Taylor-Robinson, S. D., & Khan, S. A. (2020). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. *Journal of Hepatology*, *72*, 95–103. https://doi.org/10.1016/j.jhep.2019.09.007.

[24] Correia da Costa, J. M., Vale, N., Gouveia, M. J., Botelho, M. C., Sripa, B., Santos, L. L., et al. (2014). Schistosome and liver fluke derived catechol-estrogens and helminth associated cancers. *Frontiers in Genetics*, *5*, 444. https://doi.org/10.3389/fgene.2014.00444.

[25] Daorueang, D., Thuwajit, P., Roitrakul, S., Laha, T., Kaewkes, S., Endo, Y., et al. (2012). Secreted Opisthorchis viverrini glutathione S-transferase regulates cell proliferation through AKT and ERK pathways in cholangiocarcinoma. *Parasitology International*, *61*, 155–161. https://doi.org/10.1016/j.parint.2011.07.011.

[26] Dyson, J. K., Beuers, U., Jones, D., Lohse, A. W., & Hudson, M. (2018). Primary sclerosing cholangitis. *Lancet*, *391*, 2547–2559. https://doi.org/10.1016/S0140-6736(18)30300-3.

[27] El Khatib, M., Kalnytska, A., Palagani, V., Kossatz, U., Manns, M. P., Malek, N. P., et al. (2013). Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. *Hepatology*, *57*, 1035–1045. https://doi.org/10.1002/hep.26147.

[28] Endo, K., Yoon, B. I., Pairojkul, C., Demetris, A. J., & Sirica, A. E. (2002). ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. *Hepatology*, *36*, 439–450. https://doi.org/10.1053/jhep.2002.34435.

[29] Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., et al. (2019). The tumour microenvironment and immune milieu of cholangiocarcinoma. *Liver International*, *39*, 63–78. https://doi.org/10.1111/liv.14098.

[30] Fabris, L., Sato, K., Alpini, G., & Strazzabosco, M. (2021). The tumor microenvironment in cholangiocarcinoma progression. *Hepatology*, *73*, 75–85. https://doi.org/10.1002/hep.31410.

[31] Fedorova, O. S., Fedotova, M. M., Zvonareva, O. I., Mazeina, S. V., Kovshirina, Y. V., Sokolova, T. S., et al. (2020). Opisthorchis felineus infection, risks, and morbidity in rural Western Siberia, Russian Federation. *PLoS Neglected Tropical Diseases*, *14*, e0008421. https://doi.org/10.1371/journal.pntd.0008421.

[32] Fingas, C. D., Bronk, S. F., Werneburg, N. W., Mott, J. L., Guicciardi, M. E., Cazanave, S. C., et al. (2011). Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. *Hepatology*, *54*, 2076–2088. https://doi.org/10.1002/hep.24588.

[33] Fischer, D. C., Jacoby, U., Pape, L., Ward, C. J., Kuwertz-Broeking, E., Renken, C., et al. (2009). Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). *Nephrology, Dialysis, Transplantation*, *24*, 1819–1827. https://doi.org/10.1093/ndt/gfn744.

[34] Ge, Z., & Ding, S. (2020). The Crosstalk between tumor-associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy. *Frontiers in Oncology*, *10*, 590941. https://doi.org/10.3389/fonc.2020.590941.

[35] Goeppert, B., Frauenschuh, L., Zucknick, M., Stenzinger, A., Andrulis, M., Klauschen, F., et al. (2013). Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. *British Journal of Cancer*, *109*, 2665–2674. https://doi.org/10.1038/bjc.2013.610.

[36] Gradilone, S. A., Habringer, S., Masyuk, T. V., Howard, B. N., Masyuk, A. I., & Larusso, N. F. (2014). HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis. *The American Journal of Pathology*, *184*, 600–608. https://doi.org/10.1016/j.ajpath.2013.11.027.

[37] Harris, P. C., & Torres, V. E. (2009). Polycystic kidney disease. *Annual Review of Medicine*, *60*, 321–337. https://doi.org/10.1146/annurev.med.60.101707.125712.

[38] He, D., Li, H., Yusuf, N., Elmets, C. A., Athar, M., Katiyar, S. K., et al. (2012). IL-17 mediated inflammation promotes tumor growth and progression in the skin. *PLoS One*, *7*, e32126. https://doi.org/10.1371/journal.pone.0032126.

[39] Isomoto, H., Kobayashi, S., Werneburg, N. W., Bronk, S. F., Guicciardi, M. E., Frank, D. A., et al. (2005). Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. *Hepatology*, *42*, 1329–1338. https://doi.org/10.1002/hep.20966.

[40] Jaiswal, M., LaRusso, N. F., Burgart, L. J., & Gores, G. J. (2000). Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. *Cancer Research*, *60*, 184–190.

[41] Jaiswal, M., LaRusso, N. F., Shapiro, R. A., Billiar, T. R., & Gores, G. J. (2001). Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. *Gastroenterology*, *120*, 190–199. https://doi.org/10.1053/gast.2001.20875.

[42] Jiang, L., Sun, L., Edwards, G., Manley, M., Jr., Wallace, D. P., Septer, S., et al. (2017). Increased YAP activation is associated with hepatic cyst epithelial cell proliferation in ARPKD/CHF. *Gene Expression*, *17*, 313–326. https://doi.org/10.3727/105221617X15034976037343.

[43] Job, S., Rapoud, D., Dos Santos, A., Gonzalez, P., Desterke, C., Pascal, G., et al. (2020). Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. *Hepatology*, *72*, 965–981. https://doi.org/10.1002/hep.31092.

[44] Jung, I. H., Kim, D. H., Yoo, D. K., Baek, S. Y., Jeong, S. H., Jung, D. E., et al. (2018). In vivo study of natural killer (NK) cell cytotoxicity against cholangiocarcinoma in a nude mouse model. *In Vivo*, *32*, 771–781. https://doi.org/10.21873/invivo.11307.

[45] Junking, M., Grainok, J., Thepmalee, C., Wongkham, S., & Yenchitsomanus, P. T. (2017). Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA. *Tumour Biology*, *39*. https://doi.org/10.1177/1010428317733367. 1010428317733367.

[46] Karlsen, T. H. (2016). Primary sclerosing cholangitis: 50 years of a gut-liver relationship and still no love? *Gut*, *65*, 1579–1581. https://doi.org/10.1136/gutjnl-2016-312137.

[47] Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017). Primary sclerosing cholangitis—A comprehensive review. *Journal of Hepatology*, *67*, 1298–1323. https://doi.org/10.1016/j.jhep.2017.07.022.

[48] Karlsen, T. H., Franke, A., Melum, E., Kaser, A., Hov, J. R., Balschun, T., et al. (2010). Genome-wide association analysis in primary sclerosing cholangitis. *Gastroenterology*, *138*, 1102–1111. https://doi.org/10.1053/j.gastro.2009.11.046.

[49] Keiser, J., & Utzinger, J. (2005). Emerging foodborne trematodiasis. *Emerging Infectious Diseases*, *11*, 1507–1514. https://doi.org/10.3201/eid1110.050614.

[50] Khan, S. A., Toledano, M. B., & Taylor-Robinson, S. D. (2008). Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. *HPB (Oxford)*, *10*, 77–82. https://doi.org/10.1080/13651820801992641.

[51] Kim, H. J., Kim, J. S., Joo, M. K., Lee, B. J., Kim, J. H., Yeon, J. E., et al. (2015). Hepatolithiasis and intrahepatic cholangiocarcinoma: A review. *World Journal of Gastroenterology*, *21*, 13418–13431. https://doi.org/10.3748/wjg.v21.i48.13418.

[52] Kim, E. M., Kwak, Y. S., Yi, M. H., Kim, J. Y., Sohn, W. M., & Yong, T. S. (2017). Clonorchis sinensis antigens alter hepatic macrophage polarization in vitro and in vivo. *PLoS Neglected Tropical Diseases*, *11*, e0005614. https://doi.org/10.1371/journal.pntd.0005614.

[53] Kitano, Y., Okabe, H., Yamashita, Y. I., Nakagawa, S., Saito, Y., Umezaki, N., et al. (2018). Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma. *British Journal of Cancer*, *118*, 171–180. https://doi.org/10.1038/bjc.2017.401.

[54] Kobayashi, S., Werneburg, N. W., Bronk, S. F., Kaufmann, S. H., & Gores, G. J. (2005). Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. *Gastroenterology*, *128*, 2054–2065. https://doi.org/10.1053/j.gastro.2005.03.010.

[55] Kunzmann, L. K., Schoknecht, T., Poch, T., Henze, L., Stein, S., Kriz, M., et al. (2020). Monocytes as potential mediators of pathogen-induced T-helper 17 differentiation in patients with primary sclerosing cholangitis (PSC). *Hepatology*, *72*, 1310–1326. https://doi.org/10.1002/hep.31140.

[56] Lasagni, A., Cadamuro, M., Morana, G., Fabris, L., & Strazzabosco, M. (2021). Fibrocystic liver disease: Novel concepts and translational perspectives. *Translational Gastroenterology and Hepatology*, *6*, 26. https://doi.org/10.21037/tgh-2020-04.

[57] Lazaridis, K. N., & LaRusso, N. F. (2016). Primary sclerosing cholangitis. *The New England Journal of Medicine*, *375*, 1161−1170. https://doi.org/10.1056/NEJMra1506330.

[58] Lee, S. O., Masyuk, T., Splinter, P., Banales, J. M., Masyuk, A., Stroope, A., et al. (2008). MicroRNA15a modulates expression of the cell-cycle regulator Cdc 25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. *The Journal of Clinical Investigation*, *118*, 3714−3724. https://doi.org/10.1172/JCI34922.

[59] Leone, V., Ali, A., Weber, A., Tschaharganeh, D. F., & Heikenwalder, M. (2021). Liver inflammation and hepatobiliary cancers. *Trends in Cancer*, *7*, 606−623. https://doi.org/10.1016/j.trecan.2021.01.012.

[60] Lewis, J. (2017). Pathological patterns of biliary disease. *Clinical Liver Disease*, *10*, 107–110. https://doi.org/10.1002/cld.667.

[61] Li, J. S., Han, T. J., Jing, N., Li, L., Zhang, X. H., Ma, F. Z., et al. (2014). Obesity and the risk of cholangiocarcinoma: A meta-analysis. *Tumour Biology*, *35*, 6831–6838. https://doi.org/10.1007/s13277-014-1939-4.

[62] Liu, J. Z., Hov, J. R., Folseraas, T., Ellinghaus, E., Rushbrook, S. M., Doncheva, N. T., et al. (2013). Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nature Genetics*, *45*, 670–675. https://doi.org/10.1038/ng.2616.

[63] Locatelli, L., Cadamuro, M., Spirlì, C., Fiorotto, R., Lecchi, S., Morell, C. M., et al. (2016). Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. *Hepatology*, *63*, 965–982. https://doi.org/10.1002/hep.28382.

[64] Loeuillard, E., Conboy, C. B., Gores, G. J., & Rizvi, S. (2019). Immunobiology of cholangiocarcinoma. *JHEP Reports*, *1*, 297−311. https://doi.org/10.1016/j.jhepr.2019.06.003.

[65] Luo, J. L., Maeda, S., Hsu, L. C., Yagita, H., & Karin, M. (2004). Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. *Cancer Cell*, *6*, 297−305. https://doi.org/10.1016/j.ccr.2004.08.012.

[66] Maemura, K., Natsugoe, S., & Takao, S. (2014). Molecular mechanism of cholangiocarcinoma carcinogenesis. *Journal of Hepato-Biliary-Pancreatic Sciences*, *21*, 754–760. https://doi.org/10.1002/jhbp.126.

[67] Mariotti, V., Cadamuro, M., Spirli, C., Fiorotto, R., Strazzabosco, M., & Fabris, L. (2019). Animal models of cholestasis: An update on inflammatory cholangiopathies. *Biochimica et Biophysica Acta, Molecular Basis of Disease*, *1865*, 954–964. https://doi.org/10.1016/j.bbadis.2018.07.025.

[68] Marti, P., Stein, C., Blumer, T., Abraham, Y., Dill, M. T., Pikiolek, M., et al. (2015). YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEADtranscription factors. *Hepatology*, *62*, 1497–1510. https://doi.org/10.1002/hep.27992.

[69] Masucci, M. T., Minopoli, M., & Carriero, M. V. (2019). Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. *Frontiers in Oncology*, *9*, 1146. https://doi.org/10.3389/fonc.2019.01146.

[70] Masyuk, T. V., Radtke, B. N., Stroope, A. J., Banales, J. M., Masyuk, A. I., Gradilone, S. A., et al. (2012). Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. *Gastroenterology*, *142*, 622−633. e4. https://doi.org/10.1053/j.gastro.2011.11.036.

[71] Matsumoto, K., Onoyama, T., Kawata, S., Takeda, Y., Harada, K., Ikebuchi, Y., et al. (2014). Hepatitis B and C virus infection is a risk factor for the development of cholangiocarcinoma. *Internal Medicine*, *53*, 651−654. https://doi.org/10.2169/internalmedicine.53.1410.

[72] Matsumoto, S., Yamamoto, K., Nagano, T., Okamoto, R., Ibuki, N., Tagashira, M., et al. (1999). Immunohistochemical study on phenotypical changes of hepatocytes in liver disease with reference to extracellular matrix composition. *Liver*, *19*, 32–38. https://doi.org/10.1111/j.1478-3231.1999.tb00006.x.

[73] McGee, E. E., Jackson, S. S., Petrick, J. L., Van Dyke, A. L., Adami, H. O., Albanes, D., et al. (2019). Smoking, alcohol,

and biliary tract cancer risk: A pooling project of 26 prospective studies. *Journal of the National Cancer Institute*, *111*, 1263–1278. https://doi.org/10.1093/jnci/djz103.

[74] Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., et al. (2013). Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. *Nature Communications*, *4*, 2823. https://doi.org/10.1038/ncomms3823.

[75] Mells, G. F., Kaser, A., & Karlsen, T. H. (2013). Novel insights into autoimmune liver diseases provided by genome-wide association studies. *Journal of Autoimmunity*, *46*, 41–54. https://doi.org/10.1016/j.jaut.2013.07.004.

[76] Melum, E., Franke, A., Schramm, C., Weismüller, T. J., Gotthardt, D. N., Offner, F. A., et al. (2011). Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. *Nature Genetics*, *43*(1), 17–19. https://doi.org/10.1038/ng.728.

[77] Meng, F., Henson, R., Wehbe-Janek, H., Smith, H., Ueno, Y., & Patel, T. (2007). The microRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. *The Journal of Biological Chemistry*, *282*, 8256–8264. https://doi.org/10.1074/jbc.M607712200.

[78] Michelotti, A., de Scordilli, M., Palmero, L., Guardascione, M., Masala, M., Roncato, R., et al. (2021). NAFLD-related hepatocarcinoma: The malignant side of metabolic syndrome. *Cell*, *10*, 2034. https://doi.org/10.3390/cells10082034.

[79] Montal, R., Sia, D., Montironi, C., Leow, W. Q., Esteban-Fabró , R., Pinyol, R., et al. (2020). Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. *Journal of Hepatology*, *73*, 315–327. https://doi.org/10.1016/j.jhep.2020.03.008.

[80] Morrison, C. D., Parvani, J. G., & Schiemann, W. P. (2013). The relevance of the TGF-β paradox to EMT-MET programs. *Cancer Letters*, *341*, 30–40. https://doi.org/10.1016/j.canlet.2013.02.048.

[81] Nachtergaele, S., Mydock, L. K., Krishnan, K., Rammohan, J., Schlesinger, P. H., Covey, D. F., et al. (2012). Oxysterols are allosteric activators of the oncoprotein smoothened. *Nature Chemical Biology*, *8*, 211–220. https://doi.org/10.1038/nchembio.765.

[82] Nguyen, C. T., Caruso, S., Maille, P., Beaufrere, A., Augustin, J., Favre, L., et al. (2021). Immune profiling of combined hepatocellular-cholangiocarcinoma reveals distinct subtypes and activation of gene signatures predictive of response to immunotherapy. *Clinical Cancer Research*. https://doi.org/10.1158/1078-0432.CCR-21-1219. doi: 10.1158/1078-0432.CCR-21-1219.

[83] Ninlawan, K., O'Hara, S. P., Splinter, P. L., Yongvanit, P., Kaewkes, S., Surapaitoon, A., et al. (2010). Opisthorchis viverrini excretory/secretory products induce toll-like receptor 4 upregulation and production of interleukin 6 and 8 in cholangiocyte. *Parasitology International*, *59*, 616–621. https://doi.org/10.1016/j.parint.2010.09.008.

[84] Nusse, R., & Clevers, H. (2017). Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. *Cell*, *169*, 985–999. https://doi.org/10.1016/j.cell.2017.05.016.

[85] Ohshima, H., Sawa, T., & Akaike, T. (2006). 8-nitroguanine, a product of nitrative DNA damage caused by reactive nitrogen species: Formation, occurrence, and implications in inflammation and carcinogenesis. *Antioxidants & Redox Signaling*, *8*, 1033–1045. https://doi.org/10.1089/ars.2006.8.1033.

[86] Okabe, H., Beppu, T., Ueda, M., Hayashi, H., Ishiko, T., Masuda, T., et al. (2012). Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts. *International Journal of Cancer*, *131*, 2234–2241. https://doi.org/10.1002/ijc.27496.

[87] Özdirik, B., Müller, T., Wree, A., Tacke, F., & Sigal, M. (2021). The role of microbiota in primary sclerosing cholangitis and related biliary malignancies. *International Journal of Molecular Sciences*, *22*, 6975. https://doi.org/10.3390/ijms22136975.

[88] Palmer, W. C., & Patel, T. (2012). Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. *Journal of Hepatology*, *57*, 69–76. https://doi.org/10.1016/j.jhep.2012.02.022.

[89] Panya, A., Thepmalee, C., Sawasdee, N., Sujjitjoon, J., Phanthaphol, N., Junking, M., et al. (2018). Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells. *Cancer Immunology, Immunotherapy*, *67*, 1579–1588. https://doi.org/10.1007/s00262-018-2212-2.

[90] Park, J., Tadlock, L., Gores, G. J., & Patel, T. (1999). Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. *Hepatology*, *30*, 1128–1133. https://doi.org/10.1002/hep.510300522.

[91] Pech, L., Favelier, S., Falcoz, M. T., Loffroy, R., Krause, D., & Cercueil, J. P. (2016). Imaging of Von Meyenburg

complexes. *Diagnostic and Interventional Imaging*, *97*, 401–409. https://doi.org/10.1016/j.diii.2015.05.012.

[92] Perugorria, M. J., Olaizola, P., Labiano, I., Esparza-Baquer, A., Marzioni, M., Marin, J., et al. (2019). Wnt-β-catenin signalling in liver development, health and disease. *Nature Reviews. Gastroenterology & Hepatology*, *16*, 121–136. https://doi.org/10.1038/s41575-018-0075-9.

[93] Petrick, J. L., Yang, B., Altekruse, S. F., Van Dyke, A. L., Koshiol, J., Graubard, B. I., et al. (2017). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare. *PLoS One*, *12*, e0186643. https://doi.org/10.1371/journal.pone.0186643.

[94] Piccolo, S., Dupont, S., & Cordenonsi, M. (2014). The biology of YAP/TAZ: Hippo signaling and beyond. *Physiological Reviews*, *94*, 1287–1312. https://doi.org/10.1152/physrev.00005.2014.

[95] Pinto, C., Giordano, D. M., Maroni, L., & Marzioni, M. (2018). Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology. *Biochimica et Biophysica Acta, Molecular Basis of Disease*, *1864*, 1270−1278. https://doi.org/10.1016/j.bbadis.2017.07.024.

[96] Pontecorvi, V., Carbone, M., & Invernizzi, P. (2016). The “gut microbiota” hypothesis in primary sclerosing cholangitis. *Annals of Translational Medicine*, *4*, 512. https://doi.org/10.21037/atm.2016.12.43.

[97] Prueksapanich, P., Piyachaturawat, P., Aumpansub, P., Ridtitid, W., Chaiteerakij, R., & Rerknimitr, R. (2018). Liver fluke-associated biliary tract cancer. *Gut and Liver*, *12*, 236–245. https://doi.org/10.5009/gnl17102.

[98] Puthdee, N., Sriswasdi, S., Pisitkun, T., Ratanasirintrawoot, S., Israsena, N., & Tangkijvanich, P. (2021). The LIN28B/TGF-β/TGFBI feedback loop promotes cell migration and tumour initiation potential in cholangiocarcinoma. *Cancer Gene Therapy*. https://doi.org/10.1038/s41417-021-00387-5. doi:10.1038/s41417-021-00387-5.

[99] Qian, M. B., Utzinger, J., Keiser, J., & Zhou, X. N. (2016). Clonorchiasis. *Lancet*, *387*, 800–810. https://doi.org/10.1016/S0140-6736(15)60313-0.

[100] Raggi, C., Correnti, M., Sica, A., Andersen, J. B., Cardinale, V., Alvaro, D., et al. (2017). Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. *Journal of Hepatology*, *66*, 102–115. https://doi.org/10.1016/j.jhep.2016.08.012.

[101] Reddy, S. K., Hyder, O., Marsh, J. W., Sotiropoulos, G. C., Paul, A., Alexandrescu, S., et al. (2013). Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. *Journal of Gastrointestinal Surgery*, *17*, 748–755. https://doi.org/10.1007/s11605-013-2149-x.

[102] Rimassa, L., Personeni, N., Aghemo, A., & Lleo, A. (2019). The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. *Journal of Autoimmunity*, *100* , 17–26. https://doi.org/10.1016/j.jaut.2019.03.007.

[103] Rizvi, S., & Gores, G. J. (2013). Pathogenesis, diagnosis, and management of cholangiocarcinoma. *Gastroenterology*, *145*, 1215−1229. https://doi.org/10.1053/j.gastro.2013.10.013.

[104] Rizvi, S., Yamada, D., Hirsova, P., Bronk, S. F., Werneburg, N. W., Krishnan, A., et al. (2016). A Hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma. *The Journal of Biological Chemistry*, *291*, 8031–8047. https://doi.org/10.1074/jbc.M115.698472.

[105] Rodrigues, P. M., Olaizola, P., Paiva, N. A., Olaizola, I., Agirre-Lizaso, A., Landa, A., et al. (2021). Pathogenesis of cholangiocarcinoma. *Annual Review of Pathology*, *16*, 433–463. https://doi.org/10.1146/annurev-pathol-030220-020455.

[106] Rohatgi, R., Battini, L., Kim, P., Israeli, S., Wilson, P. D., Gusella, G. L., et al. (2008). Mechanoregulation of intracellular Ca2+ in human autosomal recessive polycystic kidney disease cyst-lining renal epithelial cells. *American Journal of Physiology. Renal Physiology*, *294*, F890–F899. https://doi.org/10.1152/ajprenal.00341.2007.

[107] Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B., & Lemke, G. (2007). TAM receptors are pleiotropic inhibitors of the innate immune response. *Cell*, *131*, 1124–1136. https://doi.org/10.1016/j.cell.2007.10.034.

[108] Sarcognato, S., Sacchi, D., Fassan, M., Fabris, L., Cadamuro, M., Zanus, G., et al. (2021). Cholangiocarcinoma. *Pathologica*, *113*, 158–169. https://doi.org/10.32074/1591-951X-252.

[109] Sasaki, M., & Nakanuma, Y. (2016). New concept: Cellular senescence in pathophysiology of cholangiocarcinoma. *Expert Review of Gastroenterology & Hepatology*, *10*, 625−638. https://doi.org/10.1586/17474124.2016.1133291.

[110] Schwabe, R. F., & Greten, T. F. (2020). Gut microbiome in HCC—Mechanisms, diagnosis and therapy. *Journal of Hepatology*, *72*, 230−238. https://doi.org/10.1016/j. jhep.2019.08.016.

[111] Sekiya, S., & Suzuki, A. (2012). Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. *The Journal of Clinical Investigation*, *122*, 3914–3918. https://doi.org/10.1172/JCI63065.

[112] Seo, J. W., Kwan, B. S., Cheon, Y. K., Lee, T. Y., Shim, C. S., Kwon, S. Y., et al. (2020). Prognostic impact of hepatitis B or C on intrahepatic cholangiocarcinoma. *The Korean Journal of Internal Medicine*, *35*, 566−573. https://doi.

org/10.3904/kjim.2018.062.

[113] Shoda, J., Ueda, T., Kawamoto, T., Todoroki, T., Asano, T., Sugimoto, Y., et al. (2003). Prostaglandin E receptors in bile ducts of hepatolithiasis patients and the pathobiological significance for cholangitis. *Clinical Gastroenterology and Hepatology*, *1*, 285–296.

[114] Sia, D., Hoshida, Y., Villanueva, A., Roayaie, S., Ferrer, J., Tabak, B., et al. (2013). Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. *Gastroenterology*, *144*, 829–840. https://doi.org/10.1053/j.gastro.2013.01.001.

[115] Simbolo, M., Bersani, S., Vicentini, C., Taormina, S. V., Ciaparrone, C., Bagante, F., et al. (2021). Molecular characterization of extrahepatic cholangiocarcinoma: Perihilar and distal tumors display divergent genomic and transcriptomic profiles. *Expert Opinion on Therapeutic Targets*, *25*, 1095–1105. https://doi.org/10.1080/14728222.2021.2013801.

[116] Sirica, A. E. (2005). Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy. *Hepatology*, *41*, 5–15. https://doi.org/10.1002/hep.20537.

[117] Sirica, A. E. (2011). The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. *Nature Reviews. Gastroenterology & Hepatology*, *9*, 44–54. https://doi.org/10.1038/nrgastro.2011.222.

[118] Sirica, A. E., Gores, G. J., Groopman, J. D., Selaru, F. M., Strazzabosco, M., Wei Wang, X., et al. (2019). Intrahepatic cholangiocarcinoma: Continuing challenges and translational advances. *Hepatology*, *69*, 1803–1815. https://doi.org/10.1002/hep.30289.

[119] Sirica, A. E., Strazzabosco, M., & Cadamuro, M. (2021). Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. *Advances in Cancer Research*, *149*, 321–387. https://doi.org/10.1016/bs.acr.2020.10.005.

[120] Smoot, R. L., Werneburg, N. W., Sugihara, T., Hernandez, M. C., Yang, L., Mehner, C., et al. (2018). Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation. *Journal of Cellular Biochemistry*, *119*, 824–836. https://doi.org/10.1002/jcb.26246.

[121] Smout, M. J., Laha, T., Mulvenna, J., Sripa, B., Suttiprapa, S., Jones, A., et al. (2009). A granulin-like growth factor secreted by the carcinogenic liver fluke, Opisthorchis viverrini, promotes proliferation of host cells. *PLoS Pathogens*, *5*, e1000611. https://doi.org/10.1371/journal.ppat.1000611.

[122] Smout, M. J., Mulvenna, J. P., Jones, M. K., & Loukas, A. (2011). Expression, refolding and purification of Ov-GRN-1, a granulin-like growth factor from the carcinogenic liver fluke, that causes proliferation of mammalian host cells. *Protein Expression and Purification*, *79*, 263–270. https://doi.org/10.1016/j.pep.2011.06.018.

[123] Spirlì, C., Fabris, L., Duner, E., Fiorotto, R., Ballardini, G., Roskams, T., et al. (2003). Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMPdependent secretion in cholangiocytes. *Gastroenterology*, *124*, 737–753. https://doi.org/10.1053/gast.2003.50100.

[124] Sripa, B., Kaewkes, S., Intapan, P. M., Maleewong, W., & Brindley, P. J. (2010). Food-borne trematodiases in Southeast Asia epidemiology, pathology, clinical manifestation and control. *Advances in Parasitology*, *72*, 305–350. https://doi.org/10.1016/S0065-308X(10)72011-X.

[125] Strazzabosco, M., &Fabris, L. (2012). Development of the bile ducts: essentials for the clinical hepatologist. *Journal of Hepatology*, *56*, 1159–1170. https://doi.org/10.1016/j.jhep.2011.09.022.

[126] Sugihara, T., Isomoto, H., Gores, G., & Smoot, R. (2019). YAP and the Hippo pathway in cholangiocarcinoma. *Journal of Gastroenterology*, *54*, 485–491. https://doi.org/10.1007/s00535-019-01563-z.

[127] Sugiura, K., Mishima, T., Takano, S., Yoshitomi, H., Furukawa, K., Takayashiki, T., et al. (2019). The expression of Yes-associated protein (YAP) maintains putative cancer stemness and is associated with poor prognosis in intrahepatic cholangiocarcinoma. *The American Journal of Pathology*, *189*, 1863–1877. https://doi.org/10.1016/j.ajpath. 2019.05.014.

[128] Suksawat, M., Techasen, A., Namwat, N., Boonsong, T., Titapun, A., Ungarreevittaya, P., et al. (2018). Inhibition of endothelial nitric oxide synthase in cholangiocarcinoma cell lines—A new strategy for therapy. *FEBS Open Bio*, *8*, 513–522. https://doi.org/10.1002/2211-5463.12388.

[129] Suksawat, M., Techasen, A., Namwat, N., Yongvanit, P., Khuntikeo, N., Titapun, A., et al. (2017). Upregulation of endothelial nitric oxide synthase (eNOS) and its upstream regulators in Opisthorchis viverrini associated cholangiocarcinoma and its clinical significance. *Parasitology International*, *66*, 486–493. https://doi.org/10.1016/j.parint. 2016.04.008.

[130] Sun, D., Luo, T., Dong, P., Zhang, N., Chen, J., Zhang, S., et al. (2020). CD86+/CD206+tumor-associated macrophages

predict prognosis of patients with intrahepatic cholangiocarcinoma. *PeerJ* , *8*, e 8458. https://doi.org/10.7717/peerj.8458.

[131] Suttiprapa, S., Matchimakul, P., Loukas, A., Laha, T., Wongkham, S., Kaewkes, S., et al. (2012). Molecular expression and enzymatic characterization of thioredoxin from the carcinogenic human liver fluke Opisthorchis viverrini. *Parasitology International*, *61*, 101–106. https://doi.org/10.1016/j.parint.2011.06.018.

[132] Tadlock, L., & Patel, T. (2001). Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. *Hepatology*, *33*, 43–51. https://doi.org/10.1053/jhep.2001.20676.

[133] Tang, Q., Li, J., Zhu, H., Li, P., Zou, Z., & Xiao, Y. (2013). Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. *Mediators of Inflammation*, *2013*, 713859. https://doi.org/10.1155/2013/713859.

[134] Techasen, A., Namwat, N., Loilome, W., Duangkumpha, K., Puapairoj, A., Saya, H., et al. (2014). Tumor necrosis factor-α modulates epithelial mesenchymal transition mediators ZEB2 and S100A4 to promote cholangiocarcinoma progression. *Journal of Hepato-Biliary-Pancreatic Sciences*, *21*, 703−711. https://doi.org/10.1002/jhbp.125.

[135] Trivedi, P. J., & Adams, D. H. (2013). Mucosal immunity in liver autoimmunity: A comprehensive review. *Journal of Autoimmunity*, *46*, 97−111. https://doi.org/10.1016/j.jaut.2013.06.013.

[136] Tsunoda, T., Kakinuma, S., Miyoshi, M., Kamiya, A., Kaneko, S., Sato, A., et al. (2019). Loss of fibrocystin promotes interleukin-8-dependent proliferation and CTGF- production of biliary epithelium. *Journal of Hepatology*, *71*, 143−152. https://doi.org/10.1016/j. jhep.2019.02.024.

[137] Tyson, G. L., & El-Serag, H. B. (2011). Risk factors for cholangiocarcinoma. *Hepatology*, *54*, 173–184. https://doi.org/10.1002/hep.24351.

[138] Vale, N., Gouveia, M. J., Gärtner, F., & Brindley, P. J. (2020). Oxysterols of helminth parasites and pathogenesis of foodborne hepatic trematodiasis caused by Opisthorchis and Fasciola species. *Parasitology Research*, *119*, 1443–1453. https://doi.org/10.1007/s00436-020-06640-4.

[139] Vaquero, J., Aoudjehane, L., & Fouassier, L. (2020). Cancer-associated fibroblasts in cholangiocarcinoma. *Current Opinion in Gastroenterology*, *36*, 63–69. https://doi.org/10.1097/MOG.0000000000000609.

[140] Veigel, M. C., Prescott-Focht, J., Rodriguez, M. G., Zinati, R., Shao, L., Moore, C. A., et al. (2009). Fibropolycystic liver disease in children. *Pediatric Radiology*, *39*, 317–421. https://doi.org/10.1007/s00247-008-1070-z.

[141] Wang, J., Dong, M., Xu, Z., Song, X., Zhang, S., Qiao, Y., et al. (2018). Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. *Oncogene*, *37*, 3229–3242. https://doi.org/10.1038/s41388-018-0188-1.

[142] Wang, Z., Sheng, Y. Y., Dong, Q. Z., & Qin, L. X. (2016). Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis. *World Journal of Gastroenterology*, *22*, 3038–3051. https://doi.org/10.3748/wjg.v22.i10.3038.

[143] Wang, X. Y., Zhu, W. W., Wang, Z., Huang, J. B., Wang, S. H., Bai, F. M., et al. (2022). Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities. *Theranostics*, *12*, 260–276. https://doi.org/10.7150/thno.63417.

[144] Wehbe, H., Henson, R., Meng, F., Mize-Berge, J., & Patel, T. (2006). Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. *Cancer Research*, *66*, 10517–10524. https://doi.org/10.1158/0008-5472.CAN-06-2130.

[145] Welzel, T. M., Graubard, B. I., Zeuzem, S., El-Serag, H. B., Davila, J. A., & McGlynn, K. A. (2011). Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-Medicare database. *Hepatology*, *54*, 463–471. https://doi.org/10.1002/hep.24397.

[146] Welzel, T. M., McGlynn, K. A., Hsing, A. W., O'Brien, T. R., & Pfeiffer, R. M. (2006). Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. *Journal of the National Cancer Institute*, *98*, 873–875. https://doi.org/10.1093/jnci/djj234.

[147] Williamson, K. D., & Chapman, R. W. (2015). Primary sclerosing cholangitis: A clinical update. *British Medical Bulletin*, *114*, 53–64. https://doi.org/10.1093/bmb/ldv019.

[148] Wongjarupong, N., Assavapongpaiboon, B., Susantitaphong, P., Cheungpasitporn, W., Treeprasertsuk, S., Rerknimitr, R., et al. (2017). Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: A systematic review and meta-analysis. *BMC Gastroenterology*, *17*, 149. https://doi.org/10.1186/s12876-017-0696-4.

[149] Wu, W. R., Zhang, R., Shi, X. D., Zhu, M. S., Xu, L. B., Zeng, H., et al. (2014). Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro. *Oncology Reports*, *31*, 2515–2524. https://doi.org/10.3892/or.2014.3123.

[150] Yoon, J. H., Canbay, A. E., Werneburg, N. W., Lee, S. P., & Gores, G. J. (2004). Oxysterols induce cyclooxygenase-2

expression in cholangiocytes: Implications for biliary tract carcinogenesis. *Hepatology*, *39*, 732–738. https://doi.org/10.1002/hep.20125.

[151] Yoon, J. H., Gwak, G. Y., Lee, H. S., Bronk, S. F., Werneburg, N. W., & Gores, G. J. (2004). Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. *Journal of Hepatology*, *41*, 808–814. https://doi.org/10.1016/j.jhep.2004.07.016.

[152] Yoon, J. H., Higuchi, H., Werneburg, N. W., Kaufmann, S. H., & Gores, G. J. (2002). Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. *Gastroenterology*, *122*, 985–993. https://doi.org/10.1053/gast.2002.32410.

[153] Young, N. D., Campbell, B. E., Hall, R. S., Jex, A. R., Cantacessi, C., Laha, T., et al. (2010). Unlocking the transcriptomes of two carcinogenic parasites, Clonorchis sinensis and Opisthorchis viverrini. *PLoS Neglected Tropical Diseases*, *4*, e719. https://doi.org/10.1371/journal.pntd.0000719.

[154] Yu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., et al. (2005). The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. *Oncogene*, *24*, 6861–6869. https://doi.org/10.1038/sj.onc.1208841.

[155] Zanconato, F., Cordenonsi, M., & Piccolo, S. (2019). YAP and TAZ: A signalling hub of the tumour microenvironment. *Nature Reviews. Cancer*, *19*, 454–464. https://doi.org/10.1038/s41568-019-0168-y.

[156] Zen, Y., Harada, K., Sasaki, M., Chen, T. C., Chen, M. F., Yeh, T. S., et al. (2005). Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-beta 1 by overexpression of cyclin D1. *Laboratory Investigation*, *85*, 572–581. https://doi.org/10.1038/labinvest.3700236.

[157] Zerres, K., Rudnik-Schöneborn, S., Steinkamm, C., Becker, J., & Mücher, G. (1998). Autosomal recessive polycystic kidney disease. *Journal of Molecular Medicine*, *76*, 303–309. https://doi.org/10.1007/s001090050221.

[158] Zhang, S., Wang, J., Wang, H., Fan, L., Fan, B., Zeng, B., et al. (2018). Hippo cascade controls lineage commitment of liver tumors in mice and humans. *The American Journal of Pathology*, *188*, 995–1006. https://doi.org/10.1016/j.ajpath.2017.12.017.

[159] Zheng, Y., Ran, Y., Zhang, H., Wang, B., & Zhou, L. (2021). The microbiome in autoimmune liver diseases: Metagenomic and metabolomic changes. *Frontiers in Physiology*, *12*, 715852. https://doi.org/10.3389/fphys.2021.715852.

[160] Zhou, S. L., Dai, Z., Zhou, Z. J., Chen, Q., Wang, Z., Xiao, Y. S., et al. (2014). CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils. *Carcinogenesis*, *35*, 597–605. https://doi.org/10.1093/carcin/bgt397.

[161] Zhou, M., Wang, C., Lu, S., Xu, Y., Li, Z., Jiang, H., et al. (2021). Tumor-associated macrophages in cholangiocarcinoma: Complex interplay and potential therapeutic target. *eBioMedicine*, *67*, 103375. https://doi.org/10.1016/j.ebiom.2021.103375.

[162] Zhou, Z., Wang, P., Sun, R., Li, J., Hu, Z., Xin, H., et al. (2021). Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. *Journal for Immunotherapy of Cancer*, *9*, e001946. https://doi.org/10.1136/jitc-2020-001946.

[163] Zhou, Y., Zhao, Y., Li, B., Huang, J., Wu, L., Xu, D., et al. (2012). Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: Evidence from a meta-analysis. *BMC Cancer*, *12* , 289. https://doi.org/10.1186/1471-2407-12-289.

3 原发性肝癌瘤间和瘤内异质性的成因与功能复杂性

[1] An, F.-Q., Matsuda, M., Fujii, H., Tang, R.-F., Amemiya, H., Dai, Y.-M., et al. (2001). Tumor heterogeneity in small hepatocellular carcinoma: Analysis of tumor cell proliferation, expression and mutation of p53 AND β-catenin. *International Journal of Cancer*, *93*(4), 468–474.

[2] Brindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A., Sirica, A. E., et al. (2021). Cholangiocarcinoma. *Nature Reviews Disease Primers*, *7*(1), 65.

[3] Buczak, K., Ori, A., Kirkpatrick, J. M., Holzer, K., Dauch, D., Roessler, S., et al. (2018). Spatial tissue proteomics quantifies inter- and intratumor heterogeneity in hepatocellular carcinoma (HCC)*. *Molecular & Cellular Proteomics*, *17*(4), 810–825.

[4] Carotenuto, P., Fassan, M., Pandolfo, R., Lampis, A., Vicentini, C., Cascione, L., et al. (2017). Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. *Gut*, *66* (7), 1268–1277.

[5] Chaisaingmongkol, J., Budhu, A., Dang, H., Rabibhadana, S., Pupacdi, B., Kwon, S. M., et al. (2017). Common molecular

subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. *Cancer Cell*, *32*(1), 57–70.e53.

[6] Chuang, C. Y., Chang, H., Lin, P., Sun, S. J., Chen, P. H., Lin, Y. Y., et al. (2012). Up-regulation of osteopontin expression by aryl hydrocarbon receptor via both ligand-dependent and ligand-independent pathways in lung cancer. *Gene*, *492*(1), 262–269.

[7] Cui, R., Takahashi, F., Ohashi, R., Yoshioka, M., Gu, T., Tajima, K., et al. (2009). Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. *Lung Cancer*, *63*(3), 368–374.

[8] Dasgupta, P., Henshaw, C., Youlden, D. R., Clark, P. J., Aitken, J. F., & Baade, P. D. (2020). Global trends in incidence rates of primary adult liver cancers: A systematic review and meta-analysis. *Frontiers in Oncology*, *10*, 171.

[9] Donato, F., Tagger, A., Gelatti, U., Parrinello, G., Boffetta, P., Albertini, A., et al. (2002). Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. *American Journal of Epidemiology*, *155*(4), 323–331.

[10] Fedarko, N. S., Jain, A., Karadag, A., Van Eman, M. R., & Fisher, L. W. (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. *Clinical Cancer Research*, *7*(12), 4060–4066.

[11] Feng, M., Pan, Y., Kong, R., & Shu, S. (2020). Therapy of primary liver cancer. *Innovation (New York, N.Y.)*, *1*(2), 100032.

[12] Fostea, R. M., Fontana, E., Torga, G., & Arkenau, H.-T. (2020). Recent progress in the systemic treatment of advanced/metastatic cholangiocarcinoma. *Cancers*, *12*(9), 2599.

[13] Goltsev, Y., Samusik, N., Kennedy-Darling, J., Bhate, S., Hale, M., Vazquez, G., et al. (2018). Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. *Cell*, *174* (4), 968–981.e915.

[14] González-Silva, L., Quevedo, L., & Varela, I. (2021). Tumor functional heterogeneity unraveled by sc RNA-seq technologies: (Trends in Cancer 6, 13–19, 2020). *Trends Cancer*, *7*(3), 265.

[15] Groopman, J. D., Kensler, T. W., & Wild, C. P. (2008). Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. *Annual Review of Public Health*, *29* , 187–203.

[16] Han, D. H., Choi, G. H., Kim, K. S., Choi, J. S., Park, Y. N., Kim, S. U., et al. (2013). Prognostic significance of the worst grade in hepatocellular carcinoma with heterogeneous histologic grades of differentiation. *Journal of Gastroenterology and Hepatology*, *28*(8), 1384–1390.

[17] Henderson, N. C., Arnold, T. D., Katamura, Y., Giacomini, M. M., Rodriguez, J. D., McCarty, J. H., et al. (2013). Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. *Nature Medicine*, *19*(12), 1617–1624.

[18] Ho, D. W.-H., Tsui, Y.-M., Chan, L.-K., Sze, K. M.-F., Zhang, X., Cheu, J. W.-S., et al. (2021). Single-cell RNAsequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. *Nature Communications*, *12*(1), 3684.

[19] Ho, D. W.-H., Tsui, Y.-M., Sze, K. M.-F., Chan, L.-K., Cheung, T.-T., Lee, E., et al. (2019). Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer. *Cancer Letters*, *459*, 176–185.

[20] Hsu, H. C., Chiou, T. J., Chen, J. Y., Lee, C. S., Lee, P. H., & Peng, S. Y. (1991). Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. *Hepatology*, *13* (5), 923–928.

[21] Hu, W., Feng, Z., Eveleigh, J., Iyer, G., Pan, J., Amin, S., et al. (2002). The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. *Carcinogenesis*, *23*(11), 1781–1789.

[22] Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021). Global epidemiology of NAFLDrelated HCC: Trends, predictions, risk factors and prevention. *Nature Reviews. Gastroenterology & Hepatology*, *18*(4), 223–238.

[23] Huang, A., Zhang, X., Zhou, S.-L., Cao, Y., Huang, X.-W., Fan, J., et al. (2016). Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity. *Journal of Cancer*, *7*(13), 1907–1914.

[24] Ichim, G., & Tait, S. W. (2016). A fate worse than death: Apoptosis as an oncogenic process. *Nature Reviews. Cancer*, *16*(8), 539–548.

[25] Junnila, S., Kokkola, A., Mizuguchi, T., Hirata, K., Karjalainen-Lindsberg, M.-L., Puolakkainen, P., et al. (2010). Gene expression analysis identifies over-expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer. *Genes, Chromosomes and Cancer*, *49*(1), 28–39.

[26] Khatib, S., Pomyen, Y., Dang, H., & Wang, X. W. (2020). Understanding the cause and consequence of tumor

heterogeneity. *Trends in Cancer*, *6*(4), 267–271.

[27] Kim, S., Park, S. Y., Yong, H., Famulski, J. K., Chae, S., Lee, J. H., et al. (2008). HBV X protein targets hBubR1, which induces dysregulation of the mitotic checkpoint. *Oncogene*, *27*(24), 3457–3464.

[28] Krause, J., von Felden, J., Casar, C., Fründt, T. W., Galaski, J., Schmidt, C., et al. (2020). Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype. *BMC Cancer*, *20*(1), 1130.

[29] Kwon, S. M., Budhu, A., Woo, H. G., Chaisaingmongkol, J., Dang, H., Forgues, M., et al. (2019). Functional genomic complexity defines intratumor heterogeneity and tumor aggressiveness in liver cancer. *Scientific Reports*, *9*(1), 16930.

[30] Lazaridis, K. N., & Gores, G. J. (2005). Cholangiocarcinoma. *Gastroenterology*, *128*(6), 1655–1667.

[31] Lewis, S. M., Asselin-Labat, M.-L., Nguyen, Q., Berthelet, J., Tan, X., Wimmer, V. C., et al. (2021). Spatial omics and multiplexed imaging to explore cancer biology. *Nature Methods*, *18*(9), 997–1012.

[32] Lieber, C. S. (1994). Alcohol and the liver: 1994 update. *Gastroenterology*, *106*(4), 1085–1105.

[33] Liu, J., Dang, H., & Wang, X. W. (2018). The significance of intertumor and intratumor heterogeneity in liver cancer. *Experimental & Molecular Medicine*, *50*(1), e416.

[34] Liu, J., Tang, W., Budhu, A., Forgues, M., Hernandez, M. O., Candia, J., et al. (2020). A viral exposure signature defines early onset of hepatocellular carcinoma. *Cell*, *182*(2), 317–328.e310.

[35] Liu, Y., & Wu, F. (2010). Global burden of aflatoxin-induced hepatocellular carcinoma: A risk assessment. *Environmental Health Perspectives*, *118*(6), 818–824.

[36] Liu, L., Zhang, R., Deng, J., Dai, X., Zhu, X., Fu, Q., et al. (2021). Construction of TME and identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma. *Cancer Immunology, Immunotherapy*, *71*(1), 121–136.

[37] Ma, L., Hernandez, M. O., Zhao, Y., Mehta, M., Tran, B., Kelly, M., et al. (2019). Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. *Cancer Cell*, *36* (4), 418–430.e416.

[38] Ma, L., Wang, L., Khatib, S. A., Chang, C.-W., Heinrich, S., Dominguez, D. A., et al. (2021). Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *Journal of Hepatology*, *75*(6), 1397–1408.

[39] Marzioni, M., Glaser, S. S., Francis, H., Phinizy, J. L., LeSage, G., & Alpini, G. (2002). Functional heterogeneity of cholangiocytes. *Seminars in Liver Disease*, *22*(03), 227–240.

[40] Matsushita, H., & Takaki, A. (2019). Alcohol and hepatocellular carcinoma. *BMJ Open Gastroenterology*, *6*(1), e000260.

[41] Meacham, C. E., & Morrison, S. J. (2013). Tumour heterogeneity and cancer cell plasticity. *Nature*, *501*(7467), 328–337.

[42] Merritt, C. R., Ong, G. T., Church, S. E., Barker, K., Danaher, P., Geiss, G., et al. (2020). Multiplex digital spatial profiling of proteins and RNA in fixed tissue. *Nature Biotechnology*, *38* (5), 586–599.

[43] Mumenthaler, S. M., Foo, J., Choi, N. C., Heise, N., Leder, K., Agus, D. B., et al. (2015). The impact of microenvironmental heterogeneity on the evolution of drug resistance in cancer cells. *Cancer Informatics*, *14*(Suppl. 4), 19–31.

[44] Nakamura, H., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., et al. (2015). Genomic spectra of biliary tract cancer. *Nature Genetics*, *47*(9), 1003–1010.

[45] Nguyen, P. H. D., Ma, S., Phua, C. Z. J., Kaya, N. A., Lai, H. L. H., Lim, C. J., et al. (2021). Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. *Nature Communications*, *12*(1), 227.

[46] Nowell, P. C. (1976). The clonal evolution of tumor cell populations. *Science*, *194*(4260), 23–28.

[47] Payen, V. L., Lavergne, A., Alevra Sarika, N., Colonval, M., Karim, L., Deckers, M., et al. (2021). Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity. *JHEP Reports*, *3*(3), 100278.

[48] Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. F., & Bell, B. P. (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *Journal of Hepatology*, *45*(4), 529–538.

[49] Prasetyanti, P. R., & Medema, J. P. (2017). Intra-tumor heterogeneity from a cancer stem cell perspective. *Molecular Cancer*, *16*(1), 41.

[50] Prueksapanich, P., Piyachaturawat, P., Aumpansub, P., Ridtitid, W., Chaiteerakij, R., & Rerknimitr, R. (2018). Liver fluke-associated biliary tract cancer. *Gut and Liver*, *12*(3), 236–245.

[51] Rahmanzade, R. (2020). Redefinition of tumor capsule: Rho-dependent clustering of cancer-associated fibroblasts in favor of tensional homeostasis. *Medical Hypotheses*, *135*, 109425.

[52] Rao, C. V., Asch, A. S., & Yamada, H. Y. (2016). Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. *Carcinogenesis*, *38*(1), 2–11.

[53] Raoul, J. L., Forner, A., Bolondi, L., Cheung, T. T., Kloeckner, R., & de Baere, T. (2019). Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. *Cancer Treat Reviews*, *72*, 28–36.

[54] Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021). Advances in immunotherapy for hepatocellular carcinoma. *Nature Reviews. Gastroenterology & Hepatology*, *18*(8), 525–543.

[55] Sarni, D., & Kerem, B. (2017). Oncogene-induced replication stress drives genome instability and tumorigenesis. *International Journal of Molecular Sciences*, *18*(7), 1339.

[56] Shimada, S., Mogushi, K., Akiyama, Y., Furuyama, T., Watanabe, S., Ogura, T., et al. (2019). Comprehensive molecular and immunological characterization of hepatocellular carcinoma. *EBioMedicine*, *40*, 457–470.

[57] Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. *CA Cancer Journal of Clinicians*, *70*(1), 7–30.

[58] Ståhl, P. L., Salmén, F., Vickovic, S., Lundmark, A., Navarro, J. F., Magnusson, J., et al. (2016). Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. *Science*, *353*(6294), 78–82.

[59] Su, X., Zhao, L., Shi, Y., Zhang, R., Long, Q., Bai, S., et al. (2021). Clonal evolution in liver cancer at single-cell and single-variant resolution. *Journal of Hematology & Oncology*, *14*(1), 22.

[60] Sung, J.-Y., Shin, H.-T., Sohn, K.-A., Shin, S.-Y., Park, W.-Y., & Joung, J.-G. (2019). Assessment of intratumoral heterogeneity with mutations and gene expression profiles. *PLoS One*, *14*(7), e0219682.

[61] Svensson, V., Vento-Tormo, R., & Teichmann, S. A. (2018). Exponential scaling of single-cell RNA-seq in the past decade. *Nature Protocols*, *13*(4), 599–604.

[62] Tanaka, S., Toh, Y., Adachi, E., Matsumata, T., Mori, R., & Sugimachi, K. (1993). Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. *Cancer Research*, *53* (12), 2884–2887.

[63] Testino, G., Leone, S., & Borro, P. (2014). Alcohol and hepatocellular carcinoma: A review and a point of view. *World Journal of Gastroenterology*, *20*(43), 15943–15954.

[64] Thiele, M., Gluud, L. L., Fialla, A. D., Dahl, E. K., & Krag, A. (2014). Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: Systematic review with meta-analyses. *PLoS One*, *9*(9), e107177.

[65] Venkatesan, S., Swanton, C., Taylor, B. S., & Costello, J. F. (2017). Treatment-induced mutagenesis and selective pressures sculpt cancer evolution. *Cold Spring Harbor Perspectives in Medicine* , *7*(8), a026617.

[66] Villanueva, A., Portela, A., Sayols, S., Battiston, C., Hoshida, Y.,Méndez-González, J., et al. (2015). DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. *Hepatology* , *61*(6), 1945–1956.

[67] Vitale, A., Morales, R. R., Zanus, G., Farinati, F., Burra, P., Angeli, P., et al. (2011). Barcelona clinic liver cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: A multicentre, cohort study. *Lancet Oncology*, *12*(7), 654–662.

[68] Wang, F., Flanagan, J., Su, N., Wang, L. C., Bui, S., Nielson, A., et al. (2012). RNAscope: A novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. *Journal of Molecular Diagnostics*, *14*(1), 22–29.

[69] Wang, H., Jiang, Y., Li, B., Cui, Y., Li, D., & Li, R. (2020). Single-cell spatial analysis of tumor and immune microenvironment on whole-slide image reveals hepatocellular carcinoma subtypes. *Cancers (Basel)*, *12*(12).

[70] Wang, S., Xie, J., Zou, X., Pan, T., Zhuang, Z., Wang, Z., et al. (2020). Single-cell Multi-omics reveal heterogeneity and metastasis potential in different liver cancer cell lines. *bioRxiv*. 2020.2011.2003.367532.

[71] Welzel, T. M., Graubard, B. I., El-Serag, H. B., Shaib, Y. H., Hsing, A. W., Davila, J. A., et al. (2007). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based case-control study. *Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association*, *5*(10), 1221–1228.

[72] Wu, R., Guo, W., Qiu, X., Wang, S., Sui, C., Lian, Q., et al. (2021). Comprehensive analysis of spatial architecture in primary liver cancer. *bioRxiv*. 2021.2005.2024.445446.

[73] Xu, C., Sun, L., Jiang, C., Zhou, H., Gu, L., Liu, Y., et al. (2017). SPP1, analyzed by bioinformatics methods, promotes the metastasis in colorectal cancer by activating EMT pathway. *Biomedicine & Pharmacotherapy*, *91*, 1167–1177.

[74] Xue, R., Li, R., Guo, H., Guo, L., Su, Z., Ni, X., et al. (2016). Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma. *Gastroenterology*, *150*(4), 998–1008.

[75] Yamamoto, S., Kubo, S., Hai, S., Uenishi, T., Yamamoto, T., Shuto, T., et al. (2004). Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. *Cancer Science*, *95* (7), 592–595.

[76] Yao, Y., & Dai, W. (2014). Genomic instability and cancer. *Journal of Carcinogenesis & Mutagenesis*, *5*, 1000165.

[77] Yin, Z., Dong, C., Jiang, K., Xu, Z., Li, R., Guo, K., et al. (2019). Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma. *Journal of Hematology & Oncology*, *12*(1), 101.
[78] Zeng, B., Zhou, M., Wu, H., & Xiong, Z. (2018). SPP1 promotes ovarian cancer progression via Integrin β1/FAK/AKT signaling pathway. *OncoTargets and Therapy*, *11*, 1333–1343.
[79] Zhang, Z. (2012). Genomic landscape of liver cancer. *Nature Genetics*, *44*(10), 1075–1077.
[80] Zhang, Q.,He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., et al. (2019). Landscape and dynamics of single immune cells in hepatocellular carcinoma. *Cell*, *179*(4), 829–845.e820.
[81] Zhang, Q., Lou, Y., Yang, J., Wang, J., Feng, J., Zhao, Y., et al. (2019). Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. *Gut*, *68*(11), 2019–2031.
[82] Zhang, M., Yang, H., Wan, L., Wang, Z., Wang, H., Ge, C., et al. (2020). Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. *Journal of Hepatology*, *73*(5), 1118−1130.
[83] Zheng, H., Pomyen, Y., Hernandez, M. O., Li, C., Livak, F., Tang, W., et al. (2018). Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. *Hepatology*, *68* (1), 127−140.
[84] Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., et al. (2017). Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. *Cell*, *169*(7), 1342−1356.e1316.

4 肝细胞癌中遗传异质性的意义

[1] Abou-Alfa, G. K., & Venook, A. P. (2013). The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? *The Lancet Oncology*, *14*(7), e283–e288.
[2] Ahn, S.-M., Jang, S. J., Shim, J. H., Kim, D., Hong, S.-M., Sung, C. O., et al. (2014). Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. *Hepatology*, *60*(6), 1972–1982.
[3] Alsina-Sanchis, E., Mülfarth, R., & Fischer, A. (2021). Control of Tumor Progression by Angiocrine Factors. *Cancers*, *13*(11).
[4] Arao, T., Ueshima, K., Matsumoto, K., Nagai, T., Kimura, H., Hagiwara, S., et al. (2013). FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. *Hepatology*, *57*(4), 1407−1415.
[5] Asakawa, M., Itoh, M., Suganami, T., Sakai, T., Kanai, S., Shirakawa, I., et al. (2019). Upregulation of cancer-associated gene expression in activated fibroblasts in a mouse model of non-alcoholic steatohepatitis. *Scientific Reports*, *9*(1), 19601.
[6] Barcena-Varela, M., & Lujambio, A. (2021). The Endless Sources of Hepatocellular Carcinoma Heterogeneity. *Cancers*, *13*(11).
[7] Biffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y., et al. (2019). IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. *Cancer Discovery*, *9*(2), 282–301.
[8] Blumer, T., Fofana, I., Matter, M. S., Wang, X., Montazeri, H., Calabrese, D., et al. (2019). Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors. *Hepatology Communications*, *3*(7), 971–986.
[9] Boyault, S., Rickman, D. S., de Reynies, A., Balabaud, C., Rebouissou, S., Jeannot, E., et al. (2007). Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. *Hepatology*, *45*(1), 42–52.
[10] Brady, L., Kriner, M., Coleman, I., Morrissey, C., Roudier, M., True, L. D., et al. (2021). Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. *Nature Communications*, *12*(1), 1426.
[11] Brown, Z. J., Yu, S. J., Heinrich, B., Ma, C., Fu, Q., Sandhu, M., et al. (2018). Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. *Cancer Immunology, Immunotherapy: CII*, *67*(8), 1305−1315.
[12] Cai, Z.-X., Chen, G., Zeng, Y.-Y., Dong, X.-Q., Lin, M.-J., Huang, X.-H., et al. (2017). Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma. *International Journal of Cancer. Journal International Du Cancer*, *141*(5), 977–985.
[13] Calderaro, J., Couchy, G., Imbeaud, S., Amaddeo, G., Letouzé, E., Blanc, J.-F., et al. (2017). Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. *Journal of Hepatology*, *67*(4), 727–738.

[14] Calderaro, J., Petitprez, F., Becht, E., Laurent, A., Hirsch, T. Z., Rousseau, B., et al. (2019). Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. *Journal of Hepatology*, *70*(1), 58–65.

[15] Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Lee, J.-S., Conner, E. A., et al. (2007). Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. *The Journal of Clinical Investigation*, *117*(9), 2713–2722.

[16] Chan, L.-K., Tsui, Y.-M., Ho, D. W.-H., & Ng, I. O.-L. (2021). Cellular heterogeneity and plasticity in liver cancer. *Seminars in Cancer Biology*.

[17] Chen, H., Chong, W., Teng, C., Yao, Y., Wang, X., & Li, X. (2019). The immune response-related mutational signatures and driver genes in non-small-cell lung cancer. *Cancer Science*, *110*(8), 2348–2356.

[18] Chen, F., Zhong, Z., Tan, H.-Y., Wang, N., & Feng, Y. (2020). The significance of circulating tumor cells in patients with hepatocellular carcinoma: Real-time monitoring and moving targets for cancer therapy. *Cancers*, *12*(7).

[19] Cheng, Y., Li, H., Deng, Y., Tai, Y., Zeng, K., Zhang, Y., et al. (2018). Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. *Cell Death & Disease*, *9*(4), 422.

[20] Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., et al. (2008). Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. *Cancer Research*, *68*(16), 6779–6788.

[21] Dagogo-Jack, I., & Shaw, A. T. (2018). Tumour heterogeneity and resistance to cancer therapies. *Nature Reviews. Clinical Oncology*, *15*(2), 81–94.

[22] Dasgupta, P., Henshaw, C., Youlden, D., Clark, P., Aitken, J., & Baade, P. (2020). Global trends in incidence rates of primary adult liver cancers: A systematic review and meta-analysis. *Frontiers in Oncology*, *10*.

[23] Désert, R., Rohart, F., Canal, F., Sicard, M., Desille, M., Renaud, S., et al. (2017). Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. *Hepatology*, *66*(5), 1502–1518.

[24] Dhanasekaran, R. (2021). Deciphering tumor heterogeneity in hepatocellular carcinoma (HCC)-multi-omic and singulomic approaches. *Seminars in Liver Disease*, *41*(1), 9–18.

[25] Dhanasekaran, R., Bandoh, S., & Roberts, L. R. (2016). Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. *F1000Research*, *5*.

[26] Ding, X., He, M., Chan, A. W. H., Song, Q. X., Sze, S. C., Chen, H., et al. (2019). Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas. *Gastroenterology*, *157*(6). 1630−1645.e6.

[27] El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., et al. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *The Lancet*, *389*(10088), 2492–2502.

[28] Fang, J.-H., Xu, L., Shang, L.-R., Pan, C.-Z., Ding, J., Tang, Y.-Q., et al. (2019). Vessels that encapsulate tumor clusters (VETC) pattern is a predictor of sorafenib benefit in patients with hepatocellular carcinoma. *Hepatology*, *70*(3), 824–839.

[29] Fang, J.-H., Zhou, H.-C., Zhang, C., Shang, L.-R., Zhang, L., Xu, J., et al. (2015). A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelialmesenchymal transition-independent manner. *Hepatology*, *62*(2), 452–465.

[30] Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., et al. (2020). Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *The New England Journal of Medicine*, *382*(20), 1894–1905.

[31] Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., et al. (2020). Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, *38*(3), 193–202.

[32] Forschner, A., Battke, F., Hadaschik, D., Schulze, M., Weiβgraeber, S., Han, C.-T., et al. (2019). Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma-results of a prospective biomarker study. *Journal for Immunotherapy of Cancer*, *7*(1), 180.

[33] Fujimoto, A., Totoki,Y., Abe, T., Boroevich, K. A., Hosoda, F., Nguyen, H. H., et al. (2012). Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. *Nature Genetics*, *44*(7), 760–764.

[34] Fujiwara, N., Friedman, S., Goossens, N., & Hoshida, Y. (2018). Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. *Journal of Hepatology*, *68*(3), 526–549.

[35] Gao, Q., Wang, Z.-C., Duan, M., Lin, Y.-H., Zhou, X.-Y., Worthley, D. L., et al. (2017). Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents. *Gastroenterology*, *152*(1). 232–242.e4.

[36] Garnelo, M., Tan, A., Her, Z., Yeong, J., Lim, C. J., Chen, J., et al. (2017). Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. *Gut*, *66*(2), 342–351.

[37] Ghouri, Y. A., Mian, I., & Rowe, J. H. (2017). Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. *Journal of Carcinogenesis*, *16*(1), 1.

[38] Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I. B., et al. (2012). Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. *Nature Genetics*, *44*(6), 694–698.

[39] Guo, L., Yi, X., Chen, L., Zhang, T., Guo, H., Chen, Z., et al. (2022). Single-cell DNA sequencing reveals punctuated and gradual clonal evolution in hepatocellular carcinoma. *Gastroenterology* , *162*(1), 238–252.

[40] Harding, J. J., El Dika, I., & Abou-Alfa, G. K. (2016). Immunotherapy in hepatocellular carcinoma: Primed to make a difference? *Cancer*, *122*(3), 367–377.

[41] Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., et al. (2019). Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, *25*(7), 2116–2126.

[42] Ho, D. W. H., Chan, L. K., Chiu, Y. T., Xu, I. M. J., Poon, R. T. P., Cheung, T. T., et al. (2017). TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication. *Gut*, *66*(8), 1496–1506.

[43] Horwitz, E., Stein, I., Andreozzi, M., Nemeth, J., Shoham, A., Pappo, O., et al. (2014). Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. *Cancer Discovery*, *4*(6), 730–743.

[44] Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., et al. (2009). Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. *Cancer Research*, *69*(18), 7385–7392.

[45] Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Minguez, B., & Llovet, J. M. (2010). Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. *Seminars in Liver Disease*, *30*(1), 35–51.

[46] Hu, B., Li, H., Guo, W., Sun, Y.-F., Zhang, X., Tang, W.-G., et al. (2020). Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. *International Journal of Cancer. Journal International Du Cancer*, *146*(6), 1606–1617.

[47] Hung, M. H., Lee, J. S., Ma, C., Diggs, L. P., Heinrich, S., Chang, C. W., et al. (2021). Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. *Nature Communications*, *12*(1), 1455.

[48] Jiang, Y., Han, Q., Zhao, H., & Zhang, J. (2021). The mechanisms of HBV-induced hepatocellular carcinoma. *Journal of Hepatocellular Carcinoma*, *8*, 435–450.

[49] Jiang, Z., Jiang, X., Chen, S., Lai, Y., Wei, X., Li, B., et al. (2016). Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. *Frontiers in Immunology*, *7*, 690.

[50] Kaseb, A. O., Vence, L., Blando, J., Yadav, S. S., Ikoma, N., Pestana, R. C., et al. (2019). Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma. *Cancer Immunology Research*, *7*(9), 1390–1395.

[51] Khatib, S., Pomyen, Y., Dang, H., & Wang, X. W. (2020). Understanding the cause and consequence of tumor heterogeneity. *Trends in Cancer Research*, *6*(4), 267–271.

[52] Kim, S. S., Eun, J. W., Choi, J.-H., Woo, H. G., Cho, H. J., Ahn, H. R., et al. (2020). MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma. *Scientific Reports*, *10*(1), 17862.

[53] Kimura, T., Kato, Y., Ozawa, Y., Kodama, K., Ito, J., Ichikawa, K., et al. (2018). Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. *Cancer Science*, *109*(12), 3993–4002.

[54] Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., et al. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. *The Lancet*, *391*(10126), 1163–1173.

[55] Kurebayashi, Y., Ojima, H., Tsujikawa, H., Kubota, N., Maehara, J., Abe, Y., et al. (2018). Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification.

Hepatology, *68*(3), 1025–1041.

[56] Lachenmayer, A., Alsinet, C., Savic, R., Cabellos, L., Toffanin, S., Hoshida, Y., et al. (2012). Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, *18*(18), 4997–5007.

[57] Lee, J.-S., Chu, I.-S., Heo, J., Calvisi, D. F., Sun, Z., Roskams, T., et al. (2004). Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. *Hepatology*, *40*(3), 667–676.

[58] Lee, M., Samstein, R. M., Valero, C., Chan, T. A., & Morris, L. G. T. (2020). Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. *Human Vaccines & Immunotherapeutics*, *16*(1), 112–115.

[59] Li, J., Chen, L., Zhang, X., Zhang, Y., Liu, H., Sun, B., et al. (2014). Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin. *PLoS One*, *9*(4), e96185.

[60] Ling, S., Hu, Z., Yang, Z., Yang, F., Li, Y., Lin, P., et al. (2015). Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. *Proceedings of the National Academy of Sciences of the United States of America*, *112*(47), E6496–E6505.

[61] Liu, J., Chen, S., Wang, W., Ning, B.-F., Chen, F., Shen, W., et al. (2016). Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-β pathways. *Cancer Letters*, *379*(1), 49–59.

[62] Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., et al. (2021). Hepatocellular carcinoma. *Nature Reviews. Disease Primers*, *7*(1), 6.

[63] Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. *The New England Journal of Medicine*, *359* (4), 378–390.

[64] Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., et al. (2014). Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. *Cancer Cell*, *25*(1), 91–101.

[65] Longo, S. K., Guo, M. G., Ji, A. L., & Khavari, P. A. (2021). Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics. *Nature Reviews. Genetics*, *22* (10), 627–644.

[66] Losic, B., Craig, A. J., Villacorta-Martin, C., Martins-Filho, S. N., Akers, N., Chen, X., et al. (2020). Intratumoral heterogeneity and clonal evolution in liver cancer. *Nature Communications*, *11*(1), 291.

[67] Maishi, N., Ohba, Y., Akiyama, K., Ohga, N., Hamada, J.-I., Nagao-Kitamoto, H., et al. (2016). Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan. *Scientific Reports*, *6*, 28039.

[68] Maravelia, P., Silva, D. N., Rovesti, G., Chrobok, M., Stål, P., Lu, Y.-C., et al. (2021). Liquid biopsy in hepatocellular carcinoma: Opportunities and challenges for immunotherapy. *Cancers*, *13*(17).

[69] McCoy, M. G., Nyanyo, D., Hung, C. K., Goerger, J. P., R Zipfel, W., Williams, R. M., et al. (2019). Endothelial cells promote 3D invasion of GBM by IL-8-dependent induction of cancer stem cell properties. *Scientific Reports*, *9*(1), 9069.

[70] McGranahan, N., Favero, F., de Bruin, E. C., Birkbak, N. J., Szallasi, Z., & Swanton, C. (2015). Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. *Science Translational Medicine*, *7*(283), 283ra54.

[71] McQuerry, J. A., Chang, J. T., Bowtell, D. D. L., Cohen, A., & Bild, A. H. (2017). Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes. *Journal of Molecular Medicine*, *95*(11), 1167–1178.

[72] Mocan, T., Simão, A. L., Castro, R. E., Rodrigues, C. M. P., Słomka, A., Wang, B., et al. (2020). Liquid biopsies in hepatocellular carcinoma: Are we winning? *Journal of Clinical Medicine Research*, *9*(5).

[73] Nault, J. C., Mallet, M., Pilati, C., Calderaro, J., Bioulac-Sage, P., Laurent, C., et al. (2013). High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. *Nature Communications*, *4*, 2218.

[74] Nault, J.-C., Martin, Y., Caruso, S., Hirsch, T. Z., Bayard, Q., Calderaro, J., et al. (2020). Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. *Hepatology*, *71*(1), 164–182.

[75] Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., et al. (2014). PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. *The Journal of Experimental Medicine*, *211*(5), 781–790.

[76] Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., et al. (2017). Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *The Journal of Experimental Medicine*, *214*(3), 579–596.

[77] Peng, S., Wang, Y., Peng, H., Chen, D., Shen, S., Peng, B., et al. (2014). Autocrine vascular endothelial growth factor

signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma. *Hepatology*, *60*(4), 1264–1277.

[78] Petrick, J. L., Florio, A. A., Znaor, A., Ruggieri, D., Laversanne, M., Alvarez, C. S., et al. (2020). International trends in hepatocellular carcinoma incidence, 1978–2012. *International Journal of Cancer. Journal International Du Cancer*, *147*(2), 317–330.

[79] Plaks, V., Koopman, C. D., & Werb, Z. (2013). Cancer. Circulating tumor cells. *Science*, *341*(6151), 1186–1188.

[80] Rebouissou, S., & Nault, J.-C. (2020). Advances in molecular classification and precision oncology in hepatocellular carcinoma. *Journal of Hepatology*, *72*(2), 215–229.

[81] Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., et al. (2019). Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. *The Lancet. Respiratory Medicine*, *7*(5), 387–401.

[82] Renne, S. L., Woo, H. Y., Allegra, S., Rudini, N., Yano, H., Donadon, M., et al. (2020). Vessels encapsulating tumor clusters (VETC) is a powerful predictor of aggressive hepatocellular carcinoma. *Hepatology*, *71*(1), 183–195.

[83] Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., et al. (2019). Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. *The Lancet*, *393*(10189), 2404–2415.

[84] Rudalska, R., Dauch, D., Longerich, T., McJunkin, K., Wuestefeld, T., Kang, T.-W., et al. (2014). In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. *Nature Medicine*, *20*(10), 1138–1146.

[85] Sangro, B., Melero, I., Yau, T., Hsu, C., Kudo, M., Kim, T.-Y., et al. (2017). *Nivolumab in sorafenib-naive and-experienced patients with advanced hepatocellular carcinoma (HCC): Survival, hepatic safety, and biomarker assessments in CheckMate 040*.

[86] Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021). Advances in immunotherapy for hepatocellular carcinoma. *Nature Reviews. Gastroenterology & Hepatology*, *18*(8), 525–543.

[87] Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., et al. (2015). Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. *Nature Genetics*, *47*(5), 505–511.

[88] Sebastian, A., Hum, N. R., Martin, K. A., Gilmore, S. F., Peran, I., Byers, S. W., et al. (2020). Single-cell transcriptomic analysis of tumor-derived fibroblasts and normal tissue-resident fibroblasts reveals fibroblast heterogeneity in breast cancer. *Cancers*, *12*(5).

[89] Sharma, A., Seow, J. J. W., Dutertre, C.-A., Pai, R., Blériot, C., Mishra, A., et al. (2020). Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. *Cell*, *183*(2). 377–394.e21.

[90] Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., et al. (2017). Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. *Gastroenterology*, *153*(3), 812–826.

[91] Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. *CA: a Cancer Journal for Clinicians*, *70*(1), 7–30.

[92] Siu, E. H.-L., Chan, A. W.-H., Chong, C. C.-N., Chan, S. L., Lo, K.-W., & Cheung, S. T. (2018). Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. *Translational Gastroenterology and Hepatology*, *3*, 89.

[93] Song, G., Shi, Y., Zhang, M., Goswami, S., Afridi, S., Meng, L., et al. (2020). Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. *Cell Discovery*, *6*(1), 90.

[94] Sukowati, C. H. C., El-Khobar, K. E., & Tiribelli, C. (2021). Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. *World Journal of Stem Cells*, *13*(7), 795–824.

[95] Sun, Y.-F., Guo, W., Xu, Y., Shi, Y.-H., Gong, Z.-J., Ji, Y., et al. (2018). Circulating tumor cells from different vascular sites exhibit spatial heterogeneity in epithelial and mesenchymal composition and distinct clinical significance in hepatocellular carcinoma. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, *24*(3), 547–559.

[96] Sun, B., & Karin, M. (2012). Obesity, inflammation, and liver cancer. *Journal of Hepatology*, *56*(3), 704–713.

[97] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a Cancer*

Journal for Clinicians, *71*(3), 209–249.

[98] Swanton, C. (2012). Intratumor heterogeneity: Evolution through space and time. *Cancer Research*, *72*(19), 4875–4882.

[99] Teufel, M., Seidel, H., Köchert, K., Meinhardt, G., Finn, R. S., Llovet, J. M., et al. (2019). Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. *Gastroenterology*, *156*(6), 1731–1741.

[100] The Cancer Genome Atlas Research Network. (2017). Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. *Cell*, *169*(7), 1327–1341.

[101] Thomson, A. W., & Knolle, P. A. (2010). Antigen-presenting cell function in the tolerogenic liver environment. *Nature Reviews. Immunology*, *10*(11), 753–766.

[102] Thun, M., Linet, M. S., Cerhan, J. R., Haiman, C. A., & Schottenfeld, D. (2017). *Cancer Epidemiology and Prevention*. Oxford University Press.

[103] Totoki, Y., Tatsuno, K., Covington, K. R., Ueda, H., Creighton, C. J., Kato, M., et al. (2014). Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. *Nature Genetics*, *46*(12), 1267–1273.

[104] Turner, N. C., & Reis-Filho, J. S. (2012). Genetic heterogeneity and cancer drug resistance. *The Lancet Oncology*, *13*(4), e178–e185.

[105] Tuveson, D., & Clevers, H. (2019). Cancer modeling meets human organoid technology. *Science*, *364*(6444), 952–955.

[106] Villanueva, A. (2019). Hepatocellular Carcinoma. *The New England Journal of Medicine*, *380*, 1450–1462.

[107] World Health Organization. (2018). *Noncommunicable diseases country profiles 2018*. https://apps.who.int/iris/bitstream/handle/10665/274512/9789241514620-eng.pdf.

[108] Wu, R., Guo, W., Qiu, X., Wang, S., Sui, C., Lian, Q., et al. (2021). Comprehensive analysis of spatial architecture in primary liver cancer. *Science Advances*, *7*(51). eabg3750.

[109] Wu, C., Lin, J., Weng, Y., Zeng, D.-N., Xu, J., Luo, S., et al. (2020). Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. *The Journal of Clinical Investigation*, *130*(9), 4679–4693.

[110] Xu, X., Tao, Y., Shan, L., Chen, R., Jiang, H., Qian, Z., et al. (2018). The role of MicroRNAs in hepatocellular carcinoma. *Journal of Cancer*, *9*(19), 3557–3569.

[111] Xue, R., Li, R., Guo, H., Guo, L., Su, Z., Ni, X., et al. (2016). Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma. *Gastroenterology*, *150*(4), 998–1008.

[112] Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019). A global view of hepatocellular carcinoma: Trends, risk, prevention and management. *Nature Reviews Gastroenterology & Hepatology*, *16*, 589–604.

[113] Yin, Z., Dong, C., Jiang, K., Xu, Z., Li, R., Guo, K., et al. (2019). Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma. *Journal of Hematology & Oncology*, *12*(1), 101.

[114] Zhai, W., Lim, T. K.-H., Zhang, T., Phang, S.-T., Tiang, Z., Guan, P., et al. (2017). The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. *Nature Communications*, *8*, 4565.

[115] Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Goa, R., et al. (2019). Landscape and dynamics of single immune cells in hepatocellular carcinoma. *Cell*, *179*(4), 829–845.

[116] Zhang, Q., Lou, Y., Yang, J., Wang, J., Feng, J., Zhao, Y., et al. (2019). Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. *Gut*, *68*(11), 2019–2031.

[117] Zhang, Y., Liu, Z., Ji, K., Li, X., Wang, C., Ren, Z., et al. (2021). Clinical application value of circulating cell-free DNA in hepatocellular carcinoma. *Frontiers in Molecular Biosciences*, *8*, 736330.

[118] Zhao, Y., Li, Z.-X., Zhu, Y.-J., Fu, J., Zhao, X.-F., Zhang, Y.-N., et al. (2021). Single-cell transcriptome analysis uncovers intratumoral heterogeneity and underlying mechanisms for drug resistance in hepatobiliary tumor organoids. *Advancement of Science*, *8*(11), e2003897.

[119] Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., et al. (2018). Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *The Lancet Oncology*, *19*(7), 940–952.

[120] Zhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., et al. (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*, *20*(2), 282–296.

[121] Zhu, J., Zhang, T., Li, J., Lin, J., Liang, W., Huang, W., et al. (2019). Association between tumor mutation burden (TMB)

and outcomes of cancer patients treated with PD-1/PD-L1 inhibitions: A meta-analysis. *Frontiers in Pharmacology*, *10*, 673.

5 胆管癌的遗传基础解析

[1] Akiyama, T. (1996). The APC gene. *Nihon Rinsho*, *54*(4), 955–959.

[2] Maynard, H., Stadler, Z. K., Berger, M. F., Solit, D. B., Ly, M., Lowery, M. A., et al. (2020). Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. *Cancer*, *126*(9), 1995–2002. https://doi.org/10.1002/cncr.32740.

[3] Attia, J. (2021). *Genetic association andGWAS studies: Principles and applications*. Retrieved from https://www.uptodate.com/contents/genetic-association-and-gwas-studies-principlesand-applications.

[4] Bacon, C., & Rappold, G. A. (2012). The distinct and overlapping phenotypic spectra of FOXP1 and FOXP2 in cognitive disorders. *Human Genetics*, *131*(11), 1687–1698. https://doi.org/10.1007/s00439-012-1193-z.

[5] Barnetson, R. A., Cartwright, N., van Vliet, A., Haq, N., Drew, K., Farrington, S., et al. (2008). Classification of ambiguous mutations in DNA mismatch repair genes identified in a population-based study of colorectal cancer. *Human Mutation*, *29*(3), 367–374. https://doi.org/10.1002/humu.20635.

[6] Beer, N. L., Tribble, N. D., McCulloch, L. J., Roos, C., Johnson, P. R. V., Orho-Melander, M., et al. (2009). The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. *Human Molecular Genetics*, *18*(21), 4081–4088. https://doi.org/10.1093/hmg/ddp357.

[7] Booth, D. R., Heard, R. N., Stewart, G. J., Goris, A., Dobosi, R., Dubois, B., et al. (2009). The expanding genetic overlap between multiple sclerosis and type I diabetes. *Genes and Immunity*, *10*(1), 11–14. https://doi.org/10.1038/gene.2008.83.

[8] Bottini, N., Musumeci, L., Alonso, A., Rahmouni, S., Nika, K., Rostamkhani, M., et al. (2004). A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. *Nature Genetics*, *36*(4), 337–338. https://doi.org/10.1038/ng1323.

[9] Bouchecareilh, M. (2014). Le déficit en alpha-1-antitrypsine. *Medical Science (Paris)*, *30*(10), 889–895. https://doi.org/10.1051/medsci/20143010016.

[10] Braconi, C., & Patel, T. (2010). Cholangiocarcinoma: New insights into disease pathogenesis and biology. *Infectious Disease Clinics of North America*, *24*(4), 871–vii. https://doi.org/10.1016/j.idc.2010.07.006.

[11] Church, J., Heald, B., Burke, C., & Kalady, M. (2012). Understanding MYH-associated neoplasia. *Diseases of the Colon & Rectum*, *55*(3). Retrieved from https://journals.lww.com/dcrjournal/Fulltext/2012/03000/Understanding_MYH_Associated_Neoplasia.19.aspx.

[12] Dai, G., Liu, P., Li, X., Zhou, X., & He, S. (2019). Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis. *Medicine (Baltimore)*, *98*(7), e14324. https://doi.org/10.1097/md.0000000000014324.

[13] Dallosso, A. R., Dolwani, S., Jones, N., Jones, S., Colley, J., Maynard, J., et al. (2008). Inherited predisposition to colorectal adenomas caused by multiple rare alleles of MUTYH but not OGG1, NUDT1, NTH1 or NEIL 1, 2 or 3. *Gut*, *57*(9), 1252–1255. https://doi.org/10.1136/gut.2007.145748.

[14] Ding, X., Wang, K., Wu, Z., Yao, A., Li, J., Jiao, C., et al. (2015). The Ser326Cys polymorphism of hOGG1 is associated with intrahepatic cholangiocarcinoma susceptibility in a Chinese population. *International Journal of Clinical and Experimental Medicine*, *8*(9), 16294–16300. Retrieved from https://pubmed.ncbi.nlm.nih.gov/26629147. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659035/.

[15] Gatto, M., Bragazzi, M. C., Semeraro, R., Napoli, C., Gentile, R., Torrice, A., et al. (2010). Cholangiocarcinoma: Update and future perspectives. *Digestive and Liver Disease*, *42*(4), 253–260. https://doi.org/10.1016/j.dld.2009.12.008.

[16] Ge, Y., Paisie, T. K., Chen, S., & Concannon, P. (2019). UBASH3A regulates the synthesis and dynamics of TCR–CD3 complexes. *The Journal of Immunology*, *203*(11), 2827–2836. https://doi.org/10.4049/jimmunol.1801338.

[17] Hankey, W., Frankel, W. L., & Groden, J. (2018). Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: Implications for therapeutic targeting. *Cancer Metastasis Reviews*, *37*(1), 159–172. https://doi.org/10.1007/s10555-017-9725-6.

[18] Hoblinger, A., Grunhage, F., Sauerbruch, T., & Lammert, F. (2009). Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 gene (MRP2/ABCC2) with susceptibility to bile duct cancer. *Digestion*, *80*(1), 36–39. https://doi.org/10.1159/000212990.

[19] Ilonen, J., Lempainen, J., & Veijola, R. (2019). The heterogeneous pathogenesis of type 1 diabetes mellitus. *Nature*

Reviews Endocrinology, *15*(11), 635–650. https://doi.org/10.1038/s41574-019-0254-y.

[20] Jedlitschky, G., Hoffmann, U., & Kroemer, H. K. (2006). Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. *Expert Opinion on Drug Metabolism & Toxicology*, *2*(3), 351–366. https://doi.org/10.1517/17425255.2.3.351.

[21] Ji, S.-G., Juran, B. D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., et al. (2017). Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. *Nature Genetics*, *49*(2), 269–273. https://doi.org/10.1038/ng.3745.

[22] Jing, W., Jin, G., Zhou, X., Zhou, Y., Zhang, Y., Shao, C., et al. (2012). Diabetes mellitus and increased risk of cholangiocarcinoma: A meta-analysis. *European Journal of Cancer Prevention*, *21*(1), 24–31. https://doi.org/10.1097/CEJ.0b013e3283481d89.

[23] Karlsen, T. H., Franke, A., Melum, E., Kaser, A., Hov, J. R., Balschun, T., et al. (2010). Genome-wide association analysis in primary sclerosing cholangitis. *Gastroenterology*, *138*(3), 1102–1111. https://doi.org/10.1053/j.gastro.2009.11.046.

[24] Kasela, M., Nyström, M., & Kansikas, M. (2019). PMS2 expression decrease causes severe problems in mismatch repair. *Human Mutation*, *40*(7), 904–907. https://doi.org/10.1002/humu.23756.

[25] Kawaguchi, M., Orikawa, H., Baba, T., Fukushima, T., & Kataoka, H. (2009). Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophagestimulating protein. *The FEBS Journal*, *276*(13), 3481–3490. https://doi.org/10.1111/j.1742-4658.2009.07070.x.

[26] Kawakami, A., & Fisher, D. E. (2017). The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. *Laboratory Investigation*, *97*(6), 649–656. https://doi.org/10.1038/labinvest.2017.9.

[27] Khan, A. S., & Dageforde, L. A. (2019). Cholangiocarcinoma. *Surgical Clinics of North America*, *99*(2), 315–335. https://doi.org/10.1016/j.suc.2018.12.004.

[28] Khan, S. A., Tavolari, S., & Brandi, G. (2019). Cholangiocarcinoma: Epidemiology and risk factors. *Liver International*, *39*(S1), 19–31. https://doi.org/10.1111/liv.14095.

[29] Khan, S. A., Toledano, M. B., & Taylor-Robinson, S. D. (2008). Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. *HPB: The Official Journal of the International Hepato Pancreato Biliary Association*, *10*(2), 77–82. https://doi.org/10.1080/13651820801992641.

[30] Komiya, Y., & Habas, R. (2008). Wnt signal transduction pathways. *Organogenesis*, *4*(2), 68–75. https://doi.org/10.4161/org.4.2.5851.

[31] Krawczyk, M., Höblinger, A., Mihalache, F., Grünhage, F., Acalovschi, M., Lammert, F., et al. (2013). Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma. *Digestive and Liver Disease*, *45*(7), 612–615. https://doi.org/10.1016/j.dld.2012.12.017.

[32] Kwon, J. M., & Goate, A. M. (2000). The candidate gene approach. *Alcohol Research & Health*, *24*(3), 164–168.

[33] Lampropoulou, D. I., Laschos, K., Aravantinos, G., Georgiou, K., Papiris, K., Theodoropoulos, G., et al. (2021). Association between homeobox protein transcript antisense intergenic ribonucleic acid genetic polymorphisms and cholangiocarcinoma. *World Journal of Clinical Cases*, *9*(8), 1785–1792. https://doi.org/10.12998/wjcc.v9.i8.1785.

[34] Lee, J. Y., Keane, M. G., & Pereira, S. (2015). Diagnosis and treatment of gallstone disease. *Practitioner*, *259*(1783), 15–19 (12).

[35] Lee, T. Y., Lee, S. S., Jung, S. W., Jeon, S. H., Yun, S. C., Oh, H. C., et al. (2008). Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: A case-control study. *American Journal of Gastroenterology*, *103*(7), 1716–1720. https://doi.org/10.1111/j.1572-0241.2008.01796.x.

[36] Li, J.-S., Han, T.-J., Jing, N., Li, L., Zhang, X.-H., Ma, F.-Z., et al. (2014). Obesity and the risk of cholangiocarcinoma: A meta-analysis. *Tumor Biology*, *35*(7), 6831–6838. https://doi.org/10.1007/s13277-014-1939-4.

[37] Lipshutz, G. S., Brennan, T. V., & Warren, R. S. (2002). Thorotrast-induced liver neoplasia: A collective review. *Journal of the American College of Surgeons*, *195*(5), 713–718. https://doi.org/10.1016/S1072-7515(02)01287-5.

[38] Liu, Y., & Lu, L.-Y. (2020). BRCA1 and homologous recombination: Implications from mouse embryonic development. *Cell & Bioscience*, *10*(1), 49. https://doi.org/10.1186/s13578-020-00412-4.

[39] Loos, R. J. F., & Yeo, G. S. H. (2022). The genetics of obesity: From discovery to biology. *Nature Reviews Genetics*, *23*(2), 120–133. https://doi.org/10.1038/s41576-021-00414-z.

[40] Louie, B. H., & Kurzrock, R. (2020). BAP1: Not just a BRCA1-associated protein. *Cancer Treatment Reviews*, *90*, 102091. https://doi.org/10.1016/j.ctrv.2020.102091.

[41] Mellon, I., Rajpal, D. K., Koi, M., Boland, C. R., & Champe, G. N. (1996). Transcription-coupled repair deficiency and

mutations in human mismatch repair genes. *Science*, *272* (5261), 557–560. https://doi.org/10.1126/science.272.5261.557.

[42] Melum, E., Franke, A., Schramm, C., Weismüller, T. J., Gotthardt, D. N., Offner, F. A., et al. (2011). Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. *Nature Genetics*, *43*(1), 17–19. https://doi.org/10.1038/ng.728.

[43] Mihalache, F., Höblinger, A., Grünhage, F., Krawczyk, M., Gärtner, B. C., Acalovschi, M., et al. (2011). Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. *Alimentary Pharmacology & Therapeutics*, *33*(3), 389–394. https://doi.org/10.1111/j.1365-2036.2010.04534.x.

[44] Minde, D. P., Anvarian, Z., Rüdiger, S. G., & Maurice, M. M. (2011). Messing up disorder: How do missense mutations in the tumor suppressor protein APC lead to cancer? *Molecular Cancer*, *10*, 101. https://doi.org/10.1186/1476-4598-10-101.

[45] Mitchell, E. L., & Khan, Z. (2017). Liver disease in alpha-1 antitrypsin deficiency: Current approaches and future directions. *Current Pathobiology Reports*, *5*(3), 243–252. https://doi.org/10.1007/s40139-017-0147-5.

[46] Mosaad, Y. M. (2015). Clinical role of human leukocyte antigen in health and disease. *Scandinavian Journal of Immunology*, *82*(4), 283–306. https://doi.org/10.1111/sji.12329.

[47] Mozdarani, H., Ezzatizadeh, V., & Rahbar Parvaneh, R. (2020). The emerging role of the long non-coding RNA HOTAIR in breast cancer development and treatment. *Journal of Translational Medicine*, *18*(1), 152. https://doi.org/10.1186/s12967-020-02320-0.

[48] Noble, J. A., & Valdes, A. M. (2011). Genetics of the HLA region in the prediction of type 1 diabetes. *Current Diabetes Reports*, *11*(6), 533–542. https://doi.org/10.1007/s11892-011-0223-x.

[49] Nooron, N., Ohba, K., Takeda, K., Shibahara, S., & Chiabchalard, A. (2017). Dysregulated expression of MITF in subsets of hepatocellular carcinoma and cholangiocarcinoma. *Tohoku Journal of Experimental Medicine*, *242*(4), 291–302. https://doi.org/10.1620/tjem.242.291.

[50] Ogi, T., Limsirichaikul, S., Overmeer, R. M., Volker, M., Takenaka, K., Cloney, R., et al. (2010). Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. *Molecular Cell*, *37*(5), 714–727. https://doi.org/10.1016/j.molcel.2010.02.009.

[51] Olivier, J.-F., Fodil, N., Al Habyan, S., Gopal, A., Artusa, P., Mandl, J. N., et al. (2020). CCDC88B is required for mobility and inflammatory functions of dendritic cells. *Journal of Leukocyte Biology*, *108*(6), 1787–1802. https://doi.org/10.1002/JLB.3A0420-386R.

[52] Petrick, J. L., Yang, B., Altekruse, S. F., Van Dyke, A. L., Koshiol, J., Graubard, B. I., et al. (2017). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare. *PLoS One*, *12*(10), e0186643. https://doi.org/10.1371/journal.pone.0186643.

[53] Pitsikas, P., Lee, D., & Rainbow, A. J. (2007). Reduced host cell reactivation of oxidative DNA damage in human cells deficient in the mismatch repair gene hMSH2. *Mutagenesis*, *22* (3), 235–243. https://doi.org/10.1093/mutage/gem008.

[54] Pittman, D. L., Weinberg, L. R., & Schimenti, J. C. (1998). Identification, characterization, and genetic mapping of Rad51d, a new mouse and human RAD51/RecA-related gene. *Genomics*, *49*(1), 103–111. https://doi.org/10.1006/geno.1998.5226.

[55] Poomphakwaen, K., Promthet, S., Kamsa-Ard, S., Vatanasapt, P., Chaveepojnkamjorn, W., Klaewkla, J., et al. (2009). Risk factors for cholangiocarcinoma in Khon Kaen, Thailand: A nested case-control study. *Asian Pacific Journal of Cancer Prevention*, *10*(2), 251–258.

[56] Prawan, A., Kukongviriyapan, V., Tassaneeyakul, W., Pairojkul, C., & Bhudhisawasdi, V. (2005). Association between genetic polymorphisms of CYP1A2, arylamine N-acetyltransferase 1 and 2 and susceptibility to cholangiocarcinoma. *European Journal of Cancer Prevention*, *14*(3). Retrieved from https://journals.lww.com/eurjcancerprev/Fulltext/2005/06000/Association_between_genetic_polymorphisms_of.8.aspx.

[57] Prayong, P., Mairiang, E., Pairojkul, C., Chamgramol, Y., Mairiang, P., Bhudisawasdi, V., et al. (2014). An interleukin-6 receptor polymorphism is associated with opisthorchiasis-linked cholangiocarcinoma risk in Thailand. *Asian Pacific Journal of Cancer Prevention*, *15*(13), 5443–5447. https://doi.org/10.7314/apjcp.2014.15.13.5443.

[58] Prindle, M. J., & Loeb, L. A. (2012). DNA polymerase delta in DNA replication and genome maintenance. *Environmental and Molecular Mutagenesis*, *53*(9), 666–682. https://doi.org/10.1002/em.21745.

[59] Rao, J. R., Keating, D. J., Chen, C., & Parkington, H. C. (2012). Adiponectin increases insulin content and cell proliferation in MIN6 cells via PPARγ-dependent and PPARγ-independent mechanisms. *Diabetes, Obesity and Metabolism*, *14*(11), 983–989. https://doi.org/10.1111/j.1463-1326.2012.01626.x.

[60] Rebholz, C., Krawczyk, M., & Lammert, F. (2018). Genetics of gallstone disease. *European Journal of Clinical*

Investigation, *48*(7), e12935. https://doi.org/10.1111/eci.12935.

[61] Rizvi, S., & Gores, G. J. (2013). Pathogenesis, diagnosis, and management of cholangiocarcinoma. *Gastroenterology*, *145*(6), 1215–1229. https://doi.org/10.1053/j.gastro.2013.10.013.

[62] Şahin, S., Rüstemoğlu, A., Tekcan, A., Taşliyurt, T., Güven, H., & Yiğit, S. (2013). Investigation of associations between obesity and LEP G2548A and LEPR 668A/G polymorphisms in a Turkish population. *Disease Markers*, *35*(6), 673–677. https://doi.org/10.1155/2013/216279.

[63] Sakoda, L. C., Gao, Y.-T., Chen, B. E., Chen, J., Rosenberg, P. S., Rashid, A., et al. (2005). Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: A population-based study in Shanghai, China. *Carcinogenesis*, *27*(6), 1251–1256. https://doi.org/10.1093/carcin/bgi314.

[64] Shaib, Y., & El-Serag, H. B. (2004). The epidemiology of cholangiocarcinoma. *Seminars in Liver Disease*, *24*(2), 115–125. https://doi.org/10.1055/s-2004-828889.

[65] Sharp, R.C., Abdulrahim, M., Naser, E. S., & Naser, S. A. (2015). Genetic variations ofPTPN2 and PTPN22: Role in the pathogenesis of type 1 diabetes and Crohn's disease. *Frontiers in Cellular and Infection Microbiology*, *5*, 95. https://doi.org/10.3389/fcimb.2015.00095.

[66] Shulenin, S., Schriml, L. M., Remaley, A. T., Fojo, S., Brewer, B., Allikmets, R., et al. (2001). An ATP-binding cassette gene (ABCG5) from the ABCG (white) gene subfamily maps to human chromosome 2p21 in the region of the Sitosterolemia locus. *Cytogenetics and Cell Genetics*, *92*(3–4), 204–208. https://doi.org/10.1159/000056903.

[67] Smith, B.W., & Adams, L. A. (2011). Non-alcoholic fatty liver disease. *CriticalReviews in Clinical Laboratory Sciences*, *48*(3), 97–113. https://doi.org/10.3109/10408363.2011.596521.

[68] Speliotes, E. K., Yerges-Armstrong, L. M., Wu, J., Hernaez, R., Kim, L. J., Palmer, C. D., et al. (2011). Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. *PLoS Genetics*, *7*(3), e1001324. https://doi.org/10.1371/journal.pgen.1001324.

[69] Srivastava, D. S. L., Aggarwal, K., & Singh, G. (2020). Is NAT2 gene polymorphism associated with vitiligo? *Indian Journal of Dermatology*, *65*(3), 173–177. https://doi.org/10.4103/ijd.IJD_388_18.

[70] Tang, Q., & Hann, S. S. (2018). HOTAIR: An oncogenic long non-coding RNA in human Cancer. *Cellular Physiology and Biochemistry*, *47*(3), 893–913. https://doi.org/10.1159/000490131.

[71] Truninger, K., Menigatti, M., Luz, J., Russell, A., Haider, R., Gebbers, J.-O., et al. (2005). Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal Cancer. *Gastroenterology*, *128*(5), 1160−1171. https://doi.org/10.1053/j.gastro.2005.01.056.

[72] van der Klaauw, A., Keogh, J., Henning, E., Stephenson, C., Trowse, V. M., Fletcher, P., et al. (2015). Role of melanocortin signalling in the preference for dietary macronutrients in human beings. *Lancet*, *385*(Suppl 1), S12. https://doi.org/10.1016/s0140-6736(15)60327-0.

[73] Wardell, C. P., Fujita, M., Yamada, T., Simbolo, M., Fassan, M., Karlic, R., et al. (2018). Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. *Journal of Hepatology*, *68*(5), 959–969. https://doi.org/10.1016/j.jhep.2018.01.009.

[74] Willer, C. J., Bonnycastle, L. L., Conneely, K. N., Duren, W. L., Jackson, A. U., Scott, L. J., et al. (2007). Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes. *Diabetes*, *56*(1), 256–264. https://doi.org/10.2337/db06-0461.

[75] Wolf, J., Rose-John, S., & Garbers, C. (2014). Interleukin-6 and its receptors: A highly regulated and dynamic system. *Cytokine*, *70*(1), 11–20. https://doi.org/10.1016/j.cyto.2014.05.024.

[76] Wongjarupong, N., Assavapongpaiboon, B., Susantitaphong, P., Cheungpasitporn, W., Treeprasertsuk, S., Rerknimitr, R., et al. (2017). Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: A systematic review and meta-analysis. *BMC Gastroenterology*, *17*(1), 149. https://doi.org/10.1186/s12876-017-0696-4.

[77] Wu, S., Zhou, J., Zhang, K., Chen, H., Luo, M., Lu, Y., et al. (2020). Molecular mechanisms of PALB2 function and its role in breast Cancer management. *Frontiers in Oncology*, *10*. https://doi.org/10.3389/fonc.2020.00301.

[78] Yang, H., Jeffrey, P. D., Miller, J., Kinnucan, E., Sun, Y., Thoma, N. H., et al. (2002).BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. *Science*, *297*(5588), 1837−1848. https://doi.org/10.1126/science.297.5588.1837.

[79] Yang, J. D., Kim, B., Sanderson, S. O., Sauver, J. S., Yawn, B. P., Larson, J. J., et al. (2012). Biliary tract cancers in Olmsted County, Minnesota, 1976-2008. *American Journal of Gastroenterology* , *107*(8), 1256–1262. https://doi.org/10.1038/ajg.2012.173.

[80] Yeo, G. S. H., Chao, D. H. M., Siegert, A. M., Koerperich, Z. M., Ericson, M. D., Simonds, S. E., et al. (2021). The melanocortin pathway and energy homeostasis: From discovery to obesity therapy. *Molecular Metabolism*, *48*, 101206. https://doi.org/10.1016/j.molmet.2021.101206.

[81] Yin, J., & Zhang, J. (2011). Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application. *Zhong Nan Da Xue Xue Bao. Yi Xue Ban*, *36*(10), 927–938. https://doi.org/10.3969/j.issn.1672-7347.2011.10.002.

[82] Zhou, Y., Zhao, Y., Li, B., Huang, J., Wu, L., Xu, D., et al. (2012). Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: Evidence from a meta-analysis. *BMC Cancer*, *12* , 289. https://doi.org/10.1186/1471-2407-12-289.

6 胆道系统肿瘤分子和免疫亚型的新见解

[1] Abdel-Wahab, R., Yap, T. A., Madison, R., Pant, S., Cooke, M., Wang, K., et al. (2020). Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. *Scientific Reports*, *10*, 22087.

[2] Abou-Alfa, G. K., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., et al. (2020). Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. *The Lancet Oncology*, *21*, 796–807.

[3] Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., et al. (2020). Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. *The Lancet Oncology*, *21*, 671–684.

[4] Affo, S., Nair, A., Brundu, F., Ravichandra, A., Bhattacharjee, S., Matsuda, M., et al. (2021). Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. *Cancer Cell*, *39*, 866–882, (e811).

[5] Ahn, K. S., O'Brien, D., Kang, Y. N., Mounajjed, T., Kim, Y. H., Kim, T. S., et al. (2019). Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecularclinical analysis and potential targeted approach. *Hepatology International*, *13*, 490–500.

[6] Akita, M., Sofue, K., Fujikura, K., Otani, K., Itoh, T., Ajiki, T., et al. (2019). Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma. *HPB: The Official Journal of the International Hepato Pancreato Biliary Association*, *21*, 226–234.

[7] Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., et al. (2012). Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. *Gastroenterology*, *142*(4).

[8] Arai, Y., Totoki, Y., Hosoda, F., Shirota, T., Hama, N., Nakamura, H., et al. (2014). Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. *Hepatology*, *59*, 1427–1434.

[9] Banales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., et al. (2016). Expert consensus document: Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). *Nature Reviews. Gastroenterology & Hepatology*, *13*, 261–280.

[10] Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., et al. (2020). Cholangiocarcinoma 2020: The next horizon in mechanisms and management. *Nature Reviews. Gastroenterology & Hepatology*, *17*, 557–588.

[11] Benavides, M., Anton, A., Gallego, J., Gomez, M. A., Jimenez-Gordo, A., La Casta, A., et al. (2015). Biliary tract cancers: SEOM clinical guidelines. *Clinical & Translational Oncology*, *17* , 982–987.

[12] Boerner, T., Drill, E., Pak, L. M., Nguyen, B., Sigel, C. S., Doussot, A., et al. (2021). Genetic determinants of outcome in intrahepatic cholangiocarcinoma. *Hepatology*, *74*, 1429–1444.

[13] Boileve, A., Verlingue, L., Hollebecque, A., Boige, V., Ducreux, M., & Malka, D. (2021). Rare cancer, rare alteration: The case of NTRK fusions in biliary tract cancers. *Expert Opinion on Investigational Drugs*, *30*, 401–409.

[14] Bonneville, R., Krook, M. A., Kautto, E. A., Miya, J., Wing, M. R., Chen, H. Z., et al. (2017). Landscape of microsatellite instability across 39 cancer types. *JCO Precision Oncology*, *2017* .

[15] Borad, M. J., Champion, M. D., Egan, J. B., Liang, W. S., Fonseca, R., Bryce, A. H., et al. (2014). Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. *PLoS Genetics*, *10*, e1004135.

[16] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, *68*, 394–424.

[17] Bridgewater, J., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J. W., Patel, T., et al. (2014). Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. *Journal of Hepatology* , *60*, 1268–1289.

[18] Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017). Targeting DNA repair in cancer: Beyond PARP inhibitors. *Cancer Discovery*, *7*, 20–37.

[19] Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., et al. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature*, *575*, 217–223.

[20] Cao, J., Hu, J., Liu, S., Meric-Bernstam, F., Abdel-Wahab, R., Xu, J., et al. (2020). Intrahepatic cholangiocarcinoma: Genomic heterogeneity between eastern and Western patients. JCO precis. *Oncologia*, *4*.

[21] Carapeto, F., Bozorgui, B., Shroff, R. T., Chagani, S., Solis Soto, L., Foo, W. C., et al. (2021). The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. *Hepatology*.

[22] Chae, H., Kim, D., Yoo, C., Kim, K. P., Jeong, J. H., Chang, H. M., et al. (2019). Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. *European Journal of Cancer*, *120*, 31–39.

[23] Chaisaingmongkol, J., Budhu, A., Dang, H., Rabibhadana, S., Pupacdi, B., Kwon, S. M., et al. (2017). Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. *Cancer Cell*, *32*(57–70), e53.

[24] Chakravarty, D., Gao, J., Phillips, S. M., Kundra, R., Zhang, H., Wang, J., et al. (2017). OncoKB: A precision oncology Knowledge Base. *JCO Precision Oncology*, *2017*.

[25] Chan-On, W., Nairismagi, M. L., Ong, C. K., Lim, W. K., Dima, S., Pairojkul, C., et al. (2013). Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. *Nature Genetics*, *45*, 1474–1478.

[26] Chen, S., Xie, Y., Cai, Y., Hu, H., He, M., Liu, L., et al. (2021). Multiomic analysis reveals comprehensive tumor heterogeneity and distinct immune subtypes in multifocal intrahepatic cholangiocarcinoma. *Clinical Cancer Research*.

[27] Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., et al. (2008). Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. *Cancer Research*, *68*, 6779–6788.

[28] Chuaysri, C., Thuwajit, P., Paupairoj, A., Chau-In, S., Suthiphongchai, T., & Thuwajit, C. (2009). Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. *Oncology Reports*, *21*, 957–969.

[29] Deveson, I. W., Gong, B., Lai, K., LoCoco, J. S., Richmond, T. A., Schageman, J., et al. (2021). Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. *Nature Biotechnology*, *39*, 1115–1128.

[30] Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., et al. (2020). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials. *The Lancet Oncology*, *21*, 271–282.

[31] Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., et al. (2018). Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children. *The New England Journal of Medicine*, *378*, 731–739.

[32] Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., et al. (2020). Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1-2 trials. *The Lancet Oncology*, *21*, 261–270.

[33] Farshidfar, F., Zheng, S., Gingras, M. C., Newton, Y., Shih, J., Robertson, A. G., et al. (2017). Integrative genomic analysis of cholangiocarcinoma identifies distinct IDHmutant molecular profiles. *Cell Reports*, *18*, 2780–2794.

[34] Goeppert, B., Folseraas, T., Roessler, S., Kloor, M., Volckmar, A. L., Endris, V., et al. (2020). Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals therapeutic opportunities. *Hepatology*, *72*, 1253–1266.

[35] Goeppert, B., Roessler, S., Renner, M., Singer, S., Mehrabi, A., Vogel, M. N., et al. (2019). Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. *British Journal of Cancer*, *120*, 109–114.

[36] Goeppert, B., Toth, R., Singer, S., Albrecht, T., Lipka, D. B., Lutsik, P., et al. (2019). Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma. *Hepatology*, *69*, 2091–2106.

[37] Goyal, L., Saha, S. K., Liu, L. Y., Siravegna, G., Leshchiner, I., Ahronian, L. G., et al. (2017). Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. *Cancer Discovery*, *7*, 252–263.

[38] Goyal, L., Shi, L., Liu, L. Y., Fece De La Cruz, F., Lennerz, J. K., Raghavan, S., et al. (2019). TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. *Cancer Discovery*, *9*, 1064–1079.

[39] Graham, R. P., Barr Fritcher, E. G., Pestova, E., Schulz, J., Sitailo, L. A., Vasmatzis, G., et al. (2014). Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. *Human Pathology*, *45*, 1630–1638.

[40] Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., et al. (2021). BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. *Cancer Discovery*, *11*, 142–157.

[41] Hoshida, Y., Nijman, S. M., Kobayashi, M., Chan, J. A., Brunet, J. P., Chiang, D. Y., et al. (2009). Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. *Cancer Research*, *69*, 7385–7392.

[42] Isa, T., Tomita, S., Nakachi, A., Miyazato, H., Shimoji, H., Kusano, T., et al. (2002). Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. *Hepato-Gastroenterology*, *49*, 604–608.

[43] Jacobi, O., Ross, J. S., Goshen-Lago, T., Haddad, R., Moore, A., Sulkes, A., et al. (2021). ERBB2 pathway in biliary tract carcinoma: Clinical implications of a targetable pathway. *Oncology Research and Treatment*, *44*, 20–27.

[44] Javle, M., Roychowdhury, S., Kelley, R. K., Sadeghi, S., Macarulla, T., Weiss, K. H., et al. (2021). Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet. *Gastroenterología y Hepatología*.

[45] Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., et al. (2013). Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nature Genetics*, *45*, 1470–1473.

[46] Job, S., Rapoud, D., Dos Santos, A., Gonzalez, P., Desterke, C., Pascal, G., et al. (2020). Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. *Hepatology*, *72*, 965–981.

[47] Jusakul, A., Cutcutache, I., Yong, C. H., Lim, J. Q., Huang, M. N., Padmanabhan, N., et al. (2017). Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. *Cancer Discovery*, *7*, 1116–1135.

[48] Kim, S. G., Chan, A. O., Wu, T. T., Issa, J. P., Hamilton, S. R., & Rashid, A. (2003). Epigenetic and genetic alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas. *Gastroenterology*, *124*, 1300–1310.

[49] Konecny, G. E., & Kristeleit, R. S. (2016). PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: Current practice and future directions. *British Journal of Cancer*, *115*, 1157–1173.

[50] Kongpetch, S., Jusakul, A., Lim, J. Q., Ng, C. C. Y., Chan, J. Y., Rajasegaran, V., et al. (2020). Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma. *JCO Global Oncology*, *6*, 628–638.

[51] Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., et al. (2021). Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial. *The Lancet Oncology*, *22*, 690–701.

[52] Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., et al. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*, *357* , 409–413.

[53] Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., et al. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. *The New England Journal of Medicine* , *372*, 2509–2520.

[54] Lee, J. M., Ledermann, J. A., & Kohn, E. C. (2014). PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. *Annals of Oncology*, *25*, 32–40.

[55] Li, M., Liu, F., Zhang, F., Zhou, W., Jiang, X., Yang, Y., et al. (2019). Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: A whole-exome sequencing analysis. *Gut*, *68*, 1024–1033.

[56] Li, M., Zhang, Z., Li, X., Ye, J., Wu, X., Tan, Z., et al. (2014). Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. *Nature Genetics*, *46*, 872–876.

[57] Liu, X. S., & Mardis, E. R. (2017). Applications of immunogenomics to cancer. *Cell*, *168*, 600–612.

[58] Lowery, M. A., Ptashkin, R., Jordan, E., Berger, M. F., Zehir, A., Capanu, M., et al. (2018). Comprehensivemolecular profiling of intrahepatic and extrahepatic Cholangiocarcinomas: Potential targets for intervention. *Clinical Cancer Research*, *24*, 4154–4161.

[59] Marcus, L., Donoghue, M., Aungst, S., Myers, C. E., Helms, W. S., Shen, G., et al. (2021). FDA approval summary: Entrectinib for the treatment of NTRK gene fusion solid tumors. *Clinical Cancer Research*, *27*, 928–932.

[60] Martin-Serrano, M. A., Kepecs, B., Torres, M., Bramel, E., Haber, P., Maeda, M., et al. (2021). A novel stroma, tumor, immune microenvironment-based classification of intrahepatic cholangiocarcinoma. In *AASLD Conference 2021,*

Publication Number 197.

[61] McNamara, M. G., Lopes, A., Wasan, H., Malka, D., Goldstein, D., Shannon, J., et al. (2020). Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. *Journal of Hepatology*, *73*, 1109–1117.

[62] Momoi, H., Itoh, T., Nozaki, Y., Arima, Y., Okabe, H., Satoh, S., et al. (2001). Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma. *Journal of Hepatology* , *35*, 235–244.

[63] Montal, R., Sia, D., Montironi, C., Leow, W. Q., Esteban-Fabró , R., Pinyol, R., et al. (2020). Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. *Journal of Hepatology*, *73*, 315–327.

[64] Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020). RAS-targeted therapies: Is the undruggable drugged? *Nature Reviews. Drug Discovery*, *19*, 533–552.

[65] Nakamura, H., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., et al. (2015). Genomic spectra of biliary tract cancer. *Nature Genetics*, *47*, 1003−1010.

[66] Nakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., et al. (2020). Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. *Nature Medicine*, *26*, 1859−1864.

[67] Nepal, C., O'Rourke, C. J., Oliveira, D., Taranta, A., Shema, S., Gautam, P., et al. (2018). Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. *Hepatology*, *68*, 949–963.

[68] Nepal, C., Zhu, B., O'Rourke, C. J., Bhatt, D. K., Lee, D., Song, L., et al. (2021). Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes. *Journal of Hepatology*, *74*, 1132–1144.

[69] Oishi, N., Kumar, M. R., Roessler, S., Ji, J., Forgues, M., Budhu, A., et al. (2012). Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. *Hepatology*, *56*, 1792–1803.

[70] Ong, C. K., Subimerb, C., Pairojkul, C., Wongkham, S., Cutcutache, I., Yu, W., et al. (2012). Exome sequencing of liver fluke-associated cholangiocarcinoma. *Nature Genetics*, *44*, 690–693.

[71] Pandey, A., Stawiski, E. W., Durinck, S., Gowda, H., Goldstein, L. D., Barbhuiya, M. A., et al. (2020). Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate. *Nature Communications*, *11*, 4225.

[72] Piha-Paul, S. A., Oh, D. Y., Ueno, M., Malka, D., Chung, H. C., Nagrial, A., et al. (2020). Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. *International Journal of Cancer*, *147*, 2190–2198.

[73] Rawla, P., Sunkara, T., Thandra, K. C., & Barsouk, A. (2019). Epidemiology of gallbladder cancer. *Journal of Clinical and Experimental Hepatology*, *5*, 93−102.

[74] Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. *Science*, *359*, 1350−1355.

[75] Rizvi, S., & Gores, G. J. (2013). Pathogenesis, diagnosis, and management of cholangiocarcinoma. *Gastroenterology*, *145*, 1215–1229.

[76] Rolfo, C., Ruiz, R., Giovannetti, E., Gil-Bazo, I., Russo, A., Passiglia, F., et al. (2015). Entrectinib: A potent new TRK, ROS1, and ALK inhibitor. *Expert Opinion on Investigational Drugs*, *24*, 1493–1500.

[77] Ross, J. S., Wang, K., Gay, L., Al-Rohil, R., Rand, J. V., Jones, D. M., et al. (2014). New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. *The Oncologist*, *19*, 235–242.

[78] Ross, J., Wang, K., Javle, M., Catenacci, D., Shroff, R., Ali, S., et al. (2015). (2015). Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, *33*(15), 4009.

[79] Saha, S. K., Gordan, J. D., Kleinstiver, B. P., Vu, P., Najem, M. S., Yeo, J. C., et al. (2016). Isocitrate dehydrogenase mutations confer Dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. *Cancer Discovery*, *6*, 727−739.

[80] Saha, S. K., Parachoniak, C. A., Ghanta, K. S., Fitamant, J., Ross, K. N., Najem, M. S., et al. (2014). Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. *Nature*, *513*, 110−114.

[81] Sia, D., Hoshida, Y., Villanueva, A., Roayaie, S., Ferrer, J., Tabak, B., et al. (2013). Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. *Gastroenterology*, *144*, 829−840.

[82] Sia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., et al. (2015). Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. *Nature Communications*, *6*, 6087.

[83] Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2017). Liver cancer cell of origin, molecular class, and effects on patient prognosis. *Gastroenterology*, *152*, 745–761.

[84] Silverman, I. M., Hollebecque, A., Friboulet, L., Owens, S., Newton, R. C., Zhen, H., et al. (2021). Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to Pemigatinib. *Cancer Discovery*, *11*, 326–339.

[85] Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., et al. (2021). Sotorasib for lung cancers with KRAS p.G12C mutation. *The New England Journal of Medicine*, *384* , 2371–2381.

[86] Spizzo, G., Puccini, A., Xiu, J., Goldberg, R. M., Grothey, A., Shields, A. F., et al. (2020). Molecular profile of BRCA-mutated biliary tract cancers. *ESMO Open*, *5*, e000682.

[87] Sulkowski, P. L., Corso, C. D., Robinson, N. D., Scanlon, S. E., Purshouse, K. R., Bai, H., et al. (2017). 2-hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. *Science Translational Medicine*, *9*.

[88] Tamma, R., Annese, T., Ruggieri, S., Brunetti, O., Longo, V., Cascardi, E., et al. (2019). Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma. *European Journal of Clinical Investigation*, *49*, e13087.

[89] Terashima, T., Umemoto, K., Takahashi, H., Hosoi, H., Takai, E., Kondo, S., et al. (2019). Germline mutations in cancer-predisposition genes in patients with biliary tract cancer. *Oncotarget*, *10*, 5949–5957.

[90] Tyson, G. L., & El-Serag, H. B. (2011). Risk factors for cholangiocarcinoma. *Hepatology*, *54*, 173–184.

[91] Valle, J. W., Borbath, I., Khan, S. A., Huguet, F., Gruenberger, T., Arnold, D., et al. (2016). Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, *27*, v28–v37.

[92] Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017). New horizons for precision medicine in biliary tract cancers. *Cancer Discovery*, *7*, 943–962.

[93] Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., et al. (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *The New England Journal of Medicine*, *362*, 1273–1281.

[94] Wardell, C. P., Fujita, M., Yamada, T., Simbolo, M., Fassan, M., Karlic, R., et al. (2018). Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. *Journal of Hepatology*, *68*, 959–969.

[95] Weinberg, B. A., Xiu, J., Lindberg, M. R., Shields, A. F., Hwang, J. J., Poorman, K., et al. (2019). Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. *Journal of Gastrointestinal Oncology*, *10*, 652–662.

[96] Wu, Y. M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., et al. (2013). Identification of targetable FGFR gene fusions in diverse cancers. *Cancer Discovery*, *3*, 636–647.

[97] Yachida, S., Wood, L. D., Suzuki, M., Takai, E., Totoki, Y., Kato, M., et al. (2016). Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. *Cancer Cell*, *29*, 229–240.

[98] Yoshida, T., Sugai, T., Habano, W., Nakamura, S., Uesugi, N., Funato, O., et al. (2000). Microsatellite instability in gallbladder carcinoma: Two independent genetic pathways of gallbladder carcinogenesis. *Journal of Gastroenterology*, *35*, 768–774.

[99] Zhang, M., Yang, H., Wan, L., Wang, Z., Wang, H., Ge, C., et al. (2020). Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. *Journal of Hepatology*, *73*, 1118–1130.

[100] Zhang, Y., Zuo, C., Liu, L., Hu, Y., Yang, B., Qiu, S., et al. (2021). Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer. *Journal of Hepatology*, *75*, 1128–1141.

[101] Zou, S., Li, J., Zhou, H., Frech, C., Jiang, X., Chu, J. S., et al. (2014). Mutational landscape of intrahepatic cholangiocarcinoma. *Nature Communications*, *5*, 5696.

7 肿瘤相关成纤维细胞在肝内胆管癌进展中的作用和治疗耐药性

[1] Affo, S., Nair, A., Brundu, F., Ravichandra, A., Bhattacharjee, S., Matsuda, M., et al. (2021). Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. *Cancer Cell*, *39*(6), 866–882 e811. https://doi.org/10.1016/j.ccell.2021.03.012.

[2] Aishima, S., Taguchi, K., Sugimachi, K., Asayama, Y., Nishi, H., Shimada, M., et al. (2002). The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma. *International Journal of Surgical Pathology*, *10*(1), 47–56. https://doi.org/10.1177/106689690201000108.

[3] Aishima, S., Taguchi, K., Terashi, T., Matsuura, S., Shimada, M., & Tsuneyoshi, M. (2003). Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma. *Modern Pathology*, *16*(10), 1019–1027. https://doi.org/10.1097/01.MP.0000086860.65672.73.

[4] Augsten, M. (2014). Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. *Frontiers in Oncology*, *4*, 62. https://doi.org/10.3389/fonc.2014.00062.

[5] Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., et al. (2020). Cholangiocarcinoma 2020: The next horizon in mechanisms and management. *Nature Reviews: Gastroenterology & Hepatology*, *17*(9), 557–588. https://doi.org/10.1038/s41575-020-0310-z.

[6] Beatty, G. L., & Gladney, W. L. (2015). Immune escape mechanisms as a guide for cancer immunotherapy. *Clinical Cancer Research*, *21*(4), 687–692. https://doi.org/10.1158/1078-0432.CCR-14-1860.

[7] Bhattacharjee, S., Hamberger, F., Ravichandra, A., Miller, M., Nair, A., Affo, S., et al. (2021). Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. *Journal of Clinical Investigation*, *131*(11). https://doi.org/10.1172/JCI146987.

[8] Biffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y., et al. (2019). IL1-induced JAK/STAT signaling is antagonized by TGFbeta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. *Cancer Discovery*, *9*(2), 282–301. https://doi.org/10.1158/2159-8290.CD-18-0710.

[9] Brandi, G., Farioli, A., Astolfi, A., Biasco, G., & Tavolari, S. (2015). Genetic heterogeneity in cholangiocarcinoma: A major challenge for targeted therapies. *Oncotarget*, *6*(17), 14744–14753. https://doi.org/10.18632/oncotarget.4539.

[10] Brivio, S., Cadamuro, M., Strazzabosco, M., & Fabris, L. (2017). Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness. *World Journal of Hepatology*, *9* (9), 455–468. https://doi.org/10.4254/wjh.v9.i9.455.

[11] Cadamuro, M., Brivio, S., Mertens, J., Vismara, M., Moncsek, A., Milani, C., et al. (2019). Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. *Journal of Hepatology*, *70*(4), 700–709. https://doi.org/10.1016/j.jhep.2018.12.004.

[12] Cadamuro, M., Morton, S. D., Strazzabosco, M., & Fabris, L. (2013). Unveiling the role of tumor reactive stroma in cholangiocarcinoma: An opportunity for new therapeutic strategies. *Translational Gastrointestinal Cancer*, *2*(3), 130–144. https://doi.org/10.3978/j.issn.2224-4778.2013.04.02.

[13] Cadamuro, M., Nardo, G., Indraccolo, S., Dall'olmo, L., Sambado, L., Moserle, L., et al. (2013). Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. *Hepatology*, *58*(3), 1042–1053.https://doi.org/10.1002/hep.26384.

[14] Campbell, D. J., Dumur, C. I., Lamour, N. F., Dewitt, J. L., & Sirica, A. E. (2012). Novel organotypic culture model of cholangiocarcinoma progression. *Hepatology Research*, *42* (11), 1119–1130. https://doi.org/10.1111/j.1872-034X.2012.01026.x.

[15] Carpino, G., Cardinale, V., Di Giamberardino, A., Overi, D., Donsante, S., Colasanti, T., et al. (2021). Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. *Journal of Hepatology*, *75*(6), 1377–1386. https://doi.org/10.1016/j.jhep.2021.07.016.

[16] Chan-On, W., Nairismagi, M. L., Ong, C. K., Lim, W. K., Dima, S., Pairojkul, C., et al. (2013). Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. *Nature Genetics*, *45*(12), 1474–1478. https://doi.org/10.1038/ng.2806.

[17] Chen, J. S., Hsu, C., Chiang, N. J., Tsai, C. S., Tsou, H. H., Huang, S. F., et al. (2015). A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. *Annals of Oncology*, *26*(5), 943–949. https://doi.org/10.1093/annonc/mdv035.

[18] Chen, Y., Kim, J., Yang, S., Wang, H., Wu, C. J., Sugimoto, H., et al. (2021). Type I collagen deletion in αSMA(+) myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. *Cancer Cell*, *39*(4), 548–565 e546. https://doi.org/10.1016/j.ccell.2021.02.007.

[19] Chen, Y., McAndrews, K. M., & Kalluri, R. (2021). Clinical and therapeutic relevance of cancer-associated fibroblasts. *Nature Reviews Clinical Oncology*. https://doi.org/10.1038/s41571-021-00546-5.

[20] Chuaysri, C., Thuwajit, P., Paupairoj, A., Chau-In, S., Suthiphongchai, T., & Thuwajit, C. (2009). Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. *Oncology Reports*, *21*(4), 957–969. https://doi.org/10.3892/or_00000309.

[21] Clapéron, A., Mergey, M., Aoudjehane, L., Ho-Bouldoires, T. H., Wendum, D., Prignon, A., et al. (2013). Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor

receptor. *Hepatology*, *58*(6), 2001–2011. https://doi.org/10.1002/hep.26585.

[22] Dudley, A. C. (2012). Tumor endothelial cells. *Cold Spring Harbor Perspectives in Medicine*, *2*(3), a006536. https://doi.org/10.1101/cshperspect.a006536.

[23] Erkan, M., Reiser-Erkan, C., Michalski, C. W., Deucker, S., Sauliunaite, D., Streit, S., et al. (2009). Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. *Neoplasia*, *11*(5), 497–508. https://doi.org/10.1593/neo.81618.

[24] Fabris, L., Perugorria, M. J., Mertens, J., Bjorkstrom, N. K., Cramer, T., Lleo, A., et al. (2019). The tumour microenvironment and immune milieu of cholangiocarcinoma. *Liver International*, *39*(Suppl. 1), 63–78. https://doi.org/10.1111/liv.14098.

[25] Fabris, L., Sato, K., Alpini, G., & Strazzabosco, M. (2021). The tumor microenvironment in cholangiocarcinoma progression. *Hepatology*, *73*(Suppl. 1), 75–85. https://doi.org/10.1002/hep.31410.

[26] Fan, B., Malato, Y., Calvisi, D. F., Naqvi, S., Razumilava, N., Ribback, S., et al. (2012). Cholangiocarcinomas can originate from hepatocytes in mice. *Journal of Clinical Investigation*, *122* (8), 2911–2915. https://doi.org/10.1172/JCI63212.

[27] Fingas, C. D., Bronk, S. F., Werneburg, N. W., Mott, J. L., Guicciardi, M. E., Cazanave, S. C., et al. (2011). Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. *Hepatology*, *54*(6), 2076–2088. https://doi.org/10.1002/hep.24588.

[28] Fontugne, J., Augustin, J., Pujals, A., Compagnon, P., Rousseau, B., Luciani, A., et al. (2017). PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. *Oncotarget*, *8*(15), 24644–24651. https://doi.org/10.18632/oncotarget.15602.

[29] Frantz, C., Stewart, K. M., & Weaver, V. M. (2010). The extracellular matrix at a glance. *Journal of Cell Science*, *123*(Pt. 24), 4195–4200. https://doi.org/10.1242/jcs.023820.

[30] French, J. J., Midwinter, M. J., Bennett, M. K., Manas, D. M., & Charnley, R. M. (2005). A matrix metalloproteinase inhibitor to treat unresectable cholangiocarcinoma. *HPB: The Official Journal of the International Hepato Pancreato Biliary Association*, *7*(4), 289–291. https://doi.org/10.1080/13651820510042246.

[31] Goyal, L., Muzumdar, M. D., & Zhu, A. X. (2013). Targeting the HGF/c-MET pathway in hepatocellular carcinoma. *Clinical Cancer Research*, *19*(9), 2310–2318. https://doi.org/10.1158/1078-0432.CCR-12-2791.

[32] Goyal, L., Zheng, H., Yurgelun, M. B., Abrams, T. A., Allen, J. N., Cleary, J. M., et al. (2017). A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. *Cancer*, *123*(11), 1979–1988. https://doi.org/10.1002/cncr.30571.

[33] Grasset, E. M., Bertero, T., Bozec, A., Friard, J., Bourget, I., Pisano, S., et al. (2018). Matrix stiffening and EGFR cooperate to promote the collective invasion of cancer cells. *Cancer Research*, *78*(18), 5229–5242. https://doi.org/10.1158/0008-5472.CAN-18-0601.

[34] Hingorani, S. R., Zheng, L., Bullock, A. J., Seery, T. E., Harris, W. P., Sigal, D. S., et al. (2018). HALO 202: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. *Journal of Clinical Oncology*, *36*(4), 359–366. https://doi.org/10.1200/JCO.2017.74.9564.

[35] Hogdall, D., Lewinska, M., & Andersen, J. B. (2018). Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma. *Trends Cancer*, *4*(3), 239–255. https://doi.org/10.1016/j.trecan.2018.01.007.

[36] Iguchi, T., Aishima, S., Taketomi, A., Nishihara, Y., Fujita, N., Sanefuji, K., et al. (2009). Fascin overexpression is involved in carcinogenesis and prognosis of human intrahepatic cholangiocarcinoma: Immunohistochemical and molecular analysis. *Human Pathology*, *40*(2), 174–180. https://doi.org/10.1016/j.humpath.2008.06.029.

[37] Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., et al. (2013). Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nature Genetics*, *45*(12), 1470–1473. https://doi.org/10.1038/ng.2813.

[38] Jodele, S., Blavier, L., Yoon, J. M., & DeClerck, Y. A. (2006). Modifying the soil to affect the seed: Role of stromal-derived matrix metalloproteinases in cancer progression. *Cancer Metastasis Reviews*, *25*(1), 35–43. https://doi.org/10.1007/s10555-006-7887-8.

[39] Kawahara, N., Ono, M., Taguchi, K., Okamoto, M., Shimada, M., Takenaka, K., et al. (1998). Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. *Hepatology*, *28*(6), 1512–1517. https://doi.org/10.1002/hep.510280610.

[40] Kim, Y., Kim, M. O., Shin, J. S., Park, S. H., Kim, S. B., Kim, J., et al. (2014). Hedgehog signaling between cancer cells and hepatic stellate cells in promoting cholangiocarcinoma. *Annals of Surgical Oncology*, *21*(8), 2684–2698. https://doi.org/10.1245/s10434-014-3531-y.

[41] Kojima, Y., Acar, A., Eaton, E. N., Mellody, K. T., Scheel, C., Ben-Porath, I., et al. (2010). Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. *Proceedings of the National Academy of Sciences of the United States of America*, *107*(46), 20009–20014. https://doi.org/10.1073/pnas.1013805107.

[42] Lai, G. H., Radaeva, S., Nakamura, T., & Sirica, A. E. (2000). Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated “intestinal-type” biliary cancer chemically induced in rat liver. *Hepatology*, *31*(6), 1257–1265. https://doi.org/10.1053/jhep.2000.8108.

[43] Lamarca, A., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020). Molecular targeted therapies: Ready for “prime time” in biliary tract cancer. *Journal of Hepatology*, *73*(1), 170–185. https://doi.org/10.1016/j.jhep.2020.03.007.

[44] Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., et al. (2018). Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta. *Science Translational Medicine*, *10*(424). https://doi.org/10.1126/scitranslmed.aan5488.

[45] Le Faouder, J., Gigante, E., Leger, T., Albuquerque, M., Beaufrere, A., Soubrane, O., et al. (2019). Proteomic landscape of cholangiocarcinomas reveals three different subgroups according to their localization and the aspect of non-tumor liver. *Proteomics Clinical Applications*, *13*(1). https://doi.org/10.1002/prca.201800128, e1800128.

[46] LeBleu, V. S., & Kalluri, R. (2018). A peek into cancer-associated fibroblasts: Origins, functions and translational impact. *Disease Models & Mechanisms*, *11*(4). https://doi.org/10.1242/dmm.029447.

[47] Leelawat, K., Leelawat, S., Narong, S., & Hongeng, S. (2007). Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. *World Journal of Gastroenterology*, *13*(10), 1561–1568. https://doi.org/10.3748/wjg.v13.i10.1561.

[48] Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., et al. (2009). Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell*, *139*(5), 891–906. https://doi.org/10.1016/j.cell.2009.10.027.

[49] Leyva-Illades, D., McMillin, M., Quinn, M., & Demorrow, S. (2012). Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment. *Translational Gastrointestinal Cancer*, *1*(1), 71–80.

[50] Lin, Y., Li, B., Yang, X., Cai, Q., Liu, W., Tian, M., et al. (2019). Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment. *Neoplasia*, *21*(12), 1133–1142. https://doi.org/10.1016/j.neo.2019.10.005.

[51] Ling, H., Roux, E., Hempel, D., Tao, J., Smith, M., Lonning, S., et al. (2013). Transforming growth factor beta neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. *PLoS One*, *8*(1), e54499. https://doi.org/10.1371/journal.pone.0054499.

[52] Manzanares, M. A., Usui, A., Campbell, D. J., Dumur, C. I., Maldonado, G. T., Fausther, M., et al. (2017). Transforming growth factors alpha and beta are essential for modeling cholangiocarcinoma desmoplasia and progression in a three-dimensional organotypic culture model. *The American Journal of Pathology*, *187*(5), 1068–1092. https://doi.org/10.1016/j.ajpath.2017.01.013.

[53] McCarthy, J. B., El-Ashry, D., & Turley, E. A. (2018). Hyaluronan, cancer-associated fibroblasts and the tumor microenvironment in malignant progression. *Frontiers in Cell and Developmental Biology*, *6*, 48. https://doi.org/10.3389/fcell.2018.00048.

[54] Mertens, J. C., Fingas, C. D., Christensen, J. D., Smoot, R. L., Bronk, S. F., Werneburg, N. W., et al. (2013). Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. *Cancer Research*, *73*(2), 897–907. https://doi.org/10.1158/0008-5472.CAN-12-2130.

[55] Midwood, K. S., & Orend, G. (2009). The role of tenascin-C in tissue injury and tumorigenesis. *Journal of Cell Communications and Signaling*, *3*(3–4), 287–310. https://doi.org/10.1007/s12079-009-0075-1.

[56] Miyamoto, S., Yagi, H., Yotsumoto, F., Kawarabayashi, T., & Mekada, E. (2006). Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. *Cancer Science*, *97*(5), 341–347. https://doi.org/10.1111/j.1349-7006.2006.00188.x.

[57] Monteran, L., & Erez, N. (2019). The dark side of fibroblasts: Cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. *Frontiers in Immunology*, *10*, 1835. https://doi.org/10.3389/fimmu.2019.01835.

[58] Nagarsheth, N., Wicha, M. S., & Zou, W. (2017). Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. *Nature Reviews Immunology*, *17*(9), 559–572. https://doi.org/10.1038/nri.2017.49.

[59] Nakamura, H., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., et al. (2015). Genomic spectra of biliary tract cancer. *Nature Genetics*, *47*(9), 1003–1010. https://doi.org/10.1038/ng.3375.

[60] Northey, J. J., Przybyla, L., & Weaver, V. M. (2017). Tissue force programs cell fate and tumor aggression. *Cancer Discovery*, *7*(11), 1224–1237. https://doi.org/10.1158/2159-8290.CD-16-0733.

[61] Ohira, S., Sasaki, M., Harada, K., Sato, Y., Zen, Y., Isse, K., et al. (2006). Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. *American Journal of Pathology*, *168*(4), 1155–1168. https://doi.org/10.2353/ajpath.2006.050204.

[62] Okabe, H., Beppu, T., Hayashi, H., Horino, K., Masuda, T., Komori, H., et al. (2009). Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. *Annals of Surgical Oncology*, *16*(9), 2555–2564. https://doi.org/10.1245/s10434-009-0568-4.

[63] Okabe, H., Beppu, T., Ueda, M., Hayashi, H., Ishiko, T., Masuda, T., et al. (2012). Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts. *International Journal of Cancer*, *131*(10), 2234–2241. https://doi.org/10.1002/ijc.27496.

[64] Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., et al. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science*, *324*(5933), 1457–1461. https://doi.org/10.1126/science.1171362.

[65] Ozdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C. C., Simpson, T. R., et al. (2014). Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. *Cancer Cell*, *25*(6), 719–734. https://doi.org/10.1016/j.ccr.2014.04.005.

[66] Prakobwong, S., Yongvanit, P., Hiraku, Y., Pairojkul, C., Sithithaworn, P., Pinlaor, P., et al. (2010). Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model. *International Journal of Cancer*, *127*(11), 2576–2587. https://doi.org/10.1002/ijc.25266.

[67] Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012). Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. *Cancer Cell*, *21*(3), 418–429. https://doi.org/10.1016/j.ccr.2012.01.007.

[68] Raggi, C., Correnti, M., Sica, A., Andersen, J. B., Cardinale, V., Alvaro, D., et al. (2017). Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. *Journal of Hepatology*, *66*(1), 102–115. https://doi.org/10.1016/j.jhep.2016.08.012.

[69] Razumilava, N., & Gores, G. J. (2014). Cholangiocarcinoma. *Lancet*, *383*(9935), 2168–2179. https://doi.org/10.1016/S0140-6736(13)61903-0.

[70] Riener, M. O., Fritzsche, F. R., Soll, C., Pestalozzi, B. C., Probst-Hensch, N., Clavien, P. A., et al. (2010). Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. *Histopathology*, *56*(5), 600–606. https://doi.org/10.1111/j.1365-2559.2010.03527.x.

[71] Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., et al. (2020). A framework for advancing our understanding of cancer-associated fibroblasts. *Nature Reviews Cancer*, *20*(3), 174–186. https://doi.org/10.1038/s41568-019-0238-1.

[72] Sekiya, S., & Suzuki, A. (2012). Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. *Journal of Clinical Investigation*, *122*(11), 3914–3918. https://doi.org/10.1172/JCI63065.

[73] Shi, Y., Riese, D. J., 2nd, & Shen, J. (2020). The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. *Frontiers in Pharmacology*, *11*. https://doi.org/10.3389/fphar.2020.574667, 574667.

[74] Shirabe, K., Shimada, M., Tsujita, E., Aishima, S., Maehara, S., Tanaka, S., et al. (2004). Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis. *American Journal of Surgery*, *187*(4), 538–542. https://doi.org/10.1016/j.amjsurg.2003.12.044.

[75] Sirica, A. E. (2011). The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. *Nature Reviews Gastroenterology & Hepatology*, *9*(1), 44–54. https://doi.org/10.1038/nrgastro.2011.222.

[76] Sirica, A. E., Campbell, D. J., & Dumur, C. I. (2011). Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma. *Current Opinion in Gastroenterolgy*, *27*(3), 276–284. https://doi.org/10.1097/MOG.0b013e32834405c3.

[77] Sirica, A. E., Dumur, C. I., Campbell, D. J., Almenara, J. A., Ogunwobi, O. O., & Dewitt, J. L. (2009). Intrahepatic

cholangiocarcinoma progression: Prognostic factors and basic mechanisms. *Clinical Gastroenterology and Hepatology*, *7*(11 Suppl), S68–S78. https://doi.org/10.1016/j.cgh.2009.08.023.

[78] Sirica, A. E., & Gores, G. J. (2014). Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting. *Hepatology*, *59*(6), 2397–2402. https://doi.org/10.1002/hep.26762.

[79] Sirica, A. E., Strazzabosco, M., & Cadamuro, M. (2021). Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. *Advances in Cancer Research*, *149*, 321–387. https://doi.org/10.1016/bs.acr.2020.10.005.

[80] Tahkola, K., Ahtiainen, M., Mecklin, J. P., Kellokumpu, I., Laukkarinen, J., Tammi, M., et al. (2021). Stromal hyaluronan accumulation is associated with low immune response and poor prognosis in pancreatic cancer. *Scientific Reports*, *11*(1), 12216. https://doi.org/10.1038/s41598-021-91796-x.

[81] Tarbe, N., Losch, S., Burtscher, H., Jarsch, M., & Weidle, U. H. (2002). Identification of rat pancreatic carcinoma genes associated with lymphogenous metastasis. *Anticancer Research*, *22* (4), 2015–2027.

[82] Tarlow, B. D., Pelz, C., Naugler, W. E., Wakefield, L., Wilson, E. M., Finegold, M. J., et al. (2014). Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. *Cell Stem Cell*, *15*(5), 605–618. https://doi.org/10.1016/j.stem.2014.09.008.

[83] Terada, T., Nakanuma, Y., & Sirica, A. E. (1998). Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. *Human Pathology* , *29*(2), 175–180. https://doi.org/10.1016/s0046-8177(98)90229-5.

[84] Terada, T., Okada, Y., & Nakanuma, Y. (1996). Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. *Hepatology*, *23*(6), 1341–1344. https://doi.org/10.1053/jhep.1996.v23.pm0008675149.

[85] Thelen, A., Scholz, A., Weichert, W., Wiedenmann, B., Neuhaus, P., Gessner, R., et al. (2010). Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma. *American Journal of Gastroenterology*, *105*(5), 1123–1132. https://doi.org/10.1038/ajg.2009.674.

[86] Thompson, C. B., Shepard, H. M., O'Connor, P. M., Kadhim, S., Jiang, P., Osgood, R. J., et al. (2010). Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. *Molecular Cancer Therapeutics*, *9*(11), 3052–3064. https://doi.org/10.1158/1535-7163.MCT-10-0470.

[87] Tsimafeyeu, I., & Temper, M. (2021). Cholangiocarcinoma: An emerging target for molecular therapy. *Gastrointestinal Tumors*, *8*(4), 153–158. https://doi.org/10.1159/000517258.

[88] Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016). The role of myeloid-derived suppressor cells (MDSC) in cancer progression. *Vaccines (Basel)*, *4*(4). https://doi.org/10.3390/vaccines4040036.

[89] Utispan, K., Thuwajit, P., Abiko, Y., Charngkaew, K., Paupairoj, A., Chau-in, S., et al. (2010). Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. *Molecular Cancer*, *9*, 13. https://doi.org/10.1186/1476-4598-9-13.

[90] Van Cutsem, E., Tempero, M. A., Sigal, D., Oh, D. Y., Fazio, N., Macarulla, T., et al. (2020). Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with Hyaluronan-high metastatic pancreatic adenocarcinoma. *Journal of Clinical Oncology*, *38*(27), 3185–3194. https://doi.org/10.1200/JCO.20.00590.

[91] Vaquero, J., Aoudjehane, L., & Fouassier, L. (2020). Cancer-associated fibroblasts in cholangiocarcinoma. *Current Opinion in Gastroenterolgy*, *36*(2), 63–69. https://doi.org/10.1097/MOG.0000000000000609.

[92] Vaquero, J., Lobe, C., Tahraoui, S., Claperon, A., Mergey, M., Merabtene, F., et al. (2018). The IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma. *Clinical Cancer Research*, *24*(17), 4282–4296. https://doi.org/10.1158/1078-0432.CCR-17-3725.

[93] Walter, D., Doring, C., Feldhahn, M., Battke, F., Hartmann, S., Winkelmann, R., et al. (2017). Intratumoral heterogeneity of intrahepatic cholangiocarcinoma. *Oncotarget*, *8*(9), 14957–14968. https://doi.org/10.18632/oncotarget.14844.

[94] Wiedmann, M. W., & Mossner, J. (2010). Molecular targeted therapy of biliary tract cancer—Results of the first clinical studies. *Current Drug Targets*, *11*(7), 834–850. https://doi.org/10.2174/138945010791320818.

[95] Winer, A., Adams, S., & Mignatti, P. (2018). Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes. *Molecular Cancer Therapeutics*, *17*(6), 1147–1155. https://doi.org/10.1158/1535-7163.MCT-17-0646.

[96] Yang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., et al. (2016). FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. *Cancer Research*, *76*(14), 4124–4135. https://doi.

org/10.1158/0008-5472.CAN-15-2973.

[97] Yang, Y. M., Noureddin, M., Liu, C., Ohashi, K., Kim, S. Y., Ramnath, D., et al. (2019). Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis. *Science Translational Medicine*, *11*(496). https://doi.org/10.1126/scitranslmed.aat9284.

[98] Yang, L., Wang, Y., Mao, H., Fleig, S., Omenetti, A., Brown, K. D., et al. (2008). Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. *Journal of Hepatology*, *48*(1), 98–106. https://doi.org/10.1016/j.jhep.2007.07.032.

[99] Yanger, K., Zong, Y., Maggs, L. R., Shapira, S. N., Maddipati, R., Aiello, N. M., et al. (2013). Robust cellular reprogramming occurs spontaneously during liver regeneration. *Genes & Development*, *27*(7), 719–724. https://doi.org/10.1101/gad.207803.112.

[100] Zhang, X. F., Dong, M., Pan, Y. H., Chen, J. N., Huang, X. Q., Jin, Y., et al. (2017). Expression pattern of cancer-associated fibroblast and its clinical relevance in intrahepatic cholangiocarcinoma. *Human Pathology*, *65*, 92–100. https://doi.org/10.1016/j.humpath.2017.04.014.

[101] Zhang, M., Yang, H., Wan, L., Wang, Z., Wang, H., Ge, C., et al. (2020). Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. *Journal of Hepatology*, *73*(5), 1118–1130. https://doi.org/10.1016/j.jhep.2020.05.039.

[102] Zhao, S., Wang, J., & Qin, C. (2014). Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. *Journal of Experimental & Clinical Cancer Research*, *33*, 103. https://doi.org/10.1186/s13046-014-0103-8.

8 TGF–β在肝细胞癌进展中的机制和临床意义

[1] Alexander, J., Torbenson, M., Wu, T.-T., & Yeh, M. M. (2013). Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: A clinical and pathological study. *Journal of Gastroenterology and Hepatology*, *28*(5), 848–854. https://doi.org/10.1111/jgh.12116.

[2] Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., et al. (2017). Comprehensive and integrative genomic characterization of hepatocellular carcinoma. *Cell*, *169*(7), 1327–1341.e23. https://doi.org/10.1016/j.cell.2017.05.046.

[3] Baek, H. J., Lee, Y. M., Kim, T. H., Kim, J.-Y., Park, E. J., Iwabuchi, K., et al. (2016). Caspase-3/7-mediated cleavage of β2-spectrin is required for acetaminophen-induced liver damage. *International Journal of Biological Sciences*, *12*(2), 172–183. https://doi.org/10.7150/ijbs.13420.

[4] Baek, H. J., Lim, S. C., Kitisin, K., Jogunoori, W., Tang, Y., Marshall, M. B., et al. (2008). Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. *Hepatology*, *48*(4), 1128–1137. https://doi.org/10.1002/hep.22460.

[5] Batlle, E., & Massagué, J. (2019). Transforming growth Factor-β signaling in immunity and cancer. *Immunity*, *50*(4), 924–940. https://doi.org/10.1016/j.immuni.2019.03.024.

[6] Bertero, A., Brown, S., Madrigal, P., Osnato, A., Ortmann, D., Yiangou, L., et al. (2018). The SMAD2/3 interactome reveals that TGFβ controls m6A mRNA methylation in pluripotency. *Nature*, *555*(7695), 256–259. https://doi.org/10.1038/nature25784.

[7] Bissell, D. M., Wang, S. S., Jarnagin, W. R., & Roll, F. J. (1995). Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. *The Journal of Clinical Investigation*, *96*(1), 447–455. https://doi.org/10.1172/JCI118055.

[8] Calderaro, J., Couchy, G., Imbeaud, S., Amaddeo, G., Letouzé, E., Blanc, J.-F., et al. (2017). Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. *Journal of Hepatology*, *67*(4), 727–738. https://doi.org/10.1016/j.jhep.2017.05.014.

[9] Chayanupatkul, M., Omino, R., Mittal, S., Kramer, J. R., Richardson, P., Thrift, A. P., et al. (2017). Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. *Journal of Hepatology*, *66*(2), 355–362. https://doi.org/10.1016/j.jhep.2016.09.013.

[10] Chen, J., Gingold, J. A., & Su, X. (2019). Immunomodulatory TGF-β signaling in hepatocellular carcinoma. *Trends in Molecular Medicine*. https://doi.org/10.1016/j.molmed.2019.06.007.

[11] Chen, C.-L., Tsukamoto, H., Liu, J.-C., Kashiwabara, C., Feldman, D., Sher, L., et al. (2013). Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. *The Journal of Clinical Investigation*, *123*(7), 2832–2849. https://doi.

org/10.1172/JCI65859.

[12] Chen, J., Yao, Z.-X., Chen, J.-S., Gi, Y. J., Muñoz, N. M., Kundra, S., et al. (2016). TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. *The Journal of Clinical Investigation*, *126*(2), 527–542. https://doi.org/10.1172/JCI80937.

[13] Chen, J., Zaidi, S., Rao, S., Chen, J.-S., Phan, L., Farci, P., et al. (2018). Analysis of genomes and transcriptomes of hepatocellular carcinomas identifies mutations and gene expression changes in the transforming growth Factor-β pathway. *Gastroenterology*, *154*(1), 195–210. https://doi.org/10.1053/j.gastro.2017.09.007.

[14] Coulouarn, C., Factor, V. M., & Thorgeirsson, S. S. (2008). Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. *Hepatology* , *47*(6), 2059–2067. https://doi.org/10.1002/hep.22283.

[15] Dahl, M., Maturi, V., Lönn, P., Papoutsoglou, P., Zieba, A., Vanlandewijck, M., et al. (2014). Fine-tuning of Smad protein function by poly(ADP-ribose) polymerases and poly(ADP-ribose) Glycohydrolase during transforming growth Factor β signaling. *PLoS One*, *9*(8), e103651. https://doi.org/10.1371/journal.pone.0103651.

[16] David, C. J., & Massagué, J. (2018). Contextual determinants of TGFβ action in development, immunity and cancer. *Nature Reviews Molecular Cell Biology*, *19*(7), 419–435. https://doi.org/10.1038/s41580-018-0007-0.

[17] De Battista, D., Zamboni, F., Gerstein, H., Sato, S., Markowitz, T. E., Lack, J., et al. (2021). Molecular signature and immune landscape of HCV-associated hepatocellular carcinoma (HCC): Differences and similarities with HBV-HCC. *Journal of Hepatocellular Carcinoma*, *8*, 1399–1413. https://doi.org/10.2147/JHC.S325959.

[18] Deane, N. G., Lee, H., Hamaamen, J., Ruley, A., Washington, M. K., LaFleur, B., et al. (2004). Enhanced tumor formation in cyclin D1 × transforming growth Factor β1 double transgenic mice with characterization by magnetic resonance imaging. *Cancer Research*, *64*(4), 1315–1322. https://doi.org/10.1158/0008-5472.CAN-03-1772.

[19] Derynck, R., & Budi, E. H. (2019). Specificity, versatility, and control of TGF-β family signaling. *Science Signaling*, *12*(570), eaav5183. https://doi.org/10.1126/scisignal.aav5183.

[20] Dzieran, J., Fabian, J., Feng, T., Coulouarn, C., Ilkavets, I., Kyselova, A., et al. (2013). Comparative analysis of TGF-β/Smad signaling dependent Cytostasis in human hepatocellular carcinoma cell lines. *PLoS One*, *8*(8), e72252. https://doi.org/10.1371/journal.pone.0072252.

[21] Fabregat, I., Moreno-Càceres, J., Sánchez, A., Dooley, S., Dewidar, B., Giannelli, G., et al. (2016). TGF-β signalling and liver disease. *The FEBS Journal*, *283*(12), 2219–2232. https://doi.org/10.1111/febs.13665.

[22] Factor, V. M., Kao, C.-Y., Santoni-Rugiu, E., Woitach, J. T., Jensen, M. R., & Thorgeirsson, S. S. (1997). Constitutive expression of mature transforming growth Factor β1 in the liver accelerates hepatocarcinogenesis in transgenic mice. *Cancer Research*, *57*(11), 2089–2095. https://cancerres.aacrjournals.org/content/57/11/2089.

[23] Feng, T., Dzieran, J., Yuan, X., Dropmann, A., Maass, T., Teufel, A., et al. (2017). Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in mice. *Oncogene*, *6*(1), e294. https://doi.org/10.1038/oncsis.2016.85.

[24] Ghafoory, S., Varshney, R., Robison, T., Kouzbari, K., Woolington, S., Murphy, B., et al. (2018). Platelet TGF-β1 deficiency decreases liver fibrosis in amouse model of liver injury. *Blood Advances*, *2*(5), 470–480. https://doi.org/10.1182/bloodadvances.2017010868.

[25] Global Burden of Disease Liver Cancer Collaboration, Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., et al. (2017). The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and National Level: Results from the global burden of disease study 2015. *JAMA Oncology*, *3*(12), 1683–1691. https://doi.org/10.1001/jamaoncol.2017.3055.

[26] Gough, N. R., Xiang, X., & Mishra, L. (2021). TGF-β signaling in liver, pancreas, and gastrointestinal diseases and cancer. *Gastroenterology*, *161*(2), 434–452. e15 https://doi.org/10.1053/j.gastro.2021.04.064.

[27] Hellerbrand, C., Stefanovic, B., Giordano, F., Burchardt, E. R., & Brenner, D. A. (1999). The role of TGFβ1 in initiating hepatic stellate cell activation in vivo. *Journal of Hepatology*, *30* (1), 77–87. https://doi.org/10.1016/S0168-8278(99)80010-5.

[28] Herrera, B., Á lvarez, A. M., Beltrán, J., Valdés, F., Fabregat, I., & Fernández, M. (2004). Resistance to TGF-β-induced apoptosis in regenerating hepatocytes. *Journal of Cellular Physiology* , *201*(3), 385–392. https://doi.org/10.1002/jcp.20078.

[29] Hezel, A. F., Deshpande, V., Zimmerman, S. M., Contino, G., Alagesan, B., O'Dell, M. R., et al. (2012). TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression. *Cancer Research*, *72*(18), 4840–4845. https://

doi.org/10.1158/0008-5472.CAN-12-0634.

[30] Hill, C. S. (2016). Transcriptional control by the SMADs. *Cold Spring Harbor Perspectives in Biology*, *8*(10), a022079. https://doi.org/10.1101/cshperspect.a022079.

[31] Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., et al. (2009). Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. *Cancer Research*, *69*(18), 7385–7392. https://doi.org/10.1158/0008-5472.CAN-09-1089.

[32] Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021). Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. *Nature Reviews. Gastroenterology & Hepatology*, *18*(4), 223–238. https://doi.org/10.1038/s41575-020-00381-6.

[33] Im, Y. H., Kim, H. T., Kim, I. Y., Factor, V. M., Hahm, K. B., Anzano, M., et al. (2001). Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. *Cancer Research*, *61*(18), 6665–6668.

[34] Ioannou, G. N. (2021). Epidemiology and risk-stratification of NAFLD-associated HCC. *Journal of Hepatology*. S0168827821020079 https://doi.org/10.1016/j.jhep.2021.08.012.

[35] Jang, C.-W., Chen, C.-H., Chen, C.-C., Chen, J., Su, Y.-H., & Chen, R.-H. (2002). TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. *Nature Cell Biology*, *4*(1), 51–58. https://doi.org/10.1038/ncb731.

[36] Kanzler, S., Meyer, E., Lohse, A. W., Schirmacher, P., Henninger, J., Galle, P. R., et al. (2001). Hepatocellular expression of a dominant-negative mutant TGF-β type II receptor accelerates chemically induced hepatocarcinogenesis. *Oncogene*, *20*(36), 5015–5024. https://doi.org/10.1038/sj.onc.1204544.

[37] Karlmark, K. R., Weiskirchen, R., Zimmermann, H. W., Gassler, N., Ginhoux, F., Weber, C., et al. (2009). Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. *Hepatology*, *50*(1), 261–274. https://doi.org/10.1002/hep.22950.

[38] Kitisin, K., Ganesan, N., Tang, Y., Jogunoori, W., Volpe, E. A., Kim, S. S., et al. (2007). Disruption of transforming growth factor-β signaling through β-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. *Oncogene*, *26*(50), 7103–7110. https://doi.org/10.1038/sj.onc.1210513.

[39] Kulik, L., & El-Serag, H. B. (2019). Epidemiology and Management of Hepatocellular Carcinoma. *Gastroenterology*, *156*(2), 477–491. https://doi.org/10.1053/j.gastro.2018.08.065.

[40] Lebrin, F., Goumans, M.-J., Jonker, L., Carvalho, R. L. C., Valdimarsdottir, G., Thorikay, M., et al. (2004). Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. *The EMBO Journal*, *23*(20), 4018–4028. https://doi.org/10.1038/sj.emboj.7600386.

[41] Letouzé, E., Shinde, J., Renault, V., Couchy, G., Blanc, J.-F., Tubacher, E., et al. (2017). Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. *Nature Communications*, *8*(1), 1315. https://doi.org/10.1038/s41467-017-01358-x.

[42] Li, Y., Turpin, C. P., & Wang, S. (2017). Role of thrombospondin 1 in liver diseases. *Hepatology Research: The Official Journal of the Japan Society of Hepatology*, *47*(2), 186–193. https://doi.org/10.1111/hepr.12787.

[43] Liu, S., Ren, J., & ten Dijke, P. (2021). Targeting TGFβ signal transduction for cancer therapy. *Signal Transduction and Targeted Therapy*, *6*(1), 1–20. https://doi.org/10.1038/s41392-020-00436-9.

[44] Losic, B., Craig, A. J., Villacorta-Martin, C., Martins-Filho, S. N., Akers, N., Chen, X., et al. (2020). Intratumoral heterogeneity and clonal evolution in liver cancer. *Nature Communications*, *11*(1), 291. https://doi.org/10.1038/s41467-019-14050-z.

[45] Ma, C., Kesarwala, A. H., Eggert, T., Medina-Echeverz, J., Kleiner,D. E., Jin, P., et al. (2016). NAFLD causes selective CD4 + T lymphocyte loss and promotes hepatocarcinogenesis. *Nature*, *531*(7593), 253–257. https://doi.org/10.1038/nature16969.

[46] Majumdar, A., Curley, S. A., Wu, X., Brown, P., Hwang, J. P., Shetty, K., et al. (2012). Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. *Nature Reviews. Gastroenterology & Hepatology*, *9*(9), 530–538. https://doi.org/10.1038/nrgastro.2012.114.

[47] Malfettone, A., Soukupova, J., Bertran, E., Crosas-Molist, E., Lastra, R., Fernando, J., et al. (2017). Transforming growth factor-β-induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma. *Cancer Letters*, *392*, 39–50. https://doi.org/10.1016/j.canlet.2017.01.037.

[48] Marquardt, J. U. (2018). The role of transforming growth Factor-β in human hepatocarcinogenesis: Mechanistic and therapeutic implications from an integrative multiomics approach. *Gastroenterology*, *154*(1), 17–20. https://doi.

org/10.1053/j.gastro.2017.11.015.

[49] Marquardt, J. U., Seo, D., Andersen, J. B., Gillen, M. C., Kim, M. S., Conner, E. A., et al. (2014). Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. *Journal of Hepatology*, *60*(2), 346–353. https://doi.org/10.1016/j.jhep.2013.10.014.

[50] Meijer, C., Wiezer, M. J., Diehl, A. M., Yang, S.-Q., Schouten, H. J., Meijer, S., et al. (2000). Kupffer cell depletion by CI2MDP-liposomes alters hepatic cytokine expression and delays liver regeneration after partial hepatectomy. *Liver*, *20*(1), 66–77. https://doi.org/10.1034/j.1600-0676.2000.020001066.x.

[51] Mishra, L., Derynck, R., & Mishra, B. (2005). Transforming growth Factor-β signaling in stem cells and cancer. *Science*, *310*(5745), 68–71. https://doi.org/10.1126/science.1118389.

[52] Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., et al. (2016). Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. *Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association*, *14*(1), 124–131. https://doi.org/10.1016/j.cgh.2015.07.019.

[53] Miyazawa, K., & Miyazono, K. (2017). Regulation of TGF-β family signaling by inhibitory Smads. *Cold Spring Harbor Perspectives in Biology*, *9*(3), a022095. https://doi.org/10.1101/cshperspect.a022095.

[54] Moon, A. M., Singal, A. G., & Tapper, E. B. (2020). Contemporary epidemiology of chronic liver disease and cirrhosis. *Clinical Gastroenterology and Hepatology*, *18*(12), 2650–2666. https://doi.org/10.1016/j.cgh.2019.07.060.

[55] Morikawa, M., Derynck, R., & Miyazono, K. (2016). TGF-β and the TGF-β family: Context-dependent roles in cell and tissue physiology. *Cold Spring Harbor Perspectives in Biology*, *8*(5), a021873. https://doi.org/10.1101/cshperspect.a021873.

[56] Morris, S. M., Carter, K. T., Baek, J. Y., Koszarek, A., Yeh, M. M., Knoblaugh, S. E., et al. (2015). TGF-β signaling alters the pattern of liver tumorigenesis induced by Pten inactivation. *Oncogene*, *34*(25), 3273–3282. https://doi.org/10.1038/onc.2014.258.

[57] Oh, S.-H., Swiderska-Syn, M., Jewell, M. L., Premont, R. T., & Diehl, A. M. (2018). Liver regeneration requires Yap1-TGFβ-dependent epithelial-mesenchymal transition in hepatocytes. *Journal of Hepatology*, *69*(2), 359–367. https://doi.org/10.1016/j.jhep.2018.05.008.

[58] Paik, J. M., Golabi, P., Younossi, Y., Mishra, A., & Younossi, Z. M. (2020). Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of NAFLD. *Hepatology* , *72*(5), 1605−1616. https://doi.org/10.1002/hep.31173.

[59] Papoutsoglou, P., & Moustakas, A. (2020). Long non-coding RNAs and TGF-β signaling in cancer. *Cancer Science*, *111*(8), 2672−2681. https://doi.org/10.1111/cas.14509.

[60] Piersma, B., Bank, R. A., & Boersema, M. (2015). Signaling in fibrosis: TGF-β, WNT, and YAP/TAZ converge. *Frontiers in Medicine*, *2*, 59. https://doi.org/10.3389/fmed.2015.00059.

[61] Ramjaun, A. R., Tomlinson, S., Eddaoudi, A., & Downward, J. (2007). Upregulation of two BH3-only proteins, Bmf and Bim, during TGFβ-induced apoptosis. *Oncogene*, *26*(7), 970–981. https://doi.org/10.1038/sj.onc.1209852.

[62] Rao, S., Yang, X., Ohshiro, K., Zaidi, S., Wang, Z., Shetty, K., et al. (2021). B2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development. *Science Translational Medicine*, *13*(624), eabk2267. https://doi.org/10.1126/scitranslmed.abk2267.

[63] Rao, S., Zaidi, S., Banerjee, J., Jogunoori, W., Sebastian, R., Mishra, B., et al. (2017). Transforming growth factor-β in liver cancer stem cells and regeneration. *Hepatology Communications*, *1*(6), 477–493. https://doi.org/10.1002/hep4.1062.

[64] Reader, C. S., Vallath, S., Steele, C. W., Haider, S., Brentnall, A., Desai, A., et al. (2019). The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. *The Journal of Pathology*, *249*(3), 332–342. https://doi.org/10.1002/path.5320.

[65] Rebouissou, S., & Nault, J.-C. (2020). Advances in molecular classification and precision oncology in hepatocellular carcinoma. *Journal of Hepatology*, *72*(2), 215–229. https://doi.org/10.1016/j.jhep.2019.08.017.

[66] Russell, W. E., Coffey, R. J., Ouellette, A. J., & Moses, H. L. (1988). Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. *Proceedings of the National Academy of Sciences of the United States of America*, *85*(14), 5126–5130. https://doi.org/10.1073/pnas.85.14.5126.

[67] Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., et al. (2015). Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. *Nature Genetics*, *47*(5), 505–511. https://doi.org/10.1038/ng.3252.

[68] Sepanlou, S. G., Safiri, S., Bisignano, C., Ikuta, K. S., Merat, S., Saberifiroozi, M., et al. (2020). The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: A systematic analysis for the global burden of disease study 2017. *The Lancet Gastroenterology & Hepatology*, *5*(3), 245–266. https://doi.org/10.1016/S2468-1253(19)30349-8.

[69] Shen, Y., Wei, Y., Wang, Z., Jing, Y., He, H., Yuan, J., et al. (2015). TGF-β regulates hepatocellular carcinoma progression by inducing Treg cell polarization. *Cellular Physiology and Biochemistry*, *35*(4), 1623–1632. https://doi.org/10.1159/000373976.

[70] Shi, M., Zhu, J., Wang, R., Chen, X., Mi, L., Walz, T., et al. (2011). Latent TGF-β structure and activation. *Nature*, *474*(7351), 343–349. https://doi.org/10.1038/nature10152.

[71] Song, J. (2007). EMT or apoptosis: A decision for TGF-β. *Cell Research*, *17*(4), 289–290. https://doi.org/10.1038/cr.2007.25.

[72] Steiger, K., Gross, N., Widholz, S. A., Rad, R., Weichert, W., & Mogler, C. (2020). Genetically engineered mouse models of liver tumorigenesis reveal a wide histological Spectrum of neoplastic and non-neoplastic liver lesions. *Cancers*, *12*(8), E2265. https://doi.org/10.3390/cancers12082265.

[73] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality world-wide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209–249. https://doi.org/10.3322/caac.21660.

[74] Tang, B., Böttinger, E. P., Jakowlew, S. B., Bagnall, K. M., Mariano, J., Anver, M. R., et al. (1998).Transforming growth factor-β1 is a new form of tumor suppressorwith true haploid insufficiency. *Nature Medicine*, *4*(7), 802–807. https://doi.org/10.1038/nm0798-802.

[75] Tang, Y., Katuri, V., Dillner, A., Mishra, B., Deng, C.-X., & Mishra, L. (2003). Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. *Science (New York, N.Y.)*, *299*(5606), 574–577. https://doi.org/10.1126/science.1075994.

[76] Tang, Y., Kitisin, K., Jogunoori, W., Li, C., Deng, C.-X., Mueller, S. C., et al. (2008). Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling. *Proceedings of the National Academy of Sciences*, *105*(7), 2445–2450. https://doi.org/10.1073/pnas.0705395105.

[77] Tolcher, A. W., Berlin, J. D., Cosaert, J., Kauh, J., Chan, E., Piha-Paul, S. A., et al. (2017). A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology*, *79*(4), 673–680. https://doi.org/10.1007/s00280-017-3245-5.

[78] Tomasetti, C., Li, L., & Vogelstein, B. (2017). Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. *Science (New York, N.Y.)*, *355*(6331), 1330–1334. https://doi.org/10.1126/science.aaf9011.

[79] Tsuchida, T., & Friedman, S. L. (2017). Mechanisms of hepatic stellate cell activation. *Nature Reviews Gastroenterology & Hepatology*, *14*(7), 397–411. https://doi.org/10.1038/nrgastro.2017.38.

[80] Velasco, S., Alvarez-Muñoz, P., Pericacho, M., ten Dijke, P., Bernabéu, C., Lopez-Novoa, J. M., et al. (2008). L- and S-endoglin differentially modulate TGFβ1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. *Journal of Cell Science*, *121*(6), 913–919. https://doi.org/10.1242/jcs.023283.

[81] Wang, J., Zhao, J., Chu, E. S., Mok, M. T., Go, M. Y., Man, K., et al. (2013). Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro. *The Journal of Pathology*, *230*(4), 441–452. https://doi.org/10.1002/path.4206.

[82] Xu, P., Liu, J., & Derynck, R. (2012). Post-translational regulation of TGF-β receptor and Smad signaling. *FEBS Letters*, *586*(14), 1871–1884. https://doi.org/10.1016/j.febslet.2012.05.010.

[83] Yang, Z., Mu, Z., Dabovic, B., Jurukovski, V., Yu, D., Sung, J., et al. (2007). Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. *The Journal of Cell Biology*, *176*(6), 787–793. https://doi.org/10.1083/jcb.200611044.

[84] Yoo, J., Ghiassi, M., Jirmanova, L., Balliet, A. G., Hoffman, B., Fornace, A. J., et al. (2003). Transforming growth Factor-β-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation*. *Journal of Biological Chemistry*, *278*(44), 43001–43007. https://doi.org/10.1074/jbc.M307869200.

[85] Younes, R., & Bugianesi, E. (2018). Should we undertake surveillance for HCC in patients with NAFLD? *Journal of Hepatology*, *68*(2), 326–334. https://doi.org/10.1016/j.jhep.2017.10.006.

[86] Zhang, Y., Alexander, P. B., & Wang, X.-F. (2017). TGF-β family signaling in the control of cell proliferation and survival. *Cold Spring Harbor Perspectives in Biology*, *9*(4), a022145. https://doi.org/10.1101/cshperspect.a022145.

[87] Zhang, H., Ozaki, I., Mizuta, T., Hamajima, H., Yasutake, T., Eguchi, Y., et al. (2006). Involvement of programmed cell

death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. *Oncogene*, *25*(45), 6101–6112. https://doi.org/10.1038/sj.onc.1209634.

[88] Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., et al. (2010). Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, *16*(4), 1191–1205. https://doi.org/10.1158/1078-0432.CCR-09-1634.

9 肝内胆管癌中的基质细胞蛋白

[1] Aishima, S., Taguchi, K., Sugimachi, K., Asayama, Y., Nishi, H., Shimada, M., et al. (2002). The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cgolangiocarcinoma. *International Journal of Surgical Pathology*, *10*, 47–56.

[2] Aishima, S., Taguchi, K., Terashi, T., Matsuura, S., Shimada, M., & Tsuneyoshi, M. (2003). Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma. *Modern Pathology*, *16*, 1019–1027.

[3] Archer, A. W., Paro, A., Elfadaly, A., Tsilimigras, D., & Pawlik, T. M. (2021). Intrahepatic cholangiocarcinoma: A summative review of biomarkers and targeted therapies. *Cancers*, *13*, 5169.

[4] Aubert, A., Mercier-Gouy, P., Aguero, S., Berthier, L., Liot, S., Prigent, L., et al. (2021). Latent TGF-β activation is a hallmark of the tenascin family. *Frontiers in Immunology*, *12*, 613438.

[5] Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., et al. (2020). Tumor microenvironment complexity and therapeutic implications at a glance. *Cell Communication and Signaling: CCS*, *18*, 59.

[6] Baril, P., Gangeswaran, R., Mahon, P. C., Caulee, K., Kocher, H. M., Harada, T., et al. (2007). Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: Role of the beta 4 integrin and PI3k pathway. *Oncogene*, *26*, 2082–2094.

[7] Bornstein, P. (1995). Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1. *Journal of Cell Biology*, *130*, 503–506.

[8] Bornstein, P. (2009). Matricellular proteins: An overview. *Journal of Cell Communication and Signaling*, *3*, 163–165.

[9] Bornstein, P., & Sage, E. H. (2002). Matricellular proteins: Extracellular modulators of cell function. *Current Opinion in Cell Biology*, *14*, 608–616.

[10] Brindley, P., Bachini, M., Ilyas, S., Khan, S., Loukas, A., Sirica, A. E., et al. (2021). Cholangiocarcinoma. *Nature Reviews. Disease Primers*, *7*, 65.

[11] Brivio, S., Cadamuro, M., Strazzabosco, M., & Fabris, L. (2017). Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness. *World Journal of Hepatology*, *9*, 455–468.

[12] Cadamuro, M., Brivio, S., Stecca, T., Kaffe, E., Mariotti, V., Milani, C., et al. (2018). Animal models of cholangiocarcinoma: What they teach us about the human disease. *Clinics and Research in Hepatology and Gastroenterology*, *42*, 403–415.

[13] Cadamuro, M., Stecca, T., Brivio, S., Mariotti, V., Fiorotto, R., Spirli, C., et al. (2018). The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. *Biochimica et Biophysica Acta-Molecular Basis of Disease*, *1864*(4PtB), 1435–1443.

[14] Campbell, D. J. W., Dumur, C. I., Lamour, N. F., DeWitt, J. L., & Sirica, A. E. (2012). Novel organotypic culture model of cholangiocarcinoma progression. *Hepatology Research*, *42*, 1119–1130.

[15] Carpino, G., Cardinale, V., Di Giamberardino, A., Overi, D., Donsante, S., Colasanti, T., et al. (2021). Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. *Journal of Hepatology*, *75*, 1377–1386.

[16] Carpino, G., Overi, D., Melandro, F., Grimaldi, A., Cardinale, V., Matteo, S., et al. (2019). Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure. *Clinical Proteomics*, *16*, 37.

[17] Celià-Terrassa, T., & Kang, Y. (2018). Metastatic niche functions and therapeutic opportunities. *Nature Cell Biology*, *20*, 868–877.

[18] Chan, K.-M., Tsai, C.-Y., Yeh, C.-N., Yea, T.-S., Lee, W.-C., Jan, Y.-Y., et al. (2018). Characterization of intrahepatic cholangiocarcinoma after curative resection: Outcome, prognostic factor, and recurrence. *BMC Gastroenterology*, *18*, 180.

[19] Chen, B., Wang, Z., Sun, J., Song, Q., He, B., et al. (2016). A tenascin C targeted nanoliposome with navitoclax for specifically eradicating of cancer-associated fibroblasts. *Nanomedicine*, *12*, 131–141.

[20] Chen, Y., Ma, L., He, Q., Zhang, S., Zhang, C., & Wei, J. (2015). TGF-β expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma. *Biological Research*, *48* , 26.

[21] Cheng, C.-T., Chu, Y.-Y., Yeh, C.-N., Huang, S.-C., Chen, M.-H., Wang, S.-Y., et al. (2015). Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma. *Oncotargets and Therapy*, *8*, 1899–1907.

[22] Cheng, R., Du, Q., Ye, J., Wang, B., & Chen, Y. (2019). Prognostic value of site-specific metastases for patients with advanced intrahepatic cholangiocarcinoma. A SEER data base analysis. *Medicine*, *98*(49), e18191.

[23] Chiovaro, F., Chiquet-Ehrismann, R., & Chiquet, M. (2015). Transcriptional regulation of tenascin genes. *Cell Adhesion & Migration*, *9*(1–2), 34–47.

[24] Chong, H. C., Tan, C. K., Huang, R.-L., & Tan, N. S. (2012). Matricellular proteins: A sticky affair with cancer. *Journal of Oncology*, *351089*.

[25] Chung, J. Y.-F., Chan, M. K.-K., Li, J. S.-F., Chan, A. S.-W., Tang, P. C.-T., Leung, K.-T., et al. (2021). TGF-β signaling: From tissue fibrosis to tumor microenvironment. *International Journal of Molecular Sciences*, *22*, 7575.

[26] Clapéron, A., Mergey, M., Aoudjehane, L., Ho-Bouldoires, T. H. N., Wendum, D., Prignon, A., et al. (2013). Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. *Hepatology*, *58*, 2001–2011.

[27] Cui, D., Huang, Z., Liu, Y., & Ouyang, G. (2017). The multifaceted role of periostin in priming the tumor microenvironments for tumor progression. *Cellular and Molecular Life Sciences*, *74*, 4287–4291.

[28] Darby, I. A., Vuillier-Devillers, K., Pinault, É., Sarrazy, V., Lepreux, S., Balabaud, C., et al. (2010). Proteomic analysis of differentially expressed proteins in peripheral cholangiocarcinoma. *Cancer Microenvironment*, *4*, 73–91.

[29] Davaadorj, M., Saito, Y., Morine, Y., Ikemoto, T., Imura, S., Takasu, C., et al. (2017). Loss of secreted frizzled-related protein-1 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma. *European Journal of Surgical Oncology*, *43*, 344–350.

[30] Demarez, C., Hubert, C., Sempoux, C., & Lemaigre, F. (2016). Expression of molecular differentiation markers does not correlate with histological differentiation grade in intrahepatic cholangiocarcinoma. *PLoS One*, *11*, e0157140.

[31] Dumur, C. I., Campbell, D. J. W., DeWitt, J. W., Oyesanya, R. A., & Sirica, A. E. (2010). Differential gene expression profiling of cultured *neu*-transformed *versus* spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomas. *Experimental and Molecular Pathology*, *89*, 227–235.

[32] Fabris, L., Cadamuro, M., Cagnin, S., Strazzabosco, M., & Gores, G. J. (2020). Liver matrix in benign and malignant biliary tract disease. *Seminars in Liver Disease*, *40*(3), 282–297.

[33] Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., et al. (2019). The tumour microenvironment and immune milieu of cholangiocarcinoma. *Liver International*, *39*, 63–78.

[34] Fabris, L., Sato, K., Alpini, G., & Strazzabosco, M. (2021). The tumor microenvironment in cholangiocarcinoma progression. *Hepatology*, *73*, 75–85.

[35] Fausther, M., Lavole, E. G., & Dranoff, J. A. (2017). Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants. *PLoS One*, *12*, e0184499.

[36] Feng, D., & Gerarduzzi, C. (2020). Emerging role of matricellular proteins in systemic sclerosis. *International Journal of Molecular Sciences*, *21*, 4776.

[37] Fiorino, S., Visani, M., Masetti, M., Acquaviva, G., Tallini, G., De Leo, A., et al. (2020). Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. *Molecular Biology Reports*, *47*, 8235–8241.

[38] Fujimoto, K., Kawaguchi, T., Nakashima, O., Ono, J., Ohta, S., Kawaguchi, A., et al. (2011). Periostin, a matrix protein, has potential as a novel serodiagnostic marker for cholangiocarcinoma. *Oncology Reports*, *25*, 1211–1216.

[39] Gardini, A., Corti, B., Fiorentino, M., Altimari, A., Ercolani, G., Grazi, G. L., et al. (2005). Expression of connective tissue growth factor is a prognostic marker for patients with intrahepatic cholangiocarcinoma. *Digestive and Liver Disease*, *37*, 269–274.

[40] Gerarduzzi, C., Hartmann, U., Leask, A., & Drobetsky, E. (2020). The matrix revolution: Matricellular proteins and restructuring of the cancer microenvironment. *Cancer Research*, *80*, 2705–2717.

[41] Ghahremanifard, P., Chanda, A., Bonni, S., & Bose, P. (2020). TGF-β mediated immune evasion in cancer-spotlight on cancer-associated fibroblasts. *Cancers*, *12*, 3650.

[42] Ghajar, C. M., Peinado, H., Mori, H., Matei, I. R., Evason, K. J., Brazier, H., et al. (2013). The perivascular niche regulates breast cancer dormancy. *Nature Cell Biology*, *15*, 807–817.

[43] Giblin, S. P., & Midwood, K. S. (2015). Tenascin-C: Form versus function. *Cell Adhesion & Migration*, *9*(1–2), 48–82.

[44] Gimba, E. R. P., Brum, M. C. M., & DeMorales, G. N. (2019). Full-length osteopontin and its splice variants as modulators of chemoresistance and radioresistance (review). *International Journal of Oncology*, *54*, 420–430.

[45] González-González, L., & Alonso, J. (2018). Periostin: A matricellular protein with multiple functions in cancer development and progression. *Frontiers in Oncology*, *8*, 225.

[46] Gremlich, S., Roth-Kleiner, M., Equey, L., Fytianos, K., Schittny, J., & Cremona, T. P. (2020). Tenascin-C inactivation impacts lung structure and function beyond lung development. *Scientific Reports*, *10*, 5118.

[47] Guo, J., Fu, W., Xiang, M., Zhang, Y., Zhou, K., Xu, C.-R., et al. (2019). Notch 1 drives the formation of intrahepatic cholangiocarcinoma. *Current Medical Science*, *39*, 929–937.

[48] Hagiwara, K., Harimoto, N., Yokobori, T., Muranushi, R., Hoshino, K., Gantumur, D., et al. (2020). High co-expression of large tenascin C splice variants in stromal tissue and annexin A2 in cancer cell membranes is associated with poor prognosis in pancreatic cancer. *Annals of Surgical Oncology*, *27*, 924–930.

[49] Hahn, F., Müller, L., Mähringer-Kunz, A., Tanyildizi, Y., dos Santos, D. P., Düber, C., et al. (2020). Distant metastases in patients with intrahepatic cholangiocarcinoma: Does location matter? A retrospective analysis of 370 patients. *Journal of Oncology*. Article ID 7195373.

[50] Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. *Cell*, *144*, 646–674.

[51] Hassan, R., Blumenschein, G. R., Moore, K. N., Santin, A. D., Kindler, H. L., Nemunaitis, J. J., et al. (2020). First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic tumors. *Journal of Clinical Oncology*, *38*, 1824–1835.

[52] Hong, L., Shejiao, D., Fenrong, C., Gang, Z., & Lei, D. (2015). Periostin down-regulation attenuates the pro-fibrogenic response of hepatic stellate cells induced by TGF-β1. *Journal of Cellular and Molecular Medicine*, *19*, 2462–2468.

[53] Huang, C.-K., Aihara, A., Iwagami, Y., Yu, T., Carlson, R., Koga, H., et al. (2016). Expression of transforming growth factor β1 promotes cholangiocarcinoma development and progression. *Cancer Letters*, *380*, 153–162.

[54] Iguchi, T., Yamashita, N., Aishima, S., Kuroda, Y., Terashi, T., Sugimachi, K., et al. (2009). A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model. *Oncology*, *76*, 293–300.

[55] Isenberg, J. S., & Roberts, D. D. (2020). THBS1 (thrombospondin 1). *Atlas of Genetics and Cytogenetics in Oncology and Hematology*, *24*, 291–299.

[56] Jing, C.-Y., Fu, Y.-P., Zhou, C., Zhang, M.-X., Huang, J.-L., Gan, W., et al. (2021). Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis. *Oncogene*, *40*, 2910–2922.

[57] Katoh, D., Kozuka, Y., Noro, A., Ogawa, T., Imanaka-Yoshida, K., & Yoshida, T. (2020). Tenascin-C induces phenotypic changes in fibroblasts to myofibroblasts with high contractility through the integrin αvβ1/transforming growth factorβ/SMAD signaling axis in human breast cancer. *American Journal of Pathology*, *190*, 2123–2135.

[58] Kaur, S., Bronson, S. M., Pal-Nath, D., Miller, T. W., Soto-Pantoja, D. R., & Roberts, D. D. (2021). Functions of Thrombospondin-1 in the tumor microenvironment. *International Journal of Molecular Sciences*, *22*, 4570.

[59] Kendall, T., Verheij, J., Gaudio, E., Evert, M., Guido, M., Goeppert, B., et al. (2019). Anatomical, histomorphological and molecular classification of cholangiocarcinoma. *Liver International*, *39*, 7–18.

[60] Kii, I. (2019). Periostin functions as a scaffold for assembly of extracellular proteins. *Advances in Experimental Medicine and Biology*, *1132*, 23–32.

[61] Kii, I., & Ito, H. (2017). Periostin and its interacting proteins in the construction of extracellular architectures. *Cellular and Molecular Life Sciences*, *74*, 4269–4277.

[62] Kimawaha, P., Jusakul, A., Junsawang, P., Loilome, W., Khuntikeo, N., & Techasen, A. (2020). Circulating TGF-β1 as the potential epithelial mesenchymal transition-biomarker for diagnosis of cholangiocarcinoma. *Journal of Gastrointestinal Oncology*, *11*, 304–318.

[63] Koyama, Y., Wang, P., Liang, S., Iwaisako, K., Liu, X., Xu, J., et al. (2017). Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis. *The Journal of Clinical Investigation*, *127*, 1254–1270.

[64] Kudo, A. (2019). The structure of the periostin gene, its transcriptional control and alternative splicing and protein expression. In A. Kudo (Ed.), *Periostin, advances in experimental medicine and biology* (pp. 7–20). Springer Nature Singapore Pte Lte.

[65] Kudo, A., & Kii, I. (2018). Periostin functions in communication with extracellular matrices. *Journal of Cell Communication and Signaling*, *12*, 301–308.

[66] Kumar, P., Smith, T., Raeman, R., Chopyk, D. M., Brink, H., Liu, Y., et al. (2018). Periostin promotes liver fibrogenesis

by activating lysyl oxidase in hepatic stellate cells. *Journal of Biological Chemistry*, *293*, 12781–12792.

[67] Landry, N., Cohen, S., & Dixon, I. M. C. (2017). Periostin in cardiovascular disease and development: A tale of two distinct roles. *Basic Research in Cardiology*, *113*, 1.

[68] Laohaviroj, M., Chamgramol, Y., Pairojkul, C., Mulvenna, J., & Sripa, B. (2016). Clinicopathological significance of osteopontin in cholangiocarcinoma cases. *Asian Pacific Journal of Cancer Prevention*, *17*, 201–205.

[69] Lenga, Y., Koh, A., Perera, A. S., McCulloch, C. A., Sodek, J., & Zohar, R. (2008). Osteopontin expression is required for myofibroblast differentiation. *Circulation Research*, *102*, 319–327.

[70] Ling, H., Roux, E., Hempel, D., Tao, J., Smith, M., Lonning, S., et al. (2013). Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. *PLoS One*, *8*, E54499.

[71] Loeuillard, E., Fischbach, S. R., Gores, G. J., & Rizvi, S. (2019). Animal models of cholangiocarcinoma. *Biochimica et Biophysica Acta-Molecular Basis of Disease*, *1865*, 982–992.

[72] Loosen, S., Roderburg, C., Kauertz, K. L., Pombeiro, I., Leyh, C., Benz, F., et al. (2017). Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. *Journal of Hepatology*, *67*, 749–757.

[73] Lowy, C. M., & Oskarsson, T. (2015). Tenascin C in metastasis: A view from the invasive front. *Cell Adhesion & Migration*, *9*(1–2), 112–124.

[74] Lustri, A. M., Di Matteo, S., Fraveto, A., Costantini, D., Cantafora, A., Napoletano, C., et al. (2017). TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: a study on human primary cell cultures. *PLoS One*, *12*, e0183932.

[75] Malanchi, I., Santamaria-Martínez, A., Susanto, E., Peng, H., Lehr, H.-A., Delaloye, J.-F., et al. (2011). Interactions between cancer stem cells and their niche govern metastatic colonization. *Nature*, *481*, 85–89.

[76] Mandrekar, P., & Cardinale, V. (2018). Periostin and Mesothelin: Potential predictors of malignant progression in intrahepatic cholangiocarcinoma. *Hepatology Communications*, *2*, 481–483.

[77] Manzanares, M. Á ., Campbell, D. J. W., Maldonado, G. T., & Sirica, A. E. (2018). Overexpression of periostin and distinct mesothelin forms predict malignant progression in a rat cholangiocarcinoma model. *Hepatology Communications*, *2*, 155–172.

[78] Manzanares, M. Á ., M Usui, A., Campbell, D. J., Dumur, C. I., Maldonado, G. T., Fausther, M., et al. (2017). Transforming growth factor α and β are essential for modeling cholangiocarcinoma desmoplasia and progression in a three-dimensional organotypic culture model. *American Journal of Pathology*, *187*, 1068–1092.

[79] Matsumoto, K., & Aoki, H. (2020). The roles of tenascins in cardiovascular, inflammatory, and heritable connective tissue diseases. *Frontiers in Immunology*, *11*, 609752.

[80] McQuitty, C. E., Williams, R., Chokshi, S., & Urbani, L. (2020). Immunoregulatory role of the extracellular matrix within the liver disease microenvironment. *Frontiers in Immunology*, *11*, 574276.

[81] Mertens, J. C., Fingas, C. D., Christensen, J. D., Smoot, R. L., Bronk, S. F., Werneburg, N. W., et al. (2013). Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. *Cancer Research*, *73*, 897–907.

[82] Mino, M., Kanno, K., Okimoto, K., Sugiyama, A., Kishikawa, N., Kobayashi, T., et al. (2017). Periostin promotes malignant potential by induction of epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. *Hepatology Communications*, *1*, 1099–1109.

[83] Mizukami, T., Kamachi, H., Fujii, Y., Matsuzawa, F., Einama, T., Kawamata, F., et al. (2018). The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model. *Oncotarget*, *9*, 33844–33852.

[84] Mohr, R., Özdirik, B., Knorr, J., Wree, A., Demir, M., Tacke, F., et al. (2020). In vivo models for cholangiocarcinoma-what can we learn for human disease. *International Journal of Molecular Sciences*, *21*, 4993.

[85] Moorman, H. R., Poschel, D., Klement, J. D., Lu, C., Redd, P. S., & Liu, K. (2020). Osteopontin: A key regulator of tumor progression and immunomodulation. *Cancers*, *12*, 3379.

[86] Murphy-Ullrich, J. E. (2019). Thrombospondin 1 and its diverse roles as a regulator of extracellular matrix in fibrotic disease. *Journal of Histochemistry and Cytochemistry*, *67*, 683–699.

[87] Murphy-Ullrich, J. E., & Sage, E. H. (2014). Revisiting the matricellular concept. *Matrix Biology*, *37*, 1–14.

[88] Murphy-Ullrich, J. E., & Suto, M. J. (2018). Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease. *Matrix Biology*, *68-69*, 28–43.

[89] Nakanuma, Y., Sato, Y., Harada, K., Sasaki, M., Xu, J., & Ikeda, H. (2010). Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. *World Journal of Hepatology*, *2*, 419–427.

[90] Nakazawa, Y., Taniyama, Y., Sanada, F., Morishita, R., Nakamori, S., Morimoto, K., et al. (2018). Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cancer. *Scientific Reports*, *8*, 4013.

[91] Nomura, R., Fujii, H., Abe, M., Sugo, H., Ishizaki, Y., Kawasaki, S., et al. (2013). Mesothelin expression is a prognostic factor in cholangiocellular carcinoma. *International Surgery*, *98*, 164–169.

[92] Norris, R. A., Damon, B., Mironov, V., Kasyanov, V., Ramamurthi, A., Moreno-Rodriguez, R., et al. (2007). Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissue. *Journal of Cellular Biochemistry*, *101*, 695–711.

[93] Norris, R. A., Moreno-Rodriguez, R., Sugi, Y., Hoffman, S., Amos, J., Hart, M. M., et al. (2008). Periostin regulates atrioventricular valve maturation. *Developmental Biology*, *316*, 200–213.

[94] Papoutsoglou, P., Louis, C., & Coulouarn, C. (2019). Transforming growth factor -beta (TGFβ) signaling pathway in cholangiocarcinoma. *Cell*, *8*, 960.

[95] Riener, M.-O., Fritzsche, F. R., Soll, C., Pestalozzi, B. C., Probst-Hensch, N., Clavien, P.-A., et al. (2010). Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. *Histopathology*, *56*, 600–606.

[96] Sage, E. H., & Bornstein, P. (1991). Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. *Journal of Biological Chemistry*, *266*, 14831–14834.

[97] Sawyer, A. J., & Kyriakides, T. R. (2016). Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic location. *Advanced Drug Delivery Reviews*, *97*, 56–68.

[98] Shibata, S., & Ishiyama, J. (2013). Secreted protein acidic and rich in cysteine (SPARC) is upregulated by transforming growth factor (TGF)-β and is required for TGF-β-induced hydrogen peroxide production in fibroblasts. *Fibrogenesis & Tissue Repair*, *6*, 6.

[99] Shurin, M. R. (2018). Osteopontin controls immunosuppression in the tumor microenvironment. *Journal of Clinical Investigation*, *128*, 5209–5212.

[100] Sirica, A. E. (2012). The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. *Nature Reviews Gastroenterology & Hepatology*, *9*, 44–54.

[101] Sirica, A. E., Almenara, J. A., & Li, C. (2014). Periostin in intrahepatic cholangiocarcinoma: Pathobiological insights and clinical implications. *Experimental and Molecular Pathology*, *97*, 515–524.

[102] Sirica, A. E., Dumur, C. I., Campbell, D. J. W., Almenara, J. A., Ogunwobi, O. O., & DeWitt, J. L. (2009). Intrahepatic cholangiocarcinoma progression: Prognostic factors and basic mechanisms. *Clinical Gastroenterology and Hepatology*, *7*, S68–S78.

[103] Sirica, A. E., & Gores, G. J. (2014). Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting. *Hepatology*, *59*, 2397–2402.

[104] Sirica, A. E., Gores, G. J., Groopman, J. D., Selaru, F. M., Strazzabosco, M., Wang, X. W., et al. (2019). Intrahepatic cholangiocarcinoma: Continuing challenges and translational advances. *Hepatology*, *69*, 1803–1815.

[105] Sirica, A. E., Strazzabosco, M., & Cadamuro, M. (2021). Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. *Advances in Cancer Research*, *149*, 321–387.

[106] Sirica, A. E., Zhang, Z., Lai, G.-H., Asano, T., Shen, X.-N., Ward, D. J., et al. (2008). A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. *Hepatology*, *47*, 1178–1190.

[107] Soejima, Y., Takeuchi, M., Akashi, T., Sawabe, M., & Fukusato, T. (2018). β4 and β6 integrin expression is associated with the subclassification and clinicopathological features of intrahepatic cholangiocarcinoma. *International Journal of Molecular Sciences*, *19*, 1004.

[108] Song, Z., Chen, W., Athavale, D., Ge, X., Desert, R., Das, S., et al. (2021). Osteopontin takes center stage in chronic liver disease. *Hepatology*, *73*, 1594–1608.

[109] Sonongbua, J., Siritungyong, S., Thongchot, S., Kamolhan, T., Utispan, K., Thuwajit, P., et al. (2020). Periostin induces epithelial-to-mesenchymal transition via the integrin α5β1/TWIST axis in cholangiocarcinoma. *Oncology Reports*, *43*, 1147–1158.

[110] Sriram, R., Lo, V., Pryce, B., Antonova, L., Mears, A. J., Daneshmand, M., et al. (2015). Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1

activity. *Breast Cancer Research*, *17*, 7.

[111] Sugiyama, A., Kanno, K., Nishimichi, N., Ohta, S., Ono, J., Conway, S. J., et al. (2016). Periostin promotes hepatic fibrosis in mice by modulating hepatic stellate cell activation via α_V integrin interaction. *Journal of Gastroenterology*, *51*, 1161–1174.

[112] Sulpice, L., Rayar, M., Desille, M., Turlin, B., Fautrel, A., Boucher, E., et al. (2013). Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. *Hepatology*, *58*, 1992–2000.

[113] Suto, M. J., Gupta, V., Mathew, B., Zhang, W., Pallero, M. A., & Murphy-Ullrich, J. E. (2020). Identification of inhibitors of thrombospondin 1 activation of TGF-β. *ACS Medicinal Chemistry Letters*, *11*, 1130–1136.

[114] Takahashi, K., Meguro, K., Kawashima, H., Kashiwakuma, D., Kagami, S., Ohta, S., et al. (2019). Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. *Journal of Asthma*, *56*, 236–243.

[115] Tanaka, S., Sugimachi, K., Kameyama, T., Maehara, S., Shirabe, K., Shimada, M., et al. (2003). Human Wisp1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. *Hepatology*, *37*, 1122–1129.

[116] Teixeira, A. F., ten Dijke, P., & Zhu, H.-J. (2020). On-target anti-TGF-β therapies are not succeeding in clinical cancer treatments: What are remaining challenges? *Frontiers in Cell and Development Biology*, *8*, 605.

[117] Terashi, T., Aishima, S., Taguchi, K., Asayama, Y., Sugimachi, K., Matsuura, S., et al. (2004). Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma. *Liver International*, *24*, 38–45.

[118] Thuwajit, C., Thuwajit, P., Jamjantra, P., Pairojkul, C., Wongkham, S., Bhudhisawasdi, V., et al. (2017). Clustering of patients with intrahepatic cholangiocarcinoma based on serum periostin may be predictive of prognosis. *Oncology Letters*, *14*, 623–634.

[119] Tsilimigras, D. I., Sahara, K., Wu, L., Moris, D., Bagante, F., Guglielmi, A., et al. (2020). Very early recurrence after liver resection for intrahepatic cholangiocarcinoma. *JAMA Surgery*, *155* , 1–9.

[120] Tsukamoto, M., Yamashita, Y., Imai, K., Umezaki, N., Yamao, T., Okabe, H., et al. (2017). Predictors of cure of intrahepatic cholangiocarcinoma after hepatic resection. *Anticancer Research*, *37*, 6971–6975.

[121] Utispan, K., Sonongbua, J., Thuwajit, P., Chau-In, S., Pairojkul, C., Wongkham, S., et al. (2012). Periostin activates integrin *α5β1* through a PI3K/AKT-dependent pathway in invasion of cholangiocarcinoma. *International Journal of Oncology*, *41*, 1110–1118.

[122] Utispan, K., Thuwajit, P., Abiko, Y., Charngkaew, K., Paupairoj, A., Chau-in, S., et al. (2010). Gene expression profiling of cholangiocarcinoma-derived fibroblasts reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. *Molecular Cancer*, *9*, 13.

[123] Vaquero, J., Aoudjehane, L., & Fouassier, L. (2020). Cancer-associated fibroblasts in cholangiocarcinoma. *Current Opinion in Gastroenterology*, *36*, 63–69.

[124] Vianello, E., Kalousová, M., Dozio, E., Tacchini, L., Zima, T., & Romanelli, M. M. C. (2020). Osreopontin: The molecular bridge between fat and cardiac-renal disorders. *International Journal of Molecular Sciences*, *21*, 5568.

[125] Vijgen, S., Terris, B., & Rubbia-Brandt. (2017). Pathology of intrahepatic cholangiocarcinoma. *HepatoBiliary Surgery and Nutrition*, *6*, 22–34.

[126] Viloria, K., & Hill, N. J. (2016). Embracing the complexity of matricellular proteins: The functional and clinical significance of splice variation. *Biomolecular Concepts*, *7*, 117–132.

[127] Vincent, K. M., & Postovit, L.-M. (2018). Matricellular proteins in cancer: A focus on secreted frizzled-related proteins. *Journal of Cell Communication and Signaling*, *12*, 103–112.

[128] Wallace, D. P. (2019). Periostin in the kidney. *Advances in Experimental Medicine and Biology*, *1132*, 99–112.

[129] Wang, Z., Xiong, S., Mao, Y., Chen, M., Ma, X., Zhou, X., et al. (2016). Periostin promotes immunosuppressive premetastatic niche formation to facilitate breast tumour metastasis. *Journal of Pathology*, *239*, 484–495.

[130] Weber, C. E., Kothari, A. N., Wai, P. Y., Li, N. Y., Driver, J., Zapf, M. A. C., et al. (2015). Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. *Oncogene*, *34*, 4821–4833.

[131] Wen, Y., Feng, D., Wu, H., Liu, W., Li, H., Wang, F., et al. (2015). Defective initiation of liver regeneration in osteopontin-deficient mice after partial hepatectomy due to insufficient activation of IL-6/Stat3 pathway. *International Journal of Biological Sciences*, *11*, 1236–1247.

[132] Wong, G. S., & Rustgi, A. K. (2013). Matricellular proteins: Priming the tumour microenvironment for cancer development and metastasis. *British Journal of Cancer*, *108*, 755–761.

[133] Wu, T., & Ouyang, G. (2014). Matricellular proteins: Multifaceted extracellular regulators in tumor dormancy. *Protein & Cell*, *5*, 249–252.

[134] Wu, H., Zhang, H., Hu, L.-Y., Zhang, T.-Y., Zheng, Y.-J., Shen, F., et al. (2018). Is osteopontin a promising biomarker for cholangiocarcinoma? *Journal of Hepatology*, *68*, 199–220.

[135] Wu, W.-R., Zhang, R., Shi, X.-D., Zhu, M.-S., Xu, L.-B., Zeng, H., et al. (2014). Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness, and sensitivity to 5-fluorouracil in vitro. *Oncology Reports*, *31*, 2515–2524.

[136] Yoshida, T., Akatsuka, T., & Imanaka-Yoshida, K. (2015). Tenascin-C and integrins in cancer. *Cell Adhesion & Migration*, *9*(1–2), 96–104.

[137] Yu, L., Feng, M., Kim, H., Phung, Y., Kleiner, D. E., Gores, G. J., et al. (2010). Mesothelin as a potential therapeutic target in human cholangiocarcinoma. *Journal of Cancer*, *1*, 141–149.

[138] Yue, H., Li, W., Chen, R., Wang, J., Lu, X., & Li, J. (2021). Stromal eriostin induced by TGF-β1 facilitates the migration and invasion of ovarian cancer. *Gyenecologic Oncology*, *160*, 530–538.

[139] Zeng, J., Liu, Z., Sun, S., Xie, J., Cao, L., Lv, P., et al. (2018). Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells. *Oncology Letters*, *15*, 8681–8686.

[140] Zhang, M., Yang, H., Wan, L., Wang, Z., Wang, H., Ge, C., et al. (2020). Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. *Journal of Hepatology*, *73*, 1118–1130.

[141] Zhao, X.-Q., Ma, H.-X., Su, M.-S., & He, L. (2014). Osteopontin promoter polymorphisms at locus –443 are associated with metastasis and poor prognosis of human intrahepatic cholangiocarcinoma in Chinese population. *International Journal of Clinical and Experimental Pathology*, *7*, 6914–6921.

[142] Zheng, Y., Zhou, C., Yu, X.-X., Wu, C., Jia, H.-L., Gao, X.-M., et al. (2018). Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-catenin. *Cell Death and Disease*, *9*, 179. https://doi.org/10.1038/s41419-017-0226-x.

[143] Zhou, K.-Q., Liu, W.-F., Yang, L.-X., Sun, Y.-F., Hu, J., Chen, F.-Y., et al. (2019). Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma. *Hepatobiliary Surgery and Nutrition*, *8*, 582–596.

[144] Zhu, M., Saxton, R. E., Ramos, L., Chang, D. D., Karlan, B. Y., Gasson, J. C., et al. (2011). Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis. *Molecular Cancer Therapeutics*, *10*, 1500–1508.

[145] Zhu, J.-Z., Zhu, H.-T., Dai, Y.-N., Li, C.-X., Fang, Z.-Y., Zhao, D.-J., et al. (2016). Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: A case-control study. *Endocrine*, *51*, 91–100.

10 YAP1活化与Hippo通路信号在肝内胆管癌发生发展及治疗中的意义

[1] Bai, H., Zhang, N., Xu, Y., Chen, Q., Khan, M., Potter, J. J., et al. (2012). Yes-associated protein regulates the hepatic response after bile duct ligation. *Hepatology*, *56*(3), 1097–1107. https://doi.org/10.1002/hep.25769.

[2] Brindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A., Sirica, A. E., et al. (2021). Cholangiocarcinoma. *Nature Reviews Disease Primers*, *7*(1), 65. https://doi.org/10.1038/s41572-021-00300-2.

[3] Buckarma, E. H., Werneburg, N. W., Conboy, C. B., Kabashima, A., O'Brien, D. R., Wang, C., et al. (2020). The YAP-interacting phosphatase SHP2 can regulate transcriptional coactivity and modulate sensitivity to chemotherapy in cholangiocarcinoma. *Molecular Cancer Research*, *18*(10), 1574–1588. https://doi.org/10.1158/1541-7786.MCR-20-0165.

[4] Calvisi, D. F., Wang, C., Ho, C., Ladu, S., Lee, S. A., Mattu, S., et al. (2011). Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. *Gastroenterology*, *140*(3), 1071–1083. https://doi.org/10.1053/j.gastro.2010.12.006.

[5] Calvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., et al. (2013). Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. *Nature Cell Biology*, *15*(6), 637–646. https://doi.org/10.1038/ncb2756.

[6] Cardinale, V., Bragazzi, M. C., Carpino, G., Di Matteo, S., Overi, D., Nevi, L., et al. (2018). Intrahepatic cholangiocarcinoma: review and update. *Hepatoma Research*, *4*(6). https://doi.org/10.20517/2394-5079.2018.46.

[7] Chang, L., Azzolin, L., Di Biagio, D., Zanconato, F., Battilana, G., Lucon Xiccato, R., et al. (2018). The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. *Nature*, *563* (7730), 265–269. https://doi.org/10.1038/s41586-

018-0658-1.

[8] Chen, Y. C., Chien, C. Y., Hsu, C. C., Lee, C. H., Chou, Y. T., Shiah, S. G., et al. (2021). Obesity-associated leptin promotes chemoresistance in colorectal cancer through YAP-dependent AXL upregulation. *American Journal of Cancer Research*, *11*(9), 4220–4240. https://www.ncbi.nlm.nih.gov/pubmed/34659884.

[9] Chen, Q., Wang, H., Li, Z., Li, F., Liang, L., Zou, Y., et al. (2022). Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription. *Journal of Hepatology*, *76*(1), 135–147. https://doi.org/10.1016/j.jhep.2021.08.027.

[10] Chen, Y. L., Yen, I. C., Lin, K. T., Lai, F. Y., & Lee, S. Y. (2020). 4-Acetylantrocamol LT3, a new ubiquinone from antrodia cinnamomea, inhibits hepatocellular carcinoma HepG2 cell growth by targeting YAP/TAZ, mTOR, and WNT/beta-catenin signaling. *The American Journal of Chinese Medicine*, *48*(5), 1243–1261. https://doi.org/10.1142/S0192415X20500615.

[11] Ciraku, L., Esquea, E. M., & Reginato, M. J. (2022). O-GlcNAcylation regulation of cellular signaling in cancer. *Cellular Signaling*, *90*, 110201. https://doi.org/10.1016/j.cellsig.2021.110201.

[12] Clements, O., Eliahoo, J., Kim, J. U., Taylor-Robinson, S. D., & Khan, S. A. (2020). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. *Journal of Hepatology*, *72*(1), 95–103. https://doi.org/10.1016/j.jhep.2019.09.007.

[13] Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., et al. (2010). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature*, *465* (7300), 966. https://doi.org/10.1038/nature09132.

[14] DeRan, M., Yang, J., Shen, C. H., Peters, E. C., Fitamant, J., Chan, P., et al. (2014). Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. *Cell Reports*, *9*(2), 495–503. https://doi.org/10.1016/j.celrep.2014.09.036.

[15] Di Matteo, S., Nevi, L., Overi, D., Landolina, N., Faccioli, J., Giulitti, F., et al. (2021). Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells. *Scientific Reports*, *11*(1), 2557. https://doi.org/10.1038/s41598-021-81172-0.

[16] DiNardo, C. D., Propert, K. J., Loren, A. W., Paietta, E., Sun, Z., Levine, R. L., et al. (2013). Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. *Blood*, *121*(24), 4917–4924. https://doi.org/10.1182/blood-2013-03-493197.

[17] Driskill, J. H., & Pan, D. (2021). The Hippo pathway in liver homeostasis and pathophysiology. *Annual Review of Pathology: Mechanisms of Disease*, *16*, 299–322. https://doi.org/10.1146/annurev-pathol-030420-105050.

[18] Du, X., Shi, H., Li, J., Dong, Y., Liang, J., Ye, J., et al. (2014). Mst1/Mst2 regulate development and function of regulatory T cells through modulation of Foxo1/Foxo3 stability in autoimmune disease. *Journal of Immunology*, *192*(4), 1525–1535. https://doi.org/10.4049/jimmunol.1301060.

[19] Edwards, D. N., Ngwa, V. M., Wang, S., Shiuan, E., Brantley-Sieders, D. M., Kim, L. C., et al. (2017). The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ. *Science Signaling*, *10*(508). https://doi.org/10.1126/scisignal.aan4667.

[20] Fan, S., Gao, Y., Qu, A., Jiang, Y., Li, H., Xie, G., et al. (2022). YAP-TEAD mediates PPAR alpha-induced hepatomegaly and liver regeneration in mice. *Hepatology*, *75*(1), 74–88. https://doi.org/10.1002/hep.32105.

[21] Fan, Y., Gao, Y., Rao, J., Wang, K., Zhang, F., & Zhang, C. (2017). YAP-1 promotes tregs differentiation in hepatocellular carcinoma by enhancing TGFBR2 transcription. *Cellular Physiology and Biochemistry*, *41*(3), 1189–1198. https://doi.org/10.1159/000464380.

[22] Fan, B., Malato, Y., Calvisi, D. F., Naqvi, S., Razumilava, N., Ribback, S., et al. (2012). Cholangiocarcinomas can originate from hepatocytes in mice. *Journal of Clinical Investigation*, *122* (8), 2911–2915. https://doi.org/10.1172/JCI63212.

[23] Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., et al. (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell*, *18*(6), 553–567. https://doi.org/10.1016/j.ccr.2010.11.015.

[24] Gadd, V. L., Aleksieva, N., & Forbes, S. J. (2020). Epithelial plasticity during liver injury and regeneration. *Cell Stem Cell*, *27*(4), 557–573. https://doi.org/10.1016/j.stem.2020.08.016.

[25] Galli, G. G., Carrara, M., Yuan, W. C., Valdes-Quezada, C., Gurung, B., Pepe-Mooney, B., et al. (2015). YAP drives growth by controlling transcriptional pause release from dynamic enhancers. *Molecular Cell*, *60*(2), 328–337. https://doi.org/10.1016/j.molcel.2015.09.001.

[26] Gera, S., Ettel, M., Acosta-Gonzalez, G., & Xu, R. (2017). Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma. *World Journal of Hepatology*, *9*(6), 300–309. https://doi.org/10.4254/wjh.v9.i6.300.

[27] Gu, Y., Wang, Y., Wang, Y., Luo, J., Wang, X., Ma, M., et al. (2020). Hypermethylation of LATS2 promoter and its prognostic value in IDH-mutated low-grade gliomas. *Frontiers in Cell and Developmental Biology*, *8*, 586581. https://doi.org/10.3389/fcell.2020.586581.

[28] Guo, X., Zhao, Y., Yan, H., Yang, Y., Shen, S., Dai, X., et al. (2017). Single tumorinitiating cells evade immune clearance by recruiting type II macrophages. *Genes and Development*, *31* (3), 247–259. https://doi.org/10.1101/gad.294348.116.

[29] Han, X., Wang, Y., Pu, W., Huang, X., Qiu, L., Li, Y., et al. (2019). Lineage tracing reveals the bipotency of SOX9(+) hepatocytes during liver regeneration. *Stem Cell Reports*, *12* (3), 624–638. https://doi.org/10.1016/j.stemcr.2019.01.010.

[30] Holden, J. K., Crawford, J. J., Noland, C. L., Schmidt, S., Zbieg, J. R., Lacap, J. A., et al. (2020). Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of Hippo pathway signaling. *Cell Reports*, *31*(12), 107809. https://doi.org/10.1016/j.celrep.2020.107809.

[31] Hu, J. K., Du, W., Shelton, S. J., Oldham, M. C., DiPersio, C. M., & Klein, O. D. (2017). An FAK-YAP-mTOR signaling axis regulates stem cell-based tissue renewal in mice. *Cell Stem Cell* , *21*(1), 91−106. e106 https://doi.org/10.1016/j.stem.2017.03.023.

[32] Hu, S., Molina, L., Tao, J., Liu, S., Hassan, M., Singh, S., et al. (2020). NOTCH-YAP1/TEAD-DNMT1 axis regulates hepatocyte reprogramming into intrahepatic cholangiocarcinoma. *bioRxiv*. https://doi.org/10.1101/2020.12.03.410993.

[33] Jung, K., Kim, M., So, J., Lee, S. H., Ko, S., & Shin, D. (2021). Farnesoid X receptor activation impairs liver progenitor cell-mediated liver regeneration via the PTEN-PI3K-AKT-mTOR axis in zebrafish. *Hepatology*, *74*(1), 397–410. https://doi.org/10.1002/hep.31679.

[34] Jung, D. E., Park, S. B., Kim, K., Kim, C., & Song, S. Y. (2017). CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway. *Scientific Reports*, *7*(1), 10921. https://doi.org/10.1038/s41598-017-11094-3.

[35] Kendall, T., Verheij, J., Gaudio, E., Evert, M., Guido, M., Goeppert, B., et al. (2019). Anatomical, histomorphological and molecular classification of cholangiocarcinoma. *Liver International*, *39*(Suppl. 1), 7–18. https://doi.org/10.1111/liv.14093.

[36] Kim, M. K., Jang, J. W., & Bae, S. C. (2018). DNA binding partners of YAP/TAZ. *BMB Reports*, *51*(3), 126–133. https://doi.org/10.5483/bmbrep.2018.51.3.015.

[37] Kim, E., Kang, J. G., Kang, M. J., Park, J. H., Kim, Y. J., Kweon, T. H., et al. (2020). O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity. *Proceedings of the National Academy of Sciences of the United States of America*, *117*(25), 14259−14269. https://doi.org/10.1073/pnas.1913469117.

[38] Kim, W., Khan, S. K., Gvozdenovic-Jeremic, J., Kim, Y., Dahlman, J., Kim, H., et al. (2017). Hippo signaling interactions with Wnt/beta-catenin and Notch signaling repress liver tumorigenesis. *Journal of Clinical Investigation*, *127*(1), 137−152. https://doi.org/10.1172/JCI88486.

[39] Kim, W., Khan, S. K., Liu, Y., Xu, R., Park, O., He, Y., et al. (2018). Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma. *Gut*, *67* (9), 1692–1703. https://doi.org/10.1136/gutjnl-2017-314061.

[40] Kitagawa, K., Moriya, K., Kaji, K., Saikawa, S., Sato, S., Nishimura, N., et al. (2020). Atorvastatin augments gemcitabine-mediated anti-cancer effects by inhibiting yesassociated protein in human cholangiocarcinoma cells. *International Journal of Molecular Sciences*, *21*(20). https://doi.org/10.3390/ijms21207588.

[41] Ko, S., Russell, J. O., Molina, L. M., & Monga, S. P. (2019). Liver progenitors and adult cell plasticity in hepatic injury and repair: Knowns and unknowns. *Annual Review of Pathology: Mechanisms of Disease*, *15*, 23–50. https://doi.org/10.1146/annurevpathmechdis-012419-032824.

[42] Lee, K. P., Lee, J. H., Kim, T. S., Kim, T. H., Park, H. D., Byun, J. S., et al. (2010). The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America*, *107*(18), 8248−8253. https://doi.org/10.1073/pnas.0912203107.

[43] Li, H., Fu, L., Liu, B., Lin, X., Dong, Q., & Wang, E. (2019). Ajuba overexpression regulates mitochondrial potential and glucose uptake through YAP/Bcl-xL/GLUT1 in human gastric cancer. *Gene*, *693*, 16–24. https://doi.org/10.1016/j.gene.2019.01.018.

[44] Li, Q., Sun, Y., Jarugumilli, G. K., Liu, S., Dang, K., Cotton, J. L., et al. (2020). Lats1/2 sustain intestinal stem cells and Wnt Activation through TEAD-dependent and independent transcription. *Cell Stem Cell*, *26*(5), 675–692 e678. https://doi.org/10.1016/j.stem.2020.03.002.

[45] Li, X., Tao, J., Cigliano, A., Sini, M., Calderaro, J., Azoulay, D., et al. (2015). Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. *Oncotarget*, *6*(12), 10102–10115. https://doi.org/10.18632/oncotarget.3546.

[46] Li, X., Wu, Z., He, J., Jin, Y., Chu, C., Cao, Y., et al. (2021). OGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAP. *Oncogene*, *40*(30), 4859–4871. https://doi.org/10.1038/s41388-021-01901-7.

[47] Lin, C., & Xu, X. (2017). YAP1-TEAD1-Glut1 axis dictates the oncogenic phenotypes of breast cancer cells by modulating glycolysis. *Biomedicine and Pharmacotherapy*, *95*, 789–794. https://doi.org/10.1016/j.biopha.2017.08.091.

[48] Liu, Z., Alsaggaf, R., McGlynn, K. A., Anderson, L. A., Tsai, H. T., Zhu, B., et al. (2019). Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. *Gut*, *68*(8), 1458–1464. https://doi.org/10.1136/gutjnl-2018-317504.

[49] Liu, M., Lin, Y., Zhang, X. C., Tan, Y. H., Yao, Y. L., Tan, J., et al. (2017). Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas. *Laboratory Investigation*, *97*(11), 1354–1363. https://doi.org/10.1038/labinvest.2017.70.

[50] Liu, Y., Wu, Y., Ouyang, Y. S., He, J. J., Shen, L. L., Qi, H., et al. (2021). The combination of YAP/TAZ predicts the clinical prognosis in patients with cholangiocarcinoma after radical resection. *Zhonghua Nei Ke Za Zhi*, *60*(7), 637–643. https://doi.org/10.3760/cma.j.cn112138-20210201-00091.

[51] Liu, Y., Zhuo, S., Zhou, Y., Ma, L., Sun, Z., Wu, X., et al. (2021). Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis. *Journal of Hepatology*. https://doi.org/10.1016/j.jhep.2021.11.010.

[52] Lu, X., Peng, B., Chen, G., Pes, M. G., Ribback, S., Ament, C., et al. (2021). YAP accelerates notch-driven cholangiocarcinogenesis via mTORC1 in mice. *American Journal of Pathology*, *191*(9), 1651–1667. https://doi.org/10.1016/j.ajpath.2021.05.017.

[53] Luo, X., Campbell, N. A., He, L., O'Brien, D. R., Singer, M. S., Lemjabbar-Alaoui, H., et al. (2021). Sulfatase 2 (SULF2) monoclonal antibody 5D5 suppresses human cholangiocarcinoma xenograft growth through regulation of a SULF2-platelet-derived growth factor receptor beta-yes-associated protein signaling axis. *Hepatology*, *74*(3), 1411–1428. https://doi.org/10.1002/hep.31817.

[54] Ma, W., Han, C., Zhang, J., Song, K., Chen, W., Kwon, H., et al. (2020). The histone methyltransferase G9a promotes cholangiocarcinogenesis through regulation of the Hippo pathway kinase LATS2 and YAP signaling pathway. *Hepatology*, *72*(4), 1283−1297. https://doi.org/10.1002/hep.31141.

[55] Ma, S., Meng, Z., Chen, R., & Guan, K. L. (2019). The Hippo pathway: Biology and pathophysiology. *Annual Review of Biochemistry*, *88*, 577–604. https://doi.org/10.1146/annurev-biochem-013118-111829.

[56] Marti, P., Stein, C., Blumer, T., Abraham, Y., Dill, M. T., Pikiolek, M., et al. (2015). YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. *Hepatology*, *62*(5), 1497–1510. https://doi.org/10.1002/hep.27992.

[57] Merrell, A. J., Peng, T., Li, J., Sun, K., Li, B., Katsuda, T., et al. (2021). Dynamic transcriptional and epigenetic changes drive cellular plasticity in the liver. *Hepatology*, *74*(1), 444–457. https://doi.org/10.1002/hep.31704.

[58] Miyamura, N., Hata, S., Itoh, T., Tanaka, M., Nishio, M., Itoh, M., et al. (2017). YAP determines the cell fate of injured mouse hepatocytes in vivo. *Nature Communications*, *8*, 16017. https://doi.org/10.1038/ncomms16017.

[59] Moeini, A., Haber, P. K., & Sia, D. (2021). Cell of origin in biliary tract cancers and clinical implications. *JHEP Reports*, *3*(2), 100226. https://doi.org/10.1016/j.jhepr.2021.100226.

[60] Molina, L. M., Zhu, J., Li, Q., Pradhan-Sundd, T., Krutsenko, Y., Sayed, K., et al. (2021). Compensatory hepatic adaptation accompanies permanent absence of intrahepatic biliary network due to YAP1 loss in liver progenitors. *Cell Reports*, *36*(1), 109310. https://doi.org/10.1016/j.celrep.2021.109310.

[61] Moya, I. M., Castaldo, S. A., Van den Mooter, L., Soheily, S., Sansores-Garcia, L., Jacobs, J., et al. (2019). Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. *Science*, *366*(6468), 1029−1034. https://doi.org/10.1126/science.aaw9886.

[62] Nebbioso, A., Tambaro, F. P., Dell'Aversana, C., & Altucci, L. (2018). Cancer epigenetics: Moving forward. *PLoS Genetics*, *14*(6), e1007362. https://doi.org/10.1371/journal.pgen.1007362.

[63] Nguyen-Lefebvre, A. T., Selzner, N., Wrana, J. L., & Bhat, M. (2021). The hippo pathway: A master regulator of liver metabolism, regeneration, and disease. *The FASEB Journal*, *35* (5), e21570. https://doi.org/10.1096/fj.202002284RR.

[64] Nishio, M., Sugimachi, K., Goto, H., Wang, J., Morikawa, T., Miyachi, Y., et al. (2016). Dysregulated YAP1/TAZ and TGF-beta signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice. *Proceedings of the National Academy of*

Sciences of the United States of America, *113*(1), E71–E80. https://doi.org/10.1073/pnas.1517188113.

[65] Noto, A., De Vitis, C., Pisanu, M. E., Roscilli, G., Ricci, G., Catizone, A., et al. (2017). Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. *Oncogene*, *36*(32), 4573–4584. https://doi.org/10.1038/onc.2017.75.

[66] Pant, K., Richard, S., Peixoto, E., & Gradilone, S. A. (2020). Role of glucose metabolism reprogramming in the pathogenesis of cholangiocarcinoma. *Frontiers in Medicine (Lausanne)*, *7*, 113. https://doi.org/10.3389/fmed.2020.00113.

[67] Park, J., Kim, J. S., Nahm, J. H., Kim, S. K., Lee, D. H., & Lim, D. S. (2020). WWC1 and NF2 prevent the development of intrahepatic cholangiocarcinoma by regulating YAP/TAZ activity through LATS in mice. *Molecules and Cells*, *43*(5), 491–499. https://doi.org/10.14348/molcells.2020.0093.

[68] Patrick, S., Gowda, P., Lathoria, K., Suri, V., & Sen, E. (2021). YAP1-mediated regulation of mitochondrial dynamics in IDH1 mutant gliomas. *Journal of Cell Science*, *134*- (22). https://doi.org/10.1242/jcs.259188.

[69] Pei, T., Li, Y., Wang, J., Wang, H., Liang, Y., Shi, H., et al. (2015). YAP is a critical oncogene in human cholangiocarcinoma. *Oncotarget*, *6*(19), 17206–17220. https://doi.org/10.18632/oncotarget.4043.

[70] Peng, C., Zhu, Y., Zhang, W., Liao, Q., Chen, Y., Zhao, X., et al. (2017). Regulation of the Hippo-YAP pathway by glucose sensor O-GlcNAcylation. *Molecular Cell*, *68*(3), 591–604. e595 https://doi.org/10.1016/j.molcel.2017.10.010.

[71] Phoomak, C., Silsirivanit, A., Park, D., Sawanyawisuth, K., Vaeteewoottacharn, K., Wongkham, C., et al. (2018). O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1. *Oncogene*, *37*(42), 5648–5665. https://doi.org/10.1038/s41388-018-0366-1.

[72] Phoomak, C., Vaeteewoottacharn, K., Sawanyawisuth, K., Seubwai, W., Wongkham, C., Silsirivanit, A., et al. (2016). Mechanistic insights of O-GlcNAcylation that promote progression of cholangiocarcinoma cells via nuclear translocation of NF-kappaB. *Scientific Reports*, *6*, 27853. https://doi.org/10.1038/srep27853.

[73] Phoomak, C., Vaeteewoottacharn, K., Silsirivanit, A., Saengboonmee, C., Seubwai, W., Sawanyawisuth, K., et al. (2017). High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation. *Scientific Reports*, *7*, 43842. https://doi.org/10.1038/srep43842.

[74] Planas-Paz, L., Sun, T., Pikiolek, M., Cochran, N. R., Bergling, S., Orsini, V., et al. (2019). YAP, but not RSPO-LGR4/5, signaling in biliary epithelial cells promotes a ductular reaction in response to liver injury. *Cell Stem Cell*, *25*(1), 39–53. e10 https://doi.org/10.1016/j.stem.2019.04.005.

[75] Razumilava, N., & Gores, G. J. (2014). Cholangiocarcinoma. *Lancet*, *383*(9935), 2168–2179. https://doi.org/10.1016/S0140-6736(13)61903-0.

[76] Reggiani, F., Gobbi, G., Ciarrocchi, A., & Sancisi, V. (2021). YAP and TAZ are not identical twins. *Trends in Biochemical Sciences*, *46*(2), 154–168. https://doi.org/10.1016/j.tibs.2020.08.012.

[77] Rizvi, S., Fischbach, S. R., Bronk, S. F., Hirsova, P., Krishnan, A., Dhanasekaran, R., et al. (2018). YAP-associated chromosomal instability and cholangiocarcinoma in mice. *Oncotarget*, *9* (5), 5892–5905. https://doi.org/10.18632/oncotarget.23638.

[78] Rizvi, S., Yamada, D., Hirsova, P., Bronk, S. F., Werneburg, N. W., Krishnan, A., et al. (2016). A Hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma. *Journal of Biological Chemistry*, *291*(15), 8031–8047. https://doi.org/10.1074/jbc.M115.698472.

[79] Roh, M. S., Jeong, J. S., Kim, Y. H., Kim, M. C., & Hong, S. H. (2004). Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas. *Hepatogastroenterology*, *51*(59), 1315–1318. https://www.ncbi.nlm.nih.gov/pubmed/15362741.

[80] Saha, S. K., Parachoniak, C. A., Ghanta, K. S., Fitamant, J., Ross, K. N., Najem, M. S., et al. (2014). Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. *Nature*, *513*(7516), 110–114. https://doi.org/10.1038/nature13441.

[81] Seehawer, M., Heinzmann, F., D'Artista, L., Harbig, J., Roux, P. F., Hoenicke, L., et al. (2018). Necroptosis microenvironment directs lineage commitment in liver cancer. *Nature*, *562*(7725), 69–75. https://doi.org/10.1038/s41586-018-0519-y.

[82] Sirica, A. E., Strazzabosco, M., & Cadamuro, M. (2021). Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. *Advances in Cancer Research*, *149*, 321–387. https://doi.org/10.1016/bs.acr.2020.10.005.

[83] Smoot, R. L., Werneburg, N. W., Sugihara, T., Hernandez, M. C., Yang, L., Mehner, C., et al. (2018). Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation. *Journal of*

Cellular Biochemistry, *119*(1), 824–836. https://doi.org/10.1002/jcb.26246.

[84] Song, X., Liu, X., Wang, H., Wang, J., Qiao, Y., Cigliano, A., et al. (2019). Combined CDK4/6 and Pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma. *Clinical Cancer Research*, *25*(1), 403–413. https://doi.org/10.1158/1078-0432.CCR-18-0284.

[85] Song, H., Mak, K. K., Topol, L., Yun, K., Hu, J., Garrett, L., et al. (2010). Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. *Proceedings of the National Academy of Sciences of the United States of America*, *107*(4), 1431–1436. https://doi.org/10.1073/pnas.0911409107.

[86] Song, X., Xu, H., Wang, P., Wang, J., Affo, S., Wang, H., et al. (2021). Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. *Journal of Hepatology*, *75*(4), 888–899. https://doi.org/10.1016/j.jhep.2021.05.018.

[87] Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., et al. (2014). Metabolic control of YAP and TAZ by the mevalonate pathway. *Nature Cell Biology*, *16* (4), 357–366. https://doi.org/10.1038/ncb2936.

[88] Stavraka, C., Rush, H., & Ross, P. (2019). Combined hepatocellular cholangiocarcinoma (cHCC-CC): An update of genetics, molecular biology, and therapeutic interventions. *Journal of Hepatocellular Carcinoma*, *6*, 11–21. https://doi.org/10.2147/JHC.S159805.

[89] Sugihara, T., Isomoto, H., Gores, G., & Smoot, R. (2019). YAP and the Hippo pathway in cholangiocarcinoma. *Journal of Gastroenterology*, *54*(6), 485–491. https://doi.org/10.1007/s00535-019-01563-z.

[90] Sugimachi, K., Nishio, M., Aishima, S., Kuroda, Y., Iguchi, T., Komatsu, H., et al. (2017). Altered expression of Hippo signaling pathway molecules in intrahepatic cholangiocarcinoma. *Oncology* , *93*(1), 67–74. https://doi.org/10.1159/000463390.

[91] Sugiura, K., Mishima, T., Takano, S., Yoshitomi, H., Furukawa, K., Takayashiki, T., et al. (2019). The expression of Yes-associated protein (YAP) maintains putative cancer stemness and is associated with poor prognosis in intrahepatic cholangiocarcinoma. *American Journal of Pathology*, *189*(9), 1863–1877. https://doi.org/10.1016/j.ajpath.2019.05.014.

[92] Szeto, S. G., Narimatsu, M., Lu, M., He, X., Sidiqi, A. M., Tolosa, M. F., et al. (2016). YAP/TAZ are mechanoregulators of TGF-beta-Smad signaling and renal fibrogenesis. *Journal of the American Society of Nephrology*, *27*(10), 3117–3128. https://doi.org/10.1681/ASN.2015050499.

[93] Tang, D., Xu, L., Zhang, M., Dorfman, R. G., Pan, Y., Zhou, Q., et al. (2018). Metformin facilitates BG45induced apoptosis via an antiWarburg effect in cholangiocarcinoma cells. *Oncology Reports*, *39*(4), 1957–1965. https://doi.org/10.3892/or.2018.6275.

[94] Taniguchi, K., Wu, L. W., Grivennikov, S. I., de Jong, P. R., Lian, I., Yu, F. X., et al. (2015). A gp130-Src-YAP module links inflammation to epithelial regeneration. *Nature*, *519* (7541), 57–62. https://doi.org/10.1038/nature14228.

[95] Thamrongwaranggoon, U., Sangkhamanon, S., Seubwai, W., Saranaruk, P., Cha'on, U., & Wongkham, S. (2021). Aberrant GLUT1 expression is associated with carcinogenesis and progression of liver fluke-associated cholangiocarcinoma. *In Vivo*, *35*(1), 267–274. https://doi.org/10.21873/invivo.12255.

[96] Tiemin, P., Peng, X., Qingfu, L., Yan, W., Junlin, X., Zhefeng, H., et al. (2020). Dysregulation of the miR-148a-GLUT1 axis promotes the progression and chemoresistance of human intrahepatic cholangiocarcinoma. *Oncogenesis*, *9*(2), 19. https://doi.org/10.1038/s41389-020-0207-2.

[97] Toth, M., Wehling, L., Thiess, L., Rose, F., Schmitt, J., Weiler, S. M. E., et al. (2021). Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. *BMC Cancer*, *21*(1), 1079. https://doi.org/10.1186/s12885-021-08794-5.

[98] Tschaharganeh, D. F., Xue, W., Calvisi, D. F., Evert, M., Michurina, T. V., Dow, L. E., et al. (2014). p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. *Cell*, *158*(3), 579–592. https://doi.org/10.1016/j.cell.2014.05.051.

[99] Van Haele, M., Moya, I. M., Karaman, R., Rens, G., Snoeck, J., Govaere, O., et al. (2019). YAP and TAZ heterogeneity in primary liver cancer: An analysis of its prognostic and diagnostic role. *International Journal of Molecular Sciences*, *20*(3). https://doi.org/10.3390/ijms20030638.

[100] Vanichapol, T., Leelawat, K., & Hongeng, S. (2015). Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signalregulated kinase signaling pathway. *Molecular Medicine Reports*, *12*(3), 3265–3272. https://doi.org/10.3892/mmr.2015.3865.

[101] Wang, J., Dong, M., Xu, Z., Song, X., Zhang, S., Qiao, Y., et al. (2018). Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. *Oncogene*, *37*(24), 3229–3242. https://doi.org/10.1038/s41388-018-0188-1.

[102] Wang, J., Wang, H., Peters, M., Ding, N., Ribback, S., Utpatel, K., et al. (2019). Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. *Journal of Hepatology*, *71*(4), 742–752. https://doi.org/10.1016/j.jhep.2019.05.027.

[103] Wang, H., Wang, J., Zhang, S., Jia, J., Liu, X., Zhang, J., et al. (2021). Distinct and overlapping roles of Hippo effectors YAP and TAZ during human and mouse hepatocarcinogenesis. *Cellular and Molecular Gastroenterology and Hepatology*, *11*(4), 1095–1117. https://doi.org/10.1016/j.jcmgh.2020.11.008.

[104] Wang, W., Xiao, Z. D., Li, X., Aziz, K. E., Gan, B., Johnson, R. L., et al. (2015). AMPK modulates Hippo pathway activity to regulate energy homeostasis. *Nature Cell Biology*, *17* (4), 490–499. https://doi.org/10.1038/ncb3113.

[105] Wang, S., Xie, F., Chu, F., Zhang, Z., Yang, B., Dai, T., et al. (2017). YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKvarepsilon-mediated phosphorylation. *Nature Immunology*, *18*(7), 733−743. https://doi.org/10.1038/ni.3744.

[106] Wu, H., Liu, Y., Jiang, X. W., Li, W. F., Guo, G., Gong, J. P., et al. (2016). Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma. *Tumor Biology*, *37*(10), 13499−13508. https://doi.org/10.1007/s13277-016-5211-y.

[107] Xia, L., Chen, X., Yang, J., Zhu, S., Zhang, L., Yin, Q., et al. (2020). Long non-coding RNA-PAICC promotes the tumorigenesis of human intrahepatic cholangiocarcinoma by increasing YAP1 transcription. *Frontiers in Oncology*, *10*, 595533. https://doi.org/10.3389/fonc.2020.595533.

[108] Xu, K. D., Miao, Y., Li, P., Li, P. P., Liu, J., Li, J., et al. (2021). Licochalcone A inhibits cell growth through the downregulation of the Hippo pathway via PES1 in cholangiocarcinoma cells. *Environmental Toxicology*. https://doi.org/10.1002/tox.23422.

[109] Xu, W., Zhang, M., Li, Y., Wang, Y., Wang, K., Chen, Q., et al. (2021). YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas. *Cancer Cell International*, *21*(1), 30. https://doi.org/10.1186/s12935-020-01688-9.

[110] Yamada, D., Rizvi, S., Razumilava, N., Bronk, S. F., Davila, J. I., Champion, M. D., et al. (2015). IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. *Hepatology*, *61*(5), 1627–1642. https://doi.org/10.1002/hep.27687.

[111] Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., et al. (2009). IDH1 and IDH2 mutations in gliomas. *The New England Journal of Medicine*, *360*(8), 765−773. https://doi.org/10.1056/NEJMoa0808710.

[112] Yang, S. H., Lin, H. Y., Chang, V. H., Chen, C. C., Liu, Y. R., Wang, J., et al. (2015). Lovastatin overcomes gefitinib resistance through TNF-alpha signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo. *Oncotarget*, *6*(27), 23857−23873. https://doi.org/10.18632/oncotarget.4408.

[113] Yang, C. S., Stampouloglou, E., Kingston, N. M., Zhang, L., Monti, S., & Varelas, X. (2018). Glutamine-utilizing transaminases are a metabolic vulnerability of TAZ/YAP-activated cancer cells. *EMBO Reports*, *19*(6). https://doi.org/10.15252/embr.201643577.

[114] Yimlamai, D., Christodoulou, C., Galli, G. G., Yanger, K., Pepe-Mooney, B., Gurung, B., et al. (2014). Hippo pathway activity influences liver cell fate. *Cell*, *157*(6), 1324–1338. https://doi.org/10.1016/j.cell.2014.03.060.

[115] Yimlamai, D., Fowl, B. H., & Camargo, F. D. (2015). Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. *Journal of Hepatology*, *63*(6), 1491–1501. https://doi.org/10.1016/j.jhep.2015.07.008.

[116] Yin, F., Yu, J., Zheng, Y., Chen, Q., Zhang, N., & Pan, D. (2013). Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. *Cell*, *154*(6), 1342–1355. https://doi.org/10.1016/j.cell.2013.08.025.

[117] Yuan, H. Y., Lv, Y. J., Chen, Y., Li, D., Li, X., Qu, J., et al. (2021). TEAD4 is a novel independent predictor of prognosis in LGG patients with IDH mutation. *Open Life Science*, *16* (1), 323–335. https://doi.org/10.1515/biol-2021-0039.

[118] Yuan, W. C., Pepe-Mooney, B., Galli, G. G., Dill, M. T., Huang, H. T., Hao, M., et al. (2018). NUAK2 is a critical YAP target in liver cancer. *Nature Communications*, *9*(1), 4834. https://doi.org/10.1038/s41467-018-07394-5.

[119] Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016). YAP/TAZ at the roots of cancer. *Cancer Cell*, *29*(6), 783–803. https://doi.org/10.1016/j.ccell.2016.05.005.

[120] Zhang, N., Bai, H., David, K. K., Dong, J., Zheng, Y., Cai, J., et al. (2010). The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. *Developmental Cell*, *19*(1), 27–38. https://doi.org/10.1016/j.devcel.2010.06.015.

[121] Zhang, S., Liang, S., Wu, D., Guo, H., Ma, K., & Liu, L. (2021). LncRNA coordinates Hippo and mTORC1 pathway

activation in cancer. *Cell Death and Disease*, *12*(9), 822. https://doi.org/10.1038/s41419-021-04112-w.

[122] Zhang, X., Qiao, Y., Wu, Q., Chen, Y., Zou, S., Liu, X., et al. (2017). The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. *Nature Communications*, *8*, 15280. https://doi.org/10.1038/ncomms15280.

[123] Zhang, S., Song, X., Cao, D., Xu, Z., Fan, B., Che, L., et al. (2017). Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. *Journal of Hepatology*, *67*(6), 1194–1203. https://doi.org/10.1016/j.jhep.2017.07.006.

[124] Zhang, S., Wang, J., Wang, H., Fan, L., Fan, B., Zeng, B., et al. (2018). Hippo cascade controls lineage commitment of liver tumors in mice and humans. *American Journal of Pathology*, *188*(4), 995–1006. https://doi.org/10.1016/j.ajpath.2017.12.017.

[125] Zhu, B., Qian, W., Han, C., Bai, T., & Hou, X. (2021). Piezo 1 activation facilitates cholangiocarcinoma metastasis via Hippo/YAP signaling axis. *Molecular Therapy Nucleic Acids*, *24*, 241–252. https://doi.org/10.1016/j.omtn.2021.02.026.

[126] Zimmerman, R. L., Fogt, F., Burke, M., & Murakata, L. A. (2002). Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma. *Oncology Reports* , *9*(4), 689–692. https://www.ncbi.nlm.nih.gov/pubmed/12066193.

[127] Zong, Y., Panikkar, A., Xu, J., Antoniou, A., Raynaud, P., Lemaigre, F., et al. (2009). Notch signaling controls liver development by regulating biliary differentiation. *Development*, *136*(10), 1727–1739. https://doi.org/10.1242/dev.029140.

11 患者来源的功能性类器官作为肝胆癌个性化药物筛选的新策略

[1] Abou-Alfa, G. K., Meyer, T., Cheng, A. L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B. Y., et al. (2018). Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. *New England Journal of Medicine*, *379*(1), 54–63. https://doi.org/10.1056/NEJMoa1717002.

[2] Adisetiyo, H., Liang, M. M., Liao, C. P., Jeong, J. H., Cohen, M. B., Roy-Burman, P., et al. (2014). Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts. *Journal of Cellular Physiology*, *229*(9), 1170–1176. https://doi.org/10.1002/jcp.24546.

[3] Aparicio, S., Hidalgo, M., & Kung, A. L. (2015). Examining the utility of patient-derived xenograft mouse models. *Nature Reviews Cancer*, *15*(5), 311–316. https://doi.org/10.1038/nrc3944.

[4] Brancato, V., Oliveira, J. M., Correlo, V. M., Reis, R. L., & Kundu, S. C. (2020). Could 3D models of cancer enhance drug screening? *Biomaterials*, *232*. https://doi.org/10.1016/j.biomaterials.2019.119744, 119744.

[5] Broutier, L., Mastrogiovanni, G., Verstegen, M. M. A., Francies, H. E., Gavarro, L. M., Bradshaw, C. R., et al. (2017). Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. *Nature Medicine*, *23*(12), 1424-+. https://doi.org/10.1038/nm.4438.

[6] Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y. H., Bodoky, G., et al. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, *389*(10064), 56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.

[7] Burstein, H. J., Mangu, P. B., Somerfield, M. R., Schrag, D., Samson, D., Holt, L., et al. (2011). American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. *Journal of Clinical Oncology*, *29*(24), 3328–3330. https://doi.org/10.1200/JCO.2011.36.0354.

[8] Casak, S. J., Donoghue, M., Fashoyin-Aje, L., Jiang, X., Rodriguez, L., Shen, Y. L., et al. (2021). FDA approval summary: Atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma. *Clinical Cancer Research*, *27*(7), 1836–1841. https://doi.org/10.1158/1078-0432.CCR-20-3407.

[9] Chen, D. S., & Mellman, I. (2017). Elements of cancer immunity and the cancer-immune set point. *Nature*, *541*(7637), 321–330. https://doi.org/10.1038/nature21349.

[10] Chwalek, K., Bray, L. J., & Werner, C. (2014). Tissue-engineered 3D tumor angiogenesis models: Potential technologies for anti-cancer drug discovery. *Advanced Drug Delivery Reviews*, *79-80*, 30–39. https://doi.org/10.1016/j.addr.2014.05.006.

[11] Cobain, E. F., Wu, Y. M., Chugh, R., Worden, F., Smith, D. C., Schuetze, S. M., et al. (2021). Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors. *JAMA Oncology*, *7*(4), 525–533. https://doi.org/10.1001/jamaoncol.2020.7987.

[12] Cox, M. C., Reese, L. M., Bickford, L. R., & Verbridge, S. S. (2015). Toward the broad adoption of 3D tumor models in the cancer drug pipeline. *ACS Biomaterials Science & Engineering*, *1*(10), 877–894. https://doi.org/10.1021/

acsbiomaterials.5b00172.

[13] Davis, W., Makar, G., Mehta, P., Zhu, G. G., Somer, R., Morrison, J., et al. (2019). Next-generation sequencing in 305 consecutive patients: Clinical outcomes and management changes. *JCO Oncology Practice*, *15*(12), e1028–e1034. https://doi.org/10.1200/JOP.19.00269.

[14] De Martini, D. (2020). Empowering phase II clinical trials to reduce phase III failures. *Pharmaceutical Statistics*, *19*(3), 178–186. https://doi.org/10.1002/pst.1980.

[15] Dijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., et al. (2018). Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. *Cell*, *174*(6), 1586-+. https://doi.org/10.1016/j.cell.2018.07.009.

[16] Driehuis, E., Kretzschmar, K., & Clevers, H. (2020). Establishment of patient-derived cancer organoids for drug-screening applications. *Nature Protocols*, *15*(10), 3380–3409. https://doi.org/10.1038/s41596-020-0379-4.

[17] Dunne, L. W., Huang, Z., Meng, W. X., Fan, X. J., Zhang, N. Y., Zhang, Q. X., et al. (2014). Human decellularized adipose tissue scaffold as a model for breast cancer cell growth and drug treatments. *Biomaterials*, *35*(18), 4940–4949. https://doi.org/10.1016/j.biomaterials.2014.03.003.

[18] Ebbing, E. A., van der Zalm, A. P., Steins, A., Creemers, A., Hermsen, S., Rentenaar, R., et al. (2019). Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, *116*(6), 2237–2242. https://doi.org/10.1073/pnas.1820459116.

[19] Ferreira, L. P., Gaspar, V. M., & Mano, J. F. (2018). Design of spherically structured 3D in vitro tumor models -advances and prospects. *Acta Biomaterialia*, *75*, 11–34. https://doi.org/10.1016/j.actbio.2018.05.034.

[20] Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., et al. (2020). Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *New England Journal of Medicine*, *382*(20), 1894–1905. https://doi.org/10.1056/NEJMoa1915745.

[21] Fong, E. L. S., Harrington, D. A., Farach-Carson, M. C., & Yu, H. (2016). Heralding a new paradigm in 3D tumor modeling. *Biomaterials*, *108*, 197–213. https://doi.org/10.1016/j.biomaterials.2016.08.052.

[22] Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015). Precision medicine for cancer with next-generation functional diagnostics. *Nature Reviews Cancer*, *15*(12), 747–756. https://doi.org/10.1038/nrc4015.

[23] Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., et al. (2014). Organoid cultures derived from patients with advanced prostate cancer. *Cell*, *159*(1), 176–187. https://doi.org/10.1016/j.cell.2014.08.016.

[24] Golabi, P., Fazel, S., Otgonsuren, M., Sayiner, M., Locklear, C. T., & Younossi, Z. M. (2017). Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. *Medicine (Baltimore)*, *96*(9), e5904. https://doi.org/10.1097/MD.0000000000005904.

[25] Hack, S. P., Spahn, J., Chen, M., Cheng, A. L., Kaseb, A., Kudo, M., et al. (2020). IMbrave 050: A phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. *Future Oncology*, *16*(15), 975–989. https://doi.org/10.2217/fon-2020-0162.

[26] Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., et al. (2019). Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. *Clinical Cancer Research*, *25*(7), 2116–2126. https://doi.org/10.1158/1078-0432.CCR-18-2293.

[27] Huch, M., Bonfanti, P., Boj, S. F., Sato, T., Loomans, C. J. M., van de Wetering, M., et al. (2013). Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. *EMBO Journal*, *32*(20), 2708–2721. https://doi.org/10.1038/emboj.2013.204.

[28] Huch, M., Gehart, H., van Boxtel, R., Hamer, K., Blokzijl, F., Verstegen, M. M. A., et al. (2015). Long-term culture of genome-stable bipotent stem cells from adult human liver. *Cell*, *160*(1–2), 299–312. https://doi.org/10.1016/j.cell.2014.11.050.

[29] Jensen, C., & Teng, Y. (2020). Is it time to start transitioning from 2D to 3D cell culture? *Frontiers in Molecular Biosciences*, *7*. https://doi.org/10.3389/fmolb.2020.00033. ARTN 33.

[30] Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., et al. (2013). Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nature Genetics*, *45*(12), 1470–1473. https://doi.org/10.1038/ng.2813.

[31] Johnson, T. M. (2017). Perspective on precision medicine in oncology. *Pharmacotherapy*, *37*(9), 988–989. https://doi.org/10.1002/phar.1975.

[32] Joyce, J. A., & Fearon, D. T. (2015). T cell exclusion, immune privilege, and the tumor microenvironment. *Science*, *348*(6230), 74–80. https://doi.org/10.1126/science.aaa6204.

[33] Karthaus, W. R., Iaquinta, P. J., Drost, J., Gracanin, A., Van Boxtel, R., Wongvipat, J., et al. (2014). Identification of multipotent luminal progenitor cells in human prostate organoid cultures. *Cell* , *159*(1), 163–175. https://doi.org/10.1016/j.cell.2014.08.017.

[34] Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H. J., Chun, S. M., et al. (2019). Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. *Nature Communications*, *10*. https://doi.org/10.1038/s41467-019-11867-6. ARTN 3991.

[35] Koledova, Z., & Lu, P. F. (2017). A 3D fibroblast-epithelium co-culture model for understanding microenvironmental role in branching morphogenesis of the mammary gland. *Mammary Gland Development: Methods and Protocols*, *1501*, 217–231. https://doi.org/10.1007/978-1-4939-6475-8_10.

[36] Kong, J. C. H., Guerra, G. R., Millen, R. M., Roth, S., Xu, H. L., Neeson, P. J., et al. (2018). Tumor-infiltrating lymphocyte function predicts response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. *JCO Precision Oncology*, *2*, 1–15. https://doi.org/10.1200/Po.18.00075.

[37] Konnick, E. Q. (2020). The regulatory landscape of precision oncology laboratory medicine in the United States-perspective on the past 5 years and considerations for future regulation. *Practical Laboratory Medicine*, *21*, ARTN e00172. https://doi.org/10.1016/j.plabm.2020.e00172.

[38] Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., et al. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. *Lancet*, *391*(10126), 1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1.

[39] Lancaster, M. A., Renner, M., Martin, C. A., Wenzel, D., Bicknell, L. S., Hurles, M. E., et al. (2013). Cerebral organoids model human brain development and microcephaly. *Nature*, *501* (7467), 373-+. https://doi.org/10.1038/nature12517.

[40] Lang, P., Yeow, K., Nichols, A., & Scheer, A. (2006). Cellular imaging in drug discovery. *Nature Reviews Drug Discovery*, *5*(4), 343–356. https://doi.org/10.1038/nrd2008.

[41] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., et al. (2019). Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *New England Journal of Medicine*, *381*(16), 1535–1546. https://doi.org/10.1056/NEJMoa1910836.

[42] Lee, G. Y., Kenny, P. A., Lee, E. H., & Bissell, M. J. (2007). Three-dimensional culture models of normal and malignant breast epithelial cells. *Nature Methods*, *4*(4), 359–365. https://doi.org/10.1038/Nmeth1015.

[43] Li, L., Halpert, G., Lerner, M. G., Hu, H., Dimitrion, P., Weiss, M. J., et al. (2021). Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. *Jci*. *Insight*, *6*(12). https://doi.org/10.1172/jci.insight.138197.

[44] Li, L., Knutsdottir, H., Hui, K., Weiss, M. J., He, J., Philosophe, B., et al. (2019). Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. *Jci*. *Insight*, *4*(2), ARTN e121490. https://doi.org/10.1172/jci.insight.121490.

[45] Ling Li, H. K., Bader, J., & Selaru, F. (2019). Complext patient derived organoids(CPDOS) modeling for anti-cancer drug screening. *Gastroenterology*, *156*(6).

[46] Liu, J. Y., Li, P. F., Wang, L., Li, M., Ge, Z. H., Noordam, L., et al. (2021). Cancer-associated fibroblasts provide a stromal niche for liver cancer organoids that confers trophic effects and therapy resistance. *Cellular and Molecular Gastroenterology and Hepatology*, *11*(2), 407–431. https://doi.org/10.1016/j.jcmgh.2020.09.003.

[47] Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., et al. (2021). Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. *Nature Reviews Gastroenterology & Hepatology*, *18*(5), 293–313. https://doi.org/10.1038/s41575-020-00395-0.

[48] Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., et al. (2021). Hepatocellular carcinoma. *Nature Reviewes Disease Primers*, *7*(1), 6. https://doi.org/10.1038/s41572-020-00240-3.

[49] Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018). Molecular therapies and precision medicine for hepatocellular carcinoma. *Nature Reviews. Clinical Oncology*, *15*(10), 599–616. https://doi.org/10.1038/s41571-018-0073-4.

[50] Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. *New England Journal of Medicine*, *359*(4), 378–390. https://doi.org/10.1056/NEJMoa0708857.

[51] Mak, I. W., Evaniew, N., & Ghert, M. (2014). Lost in translation: Animal models and clinical trials in cancer treatment. *American Journal of Translational Research*, *6*(2), 114–118.

[52] Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017). Tumourassociated macrophages as treatment

targets in oncology. *Nature Reviews. Clinical Oncology*, *14* (7), 399–416. https://doi.org/10.1038/nrclinonc.2016.217.

[53] Manzanares, M. A., Campbell, D. J. W., Maldonado, G. T., & Sirica, A. E. (2018). Overexpression of periostin and distinct mesothelin forms predict malignant progression in a rat cholangiocarcinoma model. *Hepatology Communications*, *2*(2), 155–172. https://doi.org/10.1002/hep4.1131.

[54] Manzanares, M. A., Usui, A., Campbell, D. J., Dumur, C. I., Maldonado, G. T., Fausther, M., et al. (2017). Transforming growth factors alpha and beta are essential for modeling cholangiocarcinoma desmoplasia and progression in a three-dimensional organotypic culture model. *American Journal of Pathology*, *187*(5), 1068–1092. https://doi.org/10.1016/j.ajpath.2017.01.013.

[55] Marusyk, A., Tabassum, D. P., Janiszewska, M., Place, A. E., Trinh, A., Rozhok, A. I., et al. (2016). Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of breast cancer cells influencing clinical outcomes. *Cancer Research*, *76*(22), 6495–6506. https://doi.org/10.1158/0008-5472.Can-16-1457.

[56] Mullenders, J., de Jongh, E., Brousali, A., Roosen, M., Blom, J. P. A., Begthel, H., et al. (2019). Mouse and human urothelial cancer organoids: A tool for bladder cancer research. *Proceedings of the National Academy of Sciences of the United States of America*, *116*(10), 4567–4574. https://doi.org/10.1073/pnas.1803595116.

[57] Naruse, M., Ochiai, M., Sekine, S., Taniguchi, H., Yoshida, T., Ichikawa, H., et al. (2021). Re-expression of REG family and DUOXs genes in CRC organoids by co-culturing with CAFs. *Scientific Reports*, *11*(1), ARTN 2077. https://doi.org/10.1038/s41598-021-81475-2.

[58] Noel, G., Baetz, N. W., Staab, J. F., Donowitz, M., Kovbasnjuk, O., Pasetti, M. F., et al. (2017). A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions. *Scientific Reports*, *7*. https://doi.org/10.1038/srep45270. ARTN 45270.

[59] Nuciforo, S., Fofana, I., Matter, M. S., Blumer, T., Calabrese, D., Boldanova, T., et al. (2018). Organoid models of human liver cancers derived from tumor needle biopsies. *Cell Reports*, *24* (5), 1363–1376. https://doi.org/10.1016/j.celrep.2018.07.001.

[60] Ohlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., et al. (2017). Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *Journal of Experimental Medicine*, *214*(3), 579–596. https://doi.org/10.1084/jem.20162024.

[61] Ooft, S. N., Weeber, F., Dijkstra, K. K., McLean, C. M., Kaing, S., van Werkhoven, E., et al. (2019). Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. *Science Translational Medicine*, *11*(513), ARTN eaay2574. https://doi.org/10.1126/scitranslmed.aay2574.

[62] Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. *Nature Reviews Cancer*, *12*(4), 252–264. https://doi.org/10.1038/nrc3239.

[63] Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. *Nature Medicine*, *19*(11), 1423–1437. https://doi.org/10.1038/nm.3394.

[64] Radhakrishnan, J., Varadaraj, S., Dash, S. K., Sharma, A., & Verma, R. S. (2020). Organotypic cancer tissue models for drug screening: 3D constructs, bioprinting and microfluidic chips. *Drug Discovery Today*, *25*(5), 879–890. https://doi.org/10.1016/j.drudis.2020.03.002.

[65] Roerink, S. F., Sasaki, N., Lee-Six, H., Young, M. D., Alexandrov, L. B., Behjati, S., et al. (2018). Intra-tumour diversification in colorectal cancer at the single-cell level. *Nature*, *556*(7702), 457. https://doi.org/10.1038/s41586-018-0024-3.

[66] Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., et al. (2018). A living biobank of breast cancer organoids captures disease heterogeneity. *Cell*, *172*(1–2), 373-+. https://doi.org/10.1016/j.cell.2017.11.010.

[67] Saito, Y., Muramatsu, T., Kanai, Y., Ojima, H., Sukeda, A., Hiraoka, N., et al. (2019). Establishment of patient-derived organoids and drug screening for biliary tract carcinoma. *Cell Reports*, *27*(4), 1265-+. https://doi.org/10.1016/j.celrep.2019.03.088.

[68] Saito, Y., Muramatsu, T., & Saito, H. (2020). Establishment and long-term culture of organoids derived from human biliary tract carcinoma. *STAR Protocols*, *1*(1), 100009. https://doi.org/10.1016/j.xpro.2019.100009.

[69] Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., et al. (2009). Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature*, *459*(7244), 262–U147. https://doi.org/10.1038/nature07935.

[70] Seidlitz, T., & Stange, D. E. (2021). Gastrointestinal cancer organoids-applications in basic and translational cancer research. *Experimental & Molecular Medicine*, *53*(10), 1459–1470. https://doi.org/10.1038/s12276-021-00654-3.

[71] Sharma, P., & Allison, J. P. (2015a). The future of immune checkpoint therapy. *Science*, *348*(6230), 56–61. https://doi.org/10.1126/science.aaa8172.

[72] Sharma, P., & Allison, J. P. (2015b). Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. *Cell*, *161*(2), 205–214. https://doi.org/10.1016/j.cell.2015.03.030.

[73] Shroyer, N. F. (2016). Tumor organoids fill the niche. *Cell Stem Cell*, *18*(6), 686–687. https://doi.org/10.1016/j.stem.2016.05.020.

[74] Sirica, A. E. (2012). The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. *Nature Reviews Gastroenterology & Hepatology*, *9*(1), 44–54. https://doi.org/10.1038/nrgastro.2011.222.

[75] Sirica, A. E., Almenara, J. A., & Li, C. (2014). Periostin in intrahepatic cholangiocarcinoma: Pathobiological insights and clinical implications. *Experimental and Molecular Pathology*, *97*(3), 515–524. https://doi.org/10.1016/j.yexmp.2014.10.007.

[76] Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., et al. (2018). Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *New England Journal of Medicine*, *378*(24), 2288–2301. https://doi.org/10.1056/NEJMoa1716948.

[77] Stock, K., Estrada, M. F., Vidic, S., Gjerde, K., Rudisch, A., Santo, V. E., et al. (2016). Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery. *Scientific Reports*, *6*, ARTN 28951. https://doi.org/10.1038/srep28951.

[78] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a Cancer Journal for Clinicians*, *71*(3), 209–249. https://doi.org/10.3322/caac.21660.

[79] Thomas, D. W., Burns, J., Audette, J., Carroll, A., Dow-Hygelund, C., & Hay, M. (2016). *Clinical development success rates 2006–2015*. BIO Industry Analysis.

[80] Tsai, S., McOlash, L., Palen, K., Johnson, B., Duris, C., Yang, Q. H., et al. (2018). Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. *BMC Cancer*, *18*. https://doi.org/10.1186/s12885-018-4238-4. ARTN 335.

[81] Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., et al. (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *New England Journal of Medicine*, *362*(14), 1273−1281. https://doi.org/10.1056/NEJMoa0908721.

[82] van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., et al. (2015). Prospective derivation of a living organoid biobank of colorectal cancer patients. *Cell*, *161*(4), 933–945. https://doi.org/10.1016/j.cell.2015.03.053.

[83] Veninga, V., & Voest, E. E. (2021). Tumor organoids: Opportunities and challenges to guide precision medicine. *Cancer Cell*, *39*(9), 1190–1201. https://doi.org/10.1016/j.ccell.2021.07.020.

[84] Villanueva, A. (2019). Hepatocellular Carcinoma. *New England Journal of Medicine*, *380*(15), 1450–1462. https://doi.org/10.1056/NEJMra1713263.

[85] Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019). Macrophages and metabolism in the tumor microenvironment. *Cell Metabolism*, *30*(1), 36–50. https://doi.org/10.1016/j.cmet.2019.06.001.

[86] Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernandez-Mateos, J., Khan, K., et al. (2018). Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. *Science*, *359*(6378), 920-+. https://doi.org/10.1126/science.aao2774.

[87] Wong, C. H., Siah, K. W., & Lo, A. W. (2019a). Estimation of clinical trial success rates and related parameters. *Biostatistics*, *20*(2), 273–286. https://doi.org/10.1093/biostatistics/kxx069.

[88] Wong, C. H., Siah, K. W., & Lo, A. W. (2019b). Estimation of clinical trial success rates and related parameters (vol 20, pg 273, 2019). *Biostatistics*, *20*(2), 366. https://doi.org/10.1093/biostatistics/kxy072.

[89] Yao, Y., Xu, X. Y., Yang, L. F., Zhu, J., Wan, J. F., Shen, L. J., et al. (2020). Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. *Cell Stem Cell*, *26*(1), 17-+. https://doi.org/10.1016/j.stem.2019.10.010.

[90] Yap, T. A., Johnson, A., & Meric-Bernstam, F. (2021). Precision medicine in oncology-toward the integrated targeting of somatic and germline genomic aberrations. *JAMA Oncology*, *7* (4), 507–509. https://doi.org/10.1001/jamaoncol.2020.7988.

[91] Yuki, K., Cheng, N., Nakano, M., & Kuo, C. J. (2020). Organoid models of tumor immunology. *Trends in Immunology*, *41*(8), 652–664. https://doi.org/10.1016/j.it.2020.06.010.

[92] Zhang, X. M., Claerhout, S., Prat, A., Dobrolecki, L. E., Petrovic, I., Lai, Q., et al. (2013). A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. *Cancer Research*, *73*(15), 4885–4897. https://doi.org/10.1158/0008-5472.Can-12-4081.

12 胆管癌的分子治疗靶点：当前挑战与未来可能性

[1] Abou-Alfa, G. K., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., et al. (2020). Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. *The Lancet Oncology*, *21*(6), 796–807. https://doi.org/10.1016/S1470-2045(20)30157-1.

[2] Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., et al. (2020). Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. *The Lancet Oncology*, *21*(5), 671–684. https://doi.org/10.1016/S1470-2045(20)30109-1.

[3] Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., et al. (2012). Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. *Gastroenterology*, *142*(4), 1021–1031 e1015. https://doi.org/10.1053/j.gastro.2011.12.005.

[4] Arai, Y., Totoki, Y., Hosoda, F., Shirota, T., Hama, N., Nakamura, H., et al. (2014). Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. *Hepatology*, *59*(4), 1427–1434. https://doi.org/10.1002/hep.26890.

[5] Artegiani, B., van Voorthuijsen, L., Lindeboom, R. G. H., Seinstra, D., Heo, I., Tapia, P., et al. (2019). Probing the tumor suppressor function of BAP1 in CRISPR-engineered human liver organoids. *Cell Stem Cell*, *24*(6), 927–943 e926. https://doi.org/10.1016/j.stem.2019.04.017.

[6] Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., et al. (2020). Cholangiocarcinoma 2020: The next horizon in mechanisms and management. *Nature Reviews. Gastroenterology & Hepatology*, *17*(9), 557–588. https://doi.org/10.1038/s41575-020-0310-z.

[7] Boerner, T., Drill, E., Pak, L. M., Nguyen, B., Sigel, C. S., Doussot, A., et al. (2021). Genetic determinants of outcome in intrahepatic cholangiocarcinoma. *Hepatology*, *74*(3), 1429–1444. https://doi.org/10.1002/hep.31829.

[8] Boileve, A., Hilmi, M., Gougis, P., Cohen, R., Rousseau, B., Blanc, J. F., et al. (2021). Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. *European Journal of Cancer*, *143*, 55–63. https://doi.org/10.1016/j.ejca.2020.10.027.

[9] Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., et al. (2012). Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. *The Oncologist*, *17*(1), 72–79. https://doi.org/10.1634/theoncologist.2011-0386.

[10] Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., et al. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature*, *575*(7781), 217–223. https://doi.org/10.1038/s41586-019-1694-1.

[11] Chan-On, W., Nairismagi, M. L., Ong, C. K., Lim, W. K., Dima, S., Pairojkul, C., et al. (2013). Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. *Nature Genetics*, *45*(12), 1474–1478. https://doi.org/10.1038/ng.2806.

[12] Cleary, J. M., Raghavan, S., Wu, Q., Li, Y. Y., Spurr, L. F., Gupta, H. V., et al. (2021). FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma. *Cancer Discovery*, *11*(10), 2488–2505. https://doi.org/10.1158/2159-8290.CD-20-1669.

[13] Consortium I. T. P.-C. A. o. W. G. (2020). Pan-cancer analysis of whole genomes. *Nature*, *578*(7793), 82–93. https://doi.org/10.1038/s41586-020-1969-6.

[14] Cristinziano, G., Porru, M., Lamberti, D., Buglioni, S., Rollo, F., Amoreo, C. A., et al. (2021). FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. *Journal of Hepatology*, *75*(2), 351–362. https://doi.org/10.1016/j.jhep.2021.02.032.

[15] Dhillon, S. (2018). Ivosidenib: First global approval. *Drugs*, *78*(14), 1509–1516. https://doi.org/10.1007/s40265-018-0978-3.

[16] El-Khoueiry, A. B., Rankin, C., Siegel, A. B., Iqbal, S., Gong, I. Y., Micetich, K. C., et al., & D. (2014). S0941: A phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. *British Journal of Cancer*, *110*(4), 882–887. https://doi.org/10.1038/bjc.2013.801.

[17] Farshidfar, F., Zheng, S., Gingras, M. C., Newton, Y., Shih, J., Robertson, A. G., et al. (2017). Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. *Cell Reports*, *18*(11), 2780–2794.

https://doi.org/10.1016/j.celrep.2017.02.033.

[18] Forner, A., Vidili, G., Rengo, M., Bujanda, L., Ponz-Sarvise, M., & Lamarca, A. (2019). Clinical presentation, diagnosis and staging of cholangiocarcinoma. *Liver International*, *39* (Suppl. 1), 98–107. https://doi.org/10.1111/liv.14086.

[19] Goeppert, B., Roessler, S., Renner, M., Singer, S., Mehrabi, A., Vogel, M. N., et al. (2019). Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. *British Journal of Cancer*, *120*(1), 109–114. https://doi.org/10.1038/s41416-018-0199-2.

[20] Goyal, L., Saha, S. K., Liu, L. Y., Siravegna, G., Leshchiner, I., Ahronian, L. G., et al. (2017). Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. *Cancer Discovery*, *7*(3), 252–263. https://doi.org/10.1158/2159-8290.CD-16-1000.

[21] Goyal, L., Shi, L., Liu, L. Y., Fece de la Cruz, F., Lennerz, J. K., Raghavan, S., et al. (2019). TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. *Cancer Discovery*, *9*(8), 1064–1079. https://doi.org/10.1158/2159-8290.CD-19-0182.

[22] Goyal, L., Zheng, H., Yurgelun, M. B., Abrams, T. A., Allen, J. N., Cleary, J. M., et al. (2017). A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. *Cancer*, *123*(11), 1979–1988. https://doi.org/10.1002/cncr.30571.

[23] Hogdall, D., Lewinska, M., & Andersen, J. B. (2018). Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma. *Trends Cancer*, *4*(3), 239–255. https://doi.org/10.1016/j.trecan.2018.01.007.

[24] Hogdall, D., O'Rourke, C. J., Dehlendorff, C., Larsen, O. F., Jensen, L. H., Johansen, A. Z., et al. (2020). Serum IL6 as a prognostic biomarker and IL6R as a therapeutic target in biliary tract cancers. *Clinical Cancer Research*, *26*(21), 5655–5667. https://doi.org/10.1158/1078-0432.CCR-19-2700.

[25] Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., et al. (2020). KRAS(G12C) inhibition with Sotorasib in advanced solid tumors. *The New England Journal of Medicine*, *383*(13), 1207–1217. https://doi.org/10.1056/NEJMoa1917239.

[26] Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hullein, J., et al. (2021). Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. *Cancer Discovery*, *11*(11), 2780–2795. https://doi.org/10.1158/2159-8290.CD-21-0126.

[27] Javle, M., Roychowdhury, S., Kelley, R. K., Sadeghi, S., Macarulla, T., Weiss, K. H., et al. (2021). Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. *The Lancet Gastroenterology & Hepatology*, *6*(10), 803–815. https://doi.org/10.1016/S2468-1253(21)00196-5.

[28] Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., et al. (2013). Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nature Genetics*, *45*(12), 1470–1473. https://doi.org/10.1038/ng.2813.

[29] Job, S., Rapoud, D., Dos Santos, A., Gonzalez, P., Desterke, C., Pascal, G., et al. (2020). Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. *Hepatology*, *72*(3), 965–981. https://doi.org/10.1002/hep.31092.

[30] Joensuu, H., Eriksson, M., Sundby Hall, K., Reichardt, A., Hermes, B., Schutte, J., et al. (2020). Survival outcomes associated with 3 years vs 1 year of adjuvant Imatinib for patients with high-risk gastrointestinal stromal tumors: An analysis of a randomized clinical trial after 10-year follow-up. *JAMA Oncology*, *6*(8), 1241–1246. https://doi.org/10.1001/jamaoncol.2020.2091.

[31] Jolissaint, J. S., Soares, K. C., Seier, K. P., Kundra, R., Gonen, M., Shin, P. J., et al. (2021). Intrahepatic cholangiocarcinoma with lymph node metastasis: Treatment-related outcomes and the role of tumor genomics in patient selection. *Clinical Cancer Research*, *27*(14), 4101–4108. https://doi.org/10.1158/1078-0432.CCR-21-0412.

[32] Jusakul, A., Cutcutache, I., Yong, C. H., Lim, J. Q., Huang, M. N., Padmanabhan, N., et al. (2017). Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. *Cancer Discovery*, *7*(10), 1116–1135. https://doi.org/10.1158/2159-8290.CD-17-0368.

[33] Kendre, G., Marhenke, S., Lorz, G., Becker, D., Reineke-Plaass, T., Poth, T., et al. (2021). The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion-driven cholangiocarcinoma. *Hepatology*, *74*(3), 1357–1370. https://doi.org/10.1002/hep.31799.

[34] Kim, R. D., Chung, V., Alese, O. B., El-Rayes, B. F., Li, D., Al-Toubah, T. E., et al. (2020). A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. *JAMA Oncology*, *6*(6), 888–894. https://doi.

org/10.1001/jamaoncol.2020.0930.

[35] Kim, R. D., Sanoff, H. K., Poklepovic, A. S., Soares, H., Kim, J., Lyu, J., et al. (2020). A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. *Cancer*, *126*(15), 3464–3470. https://doi.org/10.1002/cncr.32964.

[36] Klein, O., Kee, D., Nagrial, A., Markman, B., Underhill, C., Michael, M., et al. (2020). Evaluation of combination Nivolumab and Ipilimumab immunotherapy in patients with advanced biliary tract cancers: Subgroup analysis of a phase 2 nonrandomized clinical trial. *JAMA Oncology*, *6*(9), 1405–1409. https://doi.org/10.1001/jamaoncol.2020.2814.

[37] Lamarca, A., Kapacee, Z., Breeze, M., Bell, C., Belcher, D., Staiger, H., et al. (2020). Molecular profiling in daily clinical practice: Practicalities in advanced cholangiocarcinoma and other biliary tract cancers. *Journal of Clinical Medicine*, *9*(9). https://doi.org/10.3390/jcm9092854.

[38] Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., et al. (2021). Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial. *The Lancet Oncology*, *22*(5), 690–701. https://doi.org/10.1016/S1470-2045(21)00027-9.

[39] Lee, J. K., Hazar-Rethinam, M., Decker, B., Gjoerup, O., Madison, R. W., Lieber, D. S., et al. (2021). The pan-tumor landscape of targetable kinase fusions in circulating tumor DNA. *Clinical Cancer Research*. https://doi.org/10.1158/1078-0432.CCR-21-2136.

[40] Lin, J., Yang, X., Long, J., Zhao, S., Mao, J., Wang, D., et al. (2020). Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. *Hepatobiliary Surgery and Nutrition*, *9*(4), 414–424. https://doi.org/10.21037/hbsn-20-338.

[41] Lowery, M. A., Ptashkin, R., Jordan, E., Berger, M. F., Zehir, A., Capanu, M., et al., & K. (2018). Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention. *Clinical Cancer Research*, *24*(17), 4154–4161. https://doi.org/10.1158/1078-0432.CCR-18-0078.

[42] Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J. P., et al. (2020). Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. *Journal of Clinical Oncology*, *38*(1), 1–10. https://doi.org/10.1200/JCO.19.02105.

[43] Marcus, L., Fashoyin-Aje, L. A., Donoghue, M., Yuan, M., Rodriguez, L., Gallagher, P. S., et al. (2021). FDA approval summary: Pembrolizumab for the treatment of tumor mutational burdaen-high solid tumors. *Clinical Cancer Research*, *27*(17), 4685–4689. https://doi.org/10.1158/1078-0432.CCR-21-0327.

[44] Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019). FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. *Clinical Cancer Research*, *25*(13), 3753–3758. https://doi.org/10.1158/1078-0432.CCR-18-4070.

[45] Mariotti, V., Fiorotto, R., Cadamuro, M., Fabris, L., & Strazzabosco, M. (2021). New insights on the role of vascular endothelial growth factor in biliary pathophysiology. *JHEP Reports*, *3* (3). https://doi.org/10.1016/j.jhepr.2021.100251, 100251.

[46] Massard, C., Michiels, S., Ferte, C., Le Deley, M. C., Lacroix, L., Hollebecque, A., et al. (2017). High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial. *Cancer Discovery*, *7*(6), 586–595. https://doi.org/10.1158/2159-8290.CD-16-1396.

[47] Mateo, J., Chakravarty, D., Dienstmann, R., Jezdic, S., Gonzalez-Perez, A., Lopez-Bigas, N., et al. (2018). A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO scale for clinical actionability of molecular targets (ESCAT). *Annals of Oncology*, *29*(9), 1895–1902. https://doi.org/10.1093/annonc/mdy263.

[48] Meric-Bernstam, F., Bahleda, R., Hierro, C., Sanson, M., Bridgewater, J., Arkenau, H. T., et al. (2021). Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: A phase I dose-expansion study. *Cancer Discovery*, *12*(2), 402–415. https://doi.org/10.1158/2159-8290.CD-21-0697.

[49] Montal, R., Sia, D., Montironi, C., Leow,W. Q., Esteban-Fabro, R., Pinyol, R., et al. (2020). Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. *Journal of Hepatology*, *73*(2), 315–327. https://doi.org/10.1016/j.jhep.2020.03.008.

[50] Nepal, C., O'Rourke, C. J., Oliveira, D., Taranta, A., Shema, S., Gautam, P., et al. (2018). Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. *Hepatology*, *68*(3), 949–963. https://doi.org/10.1002/hep.29764.

[51] Ong, C. K., Subimerb, C., Pairojkul, C., Wongkham, S., Cutcutache, I., Yu, W., et al. (2012). Exome sequencing of liver

fluke-associated cholangiocarcinoma. *Nature Genetics*, *44* (6), 690–693. https://doi.org/10.1038/ng.2273.

[52] O'Rourke, C. J., Matter, M. S., Nepal, C., Caetano-Oliveira, R., Ton, P. T., Factor, V. M., et al. (2020). Identification of a Pan-gamma-secretase inhibitor response signature for notch-driven cholangiocarcinoma. *Hepatology*, *71*(1), 196–213. https://doi.org/10.1002/hep.30816.

[53] Piha-Paul, S. A., Oh, D. Y., Ueno, M., Malka, D., Chung, H. C., Nagrial, A., et al. (2020). Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. *International Journal of Cancer*, *147*(8), 2190–2198. https://doi.org/10.1002/ijc.33013.

[54] Pirozzi, C. J., & Yan, H. (2021). The implications of IDH mutations for cancer development and therapy. *Nature Reviews. Clinical Oncology*, *18*(10), 645–661. https://doi.org/10.1038/s41571-021-00521-0.

[55] Saha, S. K., Gordan, J. D., Kleinstiver, B. P., Vu, P., Najem, M. S., Yeo, J. C., et al. (2016). Isocitrate dehydrogenase mutations confer Dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. *Cancer Discovery*, *6*(7), 727–739. https://doi.org/10.1158/2159-8290.CD-15-1442.

[56] Saha, S. K., Parachoniak, C. A., Ghanta, K. S., Fitamant, J., Ross, K. N., Najem, M. S., et al. (2014). Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. *Nature*, *513*(7516), 110–114. https://doi.org/10.1038/nature13441.

[57] Sheils, T. K., Mathias, S. L., Kelleher, K. J., Siramshetty, V. B., Nguyen, D. T., Bologa, C. G., et al. (2021). TCRD and pharos 2021: Mining the human proteome for disease biology. *Nucleic Acids Research*, *49*(D1), D1334–D1346. https://doi.org/10.1093/nar/gkaa993.

[58] Sia, D., Hoshida, Y., Villanueva, A., Roayaie, S., Ferrer, J., Tabak, B., et al. (2013). Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. *Gastroenterology*, *144*(4), 829–840. https://doi.org/10.1053/j.gastro.2013.01.001.

[59] Sia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., et al. (2015). Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. *Nature Communications*, *6*, 6087. https://doi.org/10.1038/ncomms7087.

[60] Silverman, I. M., Hollebecque, A., Friboulet, L., Owens, S., Newton, R. C., Zhen, H., et al., & C. (2021). Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to Pemigatinib. *Cancer Discovery*, *11*(2), 326–339. https://doi.org/10.1158/2159-8290.CD-20-0766.

[61] Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., et al. (2021). Sotorasib for lung cancers with KRAS p.G12C mutation. *The New England Journal of Medicine*, *384* (25), 2371–2381. https://doi.org/10.1056/NEJMoa2103695.

[62] Subbiah, V., Lassen, U., Elez, E., Italiano, A., Curigliano, G., Javle, M., et al. (2020). Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial. *The Lancet Oncology*, *21*(9), 1234–1243. https://doi.org/10.1016/S1470-2045(20)30321-1.

[63] Sun, W., Patel, A., Normolle, D., Patel, K., Ohr, J., Lee, J. J., et al. (2019). A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. *Cancer*, *125*(6), 902–909. https://doi.org/10.1002/cncr.31872.

[64] Taylor, A. M., Shih, J., Ha, G., Gao, G. F., Zhang, X., Berger, A. C., et al. (2018). Genomic and functional approaches to understanding cancer aneuploidy. *Cancer Cell*, *33*(4). https://doi.org/10.1016/j.ccell.2018.03.007. 676–689.e673.

[65] Ueno, M., Ikeda, M., Morizane, C., Kobayashi, S., Ohno, I., Kondo, S., et al. (2019). Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: A non-randomised, multicentre, open-label, phase 1 study. *The Lancet Gastroenterology & Hepatology*, *4*(8), 611–621. https://doi.org/10.1016/S2468-1253(19)30086-X.

[66] Ueno, M., Ikeda, M., Sasaki, T., Nagashima, F., Mizuno, N., Shimizu, S., et al. (2020). Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results. *BMC Cancer*, *20*(1), 1105. https://doi.org/10.1186/s12885-020-07365-4.

[67] Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., et al. (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *The New England Journal of Medicine*, *362*(14), 1273–1281. https://doi.org/10.1056/NEJMoa0908721.

[68] Verlingue, L., Malka, D., Allorant, A., Massard, C., Ferte, C., Lacroix, L., et al. (2017). Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. *European Journal of Cancer*, *87*, 122–130. https://doi.org/10.1016/j.ejca.2017.10.013.

[69] Villanueva, L., Lwin, Z., Chung, H. C., Gomez-Roca, C., Longo, F., Yanez, E., et al. (2021). Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. *Journal of Clinical Oncology*, *39*(3 Suppl).

[70] Wang, P., Dong, Q., Zhang, C., Kuan, P. F., Liu, Y., Jeck, W. R., et al. (2013). Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. *Oncogene*, *32*(25), 3091–3100. https://doi.org/10.1038/onc.2012.315.

[71] Wang, Y., Wild, A. T., Turcan, S., Wu, W. H., Sigel, C., Klimstra, D. S., et al. (2020). Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. *Science Advances*, *6*(17), eaaz3221. https://doi.org/10.1126/sciadv.aaz3221.

[72] Wu, M. J., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T. Y., et al. (2021). Mutant-IDH inhibits interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. *Cancer Discovery*. https://doi.org/10.1158/2159-8290.Cd-21-1077.

[73] Wu, Y. M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., et al. (2013). Identification of targetable FGFR gene fusions in diverse cancers. *Cancer Discovery*, *3*(6), 636–647. https://doi.org/10.1158/2159-8290.CD-13-0050.

[74] Yoo, C., Oh, D. Y., Choi, H. J., Kudo, M., Ueno, M., Kondo, S., et al. (2020). Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer. *Journal for Immunotherapy of Cancer*, *8*(1). https://doi.org/10.1136/jitc-2020-000564.

[75] Zhu, A. X., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., et al. (2021). Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: The phase 3 randomized clinical ClarIDHy trial. *JAMA Oncology*, *7*(11), 1669–1677. https://doi.org/10.1001/jamaoncol.2021.3836.

[76] Zou, S., Li, J., Zhou, H., Frech, C., Jiang, X., Chu, J. S., et al. (2014). Mutational landscape of intrahepatic cholangiocarcinoma. *Nature Communications*, *5*, 5696. https://doi.org/10.1038/ncomms6696.

13 肝细胞癌与肝内胆管癌的免疫治疗：当前策略与新兴策略

[1] Abo, T., Kawamura, T., & Watanabe, H. (2000). Physiological responses of extrathymic T cells in the liver. *Immunological Reviews*, *174*, 135–149. https://doi.org/10.1034/j.1600-0528.2002.017415.x.

[2] Abou-Alfa, G. K., Chan, S. L., Kudo, M., Lau, G., Kelley, R. K., Furuse, J., et al. (2022). Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. *Journal of Clinical Oncology*, *40*(4_Suppl), 379. https://doi.org/10.1200/JCO.2022.40.4_suppl.379.

[3] Affo, S., Yu, L. X., & Schwabe, R. F. (2017). The role of cancer-associated fibroblasts and fibrosis in liver cancer. *Annual Review of Pathology*, *12*, 153–186. https://doi.org/10.1146/annurev-pathol-052016-100322.

[4] Agdashian, D., ElGindi, M., Xie, C., Sandhu, M., Pratt, D., Kleiner, D. E., et al. (2019). The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. *Cancer Immunology, Immunotherapy*, *68*(4), 599–608. https://doi.org/10.1007/s00262-019-02299-8.

[5] Amsen, D., van Gisbergen, K., Hombrink, P., & van Lier, R. A. W. (2018). Tissue-resident memory T cells at the center of immunity to solid tumors. *Nature Immunology*, *19*(6), 538–546. https://doi.org/10.1038/s41590-018-0114-2.

[6] Ando, Y., Kumamoto, K., Matsukawa, H., Ishikawa, R., Suto, H., Oshima, M., et al. (2022). Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital-based population. *Oncology Letters*, *23*(1), 4. https://doi.org/10.3892/ol.2021.13122.

[7] Andre, T., Reyes-Vidal, J. M., Fartoux, L., Ross, P., Leslie, M., Rosmorduc, O., et al. (2008). Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: A phase II study. *British Journal of Cancer*, *99*(6), 862–867. https://doi.org/10.1038/sj.bjc.6604628.

[8] Assoun, S., Theou-Anton, N., Nguenang, M., Cazes, A., Danel, C., Abbar, B., et al. (2019). Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. *Lung Cancer*, *132*, 65–71. https://doi.org/10.1016/j.lungcan.2019.04.005.

[9] Bassaganyas, L., Pinyol, R., Esteban-Fabro, R., Torrens, L., Torrecilla, S., Willoughby, C. E., et al. (2020). Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma. *Clinical Cancer Research*, *26*(23), 6350–6361. https://doi.org/10.1158/1078-0432.CCR-20-1497.

[10] Benson, A. B., D'Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., et al. (2021). Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network*,

19(5), 541–565. https://doi.org/10.6004/jnccn.2021.0022.

[11] Berg, M., Wingender, G., Djandji, D., Hegenbarth, S., Momburg, F., Hammerling, G., et al. (2006). Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8+ T cell tolerance. *European Journal of Immunology*, *36*(11), 2960–2970. https://doi.org/10.1002/eji.200636033.

[12] Berton, D., Banerjee, S. N., Curigliano, G., Cresta, S., Arkenau, H.-T., Abdeddaim, C., et al. (2021). Antitumor activity of dostarlimab in patients with mismatch repairdeficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study. *Journal of Clinical Oncology*, *39*(15_Suppl), 2564. https://doi.org/10.1200/JCO.2021.39.15_suppl.2564.

[13] Biswas, S. K., & Mantovani, A. (2010). Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. *Nature Immunology*, *11*(10), 889–896. https://doi.org/10.1038/ni.1937.

[14] Bricard, G., Cesson, V., Devevre, E., Bouzourene, H., Barbey, C., Rufer, N., et al. (2009). Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. *Journal of Immunology*, *182*(8), 5140–5151. https://doi.org/10.4049/jimmunol.0711086.

[15] Bronte, V., Brandau, S., Chen, S. H., Colombo, M. P., Frey, A. B., Greten, T. F., et al. (2016). Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nature Communications*, *7*, 12150. https://doi.org/10.1038/ncomms12150.

[16] Brown, Z. J., Yu, S. J., Heinrich, B., Ma, C., Fu, Q., Sandhu, M., et al. (2018). Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. *Cancer Immunology, Immunotherapy*, *67*(8), 1305–1315. https://doi.org/10.1007/s00262-018-2190-4.

[17] Buonaguro, L., Mayer, A., Loeffler, M., Missel, S., Accolla, R., Ma, Y. T., et al. (2020). Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma. *Cancer Research*, *80*(16 Suppl), LB-094. https://doi.org/10.1158/1538-7445.Am2020-lb-094.

[18] Cadoux, M., Caruso, S., Pham, S., Gougelet, A., Pophillat, C., Riou, R., et al. (2021). Expression of NKG2D ligands is downregulated by beta-catenin signalling and associates with HCC aggressiveness. *Journal of Hepatology*, *74*(6), 1386–1397. https://doi.org/10.1016/j.jhep.2021.01.017.

[19] Calderaro, J., Couchy, G., Imbeaud, S., Amaddeo, G., Letouze, E., Blanc, J. F., et al. (2017). Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification. *Journal of Hepatology*, *67*(4), 727–738. https://doi.org/10.1016/j.jhep.2017.05.014.

[20] Calderaro, J., Petitprez, F., Becht, E., Laurent, A., Hirsch, T. Z., Rousseau, B., et al. (2019). Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. *Journal of Hepatology*, *70*(1), 58–65. https://doi.org/10.1016/j.jhep.2018.09.003.

[21] Cao, X., Ding, Q., Lu, J., Tao, W., Huang, B., Zhao, Y., et al. (2015). MDA5 plays a critical role in interferon response during hepatitis C virus infection. *Journal of Hepatology*, *62*(4), 771–778. https://doi.org/10.1016/j.jhep.2014.11.007.

[22] Cao, J., Hu, J., Liu, S., Meric-Bernstam, F., Abdel-Wahab, R., Xu, J., et al. (2020). Intrahepatic cholangiocarcinoma: Genomic heterogeneity between eastern and Western patients. *JCO Precision Oncology*, *4*. https://doi.org/10.1200/PO.18.00414.

[23] Chen, J., Gingold, J. A., & Su, X. (2019). Immunomodulatory TGF-beta signaling in hepatocellular carcinoma. *Trends in Molecular Medicine*, *25*(11), 1010–1023. https://doi.org/10.1016/j.molmed.2019.06.007.

[24] Chen, W., Jin, W., Hardegen, N., Lei, K. J., Li, L., Marinos, N., et al. (2003). Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *The Journal of Experimental Medicine*, *198*(12), 1875–1886. https://doi.org/10.1084/jem.20030152.

[25] Chen, M. M., Xiao, X., Lao, X. M., Wei, Y., Liu, R. X., Zeng, Q. H., et al. (2016). Polarization of tissue-resident TFH-like cells in human hepatoma bridges innate monocyte inflammation and M2b macrophage polarization. *Cancer Discovery*, *6*(10), 1182–1195. https://doi.org/10.1158/2159-8290.CD-16-0329.

[26] Cheng, A. L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., et al. (2021). Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. *The Journal of Hepatology*. https://doi.org/10.1016/j.jhep.2021.11.030.

[27] Condamine, T., & Gabrilovich, D. I. (2011). Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. *Trends in Immunology*, *32*(1), 19–25. https://doi.org/10.1016/j.it.2010.10.002.

[28] Crispe, I. N. (2009). The liver as a lymphoid organ. *Annual Review of Immunology*, *27*, 147–163. https://doi.org/10.1146/annurev.immunol.021908.132629.

[29] Das, A., Hoare, M., Davies, N., Lopes, A. R., Dunn, C., Kennedy, P. T., et al. (2008). Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. *The Journal of Experimental Medicine*, *205*(9), 2111–2124. https://doi.org/10.1084/jem.20072076.

[30] DeFalco, J., Harbell, M., Manning-Bog, A., Baia, G., Scholz, A., Millare, B., et al. (2018). Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens. *Clinical Immunology*, *187*, 37–45. https://doi.org/10.1016/j.clim.2017.10.002.

[31] Demols, A., Rocq, L., Charry, M., Neve, N. D., Verrellen, A., Ramadhan, A., et al. (2020). NTRK gene fusions in biliary tract cancers. *Journal of Clinical Oncology*, *38*(4_Suppl), 574. https://doi.org/10.1200/JCO.2020.38.4_suppl.574.

[32] Di Caro, G., Bergomas, F., Grizzi, F., Doni, A., Bianchi, P., Malesci, A., et al. (2014). Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. *Clinical Cancer Research*, *20*(8), 2147–2158. https://doi.org/10.1158/1078-0432.CCR-13-2590.

[33] Diehl, L., Schurich, A., Grochtmann, R., Hegenbarth, S., Chen, L., & Knolle, P. A. (2008). Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance. *Hepatology*, *47*(1), 296–305. https://doi.org/10.1002/hep.21965.

[34] Dieu-Nosjean, M. C., Antoine, M., Danel, C., Heudes, D., Wislez, M., Poulot, V., et al. (2008). Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. *Journal of Clinical Oncology*, *26*(27), 4410–4417. https://doi.org/10.1200/JCO.2007.15.0284.

[35] Doherty, D. G., & O'Farrelly, C. (2000). Innate and adaptive lymphoid cells in the human liver. *Immunological Reviews*, *174*, 5–20. https://doi.org/10.1034/j.1600-0528.2002.017416.x.

[36] El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., et al. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet*, *389*(10088), 2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2.

[37] El-Khoueiry, A. B., Yau, T., Kang, Y.-K., Kim, T.-Y., Santoro, A., Sangro, B., et al. (2021). Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040. *Journal of Clinical Oncology*, *39*(3_Suppl), 269. https://doi.org/10.1200/JCO.2021.39.3_suppl.269.

[38] Enrico, D., Paci, A., Chaput, N., Karamouza, E., & Besse, B. (2020). Antidrug antibodies against immune checkpoint blockers: Impairment of drug efficacy or indication of immune activation? *Clinical Cancer Research*, *26*(4), 787–792. https://doi.org/10.1158/1078-0432.CCR-19-2337.

[39] Farci, P., Shimoda, A., Coiana, A., Diaz, G., Peddis, G., Melpolder, J. C., et al. (2000). The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. *Science*, *288*(5464), 339–344. https://doi.org/10.1126/science.288.5464.339.

[40] Feun, L. G., Li, Y. Y., Wu, C., Wangpaichitr, M., Jones, P. D., Richman, S. P., et al. (2019). Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. *Cancer*, *125*(20), 3603–3614. https://doi.org/10.1002/cncr.32339.

[41] Finkin, S., Yuan, D., Stein, I., Taniguchi, K., Weber, A., Unger, K., et al. (2015). Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. *Nature Immunology*, *16*(12), 1235–1244. https://doi.org/10.1038/ni.3290.

[42] Finn, R. S., Ikeda, M., Zhu, A. X., Sung, M. W., Baron, A. D., Kudo, M., et al. (2020). Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. *Journal of Clinical Oncology*, *38*(26), 2960–2970. https://doi.org/10.1200/JCO.20.00808.

[43] Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., et al. (2020). Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *The New England Journal of Medicine*, *382*(20), 1894–1905. https://doi.org/10.1056/NEJMoa1915745.

[44] Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., et al. (2021). IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). *Journal of Clinical Oncology*, *39*(3_Suppl), 267. https://doi.org/10.1200/JCO.2021.39.3_suppl.267.

[45] Finn, R. S., Ryoo, B. Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., et al. (2020). Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. *Journal of Clinical Oncology*, *38*(3), 193–202. https://doi.org/10.1200/JCO.19.01307.

[46] Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limon, P. (2010). The polarization of immune cells in the tumor

environment by TGFbeta. *Nature Reviews. Immunology*, *10* (8), 554–567. https://doi.org/10.1038/nri2808.

[47] Flecken, T., Schmidt, N., Hild, S., Gostick, E., Drognitz, O., Zeiser, R., et al. (2014). Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. *Hepatology*, *59*(4), 1415–1426. https://doi.org/10.1002/hep.26731.

[48] Fu, J., Xu, D., Liu, Z., Shi, M., Zhao, P., Fu, B., et al. (2007). Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. *Gastroenterology*, *132*(7), 2328–2339. https://doi.org/10.1053/j.gastro.2007.03.102.

[49] Gabrilovich, D. I., & Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. *Nature Reviews. Immunology*, *9*(3), 162–174. https://doi.org/10.1038/nri2506.

[50] Gao, Q., Qiu, S. J., Fan, J., Zhou, J., Wang, X. Y., Xiao, Y. S., et al. (2007). Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. *Journal of Clinical Oncology*, *25*(18), 2586–2593. https://doi.org/10.1200/JCO.2006.09.4565.

[51] Goeppert, B., Frauenschuh, L., Renner, M., Roessler, S., Stenzinger, A., Klauschen, F., et al. (2014). BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. *Modern Pathology*, *27*(7), 1028–1034. https://doi.org/10.1038/modpathol.2013.206.

[52] Gomes, A. L., Teijeiro, A., Buren, S., Tummala, K. S., Yilmaz, M., Waisman, A., et al. (2016). Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. *Cancer Cell*, *30*(1), 161–175. https://doi.org/10.1016/j.ccell.2016.05.020.

[53] Greten, T. F., Forner, A., Korangy, F., N'Kontchou, G., Barget, N., Ayuso, C., et al. (2010). A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. *BMC Cancer*, *10*, 209. https://doi.org/10.1186/1471-2407-10-209.

[54] Han, Y., Chen, Z., Yang, Y., Jiang, Z., Gu, Y., Liu, Y., et al. (2014). Human CD14+CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. *Hepatology*, *59*(2), 567–579. https://doi.org/10.1002/hep.26694.

[55] Hastir, J. F., Delbauve, S., Larbanoix, L., Germanova, D., Goyvaerts, C., Allard, J., et al. (2020). Hepatocarcinoma induces a tumor necrosis factor-dependent Kupffer cell death pathway that Favors its proliferation upon partial hepatectomy. *Frontiers in Oncology*, *10*, 547013. https://doi.org/10.3389/fonc.2020.547013.

[56] Havel, J. J., Chowell, D., & Chan, T. A. (2019). The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. *Nature Reviews. Cancer*, *19*(3), 133–150. https://doi.org/10.1038/s41568-019-0116-x.

[57] Hedegaard, D. L., Tully, D. C., Rowe, I. A., Reynolds, G. M., Bean, D. J., Hu, K., et al. (2017). High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease. *Journal of Hepatology*, *66*(1), 28–38. https://doi.org/10.1016/j.jhep.2016.07.048.

[58] Hilmi, M., Vienot, A., Rousseau, B., & Neuzillet, C. (2019). Immune therapy for liver cancers. *Cancers (Basel)*, *12*(1). https://doi.org/10.3390/cancers12010077.

[59] Ho, W. J., Zhu, Q., Durham, J., Popovic, A., Xavier, S., Leatherman, J., et al. (2021). Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. *Nature Cancer*, *2*(9), 891–903. https://doi.org/10.1038/s43018-021-00234-4.

[60] Hornyak, L., Dobos, N., Koncz, G., Karanyi, Z., Pall, D., Szabo, Z., et al. (2018). The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. *Frontiers in Immunology*, *9*, 151. https://doi.org/10.3389/fimmu.2018.00151.

[61] Horwitz, E., Stein, I., Andreozzi, M., Nemeth, J., Shoham, A., Pappo, O., et al. (2014). Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. *Cancer Discovery*, *4*(6), 730–743. https://doi.org/10.1158/2159-8290.CD-13-0782.

[62] Hou, J., Zhang, H., Sun, B., & Karin, M. (2020). The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. *Journal of Hepatology*, *72*(1), 167–182. https://doi.org/10.1016/j.jhep.2019.08.014.

[63] Huang, J., Cai, M. Y., & Wei, D. P. (2002). HLA class I expression in primary hepatocellular carcinoma. *World Journal of Gastroenterology*, *8*(4), 654–657. https://doi.org/10.3748/wjg.v8.i4.654.

[64] Huang, R., Rao, H. Y., Yang, M., Gao, Y. H., Wang, J., Jin, Q., et al. (2021). Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy. *World Journal of Gastroenterology*, *27*(5), 404–415. https://doi.org/10.3748/wjg.v27.i5.404.

[65] Huang, S. L., Wang, Y. M., Wang, Q. Y., Feng, G. G., Wu, F. Q., Yang, L. M., et al. (2021). Mechanisms and clinical trials of hepatocellular carcinoma immunotherapy. *Frontiers in Genetics*, *12*, 691391. https://doi.org/10.3389/fgene.2021.691391.

[66] Huang, L. R., Wohlleber, D., Reisinger, F., Jenne, C. N., Cheng, R. L., Abdullah, Z., et al. (2013). Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. *Nature Immunology*, *14*(6), 574–583. https://doi.org/10.1038/ni.2573.

[67] Huang, J., Zhang, L., Chen, J., Wan, D., Zhou, L., Zheng, S., et al. (2021). The landscape of immune cells indicates prognosis and applicability of checkpoint therapy in hepatocellular carcinoma. *Frontiers in Oncology*, *11*, 744951. https://doi.org/10.3389/fonc.2021.744951.

[68] Ilie, M., Hofman, V., Ortholan, C., Bonnetaud, C., Coelle, C., Mouroux, J., et al. (2012). Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. *Cancer*, *118*(6), 1726–1737. https://doi.org/10.1002/cncr.26456.

[69] Jang, J. S., Lim, H. Y., Hwang, I. G., Song, H. S., Yoo, N., Yoon, S., et al. (2010). Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: A Korean Cancer Study Group phase II trial. *Cancer Chemotherapy and Pharmacology*, *65*(4), 641–647. https://doi.org/10.1007/s00280-009-1069-7.

[70] Jenne, C. N., & Kubes, P. (2013). Immune surveillance by the liver. *Nature Immunology*, *14*(10), 996–1006. https://doi.org/10.1038/ni.2691.

[71] Ji, J., Eggert, T., Budhu, A., Forgues, M., Takai, A., Dang, H., et al. (2015). Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. *Hepatology*, *62*(2), 481–495. https://doi.org/10.1002/hep.27822.

[72] Jiang, S. S., Tang, Y., Zhang, Y. J., Weng, D. S., Zhou, Z. G., Pan, K., et al. (2015). A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. *Oncotarget*, *6*(38), 41339–41349. https://doi.org/10.18632/oncotarget.5463.

[73] Jinushi, M., Takehara, T., Tatsumi, T., Kanto, T., Groh, V., Spies, T., et al. (2003). Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. *International Journal of Cancer*, *104*(3), 354–361. https://doi.org/10.1002/ijc.10966.

[74] Juengpanich, S., Shi, L., Iranmanesh, Y., Chen, J., Cheng, Z., Khoo, A. K., et al. (2019). The role of natural killer cells in hepatocellular carcinoma development and treatment: A narrative review. *Translational Oncology*, *12*(8), 1092–1107. https://doi.org/10.1016/j.tranon.2019.04.021.

[75] Kang, S. P., Gergich, K., Lubiniecki, G. M., de Alwis, D. P., Chen, C., Tice, M. A. B., et al. (2017). Pembrolizumab KEYNOTE-001: An adaptive study leading to accelerated approval for two indications and a companion diagnostic. *Annals of Oncology*, *28*(6), 1388–1398. https://doi.org/10.1093/annonc/mdx076.

[76] Kapanadze, T., Gamrekelashvili, J., Ma, C., Chan, C., Zhao, F., Hewitt, S., et al. (2013). Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. *Journal of Hepatology*, *59*(5), 1007–1013. https://doi.org/10.1016/j.jhep.2013.06.010.

[77] Kelley, R. K., Sangro, B., Harris, W., Ikeda, M., Okusaka, T., Kang, Y.-K., et al. (2021). Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study. *Journal of Clinical Oncology*, *39*(27), 2991–3001. https://doi.org/10.1200/jco.20.03555.

[78] Kelley, R. K., Yau, T., Cheng, A. L., Kaseb, A., Qin, S., Zhu, A. X., et al. (2022). VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial. *Annals of Oncology*, *33*(1), 114–116. https://doi.org/10.1016/j.annonc.2021.10.008.

[79] Kelly, A., Fahey, R., Fletcher, J. M., Keogh, C., Carroll, A. G., Siddachari, R., et al. (2014). CD141(+) myeloid dendritic cells are enriched in healthy human liver. *Journal of Hepatology*, *60*(1), 135–142. https://doi.org/10.1016/j.jhep.2013.08.007.

[80] Kim, J. M., Cho, S. Y., Rhu, J., Jung, M., Her, J. H., Lim, O., et al. (2021). Adjuvant therapy using ex vivo-expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study. *Annals of Hepato-Biliary-Pancreatic Surgery*, *25*(2), 206–214. https://doi.org/10.14701/ahbps.2021.25.2.206.

[81] Kim, R. D., Chung, V., Alese, O. B., El-Rayes, B. F., Li, D., Al-Toubah, T. E., et al. (2020). A phase 2 multi-institutional study of Nivolumab for patients with advanced refractory biliary tract cancer. *JAMA Oncology*, *6*(6), 888–894. https://doi.

org/10.1001/jamaoncol.2020.0930.

[82] Kim, H. J., Lee, N. S., Lee, S. C., Bae, S. B., Kim, C. K., Cheon, Y. G., et al. (2009). A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. *Cancer Chemotherapy and Pharmacology*, *64*(2), 371–377. https://doi.org/10.1007/s00280-008-0883-7.

[83] Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2007). Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. *Nature Immunology*, *8*(2), 191–197. https://doi.org/10.1038/ni1428.

[84] Klein, O., Kee, D., Nagrial, A., Markman, B., Underhill, C., Michael, M., et al. (2020). Evaluation of combination nivolumab and Ipilimumab immunotherapy in patients with advanced biliary tract cancers: Subgroup analysis of a phase 2 nonrandomized clinical trial. *JAMA Oncology*, *6*(9), 1405–1409. https://doi.org/10.1001/jamaoncol.2020.2814.

[85] Knolle, P. A., Germann, T., Treichel, U., Uhrig, A., Schmitt, E., Hegenbarth, S., et al. (1999). Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells. *Journal of Immunology*, *162*(3), 1401–1407. https://www.ncbi.nlm.nih.gov/pubmed/9973395.

[86] Knolle, P. A., & Limmer, A. (2003). Control of immune responses by savenger liver endothelial cells. *Swiss Medical Weekly*, *133*(37–38), 501–506. https://doi.org/2003/37/smw-10261.

[87] Knolle, P. A., & Thimme, R. (2014). Hepatic immune regulation and its involvement in viral hepatitis infection. *Gastroenterology*, *146*(5), 1193–1207. https://doi.org/10.1053/j.gastro.2013.12.036.

[88] Knox, J. J., Hedley, D., Oza, A., Feld, R., Siu, L. L., Chen, E., et al. (2005). Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial. *Journal of Clinical Oncology*, *23*(10), 2332–2338. https://doi.org/10.1200/JCO.2005.51.008.

[89] Koeberle, D., Saletti, P., Borner, M., Gerber, D., Dietrich, D., Caspar, C. B., et al. (2008). Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: A multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. *Journal of Clinical Oncology*, *26*(22), 3702–3708. https://doi.org/10.1200/JCO.2008.16.5704.

[90] Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., et al. (2009). Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. *Cancer Cell*, *15*(2), 114–123. https://doi.org/10.1016/j.ccr.2008.12.018.

[91] Krausgruber, T., Blazek, K., Smallie, T., Alzabin, S., Lockstone, H., Sahgal, N., et al. (2011). IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. *Nature Immunology*, *12*(3), 231–238. https://doi.org/10.1038/ni.1990.

[92] Kuang, D. M., Peng, C., Zhao, Q., Wu, Y., Zhu, L. Y., Wang, J., et al. (2010). Tumoractivated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. *Journal of Immunology*, *185*(3), 1544–1549. https://doi.org/10.4049/jimmunol.0904094.

[93] Kuang, D. M., Zhao, Q., Peng, C., Xu, J., Zhang, J. P., Wu, C., et al. (2009). Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. *The Journal of Experimental Medicine*, *206*(6), 1327–1337. https://doi.org/10.1084/jem.20082173.

[94] Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., et al. (2006). IL-23 promotes tumor incidence and growth. *Nature*, *442*(7101), 461–465. https://doi.org/10.1038/nature04808.

[95] Larson, R. C., & Maus, M. V. (2021). Recent advances and discoveries in the mechanisms and functions of CAR T cells. *Nature Reviews. Cancer*, *21*(3), 145–161. https://doi.org/10.1038/s41568-020-00323-z.

[96] Lee, J. H., Lee, J. H., Lim, Y. S., Yeon, J. E., Song, T. J., Yu, S. J., et al. (2015). Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. *Gastroenterology*, *148*(7), 1383–1391 e1386. https://doi.org/10.1053/j.gastro.2015.02.055.

[97] Lee, M. S., Ryoo, B. Y., Hsu, C. H., Numata, K., Stein, S., Verret, W., et al. (2020). Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): An open-label, multicentre, phase 1b study. *The Lancet Oncology*, *21*(6), 808–820. https://doi.org/10.1016/S1470-2045(20)30156-X.

[98] Leone, R. D., Zhao, L., Englert, J. M., Sun, I. M., Oh, M. H., Sun, I. H., et al. (2019). Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. *Science*, *366*(6468), 1013–1021. https://doi.org/10.1126/science.aav2588.

[99] Leslie, J., Geh, D., Elsharkawy, A. M., Mann, D. A., & Vacca, M. (2022). Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions. *Journal of Hepatology*. https://doi.org/10.1016/j.jhep.2022.01.029.

[100] Li, S., Han, X., Lyu, N., Xie, Q., Deng, H., Mu, L., et al. (2018). Mechanism and prognostic value of indoleamine

2,3-dioxygenase 1 expressed in hepatocellular carcinoma. *Cancer Science*, *109*(12), 3726–3736. https://doi.org/10.1111/cas.13811.

[101] Li, Q., Harden, J. L., Anderson, C. D., & Egilmez, N. K. (2016). Tolerogenic phenotype of IFN-gamma-induced IDO+ dendritic cells is maintained via an autocrine IDO-kynurenine/AhR-IDO loop. *Journal of Immunology*, *197*(3), 962–970. https://doi.org/10.4049/jimmunol.1502615.

[102] Li, Y. W., Qiu, S. J., Fan, J., Zhou, J., Gao, Q., Xiao, Y. S., et al. (2011). Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection. *Journal of Hepatology* , *54*(3), 497–505. https://doi.org/10.1016/j.jhep.2010.07.044.

[103] Li, J., Wang, W., Zhang, Y., Cieslik, M., Guo, J., Tan, M., et al. (2020). Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. *The Journal of Clinical Investigation*, *130*(5), 2712–2726. https://doi.org/10.1172/JCI134402.

[104] Lim, C. J., Lee, Y. H., Pan, L., Lai, L., Chua, C., Wasser, M., et al. (2019). Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. *Gut*, *68*(5), 916–927. https://doi.org/10.1136/gutjnl-2018-316510.

[105] Limmer, A., Ohl, J., Kurts, C., Ljunggren, H. G., Reiss, Y., Groettrup, M., et al. (2000). Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. *Nature Medicine*, *6*(12), 1348–1354. https://doi.org/10.1038/82161.

[106] Littman, D. R., & Rudensky, A. Y. (2010). Th17 and regulatory T cells in mediating and restraining inflammation. *Cell*, *140*(6), 845–858. https://doi.org/10.1016/j.cell.2010.02.021.

[107] Liu, R. X., Wei, Y., Zeng, Q. H., Chan, K. W., Xiao, X., Zhao, X. Y., et al. (2015). Chemokine (C-X-C motif) receptor 3-positive B cells link interleukin-17 inflammation to protumorigenic macrophage polarization in human hepatocellular carcinoma. *Hepatology*, *62*(6), 1779–1790. https://doi.org/10.1002/hep.28020.

[108] Liu, C. Q., Xu, J., Zhou, Z. G., Jin, L. L., Yu, X. J., Xiao, G., et al. (2018). Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. *British Journal of Cancer*, *119*(1), 80–88. https://doi.org/10.1038/s41416-018-0144-4.

[109] Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., et al. (2021). Immunotherapies for hepatocellular carcinoma. *Nature Reviews Clinical Oncology*. https://doi.org/10.1038/s41571-021-00573-2.

[110] Llovet, J. M., Kudo, M., Cheng, A.-L., Finn, R. S., Galle, P. R., Kaneko, S., et al. (2019). Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study. *Journal of Clinical Oncology*, *37*(15_Suppl), TPS4152. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS4152.

[111] Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. *The New England Journal of Medicine*, *359*(4), 378–390. https://doi.org/10.1056/NEJMoa0708857.

[112] Lumsden, A. B., Henderson, J. M., & Kutner, M. H. (1988). Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. *Hepatology*, *8*(2), 232–236. https://doi.org/10.1002/hep.1840080207.

[113] Lwin, Z., Gomez-Roca, C., Saada-Bouzid, E., Yanez, E., Muñoz, F. L., Im, S. A., et al. (2020). LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumors. *Annals of Oncology*, *31*, S1170. https://doi.org/10.1016/j.annonc.2020.08.2271.

[114] Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., et al. (2018). Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. *Science*, *360* (6391). https://doi.org/10.1126/science.aan5931.

[115] Ma, C., Kesarwala, A. H., Eggert, T., Medina-Echeverz, J., Kleiner, D. E., Jin, P., et al. (2016). NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. *Nature*, *531*(7593), 253–257. https://doi.org/10.1038/nature16969.

[116] Manne, A., Woods, E., Tsung, A., & Mittra, A. (2021). Biliary tract cancers: Treatment updates and future directions in the era of precision medicine and Immuno-oncology. *Frontiers in Oncology*, *11*, 768009. https://doi.org/10.3389/fonc.2021.768009.

[117] Mantovani, S., Oliviero, B., Varchetta, S., Mele, D., & Mondelli, M. U. (2020). Natural killer cell responses in hepatocellular carcinoma: Implications for novel immunotherapeutic approaches. *Cancers (Basel)*, *12*(4). https://doi.org/10.3390/cancers12040926.

[118] Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., et al. (2020). Association of tumor mutational burden with outcomes in patients with advanced solid tumors treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *The Lancet Oncology*, *21*(10), 1353–1365. https://doi.org/10.1016/S1470-2045(20)30445-9.

[119] Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J. P., et al. (2020). Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. *Journal of Clinical Oncology*, *38*(1), 1–10. https://doi.org/10.1200/JCO.19.02105.

[120] Matsubara, T., Kanto, T., Kuroda, S., Yoshio, S., Higashitani, K., Kakita, N., et al. (2013). TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. *Hepatology*, *57*(4), 1416–1425. https://doi.org/10.1002/hep.25965.

[121] McPhail, J., Sims, O. T., Guo, Y., Wooten, D., Herndon, J. S., & Massoud, O. I. (2021). Fibrosis improvement in patients with HCV treated with direct-acting antivirals. *European Journal of Gastroenterology & Hepatology*, *33*(7), 996–1000. https://doi.org/10.1097/MEG.0000000000001821.

[122] Merle, P., Edeline, J., Bouattour, M., Cheng, A.-L., Chan, S. L., Yau, T., et al. (2021). Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study. *Journal of Clinical Oncology*, *39*(3_Suppl), 268. https://doi.org/10.1200/JCO.2021.39.3_suppl.268.

[123] Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stange, G., Van den Bossche, J., et al. (2010). Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. *Cancer Research*, *70*(14), 5728–5739. https://doi.org/10.1158/0008-5472.CAN-09-4672.

[124] Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008). The role of myeloid cells in the promotion of tumor angiogenesis. *Nature Reviews. Cancer*, *8*(8), 618–631. https://doi.org/10.1038/nrc2444.

[125] Nehls, O., Klump, B., Arkenau, H. T., Hass, H. G., Greschniok, A., Gregor, M., et al. (2002). Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: A prospective phase II trial. *British Journal of Cancer*, *87*(7), 702–704. https://doi.org/10.1038/sj.bjc.6600543.

[126] Nehls, O., Oettle, H., Hartmann, J. T., Hofheinz, R. D., Hass, H. G., Horger, M. S., et al. (2008). Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: A prospective multicentre phase II trial. *British Journal of Cancer*, *98*(2), 309–315. https://doi.org/10.1038/sj.bjc.6604178.

[127] Nemeth, E., Baird, A. W., & O'Farrelly, C. (2009). Microanatomy of the liver immune system. *Seminars in Immunopathology*, *31*(3), 333–343. https://doi.org/10.1007/s00281-009-0173-4.

[128] Notas, G., Kisseleva, T., & Brenner, D. (2009). NK and NKT cells in liver injury and fibrosis. *Clinical Immunology*, *130*(1), 16–26. https://doi.org/10.1016/j.clim.2008.08.008.

[129] Oh, D.-Y., He, A. R., Qin, S., Chen, L.-T., Okusaka, T., Vogel, A., et al. (2022). A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. *Journal of Clinical Oncology*, *40*(4_Suppl), 378. https://doi.org/10.1200/JCO.2022.40.4_suppl.378.

[130] Oh, D.-Y., Lee, K.-H., Lee, D.-W., Kim, T. Y., Bang, J.-H., Nam, A.-R., et al. (2020). Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC). *Journal of Clinical Oncology*, *38*(15_Suppl), 4520. https://doi.org/10.1200/JCO.2020.38.15_suppl.4520.

[131] Orimo, A., & Weinberg, R. A. (2006). Stromal fibroblasts in cancer: A novel tumor-promoting cell type. *Cell Cycle*, *5*(15), 1597–1601. https://doi.org/10.4161/cc.5.15.3112.

[132] Ouyang, F. Z., Wu, R. Q., Wei, Y., Liu, R. X., Yang, D., Xiao, X., et al. (2016). Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma. *Nature Communications*, *7*, 13453. https://doi.org/10.1038/ncomms13453.

[133] Pallett, L. J., Burton, A. R., Amin, O. E., Rodriguez-Tajes, S., Patel, A. A., Zakeri, N., et al. (2020). Longevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes. *The Journal of Experimental Medicine*, *217*(9). https://doi.org/10.1084/jem.20200050.

[134] Pallett, L. J., Gill, U. S., Quaglia, A., Sinclair, L. V., Jover-Cobos, M., Schurich, A., et al. (2015). Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. *Nature Medicine*, *21*(6), 591–600. https://doi.

org/10.1038/nm.3856.

[135] Pardee, A. D., Shi, J., & Butterfield, L. H. (2014). Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. *Journal of Immunology*, *193*(11), 5723–5732. https://doi.org/10.4049/jimmunol.1400725.

[136] Parker, G. A., & Picut, C. A. (2005). Liver immunobiology. *Toxicologic Pathology*, *33*(1), 52–62. https://doi.org/10.1080/01926230590522365.

[137] Payne, K. K., Mine, J. A., Biswas, S., Chaurio, R. A., Perales-Puchalt, A., Anadon, C. M., et al. (2020). BTN3A1 governs antitumor responses by coordinating alphabeta and gammadelta T cells. *Science*, *369*(6506), 942–949. https://doi.org/10.1126/science.aay2767.

[138] Pfister, D., Nunez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., et al. (2021). NASH limits anti-tumor surveillance in immunotherapy-treated HCC. *Nature*, *592* (7854), 450–456. https://doi.org/10.1038/s41586-021-03362-0.

[139] Piha-Paul, S. A., Oh, D. Y., Ueno, M., Malka, D., Chung, H. C., Nagrial, A., et al. (2020). Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. *International Journal of Cancer*, *147*(8), 2190–2198. https://doi.org/10.1002/ijc.33013.

[140] Pinter, M., Scheiner, B., & Peck-Radosavljevic, M. (2021). Immunotherapy for advanced hepatocellular carcinoma: A focus on special subgroups. *Gut*, *70*(1), 204–214. https://doi.org/10.1136/gutjnl-2020-321702.

[141] Prieto, J., Melero, I., & Sangro, B. (2015). Immunological landscape and immunotherapy of hepatocellular carcinoma. *Nature Reviews. Gastroenterology & Hepatology*, *12*(12), 681–700. https://doi.org/10.1038/nrgastro.2015.173.

[142] Qin, S., Chen, Z., Fang, W., Ren, Z., Xu, R., Ryoo, B.-Y., et al. (2022). Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. *Journal of Clinical Oncology*, *40*(4_Suppl), 383. https://doi.org/10.1200/JCO.2022.40.4_suppl.383.

[143] Racanelli, V., & Rehermann, B. (2006). The liver as an immunological organ. *Hepatology*, *43*(2 Suppl. 1), S54–S62. https://doi.org/10.1002/hep.21060.

[144] Rahma, O. E., & Hodi, F. S. (2019). The intersection between tumor angiogenesis and immune suppression. *Clinical Cancer Research*, *25*(18), 5449–5457. https://doi.org/10.1158/1078-0432.CCR-18-1543.

[145] Rebouissou, S., & Nault, J. C. (2020). Advances in molecular classification and precision oncology in hepatocellular carcinoma. *Journal of Hepatology*, *72*(2), 215–229. https://doi.org/10.1016/j.jhep.2019.08.017.

[146] Reig, M., Forner, A., Rimola, J., Ferrer-Fabrega, J., Burrel, M., Garcia-Criado, A., et al. (2021). BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. *The Journal of Hepatology*. https://doi.org/10.1016/j.jhep.2021.11.018.

[147] Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., et al. (2021). Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2–3 study. *The Lancet Oncology*, *22*(7), 977–990. https://doi.org/10.1016/S1470-2045(21)00252-7.

[148] Riechelmann, R. P., Townsley, C. A., Chin, S. N., Pond, G. R., & Knox, J. J. (2007). Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. *Cancer*, *110* (6), 1307–1312. https://doi.org/10.1002/cncr.22902.

[149] Ritter, M., Ali, M. Y., Grimm, C. F., Weth, R., Mohr, L., Bocher, W. O., et al. (2004). Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. *Journal of Hepatology*, *41*(6), 999–1007. https://doi.org/10.1016/j.jhep.2004.08.013.

[150] Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., et al. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*, *348*(6230), 124–128. https://doi.org/10.1126/science.aaa1348.

[151] Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2007). L-arginine availability regulates T-lymphocyte cell-cycle progression. *Blood*, *109*(4), 1568–1573. https://doi.org/10.1182/blood-2006-06-031856.

[152] Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., et al. (2019). Neoantigen-directed immune escape in lung cancer evolution. *Nature*, *567*(7749), 479–485. https://doi.org/10.1038/s41586-019-1032-7.

[153] Ruiz de Galarreta, M., Bresnahan, E., Molina-Sanchez, P., Lindblad, K. E., Maier, B., Sia, D., et al. (2019). Beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. *Cancer Discovery*, *9*(8), 1124–1141. https://doi.org/10.1158/2159-8290.CD-19-0074.

[154] Sahai, V., Griffith, K. A., Beg, M. S., Shaib, W. L., Mahalingam, D., Zhen, D. B., et al. (2020). A multicenter

randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01). *Journal of Clinical Oncology*, *38*(15_Suppl), 4582. https://doi.org/10.1200/JCO.2020.38.15_suppl.4582.

[155] Salas-Benito, D., Perez-Gracia, J. L., Ponz-Sarvise, M., Rodriguez-Ruiz, M. E., Martinez-Forero, I., Castanon, E., et al. (2021). Paradigms on immunotherapy combinations with chemotherapy. *Cancer Discovery*, *11*(6), 1353–1367. https://doi.org/10.1158/2159-8290.CD-20-1312.

[156] Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., et al. (2018). Oncogenic Signaling pathways in the Cancer Genome Atlas. *Cell*, *173*(2), 321–337, e310. https://doi.org/10.1016/j.cell.2018.03.035.

[157] Sangro, B., Bruix, J., Chan, S. L., Galle, P. R., & Rimassa, L. (2022). Reply to: "An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously". *Journal of Hepatology*, *76*(2), 480–481. https://doi.org/10.1016/j.jhep.2021.10.021.

[158] Sangro, B., Gomez-Martin, C., de la Mata, M., Inarrairaegui, M., Garralda, E., Barrera, P., et al. (2013). A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. *Journal of Hepatology*, *59*(1), 81−88. https://doi.org/10.1016/j.jhep.2013.02.022.

[159] Sangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A. L., et al. (2020). Association of inflammatory biomarkers with clinical outcomes in nivolumabtreated patients with advanced hepatocellular carcinoma. *Journal of Hepatology*, *73*(6), 1460–1469. https://doi.org/10.1016/j.jhep.2020.07.026.

[160] Sawada, Y., Yoshikawa, T., Nobuoka, D., Shirakawa, H., Kuronuma, T., Motomura, Y., et al. (2012). Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival. *Clinical Cancer Research*, *18*(13), 3686–3696. https://doi.org/10.1158/1078-0432.CCR-11-3044.

[161] Shalapour, S., Lin, X. J., Bastian, I. N., Brain, J., Burt, A. D., Aksenov, A. A., et al. (2017). Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. *Nature*, *551*(7680), 340–345. https://doi.org/10.1038/nature24302.

[162] Shang, R., Song, X., Wang, P., Zhou, Y., Lu, X., Wang, J., et al. (2021). Cabozantinibbased combination therapy for the treatment of hepatocellular carcinoma. *Gut*, *70*(9), 1746–1757. https://doi.org/10.1136/gutjnl-2020-320716.

[163] Shen, X., Li, N., Li, H., Zhang, T., Wang, F., & Li, Q. (2010). Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. *Journal of Cancer Research and Clinical Oncology*, *136*(11), 1745−1754. https://doi.org/10.1007/s00432-010-0833-8.

[164] Shigeta, K., Datta, M., Hato, T., Kitahara, S., Chen, I. X., Matsui, A., et al. (2020). Dual programmed death Receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. *Hepatology*, *71*(4), 1247−1261. https://doi.org/10.1002/hep.30889.

[165] Shojaei, F., Zhong, C., Wu, X., Yu, L., & Ferrara, N. (2008). Role of myeloid cells in tumor angiogenesis and growth. *Trends in Cell Biology*, *18*(8), 372–378. https://doi.org/10.1016/j.tcb.2008.06.003.

[166] Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., et al. (2019). Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial. *JAMA Oncology*, *5*(6), 824–830. https://doi.org/10.1001/jamaoncol.2019.0270.

[167] Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., et al. (2017). Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. *Gastroenterology*, *153*(3), 812–826. https://doi.org/10.1053/j.gastro.2017.06.007.

[168] Silva, V. W., Askan, G., Daniel, T. D., Lowery, M., Klimstra, D. S., Abou-Alfa, G. K., et al. (2016). Biliary carcinomas: Pathology and the role of DNA mismatch repair deficiency. *Clinical Oncology*, *5*(5), 62. https://doi.org/10.21037/cco.2016.10.04.

[169] Song, G., Shi, Y., Zhang, M., Goswami, S., Afridi, S., Meng, L., et al. (2020). Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. *Cell Discovery*, *6*(1), 90. https://doi.org/10.1038/s41421-020-00214-5.

[170] Spahn, S., Roessler, D., Pompilia, R., Gabernet, G., Gladstone, B. P., Horger, M., et al. (2020). Clinical and genetic tumor characteristics of responding and non-responding patients to PD-1 inhibition in hepatocellular carcinoma. *Cancers (Basel)*, *12*(12). https://doi.org/10.3390/cancers12123830.

[171] Spranger, S., Bao, R., & Gajewski, T. F. (2015). Melanoma-intrinsic beta-catenin signalling prevents anti-tumor immunity. *Nature*, *523*(7559), 231–235. https://doi.org/10.1038/nature14404.

[172] Sun, T. W., Gao, Q., Qiu, S. J., Zhou, J., Wang, X. Y., Yi, Y., et al. (2012). B7-H3 is expressed in human hepatocellular

carcinoma and is associated with tumor aggressiveness and postoperative recurrence. *Cancer Immunology, Immunotherapy*, *61*(11), 2171–2182. https://doi.org/10.1007/s00262-012-1278-5.

[173] Sun, Y., Wu, L., Zhong, Y., Zhou, K., Hou, Y., Wang, Z., et al. (2021). Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. *Cell*, *184*(2), 404–421, e416. https://doi.org/10.1016/j.cell.2020.11.041.

[174] Sun, C., Xu, J., Huang, Q., Huang, M., Wen, H., Zhang, C., et al. (2017). High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. *Oncoimmunology*, *6*(1), e1264562. https://doi.org/10.1080/2162402X.2016.1264562.

[175] Tagliamonte, M., Petrizzo, A., Mauriello, A., Tornesello, M. L., Buonaguro, F. M., & Buonaguro, L. (2018). Potentiating cancer vaccine efficacy in liver cancer. *Oncoimmunology*, *7* (10), e1488564. https://doi.org/10.1080/2162402X.2018.1488564.

[176] Tan, H., Wang, S., & Zhao, L. (2017). A tumor-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways. *Clinical and Experimental Pharmacology & Physiology*, *44*(2), 213–221. https://doi.org/10.1111/1440-1681.12689.

[177] Tatsumi, T., Takehara, T., Katayama, K., Mochizuki, K., Yamamoto, M., Kanto, T., et al. (1997). Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. *Hepatology*, *25*(5), 1108–1114. https://doi.org/10.1002/hep.510250511.

[178] Teijeira, A., Garasa, S., Ochoa, M. C., Villalba, M., Olivera, I., Cirella, A., et al. (2021). IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy. *Clinical Cancer Research*, *27*(9), 2383–2393. https://doi.org/10.1158/1078-0432.CCR-20-1319.

[179] Toh, H. C., Galle, P. R., Zhu, A. X., Nicholas, A., Gaillard, V., Ducreux, M., et al. (2022). IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study. *Journal of Clinical Oncology*, *40*(4_Suppl), 470. https://doi.org/10.1200/JCO.2022.40.4_suppl.470.

[180] Valle, J. W., Kelley, R. K., Nervi, B., Oh, D. Y., & Zhu, A. X. (2021). Biliary tract cancer. *Lancet*, *397*(10272), 428–444. https://doi.org/10.1016/S0140-6736(21)00153-7.

[181] Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., et al. (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *The New England Journal of Medicine*, *362*(14), 1273–1281. https://doi.org/10.1056/NEJMoa0908721.

[182] van der Windt, D. J., Sud, V., Zhang, H., Varley, P. R., Goswami, J., Yazdani, H. O., et al. (2018). Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. *Hepatology*, *68*(4), 1347–1360. https://doi.org/10.1002/hep.29914.

[183] Vogel, A., Bathon, M., & Saborowski, A. (2021). Immunotherapies in clinical development for biliary tract cancer. *Expert Opinion on Investigational Drugs*, *30*(4), 351–363. https://doi.org/10.1080/13543784.2021.1868437.

[184] Wang, H., Rao, B., Lou, J., Li, J., Liu, Z., Li, A., et al. (2020). The function of the HGF/c-met Axis in hepatocellular carcinoma. *Frontiers in Cell and Development Biology*, *8*, 55. https://doi.org/10.3389/fcell.2020.00055.

[185] Wang, D., Saga, Y., Mizukami, H., Sato, N., Nonaka, H., Fujiwara, H., et al. (2012). Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. *International Journal of Oncology*, *40*(4), 929–934. https://doi.org/10.3892/ijo.2011.1295.

[186] Wang, F., Wang, G., Liu, T., Yu, G., Zhang, G., & Luan, X. (2014). B7-H3 was highly expressed in human primary hepatocellular carcinoma and promoted tumor progression. *Cancer Investigation*, *32*(6), 262–271. https://doi.org/10.3109/07357907.2014.909826.

[187] Wei, S., Kryczek, I., & Zou, W. (2006). Regulatory T-cell compartmentalization and trafficking. *Blood*, *108*(2), 426–431. https://doi.org/10.1182/blood-2006-01-0177.

[188] Wheeler, D. A., & Network, C. G. A. R. (2017). Comprehensive and integrative genomic characterization of hepatocellular carcinoma. *Cell*, *169*(7), 1327–1341.e1323. https://doi.org/10.1016/j.cell.2017.05.046.

[189] Wieland, D., Kemming, J., Schuch, A., Emmerich, F., Knolle, P., Neumann-Haefelin, C., et al. (2017). TCF1(+) hepatitis C virus-specific CD8(+) T cells are maintained after cessation of chronic antigen stimulation. *Nature Communications*, *8*, 15050. https://doi.org/10.1038/ncomms15050.

[190] Wilkinson, A. L., Qurashi, M., & Shetty, S. (2020). The role of sinusoidal endothelial cells in the axis of inflammation and cancer within the liver. *Frontiers in Physiology*, *11*, 990. https://doi.org/10.3389/fphys.2020.00990.

[191] Wolf, M. J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., et al. (2014). Metabolic activation of

intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. *Cancer Cell*, *26*(4), 549–564. https://doi.org/10.1016/j.ccell.2014.09.003.

[192] Wu, Y., Kuang, D. M., Pan, W. D., Wan, Y. L., Lao, X. M., Wang, D., et al. (2013). Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. *Hepatology*, *57*(3), 1107–1116. https://doi.org/10.1002/hep.26192.

[193] Wu, J., Meng, Z., Jiang, M., Zhang, E., Trippler, M., Broering, R., et al. (2010). Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. *Immunology*, *129*(3), 363–374. https://doi.org/10.1111/j.1365-2567.2009.03179.x.

[194] Xiao, X., Lao, X. M., Chen, M. M., Liu, R. X., Wei, Y., Ouyang, F. Z., et al. (2016). PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. *Cancer Discovery*, *6*(5), 546–559. https://doi.org/10.1158/2159-8290.CD-15-1408.

[195] Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., et al. (2019). Translation control of the immune checkpoint in cancer and its therapeutic targeting. *Nature Medicine*, *25* (2), 301–311. https://doi.org/10.1038/s41591-018-0321-2.

[196] Yau, T., Kang, Y. K., Kim, T. Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., et al. (2020). Efficacy and safety of nivolumab plus Ipilimumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib: The CheckMate 040 randomized clinical trial. *JAMA Oncology*, *6*(11), e204564. https://doi.org/10.1001/jamaoncol.2020.4564.

[197] Yau, T., Park, J. W., Finn, R. S., Cheng, A. L., Mathurin, P., Edeline, J., et al. (2022). Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial. *The Lancet Oncology*, *23*(1), 77–90. https://doi.org/10.1016/S1470-2045(21)00604-5.

[198] Yoon, J. G., Kim, M. H., Jang, M., Kim, H., Hwang, H. K., Kang, C. M., et al. (2021). Molecular characterization of biliary tract cancer predicts chemotherapy and programmed death 1/programmed death-ligand 1 blockade responses. *Hepatology*, *74*(4), 1914–1931. https://doi.org/10.1002/hep.31862.

[199] Zecca, A., Barili, V., Canetti, D., Regina, V., Olivani, A., Carone, C., et al. (2020). Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma. *Cancer Immunology, Immunotherapy*, *69*(8), 1589–1603. https://doi.org/10.1007/s00262-020-02561-4.

[200] Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., et al. (2019). Landscape and dynamics of single immune cells in hepatocellular carcinoma. *Cell*, *179*(4), 829–845 e820. https://doi.org/10.1016/j.cell.2019.10.003.

[201] Zhang, Q. F., Yin, W. W., Xia, Y., Yi, Y. Y., He, Q. F., Wang, X., et al. (2017). Liver-infiltrating CD11b(−)CD27(−) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. *Cellular & Molecular Immunology*, *14*(10), 819–829. https://doi.org/10.1038/cmi.2016.28.

[202] Zhao, Q., Xiao, X., Wu, Y., Wei, Y., Zhu, L. Y., Zhou, J., et al. (2011). Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. *European Journal of Immunology*, *41*(8), 2314–2322. https://doi.org/10.1002/eji.201041282.

[203] Zhao, W., Zhang, L., Xu, Y., Zhang, Z., Ren, G., Tang, K., et al. (2014). Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. *Laboratory Investigation*, *94*(2), 182–191. https://doi.org/10.1038/labinvest.2013.139.

[204] Zhao, W., Zhang, L., Yin, Z., Su, W., Ren, G., Zhou, C., et al. (2011). Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. *International Journal of Cancer*, *129*(11), 2651–2661. https://doi.org/10.1002/ijc.25920.

[205] Zheng, C., Zheng, L., Yoo, J. K., Guo, H., Zhang, Y., Guo, X., et al. (2017). Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. *Cell*, *169*(7), 1342–1356.e1316. https://doi.org/10.1016/j.cell.2017.05.035.

[206] Zhou, X., Sun, L., Jing, D., Xu, G., Zhang, J., Lin, L., et al. (2018). Galectin-9 expression predicts favorable clinical outcome in solid tumors: A systematic review and meta-analysis. *Frontiers in Physiology*, *9*, 452. https://doi.org/10.3389/fphys.2018.00452.

[207] Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., et al. (2018). Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. *The Lancet Oncology*, *19*(7), 940–952. https://doi.org/10.1016/S1470-2045(18)30351-6.

[208] Zhu, A. X., Guan, Y., Abbas, A. R., Koeppen, H., Lu, S., Hsu, C.-H., et al. (2020). Abstract CT044: Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced

hepatocellular carcinoma (HCC). *Cancer Research*, *80*(16 Suppl), CT044. https://doi.org/10.1158/1538-7445.Am2020-ct044.

[209] Zhu, X. D., Zhang, J. B., Zhuang, P. Y., Zhu, H. G., Zhang, W., Xiong, Y. Q., et al. (2008). High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. *Journal of Clinical Oncology*, *26*(16), 2707–2716. https://doi.org/10.1200/JCO.2007.15.6521.

14 肝胆肿瘤免疫治疗：新兴靶点与转化进展

[1] Abou-Alfa, G. K., Meyer, T., Cheng, A. L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B. Y., et al. (2018). Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. *New England Journal of Medicine*, *379*(1), 54–63. https://doi.org/10.1056/NEJMoa1717002.

[2] Anatelli, F., Chuang, S. T., Yang, X. J., & Wang, H. L. (2008). Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. *American Journal of Clinical Pathology*, *130*(2), 219–223. https://doi.org/10.1309/WMB5PX57Y4P8QCTY.

[3] Awad, W., Adamczyk, B., Ornros, J., Karlsson, N. G., Mani, K., & Logan, D. T. (2015). Structural aspects of N-glycosylations and the C-terminal region in human Glypican-1. *Journal of Biological Chemistry*, *290*(38), 22991–23008. https://doi.org/10.1074/jbc.M115.660878.

[4] Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., et al. (2020). Cholangiocarcinoma 2020: The next horizon in mechanisms and management. *Nature Reviews. Gastroenterology & Hepatology*, *17*(9), 557–588. https://doi.org/10.1038/s41575-020-0310-z.

[5] Bassani-Sternberg, M., Braunlein, E., Klar, R., Engleitner, T., Sinitcyn, P., Audehm, S., et al. (2016). Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. *Nature Communications*, *7*, 13404. https://doi.org/10.1038/ncomms13404.

[6] Batra, S. A., Rathi, P., Guo, L., Courtney, A. N., Fleurence, J., Balzeau, J., et al. (2020). Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. *Cancer Immunology Research*, *8*(3), 309–320. https://doi.org/10.1158/2326-6066.CIR-19-0293.

[7] Bharadwaj, U., Li, M., Chen, C., & Yao, Q. (2008). Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. *Molecular Cancer Research*, *6*(11), 1755–1765. https://doi.org/10.1158/1541-7786.mcr-08-0095.

[8] Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C., & Yao, Q. (2011a). Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. *Molecular Cancer*, *10*, 106. https://doi.org/10.1186/1476-4598-10-106.

[9] Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C., & Yao, Q. (2011b). Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. *Carcinogenesis*, *32*(7), 1013–1024. https://doi.org/10.1093/carcin/bgr075.

[10] Borad, M. J., Gores, G. J., & Roberts, L. R. (2015). Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. *Current Opinion in Gastroenterology*, *31*(3), 264–268. https://doi.org/10.1097/MOG.0000000000000171.

[11] Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007). Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. *Immunity*, *27*(1), 111–122. https://doi.org/10.1016/j.immuni.2007.05.016.

[12] Capurro, M. I., Li, F., & Filmus, J. (2009). Overgrowth of a mouse model of Simpson-Golabi-Behmel syndrome is partly mediated by Indian hedgehog. *EMBO Reports*, *10*(8), 901–907. https://doi.org/10.1038/embor.2009.98.

[13] Capurro, M. I., Shi, W., & Filmus, J. (2012). LRP1 mediates hedgehog-induced endocytosis of the GPC3-hedgehog complex. *Journal of Cell Science*, *125*(Pt 14), 3380–3389. https://doi.org/10.1242/jcs.098889.

[14] Capurro, M., Wanless, I. R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., et al. (2003). Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. *Gastroenterology*, *125*(1), 89–97. https://doi.org/10.1016/s0016-5085(03)00689-9.

[15] Capurro, M. I., Xiang, Y. Y., Lobe, C., & Filmus, J. (2005). Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. *Cancer Research*, *65* (14), 6245–6254. https://doi.org/10.1158/0008-5472.CAN-04-4244.

[16] Capurro, M. I., Xu, P., Shi, W., Li, F., Jia, A., & Filmus, J. (2008). Glypican-3 inhibits hedgehog signaling during

development by competing with patched for hedgehog binding. *Developmental Cell*, *14*(5), 700–711. https://doi.org/10.1016/j.devcel.2008.03.006.

[17] Castellarin, M., Watanabe, K., June, C. H., Kloss, C. C., & Posey, A. D., Jr. (2018). Driving cars to the clinic for solid tumors. *Gene Therapy*, *25*(3), 165–175. https://doi.org/10.1038/s41434-018-0007-x.

[18] Castelletti, L., Yeo, D., van Zandwijk, N., & Rasko, J. E. J. (2021). Anti-mesothelin CAR T cell therapy for malignant mesothelioma. *Biomarker Research*, *9*(1), 11. https://doi.org/10.1186/s40364-021-00264-1.

[19] Chaisaingmongkol, J., Budhu, A., Dang, H., Rabibhadana, S., Pupacdi, B., Kwon, S. M., et al. (2017). Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. *Cancer Cell*, *32*(1), 57–70 e53. https://doi.org/10.1016/j.ccell.2017.05.009.

[20] Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001). CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. *Annual Review of Immunology*, *19*, 565–594. https://doi.org/10.1146/annurev.immunol.19.1.565.

[21] Chang, M. C., Chen, C. A., Hsieh, C. Y., Lee, C. N., Su, Y. N., Hu, Y. H., et al. (2009). Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. *Biochemical Journal*, *424*(3), 449–458. https://doi.org/10.1042/BJ20082196.

[22] Chang, K., & Pastan, I. (1994). Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. *International Journal of Cancer*, *57*(1), 90–97. https://doi.org/10.1002/ijc.2910570117.

[23] Chang, K., & Pastan, I. (1996). Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. *Proceedings of the National Academy of Sciences of the United States of America*, *93*(1), 136–140. https://doi.org/10.1073/pnas.93.1.136.

[24] Chang, K., Pastan, I., & Willingham, M. C. (1992). Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. *International Journal of Cancer*, *50*(3), 373–381. https://doi.org/10.1002/ijc.2910500308.

[25] Chen, S. H., Hung, W. C., Wang, P., Paul, C., & Konstantopoulos, K. (2013). Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. *Scientific Reports*, *3*, 1870. https://doi.org/10.1038/srep01870.

[26] Chen, X., Chen, Y., Liang, R., Xiang, L., Li, J., Zhu, Y., et al. (2022). Combination therapy of hepatocellular carcinoma by GPC3-targeted bispecific antibody and irinotecan is potent in suppressing tumor growth in mice. *Molecular Cancer Therapeutics*, *21*(1), 149–158. https://doi.org/10.1158/1535-7163.Mct-20-1025.

[27] Cheng, R., Chen, Y., Zhou, H., Wang, B., Du, Q., & Chen, Y. (2018). B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma. *Acta Pathologica, Microbiologica, et Immunologica Scandinavica*, *126*(5), 396–402. https://doi.org/10.1111/apm.12837.

[28] Cherkassky, L., Morello, A., Villena-Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., et al. (2016). Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. *Journal of Clinical Investigation*, *126*(8), 3130–3144. https://doi.org/10.1172/JCI83092.

[29] Coelho, R., Ricardo, S., Amaral, A. L., Huang, Y. L., Nunes, M., Neves, J. P., et al. (2020).Regulation of invasion and peritoneal dissemination of ovarian cancer bymesothelin manipulation. *Oncogene*, *9*(6), 61. https://doi.org/10.1038/s41389-020-00246-2.

[30] De Cat, B., Muyldermans, S. Y., Coomans, C., Degeest, G., Vanderschueren, B., Creemers, J., et al. (2003). Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. *Journal of Cell Biology*, *163*(3), 625–635. https://doi.org/10.1083/jcb.200302152.

[31] El-Serag, H. B., Marrero, J. A., Rudolph, L., & Reddy, K. R. (2008). Diagnosis and treatment of hepatocellular carcinoma. *Gastroenterology*, *134*(6), 1752–1763. https://doi.org/10.1053/j.gastro.2008.02.090.

[32] Feng, M., Gao, W., Wang, R., Chen, W., Man, Y.-G., Figg, W. D., et al. (2013). Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. *Proceedings of the National Academy of Sciences*, *110*(12), E1083–E1091. https://doi.org/10.1073/pnas.1217868110.

[33] Finn, R. S., Merle, P., Granito, A., Huang, Y. H., Bodoky, G., Pracht, M., et al. (2018). Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. *Journal of Hepatology*, *69*(2), 353–358. https://doi.org/10.1016/j.jhep.2018.04.010.

[34] Finn, O. J., & Rammensee, H. G. (2018). Is it possible to develop Cancer vaccines to neoantigens, what are the major challenges, and how can these be overcome? Neoantigens: Nothing new in spite of the name. *Cold Spring Harbor*

Perspectives in Biology, *10*(11). https://doi.org/10.1101/cshperspect.a028829.

[35] Fleming, B. D., Urban, D. J., Hall, M., Longerich, T., Greten, T., Pastan, I., et al. (2020). The engineered anti-GPC3 immunotoxin, HN3-ABD-T20, produces regression in mouse liver cancer xenografts via prolonged serum retention. *Hepatology*, *71*(5), 1696–1711. https://doi.org/10.1002/hep.30949.

[36] Fontugne, J., Augustin, J., Pujals, A., Compagnon, P., Rousseau, B., Luciani, A., et al. (2017). PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. *Oncotarget*, *8*(15), 24644–24651. https://doi.org/10.18632/oncotarget.15602.

[37] Fu, Y., Urban, D. J., Nani, R. R., Zhang, Y.-F., Li, N., Fu, H., et al. (2018). Glypican-3-specific antibody drug conjugates targeting hepatocellular carcinoma. *Hepatology*. https://doi.org/10.1002/hep.30326.

[38] Gao, W., & Ho, M. (2011). The role of glypican-3 in regulating Wnt in hepatocellular carcinomas. *Cancer Reports*, *1*(1), 14–19. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22563565.

[39] Gao, W., Kim, H., Feng, M., Phung, Y., Xavier, C. P., Rubin, J. S., et al. (2014). Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. *Hepatology*, *60*(2), 576–587. https://doi.org/10.1002/hep.26996.

[40] Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., et al. (2014). Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. *Clinical Cancer Research*, *20*(24), 6418–6428. https://doi.org/10.1158/1078-0432.CCR-14-1170.

[41] Gao, W., Tang, Z., Zhang, Y.-F., Feng, M., Qian, M., Dimitrov, D. S., et al. (2015). Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. *Nature Communications*, *6*, 6536. https://doi.org/10.1038/ncomms7536.

[42] Gao, W., Xu, Y., Liu, J., & Ho, M. (2016). Epitope mapping by a Wnt-blocking antibody: Evidence of the Wnt binding domain in heparan sulfate. *Scientific Reports*, *6*, 26245. https://doi.org/10.1038/srep26245.

[43] Gauthier, A., & Ho, M. (2013). Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. *Hepatology Research*, *43*(2), 147–154. https://doi.org/10.1111/j.1872-034X.2012.01113.x.

[44] Greten, T. F., Forner, A., Korangy, F., N'Kontchou, G., Barget, N., Ayuso, C., et al. (2010). A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. *BioMed Central Cancer*, *10*, 209. https://doi.org/10.1186/1471-2407-10-209.

[45] Greten, T. F., & Sangro, B. (2018). Targets for immunotherapy of liver cancer. *Journal of Hepatology*, *68*, 157–166. https://doi.org/10.1016/j.jhep.2017.09.007.

[46] Gubbels, J. A. A., Belisle, J., Onda, M., Rancourt, C., Migneault, M., Ho, M., et al. (2006). Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. *Molecular Cancer*, *5*, 50. https://doi.org/10.1186/1476-4598-5-50. Artn 50.

[47] Guo, M., Zhang, H., Zheng, J., & Liu, Y. (2020). Glypican-3: A new target for diagnosis and treatment of hepatocellular carcinoma. *Journal of Cancer*, *11*(8), 2008–2021. https://doi.org/10.7150/jca.39972.

[48] Hassan, R., & Ho, M. (2008). Mesothelin targeted cancer immunotherapy. *European Journal of Cancer*, *44*(1), 46–53. https://doi.org/10.1016/j.ejca.2007.08.028.

[49] He, X., Semenov, M., Tamai, K., & Zeng, X. (2004). LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: Arrows point the way. *Development*, *131*(8), 1663–1677. https://doi.org/10.1242/dev.01117.

[50] Ho, M. (2011). Advances in liver cancer antibody therapies: A focus on glypican-3 and mesothelin. *BioDrugs*, *25*(5), 275–284. https://doi.org/10.2165/11595360-000000000-00000.

[51] Ho, M., Bera, T. K., Willingham, M. C., Onda, M., Hassan, R., FitzGerald, D., et al. (2007). Mesothelin expression in human lung cancer. *Clinical Cancer Research*, *13*(5), 1571–1575. https://doi.org/10.1158/1078-0432.CCR-06-2161.

[52] Ho, M., Feng, M., Fisher, R. J., Rader, C., & Pastan, I. (2011). A novel high-affinity human monoclonal antibody to mesothelin. *International Journal of Cancer*, *128*(9), 2020–2030. https://doi.org/10.1002/ijc.25557.

[53] Ho, M., Hassan, R., Zhang, J., Wang, Q. C., Onda, M., Bera, T., et al. (2005). Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. *Clinical Cancer Research*, *11*(10), 3814–3820. https://doi.org/10.1158/1078-0432.Ccr-04-2304.

[54] Ho, M., & Kim, H. (2011). Glypican-3: A new target for cancer immunotherapy. *European Journal of Cancer*, *47*(3), 333–338. https://doi.org/10.1016/j.ejca.2010.10.024.

[55] Ho, M., Onda, M., Wang, Q. C., Hassan, R., Pastan, I., & Lively, M. O. (2006). Mesothelin is shed from tumor cells. *Cancer Epidemiology Biomarkers & Prevention*, *15*(9), 1751. https://doi.org/10.1158/1055-9965.Epi-06-0479.

[56] Hsu, H. C., Cheng, W., & Lai, P. L. (1997). Cloning and expression of a developmentally regulated transcriptMXR7 in hepatocellular carcinoma: Biological significance and temporospatial distribution. *Cancer Research*, *57*(22), 5179–5184. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9371521.

[57] Ishiguro, T., Sano, Y., Komatsu, S. I., Kamata-Sakurai, M., Kaneko, A., Kinoshita, Y., et al. (2017). An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. *Science Translational Medicine*, *9*(410), 4291. https://doi.org/10.1126/scitranslmed.aal4291.

[58] Jiang, Z., Jiang, X., Chen, S., Lai, Y., Wei, X., Li, B., et al. (2016). Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. *Frontiers in Immunology*, *7*, 690. https://doi.org/10.3389/fimmu.2016.00690.

[59] Johnson, R., & Halder, G. (2014). The two faces of hippo: Targeting the hippo pathway for regenerative medicine and cancer treatment. *Nature Reviews. Drug Discovery*, *13*(1), 63–79. https://doi.org/10.1038/nrd4161.

[60] Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., et al. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature*, *596*(7873), 583–589. https://doi.org/10.1038/s41586-021-03819-2.

[61] Kaeding, A. J., Barwe, S. P., Gopalakrishnapillai, A., Ries, R. E., Alonzo, T. A., Gerbing, R. B., et al. (2021). Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. *Blood Advances*, *5*(9), 2350–2361. https://doi.org/10.1182/bloodadvances.2021004424.

[62] Kaneko, O., Gong, L., Zhang, J., Hansen, J. K., Hassan, R., Lee, B., et al. (2009). A binding domain on mesothelin for CA125/MUC16. *Journal of Biological Chemistry*, *284*(6), 3739–3749. https://doi.org/10.1074/jbc.M806776200.

[63] Kim, H., & Ho, M. (2018). Isolation of antibodies to heparan sulfate on glypicans by phage display. *Current Protocols in Protein Science*, *94*(1). https://doi.org/10.1002/cpps.66, e66.

[64] Kim, M. S., Saunders, A. M., Hamaoka, B. Y., Beachy, P. A., & Leahy, D. J. (2011). Structure of the protein core of the glypican dally-like and localization of a region important for hedgehog signaling. *Proceedings of the National Academy of Sciences of the United States of America*, *108*(32), 13112–13117. https://doi.org/10.1073/pnas.1109877108.

[65] Kojima, T., Oh-eda, M., Hattori, K., Taniguchi, Y., Tamura, M., Ochi, N., et al. (1995). Molecular cloning and expression of megakaryocyte potentiating factor cDNA. *Journal of Biological Chemistry*, *270*(37), 21984–21990. https://doi.org/10.1074/jbc.270.37.21984.

[66] Kolluri, A.,& Ho, M. (2019). The role of Glypican-3 in regulating Wnt, YAP, and hedgehog in liver cancer. *Frontiers in Oncology*, *9*, 708. https://doi.org/10.3389/fonc.2019.00708.

[67] Koyama, Y., Wang, P., Liang, S., Iwaisako, K., Liu, X., Xu, J., et al. (2017). Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis. *Journal of Clinical Investigation*, *127*(4), 1254–1270. https://doi.org/10.1172/JCI88845.

[68] Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., et al. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. *Lancet*, *391*(10126), 1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1.

[69] Lee, J. H., & Lee, S. W. (2017). The roles of carcinoembryonic antigen in liver metastasis and therapeutic approaches. *Gastroenterology Research and Practice*, *2017*, 7521987. https://doi.org/10.1155/2017/7521987.

[70] Li, D., English, H., Hong, J., Liang, T., Merlino, G., Day, C.-P., et al. (2021). A novel PD-L1-targeted shark VNAR single domain-based CAR-T strategy for treating breast cancer and liver cancer. *bioRxiv*. https://doi.org/10.1101/2021.07.20.453144. 2021.2007.2020.453144.

[71] Li, N., Gao, W., Zhang, Y.-F., & Ho, M. (2018). Glypicans as cancer therapeutic targets. *Trends in Cancer*, *4*(11), 741–754. https://doi.org/10.1016/j.trecan.2018.09.004.

[72] Li, D., Li, N., Zhang, Y.-F., Fu, H., Feng, M., Schneider, D., et al. (2020). Persistent polyfunctional chimeric antigen receptor T cells that target Glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. *Gastroenterology*, *158*(8), 2250–2265. https://doi.org/10.1053/j.gastro.2020.02.011.

[73] Li, K., Qian, S., Huang, M., Chen, M., Peng, L., Liu, J., et al. (2021). Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy. *American Journal of Translational Research*, *13*(1), 156–167. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/33527015.

[74] Li, N., Spetz, M. R., & Ho, M. (2020). The role of glypicans in cancer progression and therapy. *Journal of Histochemistry & Cytochemistry*, *68*(12), 841–862. https://doi.org/10.1369/0022155420933709.

[75] Li, N., Wei, L., Liu, X., Bai, H., Ye, Y., Li, D., et al. (2019). A frizzled-like cysteine rich domain in glypican-3 mediates Wnt binding and regulates hepatocellular carcinoma tumor growth in mice. *Hepatology*, *70*(4), 1231–1245. https://doi.

org/10.1002/hep.30646.

[76] Liu, X., Chan, A., Tai, C. H., Andresson, T., & Pastan, I. (2020). Multiple proteases are involved in mesothelin shedding by cancer cells. *Communications Biology*, *3*(1), 728. https://doi.org/10.1038/s42003-020-01464-5.

[77] Liu, Y., Wang, X., & Yang, Y. (2020). Hepatic hippo signaling inhibits development of hepatocellular carcinoma. *Clinical and Molecular Hepatology*, *26*(4), 742–750. https://doi.org/10.3350/cmh.2020.0178.

[78] Liu, H., Xu, Y., Xiang, J., Long, L., Green, S., Yang, Z., et al. (2017). Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer. *Clinical Cancer Research*, *23*(2), 478–488. https://doi.org/10.1158/1078-0432.CCR-16-1203.

[79] Losic, B., Craig, A. J., Villacorta-Martin, C., Martins-Filho, S. N., Akers, N., Chen, X., et al. (2020). Intratumoral heterogeneity and clonal evolution in liver cancer. *Nature Communications*, *11*(1), 291. https://doi.org/10.1038/s41467-019-14050-z.

[80] Lu, L., Jiang, J., Zhan, M., Zhang, H., Wang, Q. T., Sun, S. N., et al. (2021). Targeting tumor-associated antigens in hepatocellular carcinoma for immunotherapy: Past pitfalls and future strategies. *Hepatology*, *73*(2), 821–832. https://doi.org/10.1002/hep.31502.

[81] Lv, J., & Li, P. (2019). Mesothelin as a biomarker for targeted therapy. *Biomarker Research*, *7*(1), 18. https://doi.org/10.1186/s40364-019-0169-8.

[82] Ma, L., Hernandez, M. O., Zhao, Y., Mehta, M., Tran, B., Kelly, M., et al. (2019). Tumor cell biodiversity drives microenvironmental reprogramming in liver Cancer. *Cancer Cell*, *36* (4). https://doi.org/10.1016/j.ccell.2019.08.007.418–430.e416.

[83] Manzanares, M. A., Campbell, D. J. W., Maldonado, G. T., & Sirica, A. E. (2018). Overexpression of periostin and distinct mesothelin forms predict malignant progression in a rat cholangiocarcinoma model. *Hepatology Communications*, *2*(2), 155–172. https://doi.org/10.1002/hep4.1131.

[84] Martin, D., Degese, M. S., Vitale-Cross, L., Iglesias-Bartolome, R., Valera, J. L. C., Wang, Z., et al. (2018). Assembly and activation of the hippo signalome by FAT1 tumor suppressor. *Nature Communications*, *9*(1), 2372. https://doi.org/10.1038/s41467-018-04590-1.

[85] McGrath, N. A., Fu, J., Gu, S. Z., & Xie, C. (2020). Targeting cancer stem cells in cholangiocarcinoma (review). *International Journal of Oncology*, *57*(2), 397–408. https://doi.org/10.3892/ijo.2020.5074.

[86] Meng, P., Zhang, Y. F., Zhang, W., Chen, X., Xu, T., Hu, S., et al. (2021). Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells. *Scientific Reports*, *11*(1), 40. https://doi.org/10.1038/s41598-020-79524-3.

[87] Miyamoto, M., Ojima, H., Iwasaki, M., Shimizu, H., Kokubu, A., Hiraoka, N., et al. (2011). Prognostic significance of overexpression of c-met oncoprotein in cholangiocarcinoma. *British Journal of Cancer*, *105*(1), 131–138. https://doi.org/10.1038/bjc.2011.199.

[88] Moentenich, V., Comut, E., Gebauer, F., Tuchscherer, A., Bruns, C., Schroeder, W., et al. (2020). Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies. *Therapeutic Advances in Medical Oncology*, *12*. https://doi.org/10.1177/1758835920917571, 1758835920917571.

[89] Montalbano, M., Georgiadis, J., Masterson, A. L., McGuire, J. T., Prajapati, J., Shirafkan, A., et al. (2017). Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma (review). *Oncology Reports*, *37*(3), 1291–1300. https://doi.org/10.3892/or.2017.5387.

[90] Nakano, K., Orita, T., Nezu, J., Yoshino, T., Ohizumi, I., Sugimoto, M., et al. (2009). Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. *Biochemical and Biophysical Research Communications*, *378*(2), 279–284. https://doi.org/10.1016/j.bbrc.2008.11.033.

[91] Nomura, R., Fujii, H., Abe, M., Sugo, H., Ishizaki, Y., Kawasaki, S., et al. (2013). Mesothelin expression is a prognostic factor in cholangiocellular carcinoma. *International Surgery*, *98* (2), 164–169. https://doi.org/10.9738/Intsurg-D-13-00001.1.

[92] Parinyanitikul, N., Blumenschein, G. R., Wu, Y., Lei, X., Chavez-Macgregor, M., Smart, M., et al. (2013). Mesothelin expression and survival outcomes in triple receptor negative breast cancer. *Clinical Breast Cancer*, *13*(5), 378–384. https://doi.org/10.1016/j.clbc.2013.05.001.

[93] Pastan, I., & Hassan, R. (2014). Discovery of mesothelin and exploiting it as a target for immunotherapy. *Cancer Research*, *74*(11), 2907–2912. https://doi.org/10.1158/0008-5472.CAN-14-0337.

[94] Phung, Y., Gao, W., Man, Y.-G., Nagata, S., & Ho, M. (2012). High-affinity monoclonal antibodies to cell surface tumor

antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. *MAbs*, *4*(5), 592–599. https://doi.org/10.4161/mabs.20933.

[95] Prieve, M. G., & Moon, R. T. (2003). Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells. *BMC Developmental Biology* , *3*, 2.

[96] Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., et al. (2004). Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. *Journal of Biological Chemistry*, *279*(10), 9190–9198. https://doi.org/10.1074/jbc.M312372200.

[97] Sangro, B., Sarobe, P., Hervas-Stubbs, S., & Melero, I. (2021). Advances in immunotherapy for hepatocellular carcinoma. *Nature Reviews. Gastroenterology & Hepatology*, *18*(8), 525–543. https://doi.org/10.1038/s41575-021-00438-0.

[98] Sarobe, P., Huarte, E., Lasarte, J. J., & Borras-Cuesta, F. (2004). Carcinoembryonic antigen as a target to induce anti-tumor immune responses. *Current Cancer Drug Targets*, *4*(5), 443–454. https://doi.org/10.2174/1568009043332916.

[99] Shi, D., Shi, Y., Kaseb, A. O., Qi, X., Zhang, Y., Chi, J., et al. (2020). Chimeric antigen receptor-Glypican-3 T-cell therapy for advanced hepatocellular carcinoma: Results of phase I trials. *Clinical Cancer Research*, *26*(15), 3979–3989. https://doi.org/10.1158/1078-0432.CCR-19-3259.

[100] Shimada, M., Sugimoto, K., Iwahashi, S., Utsunomiya, T., Morine, Y., Imura, S., et al. (2010). CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. *Journal of Gastroenterology*, *45*(8), 896–902. https://doi.org/10.1007/s00535-010-0235-3.

[101] Shiraishi, T., Shinto, E., Mochizuki, S., Tsuda, H., Kajiwara, Y., Okamoto, K., et al. (2019). Mesothelin expression has prognostic value in stage IotaIota/IotaIotaIota colorectal cancer. *Virchows Archiv*, *474*(3), 297–307. https://doi.org/10.1007/s00428-018-02514-4.

[102] Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2017). Liver cancer cell of origin, molecular class, and effects on patient prognosis. *Gastroenterology*, *152*(4), 745–761. https://doi.org/10.1053/j.gastro.2016.11.048.

[103] Simpson, A. J., Caballero, O. L., Jungbluth, A., Chen, Y. T., & Old, L. J. (2005). Cancer/testis antigens, gametogenesis and cancer. *Nature Reviews. Cancer*, *5*(8), 615–625. https://doi.org/10.1038/nrc1669.

[104] Sulpice, L., Rayar, M., Turlin, B., Boucher, E., Bellaud, P., Desille, M., et al. (2014). Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma. *Journal of Surgical Research*, *192*(1), 117–123. https://doi.org/10.1016/j.jss.2014.05.017.

[105] Sun, T. W., Gao, Q., Qiu, S. J., Zhou, J., Wang, X. Y., Yi, Y., et al. (2012). B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. *Cancer Immunology, Immunotherapy*, *61*(11), 2171–2182. https://doi.org/10.1007/s00262-012-1278-5.

[106] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *A Cancer Journal for Clinicians*, *71*(3), 209–249. https://doi.org/10.3322/caac.21660.

[107] Svensson, G., Awad, W., Hakansson, M., Mani, K., & Logan, D. T. (2012). Crystal structure of N-glycosylated human glypican-1 core protein: Structure of two loops evolutionarily conserved in vertebrate glypican-1. *Journal of Biological Chemistry*, *287*(17), 14040–14051. https://doi.org/10.1074/jbc.M111.322487.

[108] Takai, H., Kato, A., Kinoshita, Y., Ishiguro, T., Takai, Y., Ohtani, Y., et al. (2009). Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages. *Cancer Biology & Therapy*, *8*(10), 930–938.

[109] Tang, Z., Qian, M., & Ho, M. (2013). The role of mesothelin in tumor progression and targeted therapy. *Anti-Cancer Agents in Medicinal Chemistry*, *13*(2), 276–280. https://doi.org/10.2174/1871520611313020014.

[110] Thompson, M. D., & Monga, S. P. (2007). WNT/beta-catenin signaling in liver health and disease. *Hepatology*, *45*(5), 1298–1305. https://doi.org/10.1002/hep.21651.

[111] Uehara, N., Matsuoka, Y., & Tsubura, A. (2008). Mesothelin promotes anchorageindependent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. *Molecular Cancer Research*, *6*(2), 186–193. https://doi.org/10.1158/1541-7786.MCR-07-0254.

[112] Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., et al. (2019). Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, *30*(5), 871–873. https://doi.org/10.1093/annonc/mdy510.

[113] Wang, C., Gao, W., Feng, M., Pastan, I., & Ho, M. (2017). Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. *Oncotarget*, *8*(20), 32450–32460. https://doi.org/10.18632/oncotarget.10592.

[114] Wu, X., Luo, H., Shi, B., Di, S., Sun, R., Su, J., et al. (2019). Combined antitumor effects of sorafenib and GPC3-CAR T cells in mouse models of hepatocellular carcinoma. *Molecular Therapy*, *27*(8), 1483–1494. https://doi.org/10.1016/j.ymthe.2019.04.020.

[115] Wykosky, J., Fenton, T., Furnari, F., & Cavenee, W. K. (2011). Therapeutic targeting of epidermal growth factor receptor in human cancer: Successes and limitations. *Chinese Journal of Cancer*, *30*(1), 5–12. https://doi.org/10.5732/cjc.010.10542.

[116] Xiang, X., Feng, M., Felder, M., Connor, J. P., Man, Y. G., Patankar, M. S., et al. (2011). HN125: A novel immunoadhesin targeting MUC16 with potential for cancer therapy. *Journal of Cancer* , *2*, 280–291.

[117] Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019). A global view of hepatocellular carcinoma: Trends, risk, prevention and management. *Nature Reviews Gastroenterology & Hepatology*, *16*(10), 589–604. https://doi.org/10.1038/s41575-019-0186-y.

[118] Ying, F., Daniel, J. U., Roger, R. N., Yi-Fan, Z., Nan, L, Haiying, Fu, et al. (2019). Glypican-3-specific antibody drug conjugates targeting hepatocellular carcinoma. *Hepatology*, *70*(2), 563–576. https://doi.org/10.1002/hep.30326.

[119] Yokota, K., Serada, S., Tsujii, S., Toya, K., Takahashi, T., Matsunaga, T., et al. (2021). Anti-Glypican-1 antibody-drug conjugate as potential therapy against tumor cells and tumor vasculature for Glypican-1-positive cholangiocarcinoma. *Molecular Cancer Therapeutics*, *20*(9), 1713–1722. https://doi.org/10.1158/1535-7163.MCT-21-0015.

[120] Yu, L., Feng, M., Kim, H., Phung, Y., Kleiner, D. E., Gores, G. J., et al. (2010). Mesothelin as a potential therapeutic target in human cholangiocarcinoma. *Journal of Cancer*, *1*, 141–149. https://doi.org/10.7150/jca.1.141.

[121] Yu, M., Luo, H., Fan, M., Wu, X., Shi, B., Di, S., et al. (2018). Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma. *Molecular Therapy*, *26*(2), 366–378. https://doi.org/10.1016/j.ymthe.2017.12.012.

[122] Yuan, S. F., Li, K. Z., Wang, L., Dou, K. F., Yan, Z., Han, W., et al. (2005). Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. *World Journal of Gastroenterology*, *11*(30), 4661–4666. https://doi.org/10.3748/wjg.v11.i30.4661.

[123] Zhang, Y., Chertov, O., Zhang, J., Hassan, R., & Pastan, I. (2011). Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding. *Cancer Research*, *71* (17), 5915–5922. https://doi.org/10.1158/0008-5472.CAN-11-0466.

[124] Zhang, Y.-F., & Ho, M. (2017). Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examples. *MAbs*, *9*(3), 419–429. https://doi.org/10.1080/19420862.2017.1289302.

[125] Zhang, Z., Jiang, D., Yang, H., He, Z., Liu, X., Qin, W., et al. (2020). Correction: Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. *Cell Death & Disease*, *11*(4), 235. https://doi.org/10.1038/s41419-020-2450-z.

[126] Zhang, Q., Liu, G., Liu, J., Yang, M., Fu, J., Liu, G., et al. (2021). The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice. *Molecular Therapy-Oncolytics*, *20*, 556–568. https://doi.org/10.1016/j.omto.2021.02.013.

[127] Zhang, Y. F., Phung, Y., Gao, W., Kawa, S., Hassan, R., Pastan, I., et al. (2015). New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma. *Scientific Reports*, *5*, 9928. https://doi.org/10.1038/srep09928.

[128] Zhao, Y., Moon, E., Carpenito, C., Paulos, C. M., Liu, X., Brennan, A. L., et al. (2010). Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. *Cancer Research*, *70*(22), 9053–9061. https://doi.org/10.1158/0008-5472.CAN-10-2880.

[129] Zhao, Q., Yu, W. L., Lu, X. Y., Dong, H., Gu, Y. J., Sheng, X., et al. (2016). Combined hepatocellular and cholangiocarcinoma originating from the same clone: A pathomolecular evidence-based study. *Chinese Journal of Cancer*, *35*(1), 82. https://doi.org/10.1186/s40880-016-0146-7.

[130] Zheng, Y., Li, Y., Feng, J., Li, J., Ji, J., Wu, L., et al. (2021). Cellular based immunotherapy for primary liver cancer. *Journal of Experimental & Clinical Cancer Research*, *40*(1), 250. https://doi.org/10.1186/s13046-021-02030-5.

[131] Zhu, A. X., Gold, P. J., El-Khoueiry, A. B., Abrams, T. A., Morikawa, H., Ohishi, N., et al. (2013). First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. *Clinical Cancer Research*, *19*(4), 920–928. https://doi.org/10.1158/1078-0432.CCR-12-2616.

[132] Zucman-Rossi, J., Villanueva, A., Nault, J. C., & Llovet, J. M. (2015). Genetic landscape and biomarkers of hepatocellular carcinoma. *Gastroenterology*, *149*(5). https://doi.org/10.1053/j.gastro.2015.05.061. 1226–1239.e1224.